Compounds > danazol
Page last updated: 2024-09-22

danazol

Description

Danazol: A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID28417
CHEMBL ID1479
CHEBI ID4315
SCHEMBL ID21107
MeSH IDM0005648

Synonyms (119)

Synonym
AC-6836
BRD-K48970916-001-03-0
danol
chronogyn
danocrine
winobanin
win 17,757
nsc-270916
17.alpha.-pregna-2, {4-dien-20-yno[2,3-d]isoxazol-17-ol}
pregna-2, {4-dien-20-yno[2,3-d]isoxazol-17-ol,} (17.alpha.)-
1-ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1h-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol
ethynyl(dimethyl)[?]ol
win 17, 757
(1r,3as,3br,10ar,10bs,12as)-1-ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1h-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol
PRESTWICK_150
cas-17230-88-5
BPBIO1_000100
NCGC00179665-01
cyclomen
PRESTWICK3_000105
PRESTWICK2_000105
BSPBIO_000090
pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol, (17alpha)-
einecs 241-270-1
danokrin
17-alpha-pregn-4-en-20-yno(2,3-d)isoxazol-17-ol
ccris 6747
pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol,(17alpha)-
danazole
danazolum [inn-latin]
17-alpha-2,4-pregnadien-20-yno(2,3-d)isoxazol-17-ol
ladogal
17alpha-pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol
danazolum
[1,2]oxazolo[4',5':2,3]-17alpha-pregn-4-en-20-yn-17-ol
CHEBI:4315 ,
17230-88-5
C06938
danazol
DB01406
danocrine (tn)
danazol (jp17/usp/inn)
D00289
NCGC00164400-01
PRESTWICK0_000105
PRESTWICK1_000105
SPBIO_002029
MLS001306473
smr000058321
MLS001066617
HMS2090A22
win-17757
CHEMBL1479
HMS1568E12
NCGC00179665-02
HMS2095E12
HMS3259M10
vasaloc
win-17,757
optina
danzol
unii-n29qww3buo
danazol [usan:usp:inn:ban:jan]
n29qww3buo ,
danogen
NCGC00255335-01
dtxcid202880
dtxsid2022880 ,
tox21_301940
tox21_112114
(1s,2r,13r,14s,17r,18s)-17-ethynyl-2,18-dimethyl-7-oxa-6-azapentacyclo[11.7.0.0^{2,10}.0^{4,8}.0^{14,18}]icosa-4(8),5,9-trien-17-ol
HMS2231M08
S9506 ,
AKOS015961192
2,4,17alpha-pregnadien-20-yno[2,3-d]-isoxa-zol-17-ol
1-ethynyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-10a,12a-dimethyl-1h-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol
danazol [mi]
danazol [usan]
danazol [orange book]
danazol [inn]
danazol [mart.]
danazol [vandf]
danazol [who-dd]
danazol [usp-rs]
pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol,(17.alpha.)-
danazol [jan]
danazol [usp monograph]
17.alpha.-pregna-2,4-dien-20-yno(2,3)-disoxazol-17-ol
gtpl6942
bdbm50423541
CCG-220105
NC00557
SCHEMBL21107
NCGC00179665-04
tox21_112114_1
CS-4547
W-107864
HY-B1029
mfcd00056838
sr-01000760722
SR-01000760722-2
SR-05000000445-2
sr-05000000445
(17a)-pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol
17a-pregna-2,4-dien-20-yne-[2,3-d]isoxazole-17b-ol
17 alpha-pregna-2,4-dien-20-yno[2,3-d] isoxazol-17 beta-ol
1h-cyclopenta[7,8]phenanthro[3,2-d]isoxazole- pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol deriv.
2,3-isoxazolethisterone
HMS3712E12
(1s,2r,13r,14s,17r,18s)-17-ethynyl-2,18-dimethyl-7-oxa-6-azapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5,9-trien-17-ol
Q419652
17a-pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol
AS-13035
BCP11914
(1r,3as,3br,10ar,10bs,12as)-1-ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1h-cyclopenta[7,8]phenanthro[3,2-d][1,2]oxazol-1-ol
danazol, usp
pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17alpha)-
1-(p-tosyl)-3,4,4-trimethyl-2-imidazoliniumiodide
danazol 100 microg/ml in acetonitrile

Research Excerpts

Overview

ExcerptReference
"Danazol is an attenuated androgen and is used in the treatment of aplastic anemia (AA) in resource constraint settings. "( Bose, P; Khadwal, A; Khurana, H; Lad, D; Malhotra, P; Prakash, G; Sachdeva, MU; Varma, N; Varma, S; Yanamandra, U, 2018)
"Danazol is a steroid analogue with anabolic and androgenic effects and is indicated for the treatment of endometriosis, fibrocystic diseases of the breast, and hereditary angioedema. "( Chen, CH; Hsieh, CY, 2008)
"Danazol is a synthetic androgen derivative frequently used as prophylaxis in patients with hereditary angioedema (HAE) due to complement-1 esterase inhibitor deficiency. "( Birjmohun, RS; Dallinga-Thie, GM; Hofstra, JJ; Kastelein, JJ; Kees Hovingh, G; Levi, M; Meijers, JC; Stroes, ES, 2008)
"Danazol is a drug most widely used for the prophylaxis of hereditary angioedema resulting from the deficiency of the C1-inhibitor. "( Csuka, D; Czaller, I; Farkas, H; Füst, G; Harmat, G; Jakab, L; Karádi, I; Prohászka, Z; Széplaki, G; Valentin, S; Varga, L; Vas, A; Visy, B, 2010)
"Danazol is a useful drug in the treatment of SLE patients, especially in patients with refractory thrombocytopenia, autoimmune hemolytic anemia, and premenstrual flares, and in some mild nonhematologic manifestations of SLE. "( Letchumanan, P; Thumboo, J, 2011)
"Danazol is a steroid analogue approved for the treatment of endometriosis, fibrocystic breast disease, and hereditary angioedema."( Cvetkovic, Z; Neskovic, AN; Putnikovic, B; Stankovic, I; Vlahovic-Stipac, A, 2010)
"Danazol is a synthetic steroid with anti-oestrogenic and anti progestogenic activity, and weak androgenic properties."( Augood, C; Beaumont, H; Duckitt, K; Lethaby, A, 2007)
"Danazol appears to be an effective treatment for heavy menstrual bleeding compared to other medical treatments. "( Augood, C; Beaumont, H; Duckitt, K; Lethaby, A, 2007)
"Danazol is a popular gonadotropin inhibitor used for the treatment of endometriosis, breast disease and hereditary angioedema."( Chang, YY; Chen, SD; Lan, MY; Li, TH; Liu, JS; Wu, YS, 2007)
"Danazol is a useful addition to the range of antihormones that can be used to suppress the symptoms of severe hormone-related benign breast disease."( Hughes, LE; Mansel, RE; Wisbey, JR, 1982)
"Danazol is a new agent which also suppresses gonadotropins, but it is an impeded androgen with negligible estrogen effects."( Check, JH, 1980)
"Danazol is a testosterone (T) derivative widely used in the clinical treatment of endometriosis. "( Damber, JE; Damber, MG; Nilsson, B; Södergård, R; von Schoultz, B, 1983)
"Danazol is a widely used drug that causes few major adverse reactions, most of which are rapidly reversible upon cessation of therapy. "( Enyeart, JJ; Price, WA, 1984)
"Danazol is a synthetic steroid, derivative of 17 alpha-ethinyl testosterone."( Dmowski, WP, 1982)
"Danazol is an effective agent for the prophylaxis of the recurrent attacks of mucocutaneous and visceral swelling which occur in patients with hereditary angioedema (HAE). "( Frank, MM; Hosea, SW, 1980)
"Danazol is a synthetic steroid with antigonadotropic properties useful in treating endometriosis, especially in young infertile women. "( Gambrell, RD; Graham, RL, 1980)
"Danazol proved to be an excellent hormonal agent in the management of fibrocystic disease of the breast."( Asch, RH; Greenblatt, RB; Nezhat, C, 1980)
"Danazol is a semisynthetic androgen that is used in the treatment of endometriosis and hereditary angioedema. "( Bretza, JA; Novey, HS; Vaziri, ND; Warner, AS, 1980)
"Danazol is a steroid with androgenic and anabolic effects and it adversely affects lipid metabolism."( Kauppila, A, 1993)
"Danazol is a synthetic androgen that increases triiodothyronine resin uptake and decreases total thyroxine, secondary to a decrease in thyroid-binding globulin levels."( Heironimus, JD; Katz, N; Toney, MO, 1993)
"Danazol is a synthetic steroid, derived from 17-alpha ethinyltestosterone and it is used primarily in the treatment of endometriosis. "( Arteaga, E; Bianchi, M; Duque, G; Fernández, C, 1995)
"Danazol appears to be a good alternative treatment in PNH."( Ahn, YS; Harrington, WJ; Horstman, LL; Jy, W; Kolodny, L, 1997)
"Danazol therapy seems to be a useful and well-tolerated treatment for refractory immune thrombocytopenia associated with different rheumatic diseases."( Blanco, R; González-Gay, MA; Martinez-Taboada, VM; Rodriguez-Valverde, V; Sanchez-Andrade, A, 1997)
"Danazol is a versatile drug and despite its recognised efficacy in controlling endometriosis, little is known about is cytotoxicity and mechanism of action."( Kunstmann, P; Stevenson, AF; Xing, X, 2000)
"Danazol is a synthetic androgenic steroid used clinically for the treatment of a wide variety of disorders. "( Alvarado, RG; Liu, JY; Zwolak, RM, 2001)
"Danazol is a synthetic steroid with anti-oestrogenic and anti progestogenic activity, and weak androgenic properties."( Augood, C; Beaumont, H; Duckitt, K; Lethaby, A, 2002)
"Danazol appears to be an effective treatment for heavy menstrual bleeding compared to other medical treatments, though it is uncertain whether it is acceptable to women. "( Augood, C; Beaumont, H; Duckitt, K; Lethaby, A, 2002)
"Danazol appears to be an efficacious drug for prophylaxis of hereditary angioedema."( Fireman, P; Green, RL; Levine, MI; Rothbach, C, 1979)
"Danazol is the 2,3-isoxasol derivative of 17alpha-ethinyl testosterone."( Jones, GS; Sapp, KC; Wentz, AC, 1976)
"Danazol is an effective drug in the treatment of endometriosis. "( Busacca, M; Di Blasio, AM; Sabbadini, MG; Viganó, P; Vignali, M, 1992)
"Danazol is an attenuated androgen with minimal virilizing effects."( Berger, JR; Emerson, S; Harrington, WJ; Phillips, S; Sheremata, WA; Snodgrass, SR, 1991)
"Danazol is an antigonadotropin and is used to treat endometriosis, benign breast disease, precocious puberty, hereditary angioneurotic edema, menorrhagia, some types of infertility, and gynecomastia."( Jindal, DP; Kumar, M; Singh, H; Yadav, MR, 1991)
"Danazol is a synthetic attenuated androgen that can interfere with normal interactions between the pituitary-hypothalamic axis and the gonads. "( Donaldson, VH, 1989)
"Danazol proved to be a good post-coital contraceptive with a high rate of efficacy and good tolerability."( Pejrani, G; Tessari, S, 1989)
"Danazol does not seem to be an effective treatment for unexplained primary infertility."( Beynon, JL; Iffland, CA; Shaw, RW, 1989)
"Danazol is a good alternative to splenectomy in elderly persons, especially in women."( Ahn, YS; Duncan, R; Garcia, R; Harrington, WJ; Mylvaganam, R; Rocha, R, 1989)
"danazol appears to be a useful adjunctive treatment for refractory autoimmune thrombocytopenia associated with systemic lupus erythematosus."( Johnson, SC; West, SG, 1988)
"Danazol is a synthetic steroid that inhibits the gonadotropin secretion. "( Amoroso, D; Ardizzoni, A; Bertelli, G; Conte, PF; Michelotti, A; Pronzato, P; Rosso, R, 1987)

Effects

ExcerptReference
"Danazol has an inhibitory effect on the autoimmunologic response associated with adenomyosis."( Fujimori, R; Hayakawa, M; Kodama, H; Kushima, T; Maki, M; Ohtomo, K; Ota, H; Shidara, Y; Takahashi, H, 1992)
"Danazol has previously demonstrated improvements in myelofibrosis-associated anemia."( Camoriano, J; Dueck, A; Gano, K; Gowin, K; Hoffman, R; Kosiorek, H; Mascarenhas, J; Mesa, R; Palmer, J; Reeder, C; Tibes, R, 2017)
"Danazol has been used in the treatment of endometriosis and heavy menstrual bleeding for more than 40 years. "( Godin, R; Marcoux, V, 2015)
"Danazol has been used successfully in the treatment of hematologic manifestations of SLE such as thrombocytopenia, Evan's syndrome, autoimmune hemolytic anemia, and a case of red cell aplasia."( Letchumanan, P; Thumboo, J, 2011)
"Danazol has minimal activity in advanced, recurrent, or persistent endometrial carcinoma."( Benda, J; Brunetto, VL; Covens, A; Lentz, SS; Markman, M; Orr, JW, 2003)
"Danazol has the potential for medical management of uterine arteriovenous malformations in hemodynamically stable patients who do not respond to embolization."( Iwasa, M; Maruo, T; Takeuchi, K; Yamada, T, 2003)
"Danazol, which has been used as a medicine for endometriosis, has a valid effect in pretreatment of patients receiving in vitro fertilization and embryo transfer, although its reproductive mechanism remains unclear. "( Kusakabe, K; Li, ZL; Morishima, S; Nakamuta, N; Otsuki, Y, 2007)
"Danazol has much to offer in the treatment of benign breast disease, and represents an important advance over 'traditional' hormonal regimens proposed in the past."( Ben-Nun, I; Greenblatt, B, 1980)
"Danazol has been used in humans with immune-mediated hemolytic anemia and thrombocytopenia with some success."( Miller, E, 1997)
"Danazol has now few indications in regards to its clinical and metabolic side-effects."( Audebert, A, 1999)
"Danazol has been used with success in some hematological diseases, but there is no report of this treatment in acute leukemia. "( Canioni, D; Damaj, G; Hermine, O; Lefrère, F; Radford-Weiss, I; Rubio, MT; Valensi, F; Varet, B, 2002)
"Danazol has an inhibitory effect on the autoimmunologic response associated with adenomyosis."( Fujimori, R; Hayakawa, M; Kodama, H; Kushima, T; Maki, M; Ohtomo, K; Ota, H; Shidara, Y; Takahashi, H, 1992)
"Danazol thus has both anabolic and androgenic effects on body composition."( Bruce, R; Lees, B; McSweeney, G; Shaw, RW; Stevenson, JC; Whitcroft, SI, 1991)
"Danazol has been used, without universal success, in the treatment of other gynecologic and certain hematologic disorders."( Donaldson, VH, 1989)
"Danazol has been used following screening laparoscopy to avoid the discomfort, expense and risk of laparotomy."( Martin, DC, 1985)
"Danazol has been proposed as the sole agent to treat this condition; however, the results for pregnancy rates do not give as much cause for enthusiasm at the present time as they did when this drug was introduced."( Chong, AP, 1985)
"Danazol has recently been reported to be an effective mode of treatment for patients with refractory immune thrombocytopenic purpura. "( Auger, M; Bellingham, AJ; McVerry, BA, 1985)

Actions

ExcerptReference
"Danazol does not cause a consistent and significant suppression of basal gonadotropin concentrations in premenopausal women."( Döberl, A; Jeppsson, S; Rannevik, G, 1984)
"Danazol did not inhibit aromatase."( Barbieri, RL; Osathanondh, R; Ryan, KJ, 1981)
"Danazol did not inhibit growth of cells cultured over type V collagen substrate, whereas growth of those grown over type IV collagen was greatly inhibited."( Negami, AI; Sasaki, H; Tominaga, T, 1993)
"Danazol was found to inhibit multiple enzymes of steroidogenesis directly in the pregnant mare serum (PMS)-treated hamster ovary and the rat testis and adrenal in vitro. "( Barbieri, RL; Canick, JA; Davies, IJ; Makris, A; Ryan, KJ; Todd, RB, 1977)
"Danazol may inhibit the metabolism of warfarin and/or it may have a direct effect on the coagulation and fibrinolytic systems."( Katz, MD; Mahaffey, KW; Meeks, ML, 1992)
"Danazol also displays immunoregulatory effects both in vivo and in vitro."( Dmowski, WP, 1990)
"Danazol is known to cause marked suppression of sex hormone binding globulin (SHBG) levels in plasma and to increase the proportion of plasma testosterone unbound to protein but the effect on the concentration of total and free testosterone is unclear. "( Dowsett, M; Forbes, KL; Jeffcoate, SL; Mudge, JE; Rose, GL, 1986)

Treatment

ExcerptReference
"Danazol treatment is highly effective in relieving pain and decreasing CA-125 concentrations in the plasma."( Czyż, M; Duechler, M; Kowalczyk-Amico, K; Suzin, J; Szubert, M; Szuławska, A, 2014)
"Danazol-treated (4 mg/kg/d) CBA mice showed prolonged allograft survival (median survival time [MST], 63 days)."( Amano, A; Jin, X; Niimi, M; Uchiyama, M; Watanabe, T; Zhang, Q, 2012)
"Danazol treatment with a concentration greater than 10(-6) M significantly suppressed aromatase activity of endometriosis-derived stromal cells under basal and prostaglandin E(2) (PGE(2))-stimulated conditions. "( Inoue, M; Kasai, T; Murakami, K; Nomura, K; Shinohara, K; Shozu, M, 2006)
"Danazol treatment does not seem to jeopardize maintenance of urinary continence in young females."( Forman, A; Iosif, S; Jeppsson, S; Mellqvist, P; Rannevik, G; Ulmsten, U, 1981)
"Danazol treatment had no effect on levels of androstenedione or dehydroepiandrosterone and its sulphate."( Anderson, AB; Chimbira, TH; Cope, E; Turnbull, AC, 1980)
"Danazol treatment appeared helpful for women who had mild or moderate endometriotic disease."( Letchworth, AT; Noble, AD, 1980)
"The danazol treatment appeared helpful for those women who had mild or moderate endometriotic disease."( Letchworth, AT; Noble, AD, 1980)
"In danazol-treated group, the binding capacity of PR decreased but not that of E2R."( Huang, HF; Wang, M, 1994)
"Danazol treatment in vitro or in vivo suppresses PBM-mediated enhancement of endometrial cell proliferation. "( Braun, DP; Dmowski, WP; Gebel, H, 1994)
"Both danazol treatment regimens were significantly more successful in reducing menstrual blood loss to within the normal range than was norethindrone."( Higham, JM; Shaw, RW, 1993)
"The danazol treatment relieved the symptoms of angioedema and increased the C1 INH activity and concentration with the normalization of CH50, C1q and C4 levels."( Hashimoto, S; Higa, S; Hirata, H; Kawase, I; Minami, S; Saeki, Y; Suemura, M; Tanaka, T, 2002)
"Danazol treatment may also be given postoperatively after conservative operations."( Letchworth, AT; Noble, AD, 1979)
"Danazol treatment was associated with minimal toxicity, but clinically meaningful responses were rare."( Abrahm, J; Cassileth, PA; Cines, DB; Edelstein, M; Nowell, PC; Schreiber, AD; Stadtmauer, EA, 1991)
"Danazol treatment, which also gave rise to these effects, was accompanied by weight gain, myalgia and acne in a considerable proportion of women, as well as other anabolic and androgenic side effects."( de Looze, S; Trabant, H; Widdra, W, 1990)
"The danazol treatment met with a greater measure of patient acceptability than did Yuzpe's regimen, due mainly to the smaller number of side effects."( Colombo, UF; Molla, R; Zuliani, G, 1990)
"Danazol treatment is not associated with loss of bone."( Gardner, R; Lees, B; Shaw, RW; Stevenson, JC, 1989)
"Danazol treatment reduced significantly the PRL response."( Acién, P; Graells, M; Lloret, M, 1989)
"Upon Danazol-treatment the endometrium showed a patterns resembling that in atrophy or in early proliferations stage of the menstrual cycle."( Balogh, I; Gouth, J; Hidvégi, J; Szarvas, Z; Zsolnai, B, 1989)
"Danazol treatment also caused significant elevations of several protease inhibitors, particularly antichymotrypsin which has been reported previously to be low in cholinergic urticaria."( Eftekhari, N; Greaves, MW; Ward, AM; Wong, E, 1987)
"Treatment with Danazol caused more adverse events than NSAIDs (OR 7.0; 95% CI 1.7 to 28.2) and progestogens (OR 4.05, 95% CI 1.6 to10.2)."( Augood, C; Beaumont, H; Duckitt, K; Lethaby, A, 2007)
"Treatment with danazol (including adjunctive to surgical therapy) was effective in relieving painful symptoms related to endometriosis when compared to placebo. "( Farquhar, C; Prentice, A; Selak, V; Singla, A, 2007)
"Treatment with danazol inhibited the fluctuations in circulating gonadotropins and invariably caused low levels of ovarian hormones."( Akerlund, M, 1984)
"Treatment with danazol resulted in a rise of the complement fraction levels and cessation of angioneurotic oedema."( Bonsmann, G; Hamm, H; Krukenmeyer, J; Nashan, D; Sunderkötter, C, 1995)
"Rats treated with Danazol for 14 days at 17-19 weeks of age showed a decrease of plasma gonadotropins associated with ovarian hypofunction, persistent diestrus, and a smaller number of corpora lutea in ovary, resulting in no BrdU-immunoreactive (S-phase) cells in endometrial epithelium and lower activity of thymidine kinase in the uterus compared with control."( Kasahara, N; Kudo, H; Kuwa, K; Mori, T; Nagasawa, H; Sakamoto, S; Sassa, S; Sugiura, Y; Suzuki, S, 1993)
"Treatment with danazol reduced the number of cells in T cell subsets, adhesion molecules, or HLA antigen expression, especially of gamma delta T cells, to 39.5% of the pretreatment value in patients with endometriosis."( Hayakawa, M; Igarashi, S; Matsui, T; Ota, H; Tanaka, H; Tanaka, T, 1996)
"Treatment with danazol (including adjunctive surgical therapy) was effective in relieving painful symptoms related to endometriosis when compared to placebo. "( Farquhar, C; Prentice, A; Selak, V; Singla, A, 2000)
"Treatment with danazol (including adjunctive surgical therapy) was effective in relieving painful symptoms related to endometriosis when compared to placebo. "( Farquhar, C; Prentice, A; Selak, V; Singla, A, 2001)
"Treatment with danazol caused more adverse events than NSAIDs (OR 7.0; 95% CI 1.7, 28.2) and progestogens (OR 4.05, 95% CI 1.6, 10.2), but this did not appear to affect adherence to treatment."( Augood, C; Beaumont, H; Duckitt, K; Lethaby, A, 2002)
"Treatment with danazol is indicated for young women with mild or moderate endometriosis."( Letchworth, AT; Noble, AD, 1979)
"Treatment with danazol yielded clinical improvement of urinary control and gait disturbances in 7 out of the 8 patients."( Costa, G; Meireles, A; Melo, A; Moura, L, 1992)
"Treatment with Danazol had no significant effect on tissue levels of 3H E1S or on the CRE1S E1 or MCR-E1S."( Ghilchik, MW; Purohit, A; Reed, MJ; Riaz, AA, 1992)
"Treatment with danazol was associated with a decline in monocyte Fc gamma receptor number without significantly altering the elevated PAIgG or PBIgG levels."( Abrahm, J; Cassileth, PA; Cines, DB; Edelstein, M; Nowell, PC; Schreiber, AD; Stadtmauer, EA, 1991)
"Treatment with Danazol led to suppression of both menstruation and hemoptysis, thus confirming the clinical diagnosis."( Castillo, A; Meneses, M; Rosa, G; Saldías, F, 1991)
"When treated with danazol by mouth, the hemoglobin level increased approximately 2 to 5 grams in each patient within 3 week, and clinical hemoglobinuria improved."( Abe, T; Hama, H; Kamakura, M; Kinoshita, T; Matsuda, J; Nakayama, A; Oguchi, J; Yamanaka, M; Yoshimura, Y, 1990)
"Treatment with danazol for 18 months cleared both conditions and was well tolerated."( Duhra, P; Holmes, J; Porter, DI, 1990)
"Treatment with danazol (600 mg/day), or with medroxyprogesterone acetate (100 mg/day) after laparoscopy also resulted in significant decreases in the serum PP14 concentration."( Kauppila, A; Rönnberg, L; Seppälä, M; Suikkari, AM; Telimaa, S, 1989)
"Treatment with danazol, 600 mg daily, raised the serum level of C-1-INH, but not of C4."( Jipp, P; Kleinhans, D; Rüther, U; Schach, A, 1986)
"Treatment with danazol was associated with a reduction in both the breast size and the prolactin level."( Kahl, LE; Klein, I; Medsger, TA, 1985)

Roles (3)

RoleDescription
anti-estrogenA drug which acts to reduce estrogenic activity in the body, either by reducing the amount of estrogen or by reducing the activity of whatever estrogen is present.
estrogen antagonistA compound which inhibits or antagonises the biosynthesis or actions of estrogens.
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
17beta-hydroxy steroidA 17-hydroxy steroid in which the hydroxy group at position 17 has a beta-configuration.
terminal acetylenic compoundAn acetylenic compound which a carbon of the C#C moiety is attached to a hydrogen atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (80)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency17.78280.01846.806014.1254AID624417
pregnane X receptorRattus norvegicus (Norway rat)Potency14.12540.025127.9203501.1870AID651751
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency56.56883.189029.884159.4836AID1224846; AID1224894
RAR-related orphan receptor gammaMus musculus (house mouse)Potency18.04480.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency48.96620.173734.304761.8120AID1346859
SMAD family member 3Homo sapiens (human)Potency48.96620.173734.304761.8120AID1346859
TDP1 proteinHomo sapiens (human)Potency33.49830.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency5.96430.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency13.77870.000221.22318,912.5098AID1259243; AID1259247; AID1259381; AID588515; AID743035; AID743036; AID743040; AID743042; AID743053; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency36.82140.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency28.91400.001022.650876.6163AID1224838; AID1224893
progesterone receptorHomo sapiens (human)Potency0.75210.000417.946075.1148AID1346784; AID1346795; AID1347036
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency3.46710.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency36.60650.000214.376460.0339AID588533; AID720691; AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency33.37510.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency16.17610.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency23.90210.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency37.12970.375827.485161.6524AID743217; AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency36.86860.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency22.50230.000229.305416,493.5996AID1259244; AID1259248; AID588514; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080; AID743091
GVesicular stomatitis virusPotency1.38030.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency13.80290.00108.379861.1304AID1645840
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency34.07670.001024.504861.6448AID588535; AID743212; AID743215; AID743227
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency35.99350.001019.414170.9645AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency30.24190.023723.228263.5986AID588541; AID743222; AID743223; AID743241
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency25.02690.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency15.16460.001628.015177.1139AID1224843; AID1224895
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency0.37900.057821.109761.2679AID1159526
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency7.94330.10009.191631.6228AID1346983
Histone H2A.xCricetulus griseus (Chinese hamster)Potency126.79300.039147.5451146.8240AID1224845
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency89.12513.548119.542744.6684AID743266
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency22.55730.000323.4451159.6830AID743065; AID743066; AID743067
heat shock protein beta-1Homo sapiens (human)Potency57.13250.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency29.59720.000627.21521,122.0200AID651741; AID743202; AID743219
gemininHomo sapiens (human)Potency32.64270.004611.374133.4983AID624296
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency16.13660.005612.367736.1254AID624032
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency27.17400.001557.789015,848.9004AID1259244
Rap guanine nucleotide exchange factor 3Homo sapiens (human)Potency3.16236.309660.2008112.2020AID720707
Interferon betaHomo sapiens (human)Potency2.78590.00339.158239.8107AID1347407; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency1.38030.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency76.95880.002319.595674.0614AID651631; AID720552
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency27.17400.001551.739315,848.9004AID1259244
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency1.38030.01238.964839.8107AID1645842
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency61.13060.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency61.13060.011912.222168.7989AID651632
cytochrome P450 2C9, partialHomo sapiens (human)Potency1.38030.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)15.80000.11007.190310.0000AID1443990; AID1449628; AID1473738
Estrogen receptorHomo sapiens (human)IC50 (µMol)17.79000.00000.723732.7000AID625258
Estrogen receptorHomo sapiens (human)Ki5.08300.00000.42297.9070AID625258
Glucocorticoid receptorHomo sapiens (human)IC50 (µMol)4.31400.00000.495310.0000AID625263
Glucocorticoid receptorHomo sapiens (human)Ki1.96100.00010.38637.0010AID625263
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)0.01900.00011.774010.0000AID1209992
Glycine receptor subunit alpha-1Rattus norvegicus (Norway rat)IC50 (µMol)4.31400.00150.76005.0740AID625263
Glycine receptor subunit alpha-1Rattus norvegicus (Norway rat)Ki1.96100.00070.76537.0010AID625263
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)IC50 (µMol)5.69800.00041.877310.0000AID625207
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)Ki5.65100.00322.28879.3160AID625207
Alpha-2A adrenergic receptorHomo sapiens (human)IC50 (µMol)18.32800.00001.44217.3470AID625201
Alpha-2A adrenergic receptorHomo sapiens (human)Ki6.87300.00010.807410.0000AID625201
Adenosine receptor A3Homo sapiens (human)IC50 (µMol)11.16000.00001.89408.5470AID625196
Adenosine receptor A3Homo sapiens (human)Ki6.30900.00000.930610.0000AID625196
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)0.30000.00002.800510.0000AID625248
Beta-3 adrenergic receptorHomo sapiens (human)IC50 (µMol)17.02000.00233.24158.0600AID625206
Beta-3 adrenergic receptorHomo sapiens (human)Ki12.76500.00302.30986.0450AID625206
Androgen receptorRattus norvegicus (Norway rat)IC50 (µMol)0.01200.00101.979414.1600AID625228
Androgen receptorRattus norvegicus (Norway rat)Ki0.00800.00031.21858.9270AID625228
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)11.16000.00021.874210.0000AID625196
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)Ki6.30900.00010.949010.0000AID625196
Alpha-2B adrenergic receptorHomo sapiens (human)IC50 (µMol)23.16300.00001.23808.1590AID625202
Alpha-2B adrenergic receptorHomo sapiens (human)Ki10.57400.00020.725710.0000AID625202
Alpha-2C adrenergic receptorHomo sapiens (human)IC50 (µMol)23.75200.00001.47257.8980AID625203
Alpha-2C adrenergic receptorHomo sapiens (human)Ki3.45100.00030.483410.0000AID625203
Muscarinic acetylcholine receptor M3Homo sapiens (human)IC50 (µMol)17.74700.00011.01049.9280AID625153
Muscarinic acetylcholine receptor M3Homo sapiens (human)Ki3.76200.00000.54057.7600AID625153
Glycine receptor subunit betaRattus norvegicus (Norway rat)IC50 (µMol)4.31400.00150.76005.0740AID625263
Glycine receptor subunit betaRattus norvegicus (Norway rat)Ki1.96100.00070.78467.0010AID625263
Substance-K receptorHomo sapiens (human)IC50 (µMol)26.58000.00013.12109.5530AID625227
Substance-K receptorHomo sapiens (human)Ki8.86000.00011.92429.7930AID625227
D(1A) dopamine receptorHomo sapiens (human)IC50 (µMol)20.44900.00031.84739.2250AID625252
D(1A) dopamine receptorHomo sapiens (human)Ki10.22500.00010.836310.0000AID625252
Glycine receptor subunit alpha-2Rattus norvegicus (Norway rat)IC50 (µMol)4.31400.00150.80445.0740AID625263
Glycine receptor subunit alpha-2Rattus norvegicus (Norway rat)Ki1.96100.00070.78467.0010AID625263
Sodium-dependent noradrenaline transporter Homo sapiens (human)IC50 (µMol)5.69800.00081.541620.0000AID625207
Sodium-dependent noradrenaline transporter Homo sapiens (human)Ki5.65100.00031.465610.0000AID625207
Glycine receptor subunit alpha-3Rattus norvegicus (Norway rat)IC50 (µMol)4.31400.00150.76005.0740AID625263
Glycine receptor subunit alpha-3Rattus norvegicus (Norway rat)Ki1.96100.00070.78467.0010AID625263
5-hydroxytryptamine receptor 2AHomo sapiens (human)IC50 (µMol)8.85000.00010.88018.8500AID625192
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ki2.52800.00000.385510.0000AID625192
Sodium-dependent serotonin transporterHomo sapiens (human)IC50 (µMol)15.42000.00010.86458.7096AID625222
Sodium-dependent serotonin transporterHomo sapiens (human)Ki8.19300.00000.70488.1930AID625222
Mu-type opioid receptorHomo sapiens (human)IC50 (µMol)14.07900.00010.813310.0000AID625163
Mu-type opioid receptorHomo sapiens (human)Ki5.71500.00000.419710.0000AID625163
D(3) dopamine receptorHomo sapiens (human)IC50 (µMol)28.86000.00011.01788.7960AID625254
D(3) dopamine receptorHomo sapiens (human)Ki9.80000.00000.602010.0000AID625254
Kappa-type opioid receptorHomo sapiens (human)IC50 (µMol)15.51800.00001.201110.0000AID625162
Kappa-type opioid receptorHomo sapiens (human)Ki6.20700.00000.362410.0000AID625162
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)11.16000.00001.819410.0000AID625196
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Ki6.30900.00000.965010.0000AID625196
Cytochrome P450 2J2Homo sapiens (human)IC50 (µMol)0.03170.01202.53129.4700AID1209989; AID1209992; AID1209993
Cytochrome P450 2J2Homo sapiens (human)Ki0.02000.02000.09330.1900AID1209988
Sodium-dependent dopamine transporter Homo sapiens (human)IC50 (µMol)6.84200.00071.841946.0000AID625256
Sodium-dependent dopamine transporter Homo sapiens (human)Ki5.43600.00021.11158.0280AID625256
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sex hormone-binding globulinHomo sapiens (human)Kd0.00630.00020.34964.7863AID318680
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (580)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 3Homo sapiens (human)
signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 3Homo sapiens (human)
associative learningRap guanine nucleotide exchange factor 3Homo sapiens (human)
Rap protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
intracellular signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of GTPase activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of protein export from nucleusRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of stress fiber assemblyRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
establishment of endothelial barrierRap guanine nucleotide exchange factor 3Homo sapiens (human)
cellular response to cAMPRap guanine nucleotide exchange factor 3Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 3Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
antral ovarian follicle growthEstrogen receptorHomo sapiens (human)
epithelial cell developmentEstrogen receptorHomo sapiens (human)
chromatin remodelingEstrogen receptorHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
signal transductionEstrogen receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayEstrogen receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationEstrogen receptorHomo sapiens (human)
androgen metabolic processEstrogen receptorHomo sapiens (human)
male gonad developmentEstrogen receptorHomo sapiens (human)
negative regulation of gene expressionEstrogen receptorHomo sapiens (human)
positive regulation of phospholipase C activityEstrogen receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayEstrogen receptorHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptorHomo sapiens (human)
response to estradiolEstrogen receptorHomo sapiens (human)
regulation of toll-like receptor signaling pathwayEstrogen receptorHomo sapiens (human)
negative regulation of smooth muscle cell apoptotic processEstrogen receptorHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionEstrogen receptorHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
response to estrogenEstrogen receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
fibroblast proliferationEstrogen receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEstrogen receptorHomo sapiens (human)
stem cell differentiationEstrogen receptorHomo sapiens (human)
regulation of inflammatory responseEstrogen receptorHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
RNA polymerase II preinitiation complex assemblyEstrogen receptorHomo sapiens (human)
uterus developmentEstrogen receptorHomo sapiens (human)
vagina developmentEstrogen receptorHomo sapiens (human)
prostate epithelial cord elongationEstrogen receptorHomo sapiens (human)
prostate epithelial cord arborization involved in prostate glandular acinus morphogenesisEstrogen receptorHomo sapiens (human)
regulation of branching involved in prostate gland morphogenesisEstrogen receptorHomo sapiens (human)
mammary gland branching involved in pregnancyEstrogen receptorHomo sapiens (human)
mammary gland alveolus developmentEstrogen receptorHomo sapiens (human)
epithelial cell proliferation involved in mammary gland duct elongationEstrogen receptorHomo sapiens (human)
protein localization to chromatinEstrogen receptorHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptorHomo sapiens (human)
negative regulation of miRNA transcriptionEstrogen receptorHomo sapiens (human)
regulation of epithelial cell apoptotic processEstrogen receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
regulation of gluconeogenesisGlucocorticoid receptorHomo sapiens (human)
chromatin organizationGlucocorticoid receptorHomo sapiens (human)
regulation of DNA-templated transcriptionGlucocorticoid receptorHomo sapiens (human)
apoptotic processGlucocorticoid receptorHomo sapiens (human)
chromosome segregationGlucocorticoid receptorHomo sapiens (human)
signal transductionGlucocorticoid receptorHomo sapiens (human)
glucocorticoid metabolic processGlucocorticoid receptorHomo sapiens (human)
gene expressionGlucocorticoid receptorHomo sapiens (human)
microglia differentiationGlucocorticoid receptorHomo sapiens (human)
adrenal gland developmentGlucocorticoid receptorHomo sapiens (human)
regulation of glucocorticoid biosynthetic processGlucocorticoid receptorHomo sapiens (human)
synaptic transmission, glutamatergicGlucocorticoid receptorHomo sapiens (human)
maternal behaviorGlucocorticoid receptorHomo sapiens (human)
intracellular glucocorticoid receptor signaling pathwayGlucocorticoid receptorHomo sapiens (human)
glucocorticoid mediated signaling pathwayGlucocorticoid receptorHomo sapiens (human)
positive regulation of neuron apoptotic processGlucocorticoid receptorHomo sapiens (human)
negative regulation of DNA-templated transcriptionGlucocorticoid receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
astrocyte differentiationGlucocorticoid receptorHomo sapiens (human)
cell divisionGlucocorticoid receptorHomo sapiens (human)
mammary gland duct morphogenesisGlucocorticoid receptorHomo sapiens (human)
motor behaviorGlucocorticoid receptorHomo sapiens (human)
cellular response to steroid hormone stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to glucocorticoid stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to dexamethasone stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to transforming growth factor beta stimulusGlucocorticoid receptorHomo sapiens (human)
neuroinflammatory responseGlucocorticoid receptorHomo sapiens (human)
positive regulation of miRNA transcriptionGlucocorticoid receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayGlucocorticoid receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
inflammatory responseAdenosine receptor A3Homo sapiens (human)
signal transductionAdenosine receptor A3Homo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A3Homo sapiens (human)
regulation of heart contractionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A3Homo sapiens (human)
response to woundingAdenosine receptor A3Homo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell migrationAdenosine receptor A3Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityAdenosine receptor A3Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A3Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A3Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
receptor-mediated endocytosisBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
carbohydrate metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
generation of precursor metabolites and energyBeta-3 adrenergic receptorHomo sapiens (human)
energy reserve metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
response to coldBeta-3 adrenergic receptorHomo sapiens (human)
heat generationBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-3 adrenergic receptorHomo sapiens (human)
eating behaviorBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-3 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-3 adrenergic receptorHomo sapiens (human)
MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
angiogenesisAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vascular associated smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2B adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2B adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of blood pressureAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of smooth muscle contractionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2C adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2C adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2C adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2C adrenergic receptorHomo sapiens (human)
calcium-mediated signalingMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of monoatomic ion transmembrane transporter activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
synaptic transmission, cholinergicMuscarinic acetylcholine receptor M3Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of insulin secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein modification processMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ligand-gated ion channel signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M3Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M3Homo sapiens (human)
muscle contractionSubstance-K receptorHomo sapiens (human)
tachykinin receptor signaling pathwaySubstance-K receptorHomo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmissionSubstance-K receptorHomo sapiens (human)
intestine smooth muscle contractionSubstance-K receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionSubstance-K receptorHomo sapiens (human)
operant conditioningSubstance-K receptorHomo sapiens (human)
positive regulation of vascular permeabilitySubstance-K receptorHomo sapiens (human)
positive regulation of monoatomic ion transportSubstance-K receptorHomo sapiens (human)
positive regulation of smooth muscle contractionSubstance-K receptorHomo sapiens (human)
response to electrical stimulusSubstance-K receptorHomo sapiens (human)
prolactin secretionSubstance-K receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionSubstance-K receptorHomo sapiens (human)
positive regulation of flagellated sperm motilitySubstance-K receptorHomo sapiens (human)
temperature homeostasisD(1A) dopamine receptorHomo sapiens (human)
conditioned taste aversionD(1A) dopamine receptorHomo sapiens (human)
behavioral fear responseD(1A) dopamine receptorHomo sapiens (human)
regulation of protein phosphorylationD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(1A) dopamine receptorHomo sapiens (human)
response to amphetamineD(1A) dopamine receptorHomo sapiens (human)
protein import into nucleusD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
activation of adenylate cyclase activityD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
synapse assemblyD(1A) dopamine receptorHomo sapiens (human)
memoryD(1A) dopamine receptorHomo sapiens (human)
mating behaviorD(1A) dopamine receptorHomo sapiens (human)
grooming behaviorD(1A) dopamine receptorHomo sapiens (human)
adult walking behaviorD(1A) dopamine receptorHomo sapiens (human)
visual learningD(1A) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(1A) dopamine receptorHomo sapiens (human)
astrocyte developmentD(1A) dopamine receptorHomo sapiens (human)
dopamine transportD(1A) dopamine receptorHomo sapiens (human)
transmission of nerve impulseD(1A) dopamine receptorHomo sapiens (human)
neuronal action potentialD(1A) dopamine receptorHomo sapiens (human)
dentate gyrus developmentD(1A) dopamine receptorHomo sapiens (human)
striatum developmentD(1A) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of cell migrationD(1A) dopamine receptorHomo sapiens (human)
peristalsisD(1A) dopamine receptorHomo sapiens (human)
operant conditioningD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
vasodilationD(1A) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
maternal behaviorD(1A) dopamine receptorHomo sapiens (human)
positive regulation of potassium ion transportD(1A) dopamine receptorHomo sapiens (human)
glucose importD(1A) dopamine receptorHomo sapiens (human)
habituationD(1A) dopamine receptorHomo sapiens (human)
sensitizationD(1A) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(1A) dopamine receptorHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(1A) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic potentiationD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic depressionD(1A) dopamine receptorHomo sapiens (human)
cellular response to catecholamine stimulusD(1A) dopamine receptorHomo sapiens (human)
modification of postsynaptic structureD(1A) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of neuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
monoamine transportSodium-dependent serotonin transporterHomo sapiens (human)
response to hypoxiaSodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transportSodium-dependent serotonin transporterHomo sapiens (human)
response to nutrientSodium-dependent serotonin transporterHomo sapiens (human)
memorySodium-dependent serotonin transporterHomo sapiens (human)
circadian rhythmSodium-dependent serotonin transporterHomo sapiens (human)
response to xenobiotic stimulusSodium-dependent serotonin transporterHomo sapiens (human)
response to toxic substanceSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of gene expressionSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of serotonin secretionSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of synaptic transmission, dopaminergicSodium-dependent serotonin transporterHomo sapiens (human)
response to estradiolSodium-dependent serotonin transporterHomo sapiens (human)
social behaviorSodium-dependent serotonin transporterHomo sapiens (human)
vasoconstrictionSodium-dependent serotonin transporterHomo sapiens (human)
sperm ejaculationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of neuron differentiationSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of cell cycleSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of organ growthSodium-dependent serotonin transporterHomo sapiens (human)
behavioral response to cocaineSodium-dependent serotonin transporterHomo sapiens (human)
enteric nervous system developmentSodium-dependent serotonin transporterHomo sapiens (human)
brain morphogenesisSodium-dependent serotonin transporterHomo sapiens (human)
serotonin uptakeSodium-dependent serotonin transporterHomo sapiens (human)
membrane depolarizationSodium-dependent serotonin transporterHomo sapiens (human)
platelet aggregationSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to retinoic acidSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to cGMPSodium-dependent serotonin transporterHomo sapiens (human)
regulation of thalamus sizeSodium-dependent serotonin transporterHomo sapiens (human)
conditioned place preferenceSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion transmembrane transportSodium-dependent serotonin transporterHomo sapiens (human)
amino acid transportSodium-dependent serotonin transporterHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
response to ethanolD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(3) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
learning or memoryD(3) dopamine receptorHomo sapiens (human)
learningD(3) dopamine receptorHomo sapiens (human)
locomotory behaviorD(3) dopamine receptorHomo sapiens (human)
visual learningD(3) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(3) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(3) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(3) dopamine receptorHomo sapiens (human)
response to histamineD(3) dopamine receptorHomo sapiens (human)
social behaviorD(3) dopamine receptorHomo sapiens (human)
response to cocaineD(3) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(3) dopamine receptorHomo sapiens (human)
response to morphineD(3) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(3) dopamine receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionD(3) dopamine receptorHomo sapiens (human)
acid secretionD(3) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(3) dopamine receptorHomo sapiens (human)
negative regulation of oligodendrocyte differentiationD(3) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(3) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(3) dopamine receptorHomo sapiens (human)
musculoskeletal movement, spinal reflex actionD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(3) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(3) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(3) dopamine receptorHomo sapiens (human)
positive regulation of dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(3) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(3) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(3) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(3) dopamine receptorHomo sapiens (human)
immune responseKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
chemical synaptic transmissionKappa-type opioid receptorHomo sapiens (human)
sensory perceptionKappa-type opioid receptorHomo sapiens (human)
locomotory behaviorKappa-type opioid receptorHomo sapiens (human)
sensory perception of painKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
response to insulinKappa-type opioid receptorHomo sapiens (human)
positive regulation of dopamine secretionKappa-type opioid receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionKappa-type opioid receptorHomo sapiens (human)
response to nicotineKappa-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
maternal behaviorKappa-type opioid receptorHomo sapiens (human)
eating behaviorKappa-type opioid receptorHomo sapiens (human)
response to estrogenKappa-type opioid receptorHomo sapiens (human)
estrous cycleKappa-type opioid receptorHomo sapiens (human)
response to ethanolKappa-type opioid receptorHomo sapiens (human)
regulation of saliva secretionKappa-type opioid receptorHomo sapiens (human)
behavioral response to cocaineKappa-type opioid receptorHomo sapiens (human)
sensory perception of temperature stimulusKappa-type opioid receptorHomo sapiens (human)
defense response to virusKappa-type opioid receptorHomo sapiens (human)
cellular response to lipopolysaccharideKappa-type opioid receptorHomo sapiens (human)
cellular response to glucose stimulusKappa-type opioid receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeKappa-type opioid receptorHomo sapiens (human)
positive regulation of potassium ion transmembrane transportKappa-type opioid receptorHomo sapiens (human)
response to acrylamideKappa-type opioid receptorHomo sapiens (human)
positive regulation of eating behaviorKappa-type opioid receptorHomo sapiens (human)
conditioned place preferenceKappa-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayKappa-type opioid receptorHomo sapiens (human)
fatty acid metabolic processCytochrome P450 2J2Homo sapiens (human)
icosanoid metabolic processCytochrome P450 2J2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2J2Homo sapiens (human)
regulation of heart contractionCytochrome P450 2J2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2J2Homo sapiens (human)
linoleic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
organic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
monoamine transportSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent dopamine transporter Homo sapiens (human)
lactationSodium-dependent dopamine transporter Homo sapiens (human)
sensory perception of smellSodium-dependent dopamine transporter Homo sapiens (human)
locomotory behaviorSodium-dependent dopamine transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent dopamine transporter Homo sapiens (human)
response to iron ionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine transportSodium-dependent dopamine transporter Homo sapiens (human)
adenohypophysis developmentSodium-dependent dopamine transporter Homo sapiens (human)
response to nicotineSodium-dependent dopamine transporter Homo sapiens (human)
positive regulation of multicellular organism growthSodium-dependent dopamine transporter Homo sapiens (human)
regulation of dopamine metabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to cocaineSodium-dependent dopamine transporter Homo sapiens (human)
dopamine biosynthetic processSodium-dependent dopamine transporter Homo sapiens (human)
dopamine catabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to ethanolSodium-dependent dopamine transporter Homo sapiens (human)
cognitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent dopamine transporter Homo sapiens (human)
response to cAMPSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
prepulse inhibitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
hyaloid vascular plexus regressionSodium-dependent dopamine transporter Homo sapiens (human)
amino acid transportSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine transportSodium-dependent dopamine transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent dopamine transporter Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (185)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein domain specific bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
TFIIB-class transcription factor bindingEstrogen receptorHomo sapiens (human)
transcription coregulator bindingEstrogen receptorHomo sapiens (human)
transcription corepressor bindingEstrogen receptorHomo sapiens (human)
transcription coactivator bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
chromatin bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
nuclear receptor activityEstrogen receptorHomo sapiens (human)
steroid bindingEstrogen receptorHomo sapiens (human)
protein bindingEstrogen receptorHomo sapiens (human)
calmodulin bindingEstrogen receptorHomo sapiens (human)
beta-catenin bindingEstrogen receptorHomo sapiens (human)
zinc ion bindingEstrogen receptorHomo sapiens (human)
TBP-class protein bindingEstrogen receptorHomo sapiens (human)
enzyme bindingEstrogen receptorHomo sapiens (human)
protein kinase bindingEstrogen receptorHomo sapiens (human)
nitric-oxide synthase regulator activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor bindingEstrogen receptorHomo sapiens (human)
estrogen response element bindingEstrogen receptorHomo sapiens (human)
identical protein bindingEstrogen receptorHomo sapiens (human)
ATPase bindingEstrogen receptorHomo sapiens (human)
14-3-3 protein bindingEstrogen receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingEstrogen receptorHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
core promoter sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription factor activityGlucocorticoid receptorHomo sapiens (human)
RNA bindingGlucocorticoid receptorHomo sapiens (human)
nuclear receptor activityGlucocorticoid receptorHomo sapiens (human)
nuclear glucocorticoid receptor activityGlucocorticoid receptorHomo sapiens (human)
steroid bindingGlucocorticoid receptorHomo sapiens (human)
protein bindingGlucocorticoid receptorHomo sapiens (human)
zinc ion bindingGlucocorticoid receptorHomo sapiens (human)
TBP-class protein bindingGlucocorticoid receptorHomo sapiens (human)
protein kinase bindingGlucocorticoid receptorHomo sapiens (human)
identical protein bindingGlucocorticoid receptorHomo sapiens (human)
Hsp90 protein bindingGlucocorticoid receptorHomo sapiens (human)
steroid hormone bindingGlucocorticoid receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingGlucocorticoid receptorHomo sapiens (human)
estrogen response element bindingGlucocorticoid receptorHomo sapiens (human)
androgen bindingSex hormone-binding globulinHomo sapiens (human)
protein bindingSex hormone-binding globulinHomo sapiens (human)
steroid bindingSex hormone-binding globulinHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A3Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
norepinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
protein bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta3-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
beta-3 adrenergic receptor bindingBeta-3 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-3 adrenergic receptorHomo sapiens (human)
epinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2B adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2B adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2C adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingAlpha-2C adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2C adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2C adrenergic receptorHomo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
signaling receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
tachykinin receptor activitySubstance-K receptorHomo sapiens (human)
protein bindingSubstance-K receptorHomo sapiens (human)
substance K receptor activitySubstance-K receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via GsD(1A) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(1A) dopamine receptorHomo sapiens (human)
protein bindingD(1A) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine bindingD(1A) dopamine receptorHomo sapiens (human)
arrestin family protein bindingD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(1A) dopamine receptorHomo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
integrin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic cation channel activitySodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySodium-dependent serotonin transporterHomo sapiens (human)
protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
antiporter activitySodium-dependent serotonin transporterHomo sapiens (human)
syntaxin-1 bindingSodium-dependent serotonin transporterHomo sapiens (human)
cocaine bindingSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion bindingSodium-dependent serotonin transporterHomo sapiens (human)
identical protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
nitric-oxide synthase bindingSodium-dependent serotonin transporterHomo sapiens (human)
actin filament bindingSodium-dependent serotonin transporterHomo sapiens (human)
serotonin bindingSodium-dependent serotonin transporterHomo sapiens (human)
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(3) dopamine receptorHomo sapiens (human)
protein bindingD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(3) dopamine receptorHomo sapiens (human)
G protein-coupled opioid receptor activityKappa-type opioid receptorHomo sapiens (human)
protein bindingKappa-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingKappa-type opioid receptorHomo sapiens (human)
dynorphin receptor activityKappa-type opioid receptorHomo sapiens (human)
neuropeptide bindingKappa-type opioid receptorHomo sapiens (human)
monooxygenase activityCytochrome P450 2J2Homo sapiens (human)
iron ion bindingCytochrome P450 2J2Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
isomerase activityCytochrome P450 2J2Homo sapiens (human)
linoleic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
hydroperoxy icosatetraenoate isomerase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 5,6-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
heme bindingCytochrome P450 2J2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2J2Homo sapiens (human)
protease bindingSodium-dependent dopamine transporter Homo sapiens (human)
signaling receptor bindingSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
protein bindingSodium-dependent dopamine transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine bindingSodium-dependent dopamine transporter Homo sapiens (human)
amine bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein-containing complex bindingSodium-dependent dopamine transporter Homo sapiens (human)
metal ion bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein phosphatase 2A bindingSodium-dependent dopamine transporter Homo sapiens (human)
heterocyclic compound bindingSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (100)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
cortical actin cytoskeletonRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
microvillusRap guanine nucleotide exchange factor 3Homo sapiens (human)
endomembrane systemRap guanine nucleotide exchange factor 3Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
lamellipodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
filopodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular exosomeRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
nucleoplasmEstrogen receptorHomo sapiens (human)
transcription regulator complexEstrogen receptorHomo sapiens (human)
cytoplasmEstrogen receptorHomo sapiens (human)
Golgi apparatusEstrogen receptorHomo sapiens (human)
cytosolEstrogen receptorHomo sapiens (human)
plasma membraneEstrogen receptorHomo sapiens (human)
membraneEstrogen receptorHomo sapiens (human)
chromatinEstrogen receptorHomo sapiens (human)
euchromatinEstrogen receptorHomo sapiens (human)
protein-containing complexEstrogen receptorHomo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
nucleusGlucocorticoid receptorHomo sapiens (human)
nucleusGlucocorticoid receptorHomo sapiens (human)
nucleoplasmGlucocorticoid receptorHomo sapiens (human)
cytoplasmGlucocorticoid receptorHomo sapiens (human)
mitochondrial matrixGlucocorticoid receptorHomo sapiens (human)
centrosomeGlucocorticoid receptorHomo sapiens (human)
spindleGlucocorticoid receptorHomo sapiens (human)
cytosolGlucocorticoid receptorHomo sapiens (human)
membraneGlucocorticoid receptorHomo sapiens (human)
nuclear speckGlucocorticoid receptorHomo sapiens (human)
synapseGlucocorticoid receptorHomo sapiens (human)
chromatinGlucocorticoid receptorHomo sapiens (human)
protein-containing complexGlucocorticoid receptorHomo sapiens (human)
extracellular regionSex hormone-binding globulinHomo sapiens (human)
extracellular exosomeSex hormone-binding globulinHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
presynaptic membraneAdenosine receptor A3Homo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A3Homo sapiens (human)
dendriteAdenosine receptor A3Homo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
synapseAdenosine receptor A3Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
receptor complexBeta-3 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
cytosolAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cell surfaceAlpha-2B adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-2C adrenergic receptorHomo sapiens (human)
endosomeAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basal plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basolateral plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneGlycine receptor subunit betaRattus norvegicus (Norway rat)
plasma membraneSubstance-K receptorHomo sapiens (human)
sperm flagellumSubstance-K receptorHomo sapiens (human)
sperm headSubstance-K receptorHomo sapiens (human)
sperm midpieceSubstance-K receptorHomo sapiens (human)
sperm midpieceSubstance-K receptorHomo sapiens (human)
plasma membraneSubstance-K receptorHomo sapiens (human)
nucleusD(1A) dopamine receptorHomo sapiens (human)
endoplasmic reticulum membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
ciliumD(1A) dopamine receptorHomo sapiens (human)
presynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
dendritic spineD(1A) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
ciliary membraneD(1A) dopamine receptorHomo sapiens (human)
non-motile ciliumD(1A) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(1A) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
focal adhesionSodium-dependent serotonin transporterHomo sapiens (human)
endosome membraneSodium-dependent serotonin transporterHomo sapiens (human)
endomembrane systemSodium-dependent serotonin transporterHomo sapiens (human)
presynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
membrane raftSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
postsynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
serotonergic synapseSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
neuron projectionSodium-dependent serotonin transporterHomo sapiens (human)
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
synapseD(3) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
nucleoplasmKappa-type opioid receptorHomo sapiens (human)
mitochondrionKappa-type opioid receptorHomo sapiens (human)
cytosolKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
membraneKappa-type opioid receptorHomo sapiens (human)
sarcoplasmic reticulumKappa-type opioid receptorHomo sapiens (human)
T-tubuleKappa-type opioid receptorHomo sapiens (human)
dendriteKappa-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneKappa-type opioid receptorHomo sapiens (human)
presynaptic membraneKappa-type opioid receptorHomo sapiens (human)
perikaryonKappa-type opioid receptorHomo sapiens (human)
axon terminusKappa-type opioid receptorHomo sapiens (human)
postsynaptic membraneKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
neuron projectionKappa-type opioid receptorHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2J2Homo sapiens (human)
extracellular exosomeCytochrome P450 2J2Homo sapiens (human)
cytoplasmCytochrome P450 2J2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2J2Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
cytoplasmSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
cell surfaceSodium-dependent dopamine transporter Homo sapiens (human)
membraneSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
neuron projectionSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell bodySodium-dependent dopamine transporter Homo sapiens (human)
axon terminusSodium-dependent dopamine transporter Homo sapiens (human)
membrane raftSodium-dependent dopamine transporter Homo sapiens (human)
postsynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
dopaminergic synapseSodium-dependent dopamine transporter Homo sapiens (human)
flotillin complexSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
presynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent dopamine transporter Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (175)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID318680Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
An updated steroid benchmark set and its application in the discovery of novel nanomolar ligands of sex hormone-binding globulin.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1473955Ratio of drug concentration at steady state in human at 50 to 400 mg, po BID after 12 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1137010Inhibition of pituitary gonadotropin activity in rat assessed as decrease of testicular weight at 100 mg/kg, po for 14 days1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Isolation, synthesis, and biological activity of five metabolites of danazol.
AID1137012Inhibition of pituitary gonadotropin activity in rat assessed as decrease of number of vaginal estrous days at 20 mg/kg, ip for 14 days1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Isolation, synthesis, and biological activity of five metabolites of danazol.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1179640Agonist activity at androgen receptor (unknown origin) expressed in human HepG2 cells assessed as relative luciferase activity at 10 uM by MMTV promoter-driven luciferase reporter gene assay relative to untreated vehicle control2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Triterpenes from Alisma orientalis act as androgen receptor agonists, progesterone receptor antagonists, and glucocorticoid receptor antagonists.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1209993Inhibition of recombinant CYP2J2 (unknown origin)-mediated terfenadine hydroxylation in presence of NADPH2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1210014Inhibition of recombinant CYP2J2 (unknown origin)-mediated astemizole O-demethylation assessed as remaining activity at 30 uM after 5 mins by LC-MS/MS analysis relative to control2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID1209990Inhibition of CYP2J2-mediated astemizole O-demethylation in human liver microsomes after 8 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID205774Inhibition of steroid sulfatase activity of JEG-3 cells by the compound at 20 uM, activity was determined by considering total labeled estrone ([3H]E1) formed from labeled estrone sulfate ([3H]-E1S)2000Journal of medicinal chemistry, Nov-16, Volume: 43, Issue:23
Structure-activity relationships of 17alpha-derivatives of estradiol as inhibitors of steroid sulfatase.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1210013Inhibition of recombinant CYP2J2 (unknown origin)-mediated terfenadine hydroxylation assessed as remaining activity at 30 uM after 5 mins by LC-MS analysis relative to control2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1443990Inhibition of recombinant human BSEP expressed in baculovirus infected sf9 cell plasma membrane vesicles assessed as reduction in ATP-dependent [3H]-taurocholate uptake in to vesicles after 15 to 20 mins2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1137011Inhibition of pituitary gonadotropin activity in rat assessed as decrease of ovarian weight at 20 mg/kg, ip for 14 days1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Isolation, synthesis, and biological activity of five metabolites of danazol.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1473954Drug concentration at steady state in human at 50 to 400 mg, po BID after 12 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1209988Mixed inhibition of recombinant CYP2J2 (unknown origin)-mediated astemizole O-demethylation in presence of NADPH2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID1137005Drug metabolism in human assessed as 6beta,17-dihydroxy-2alpha-(hydroxymethyl)-17alpha-pregn-4-en-20-yn-3-one level in urine at 800 mg, po after 24 hrs by TLC analysis1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Isolation, synthesis, and biological activity of five metabolites of danazol.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1635444Aqueous solubility of compound after 48 hrs by HPLC analysis2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Tetrahydroisoquinoline-Derived Urea and 2,5-Diketopiperazine Derivatives as Selective Antagonists of the Transient Receptor Potential Melastatin 8 (TRPM8) Channel Receptor and Antiprostate Cancer Agents.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID507146Inhibition of mitosis in human HeLa cells by imaging analysis2008Nature chemical biology, Jan, Volume: 4, Issue:1
Integrating high-content screening and ligand-target prediction to identify mechanism of action.
AID1209989Inhibition of recombinant CYP2J2 (unknown origin)-mediated astemizole O-demethylation preincubated for 30 mins followed by substrate addition in presence of NADPH2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1137006Drug metabolism in human assessed as 6beta,17-dihydroxy-2-(hydroxymethyl)-17alpha-pregna-1,4-dien-20-yn-3-one level in urine at 800 mg, po after 24 hrs by TLC analysis1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Isolation, synthesis, and biological activity of five metabolites of danazol.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1137001Drug metabolism in rhesus monkey assessed as 17-hydroxy-17alpha-pregn-4-en-20-yn-3-one level in urine at 50 mg/kg, po bid after 24 hrs by TLC analysis1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Isolation, synthesis, and biological activity of five metabolites of danazol.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID507145Cytotoxicity against human HeLa cells assessed as inhibition of DNA replication by imaging analysis2008Nature chemical biology, Jan, Volume: 4, Issue:1
Integrating high-content screening and ligand-target prediction to identify mechanism of action.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1137008Inhibition of pituitary gonadotropin activity in rat assessed as decrease of ventral prostate weight at 100 mg/kg, po for 14 days1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Isolation, synthesis, and biological activity of five metabolites of danazol.
AID1209973Inhibition of CYP2D6 in human liver microsomes using dextromethorphan as substrate after 8 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1443991Induction of mitochondrial dysfunction in Sprague-Dawley rat liver mitochondria assessed as inhibition of mitochondrial respiration per mg mitochondrial protein measured for 20 mins by A65N-1 oxygen probe based fluorescence assay2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1209987Inhibition of CYP2J2 in human liver microsomes using 7 probe cocktail containing phenacetin, paclitaxel, diclofenac, S-mephenytoin, dextromethorphan, astemizole and midazolam after 8 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID1137004Drug metabolism in human assessed as 17-hydroxy-2-(hydroxymethyl)-17alpha-pregna-1,4-dien-20-yn-3-one level in urine at 800 mg, po after 24 hrs by TLC analysis1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Isolation, synthesis, and biological activity of five metabolites of danazol.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1209974Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1443995Hepatotoxicity in human assessed as drug-induced liver injury2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1473953AUC in human at 50 to 400 mg, po BID after 12 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID678719Metabolic stability in human liver microsomes assessed as medium signal/noise ratio (S/N of 10 to 100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1137009Inhibition of pituitary gonadotropin activity in rat assessed as decrease of seminal vesicles weight at 100 mg/kg, po for 14 days1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Isolation, synthesis, and biological activity of five metabolites of danazol.
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1210016Inhibition of CYP2C8 in human liver microsomes using paclitaxel as substrate after 8 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID1210017Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 8 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1210015Inhibition of CYP1A2 in human liver microsomes using phenacetin as substrate after 8 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1209972Inhibition of CYP2C19 in human liver microsomes using S-mephenytoin as substrate after 8 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID455986Permeability across human Caco-2 cells2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1137003Drug metabolism in human assessed as 17-hydroxy-2alpha-(hydroxymethyl)-17apregn-4-en-20-yn-3-one level in urine at 800 mg, po after 24 hrs by TLC analysis1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Isolation, synthesis, and biological activity of five metabolites of danazol.
AID302758Solubility by shake flask method2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Poorly soluble marketed drugs display solvation limited solubility.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1443992Total Cmax in human administered as single dose2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1209992Inhibition of recombinant CYP2J2 (unknown origin)-mediated astemizole O-demethylation in presence of NADPH2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1346911Rat Androgen receptor (3C. 3-Ketosteroid receptors)1980American journal of obstetrics and gynecology, Feb-15, Volume: 136, Issue:4
Danazol binding and translocation of steroid receptors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,245)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990896 (39.91)18.7374
1990's653 (29.09)18.2507
2000's385 (17.15)29.6817
2010's253 (11.27)24.3611
2020's58 (2.58)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials288 (11.99%)5.53%
Reviews392 (16.32%)6.00%
Case Studies540 (22.48%)4.05%
Observational4 (0.17%)0.25%
Other1,178 (49.04%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (35)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Combination of Iguratimod and Danazol Versus Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia: A Randomized, Controlled, Multicenter, Open-label Trial[NCT05281068]Phase 2120 participants (Anticipated)Interventional2021-09-01Recruiting
Effect of Danazol on Endometrial αvβ3 Integrin Expression in Patients With Unexplained Recurrent Implantation Failure - A Self-controlled Clinical Trial[NCT03563664]Phase 338 participants (Actual)Interventional2015-08-01Completed
A Comparative, Open-Label, Randomized, Parallel Group Study to Determine Intraperitoneal Fluids, Tissue, and Serum Concentrations of VML-0501 Following Five Days of Daily Vaginal Applications of Single Dose of VML-0501 (100 mg Danazol), in Comparison to F[NCT03352076]Phase 230 participants (Actual)Interventional2017-12-28Completed
The Combination of Terbutaline and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia[NCT04481282]Phase 240 participants (Anticipated)Interventional2020-07-08Recruiting
Essai Bayésien de Phase I/II évaluant l'efficacité et la tolérance du Danazol Chez Les Patients Ayant Une Atteinte hématologique ou Pulmonaire sévère liée à Une téloméropathie - ANDROTELO[NCT03710356]Phase 1/Phase 240 participants (Anticipated)Interventional2018-10-20Not yet recruiting
The Combination of Atorvastatin, Acetylcysteine and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia[NCT03460808]Phase 1/Phase 2200 participants (Anticipated)Interventional2018-03-10Not yet recruiting
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Multicenter Evaluation of the Use of Topically Administered Danazol Versus Placebo in Subjects With Pain Associated With Fibrocystic Breast Disease[NCT00744276]Phase 260 participants (Anticipated)Interventional2007-01-31Completed
Phase II Trial of Romiplostim With Danazol in Patients With Eltrombopag-resistant Immune Thrombocytopenia[NCT04289207]Phase 255 participants (Anticipated)Interventional2020-03-01Not yet recruiting
Far Eastern Memorial Hospital[NCT05697471]Phase 3120 participants (Anticipated)Interventional2023-02-25Recruiting
[NCT01105793]Phase 220 participants (Anticipated)Interventional2010-06-30Completed
Evaluation of Haematological Improvement in Patients With Low-risk MDS by Comparing VBaP With Danazol in Patients Who Have Either Received Erythropoiesis Stimulating Agents (ESA) and Lost Response, Not Responded to ESA or Are Deemed Unlikely to Respond to[NCT04997811]Phase 2120 participants (Anticipated)Interventional2021-12-21Recruiting
Phase II Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura[NCT00953771]Phase 229 participants (Actual)Interventional2008-10-31Terminated(stopped due to low enrollment)
[NCT00758953]Phase 266 participants (Actual)Interventional2007-02-28Completed
The Combination of Sitagliptin and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia: A Randomized, Controlled, Multicenter, Open-label Trial[NCT05353673]Phase 2120 participants (Anticipated)Interventional2021-06-01Recruiting
A Phase II Single Center Single Arm Pilot Study Administering Danazol for Treatment of Cytopenias in Patients With Cirrhosis[NCT04873102]Phase 210 participants (Anticipated)Interventional2023-05-31Recruiting
The Combination of Tacrolimus and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia: A Randomized, Controlled, Open-label Trial[NCT05471050]Phase 2120 participants (Anticipated)Interventional2022-03-02Recruiting
A Randomized, Placebo-Controlled, Parallel Treatment Group, Double-Masked Study to Evaluate the Efficacy and Safety of Two Doses of Oral DMI-5207 in Adult Subjects With Diabetic Macular Edema[NCT02002403]Phase 234 participants (Actual)Interventional2011-01-31Completed
Low Dose Danazol for the Treatment of Telomere Related Diseases[NCT03312400]Phase 240 participants (Anticipated)Interventional2018-02-08Recruiting
Phase I/II Dose Escalation Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita[NCT01001598]Phase 1/Phase 25 participants (Actual)Interventional2009-11-30Terminated(stopped due to Study was terminated due to under enrollment)
A Randomized Trial of Recombinant Human Thrombopoietin Versus Placebo for Low/Intermediate-1 Risk Myelodysplastic Syndromes With Thrombocytopenia[NCT04324060]Phase 2/Phase 375 participants (Anticipated)Interventional2020-03-01Active, not recruiting
Low-dose Baricitinib Plus Danazol Versus Danazol for Patients With Steroid-resistant/Relapse Immune Thrombocytopenia: A Multicenter, Randomized, Open-label Phase 2 Trial[NCT05852847]Phase 2216 participants (Anticipated)Interventional2023-05-16Recruiting
The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis[NCT04638517]Phase 250 participants (Anticipated)Interventional2021-09-07Recruiting
Study of Exposure to Substances Prohibited by the World Anti-Doping Agency in Healthy Volunteers.[NCT04757532]Phase 19 participants (Actual)Interventional2020-12-03Completed
A Phase 2 Pilot Trial of Ruxolitinib Combined With Danazol for Patients With Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET) and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering From Anemia[NCT01732445]Phase 214 participants (Actual)Interventional2013-04-30Completed
A Multicenter, Open-label, Randomized, Controlled, Phase 2 Trial Comparing the Efficacy and Safety of Teriflunomide Plus Danazol in Patients With Steroid-resistant/Relapse ITP[NCT06176911]Phase 2124 participants (Anticipated)Interventional2023-12-05Recruiting
The Combination of Oral All-trans Retinoic Acid and Danazol vs Danazol as Second-line Treatment in Adult Immune Thrombocytopenia: a Multicenter, Randomized, Open-label Trial[NCT01667263]Phase 2130 participants (Actual)Interventional2012-06-01Completed
Treatment With Danazol Before Controlled Ovarian Hyperstimulation in Women With Endometriosis Undergoing IVF[NCT01779232]Phase 4150 participants (Actual)Interventional2012-10-31Completed
Male Hormones for Telomere Related Diseases[NCT01441037]Phase 1/Phase 227 participants (Actual)Interventional2011-07-19Completed
Phase II Study of Danazol in Advanced or Recurrent Endometrial Cancer[NCT00003946]Phase 20 participants Interventional1999-08-31Completed
A Randomized, Double-blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic, Anemic Subjects With Primary Myelofibrosis (PMF), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET[NCT04173494]Phase 3195 participants (Actual)Interventional2020-02-07Completed
Effects of Telomerase Reactivation With Danazol in Ovarian Function.[NCT04058678]19 participants (Actual)Interventional2020-01-30Completed
PRETELL: PREvention of TELomere-related Complications After Lung Transplant[NCT04807309]Phase 1/Phase 20 participants (Actual)Interventional2021-01-01Withdrawn(stopped due to Lack of financial support)
A Multicenter Randomized Trial of Second Line Treatment for Corticosteroid-Resistant or Relapsed Immune Thrombocytopenia: Combined Terbutaline and Danazol Versus Danazol Monotherapy[NCT05494307]Phase 2228 participants (Anticipated)Interventional2022-09-01Not yet recruiting
Combination of Danazole With Berberine in the Treatment of ITP[NCT03909763]Phase 255 participants (Actual)Interventional2016-01-20Active, not recruiting
A Randomized, Placebo-Controlled, Parallel, Double-Masked Study to Evaluate the Efficacy and Safety of Two Doses of Oral Optina™ in Adult Patients With Diabetic Macular Edema[NCT01821677]Phase 2354 participants (Actual)Interventional2013-02-26Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Length of Stay

(NCT00953771)
Timeframe: up to 30 days

Interventiondays (Mean)
Danazol, Plex, Steroids27.3
Historic Control24.9

Number of Plasma Exchanges

The total number of plasma exchanges performed after initiation of the first plasma exchange. (NCT00953771)
Timeframe: up to 60 days

Interventionexchanges (Mean)
Danazol, Plex, Steroids14.8
Historic Control16.1

Number of Relapses

(NCT00953771)
Timeframe: up to 12 years

InterventionParticipants (Count of Participants)
Danazol, Plex, Steroids1
Historic Control8

Time to Relapse

(NCT00953771)
Timeframe: up to 12 years

Interventionmonths (Median)
Danazol, Plex, Steroids43
Historic Control53.3

Time to Remission

(NCT00953771)
Timeframe: up to 30 days

Interventiondays (Mean)
Danazol, Plex, Steroids11.4
Historic Control11.0

Number of Participants With Complete and Continuous Response Rate

(NCT00953771)
Timeframe: At 2 Years

,
InterventionParticipants (Count of Participants)
Complete Response RateContinuous Response Rate
Danazol, Plex, Steroids98
Historic Control1716

Number of Participants With Toxicity Associated With Danazol Therapy: Virilization, and/or New or Progressive Evidence of Either Hepatic or Renal Toxicity at a Grade II Level Using National Cancer Institute Common Toxicity Criteria (NCI-CTC).

All toxicities were collected and adjudicated to definitely-related, possibly-related, or unrelated to the treatment. (NCT01001598)
Timeframe: 48 weeks (24 weeks treatment and 24 weeks extension phase)

InterventionParticipants (Count of Participants)
Virilization - definitely relatedHepatic - possibly related
Danazol21

The Optimal Dose and Number of Participants With Hematologic Response Rate in Fanconi Anemia (FA) and Dyskeratosis Congenita (DC) Patients Receiving Danazol Therapy

"The optimal dose could not be calculated because the number of participants needed to do this were not enrolled. Hematologic response rate (HR) was calculated for each participant at Week 12, 18, and 24. HR was defined by hemoglobin (Hg), platelets or neutrophil response. Please find the evaluation criteria used below:~Hemoglobin response: Hgb≥8 g/dL if baseline Hgb≤7 g/dL, or Hgb rise ≥1 g/dL from baseline if baseline Hgb>7 g/dL. No RBC transfusion during the 8 weeks prior to response evaluation.~Platelet response: Platelet count ≥30,000/ μL if baseline platelet count ≤20,000/ μL, or platelet count rise >10,000/ μL from baseline if baseline platelet count >20,000/ μL. No platelet transfusion during the 4 weeks prior to response evaluation.~ANC response: ANC count ≥1,000/ μL if baseline ANC count ≤500/ μL, or ANC count rise >500/ μL from baseline if baseline ANC count >500/ μL." (NCT01001598)
Timeframe: 12, 18 and 24 weeks

InterventionParticipants (Count of Participants)
HR by hemoglobin at 12 weeksHR by hemoglobin at 18 weeksHR by hemoglobin at 24 weeksHR by platelets at 12 weeksHR by platelets at 18 weeksHR by platelets at 24 weeksHR by neutrophils at 12 weeksHR by neutrophils at 18 weeksHR by neutrophils at 24 weeks
Danazol333002002

Best Overall Response Rate as Determined by International Working Group Criteria

Best overall response rate as determined by International Working Group criteria: An evaluable patient will be classified as a responder for the primary endpoint if the patient's best overall response is CR, PR or CI (Clinical Improvement) as determined by International Working Group Criteria over all cycles of study treatment. The percentage of successes will be estimated by the number of successes (defined as complete response, partial response, or clinical improvement) divided by the total number of evaluable patients times 100. Confidence intervals for the true success proportion will be calculated according to the approach of Duffy and Santner. (NCT01732445)
Timeframe: Up to 2 years

Interventionpercentage of patients with CR, PR or CI (Number)
Supportive Care (Ruxolitinib Phosphate and Danazol)28.6

Patient-reported Symptoms Assessed Using the MPN-SAF, as Measured by the Percentage of Patients With a Decrease in MPN-SAF TSS Greater Than 50% From Baseline

Patient-reported symptoms will be described at each time point using the mean, confidence interval, median, and range. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) will be analyzed using published scoring algorithms. MPN-SAF includes 27 items scored on a scale of 0 to 10. The MPN-SAF Total Symptom Score (TSS) (range 0-100) was computed according to the published scoring algorithm. Higher scores represent worse symptom burden. The percentage of patients with a decrease in MPN-SAF TSS greater than 50% from baseline and 95% confidence interval are reported below. (NCT01732445)
Timeframe: Baseline to up to 2 years

Interventionpercentage of patients (Number)
Supportive Care (Ruxolitinib Phosphate and Danazol)28.6

Survival Time

Survival time is defined as the time from registration to death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier. The median and 95% confidence interval are reported below. (NCT01732445)
Timeframe: From registration to death due to any cause, assessed up to 2 years

Interventionmonths (Median)
Supportive Care (Ruxolitinib Phosphate and Danazol)19.2

Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (v4)

"The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns within patient groups. In addition, we will review all adverse event data that is graded as 3, 4, or 5 and classified as either unrelated or unlikely to be related to study treatment in the event of an actual relationship developing. The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below." (NCT01732445)
Timeframe: Up to 2 years

Interventionpercentage of patients (Number)
Platelet count decreasedAnemiaWhite blood cell decreasedNeutrophil count decreasedHypertensionPremature menopause
Supportive Care (Ruxolitinib Phosphate and Danazol)7.164.37.114.37.17.1

Number of Patients Having Attenuation of Accelerated Telomere Attrition

The primary efficacy end point was a 20% reduction in the annual rate of telomere attrition measured at 24 months. The biologic response at 24 months, was defined as a reduction in the telomere length attrition rate to 96 bp per year or less. The normal rate of telomere loss of approximately 60 bp per year. Telomere length was determined with a semiautomated, Clinical Laboratory Improvement Amendments (CLIA)-approved real-time quantitative PCR (qPCR) assay performed in triplicate and validated for human cells (NCT01441037)
Timeframe: 24 months

InterventionParticipants (Count of Participants)
Danazol12

Change From Baseline in Cancer-related Fatigue as Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) at Week 24

"The EORTC QLQ-C30 is comprised of 5 functional scales (physical, role, emotional, social, cognitive), eight single item symptom scales (fatigue, pain, nausea/vomiting, appetite loss, constipation, diarrhea, insomnia, dyspnea), as well as sub-scales assessing global health/quality of life and financial impact. Most items use a 4-point Likert scale from not at all to very much and a one-week recall period with the exception of the final two items which use a 7 point scale response from very poor to excellent. Scores were averaged and transformed to a 0-100 scale, with higher scores representing better functioning/quality of life. An increase in scores from Baseline indicated an improved functioning/quality of life, and a decrease in scores from Baseline indicated a worsened functioning/quality of life. Baseline was the last assessment done before or on the day of first dose date. Change from Baseline was defined as the post-Baseline value minus Baseline value." (NCT04173494)
Timeframe: Baseline and Week 24

InterventionScores on a scale (Least Squares Mean)
MMB 200 mg QD + Placebo-14.34
DAN 300 mg BID + Placebo-3.52

Change From Baseline in Disease-related Fatigue as Assessed by MFSAF TSS v4.0 at Week 24

The MFSAF v4.0 comprises 7 domains representing the 7 most relevant symptoms of MF identified through existing participant- and clinician-based evidence: fatigue, night sweats, pruritus, abdominal discomfort, pain under the left ribs, early satiety, and bone pain. Participants scored each symptom domain using an 11-point numeric rating scale ranging from 0 (absent) to 10 (worst imaginable). Data has been reported for Disease-related Fatigue domain measured using an 11-point numeric rating scale ranging from 0 (absent) to 10 (worst imaginable), higher score indicates worst outcome. An increase in score from Baseline indicated a worsening of fatigue and a decrease in score from Baseline indicated an improvement in fatigue. Baseline was the last assessment done before or on the day of first dose date. Change from Baseline was defined as the post-Baseline value minus Baseline value. (NCT04173494)
Timeframe: Baseline and Week 24

InterventionScores on a scale (Least Squares Mean)
MMB 200 mg QD + Placebo-1.53
DAN 300 mg BID + Placebo-0.82

Change From Baseline in MFSAF TSS at Week 24

TSS was measured using the MFSAF v4.0. The MFSAF v4.0 comprises 7 domains representing the 7 most relevant symptoms of MF identified through existing participant and clinician-based evidence: fatigue, night sweats, pruritus, abdominal discomfort, pain under the left ribs, early satiety, and bone pain. Participants scored each symptom domain using an 11-point numeric rating scale ranging from 0 (absent) to 10 (worst imaginable). The MFSAF TSS was calculated as the sum of scores of the 7 domains for a possible range of scores of 0 to 70, with a higher TSS corresponding to more severe symptoms. A reduction from Baseline corresponded to a lessening of MF symptoms. Baseline was the last assessment done before or on the day of first dose date. Change from Baseline was defined as the post-Baseline value minus Baseline value. (NCT04173494)
Timeframe: Baseline and Week 24

InterventionScores on a scale (Least Squares Mean)
MMB 200 mg QD + Placebo-9.36
DAN 300 mg BID + Placebo-3.13

Change From Baseline in Physical Function Score as Assessed by Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function Short Form 10b at Week 24

PROMIS Physical Function Short Form 10b consists of 14 questions; each with a 5-point response. PROMIS short form assesses self-reported capability of a participant rather than actual performance of physical activities. This includes functioning of one's upper extremities (dexterity), lower extremities (walking or mobility), and central regions (neck, back) as well as instrumental activities of daily living, such as running errands. Participants scored each response on a scale from 1 (unable to do) to 5 (without any difficulty, or not at all). Total possible range of scores was 14 to 70, with higher scores corresponding to a greater physical function ability. An increase in score from Baseline indicated an improvement in physical function ability and a decrease in score from Baseline indicated a reduction in physical function ability. Baseline was last assessment done before or on the day of first dose date. Change from Baseline was defined as post-Baseline value minus Baseline value. (NCT04173494)
Timeframe: Baseline and Week 24

InterventionScores on a scale (Least Squares Mean)
MMB 200 mg QD + Placebo1.19
DAN 300 mg BID + Placebo-0.11

Duration of MFSAF TSS Response

Duration of MFSAF TSS response is defined as the number of days from the start of the initial 28-day period in which a participant had a >= 50% reduction from Baseline TSS to the first day of the 7-day assessment that determines the mean TSS for the 28-day period during which the participants TSS equals or exceeds their Baseline value. (NCT04173494)
Timeframe: Up to a maximum of 151 weeks

InterventionDays (Median)
MMB 200 mg QD + Placebo286.00
DAN 300 mg BID + PlaceboNA

Duration of TI in Baseline TD Participants

Duration of TI is defined as the number of days from (a) the first day of a 12-week period that satisfies the 12-week TI status definition, to (b) the first RBC transfusion or Hgb level < 8 g/dL (except in the case of clinically overt bleeding). (NCT04173494)
Timeframe: Up to a maximum of 151 weeks

InterventionDays (Median)
MMB 200 mg QD + PlaceboNA
DAN 300 mg BID + PlaceboNA

Duration of TI Response

Duration of TI is defined as the number of days from (a) the first day of a 12-week period that satisfies the 12-week TI status definition, to (b) the first RBC transfusion or Hgb level < 8 g/dL (except in the case of clinically overt bleeding). (NCT04173494)
Timeframe: Up to a maximum of 151 weeks

InterventionDays (Median)
MMB 200 mg QD + PlaceboNA
DAN 300 mg BID + PlaceboNA

Leukemia-free Survival (LFS)

LFS is defined as the interval from first study drug dosing date (or randomization date for participants who did not receive treatment) to any evidence of leukemic transformation and/or death (from any cause). (NCT04173494)
Timeframe: Up to a maximum of 151 weeks

InterventionDays (Median)
MMB 200 mg QD + Placebo624.0
DAN 300 mg BID + PlaceboNA

Mean Cumulative Number of Whole Blood Units Transfused Over 24 Weeks

Cumulative transfusion risk was calculated as the estimated mean cumulative number of whole blood units transfused during the study. (NCT04173494)
Timeframe: Up to Week 24

InterventionWhole blood units (Mean)
MMB 200 mg QD + Placebo6.55
DAN 300 mg BID + Placebo10.86

Number of Baseline TD Participants With TI Status at Week 24

Participants were defined as having TD if they met both of the following requirements in the 8 weeks immediately before the end of Week 24: >= 4 red blood cell or whole blood units were transfused (except in the case of clinically overt bleeding), each in response to a hemoglobin assessment of <= 9.5 g/dL; and there were >= 2 hemoglobin assessments with >= 28 days between the earliest and latest hemoglobin assessments. TI status was defined as not requiring red blood cell transfusion (except in the case of clinically overt bleeding) for >= 12 weeks immediately prior to the end of Week 24, with hemoglobin levels >= 8 g/dL. (NCT04173494)
Timeframe: Week 24

InterventionParticipants (Count of Participants)
MMB 200 mg QD + Placebo9
DAN 300 mg BID + Placebo3

Overall Survival (OS)

Overall survival is defined as the interval from the first study drug dosing date (or randomization date for participants who did not receive treatment) to death from any cause. (NCT04173494)
Timeframe: Up to a maximum of 151 weeks

InterventionDays (Median)
MMB 200 mg QD + Placebo624.0
DAN 300 mg BID + PlaceboNA

Percentage of Participants With <=4 RBC Units Transfused Over 24-weeks

Percentage of participants with <=4 RBC units transfused over 24-weeks were reported. (NCT04173494)
Timeframe: Up to 24 weeks

InterventionPercentage of participants (Number)
MMB 200 mg QD + Placebo55.38
DAN 300 mg BID + Placebo44.62

Percentage of Participants With Transfusion Dependence (TD) Status at Week 24

TD status at Week 24 is defined as requirement of >=4 RBC units in an 8-week period immediately prior to the end of Week 24. (NCT04173494)
Timeframe: Week 24

InterventionPercentage of participants (Number)
MMB 200 mg QD + Placebo15.38
DAN 300 mg BID + Placebo24.62

Percentage of Participants With Transfusion Independence (TI) at Week 24

TI status was defined as not receiving red blood cell (RBC) or whole blood transfusion for >=12 weeks, with no hemoglobin (Hgb) level < 8 grams per deciliter (g/dL) during the same interval. Percentage of participants with TI have been presented. (NCT04173494)
Timeframe: Week 24

InterventionPercentage of Participants (Number)
MMB 200 mg QD + Placebo30.0
DAN 300 mg BID + Placebo20.00

Percentage of Participants With Zero RBC Units Transfused Over 24-Weeks

Percentage of participants with zero RBC units transfused over 24-weeks were reported. (NCT04173494)
Timeframe: Up to 24 weeks

InterventionPercentage of participants (Number)
MMB 200 mg QD + Placebo35.38
DAN 300 mg BID + Placebo16.92

Splenic Response Rate (SRR) of >= 35% at Week 24

Splenic response rate (SRR) is defined as the percentage of participants who have reduction in spleen volume of >=35 % from Baseline at the end of Week 24. Baseline was the last assessment done before or on the day of first dose date. (NCT04173494)
Timeframe: Baseline and Week 24

InterventionPercentage of Participants (Number)
MMB 200 mg QD + Placebo22.31
DAN 300 mg BID + Placebo3.08

Splenic Response Rate (SRR) of >=25% at Week 24

Splenic response rate (SRR) is defined as the percentage of participants who have reduction in spleen volume of >=25% from Baseline at the end of Week 24. Baseline was the last assessment done before or on the day of first dose date. (NCT04173494)
Timeframe: Baseline and Week 24

InterventionPercentage of Participants (Number)
MMB 200 mg QD + Placebo39.23
DAN 300 mg BID + Placebo6.15

Total Symptom Score (TSS) Response Rate at Week 24

Myelofibrosis Symptom Assessment Form (MFSAF) TSS version (v) 4.0 response rate was defined as percentage of participants with a >= 50 percent (%) reduction from Baseline in mean MFSAF TSS over consecutive 28-day period immediately before end of Week 24. TSS response rate was measured using MFSAF v4.0. MFSAF v4.0 comprises 7 domains representing 7 most relevant symptoms of myelofibrosis (MF) identified through existing participant and clinician-based evidence: fatigue,night sweats,pruritus,abdominal discomfort,pain under left ribs,early satietyand bone pain. Participants scored each symptom domain using an 11-point numeric rating scale ranging from 0(absent) to 10(worst imaginable). The MFSAF TSS was calculated as sum of scores of 7 domains for a possible range of scores of 0 to 70, with a higher TSS corresponding to more severe symptoms. A reduction from Baseline corresponded to a lessening of MF symptoms. Baseline was the last assessment done before or on the day of first dose date. (NCT04173494)
Timeframe: Baseline and Week 24

InterventionPercentage of participants (Number)
MMB 200 mg QD + Placebo24.62
DAN 300 mg BID + Placebo9.23

Number of Participants With Serious Adverse Events (SAEs) and Non-serious Adverse Events (Non-SAEs)- From Week 24 to a Maximum of 151 Weeks

An AE is any untoward medical occurrence in a trial participant administered an investigational product(s), a comparator product, or an approved drug regardless of the causal relationship with treatment. An SAE is an AE that Results in death, life threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, results in a congenital anomaly/birth defect or any important medical events as per medical or scientific judgment. Adverse events which were not Serious were considered as Non-Serious adverse events. (NCT04173494)
Timeframe: From Week 24 to a maximum of 151 weeks

,
InterventionParticipants (Count of Participants)
Any non-SAEsAny SAEs
DAN 300 mg BID to MMB 200 mg QD- Open-Label Extended Treatment Period2812
MMB 200 mg QD- Open-Label Extended Treatment Period5730

Number of Participants With Serious Adverse Events (SAEs) and Non-serious Adverse Events (Non-SAEs)- up to Week 24

An adverse event (AE) is any untoward medical occurrence in a trial participant administered an investigational product(s), a comparator product, or an approved drug regardless of the causal relationship with treatment. An SAE is an AE that Results in death, life threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, results in a congenital anomaly/birth defect or any important medical events as per medical or scientific judgment. Adverse events which were not Serious were considered as Non-Serious adverse events. (NCT04173494)
Timeframe: Up to Week 24

,
InterventionParticipants (Count of Participants)
Any non-SAEsAny SAEs
DAN 300 mg BID + Placebo- Randomized Double-Blind Treatment Period5526
MMB 200 mg QD + Placebo- Randomized Double-Blind Treatment Period10845

Percentage of Participants With a Hemoglobin Response

Hemoglobin responses are defined as increases of >= 1, >= 1.5, or >= 2 g/dL from Baseline in Hgb, as measured over a (rolling) period of at least 12 consecutive weeks falling entirely before the end of Week 24. Baseline was the last assessment done before or on the day of first dose date. Data has been reported for percentage of participants who had >= 1, >= 1.5, or >= 2 g/dL increase from Baseline in hemoglobin. (NCT04173494)
Timeframe: Baseline and Week 24

,
InterventionPercentage of participants (Number)
>=1g/dL Increase>=1.5g/dL Increase>=2g/dL Increase
DAN 300 mg BID + Placebo33.8523.0820.00
MMB 200 mg QD + Placebo53.0840.0029.23

DOR

duration of response (DOR) (NCT03909763)
Timeframe: 2 years

Interventionmonths (Mean)
Berberine Plus Danazol9.2

The Count of Participants That Achieved 6-month Sustained Response

6-month sustained response defined as platelet count of 30×10⁹/L or more and at least a doubling of baseline platelet count (partial response (PR)), or a platelet count of 100×10⁹/L or more and the absence of bleeding without rescue medication(complete response (CR)) (NCT03909763)
Timeframe: 6 month

InterventionParticipants (Count of Participants)
Berberine Plus Danazol28

the Count of Participants That Achieved Initial Response

Initial response by day 28. Initial response includes partial response (PLT of 30×10⁹/L or more and at least a doubling of baseline platelet count) and complete response (PLT of 100×10⁹/L or more and the absence of bleeding without rescue medication). (NCT03909763)
Timeframe: 4 weeks

InterventionParticipants (Count of Participants)
Berberine Plus Danazol21

Change in Best Corrected Visual Acuity (BCVA)

Change from baseline score to the week 12 score in the number of letters read on an eye chart in accordance with Early Treatment Diabetic Retinopathy Study (ETDRS) of the Intent to Treat (ITT) population of all treated subjects. A positive number indicates more letters could be read. (NCT01821677)
Timeframe: Determined at Baseline and Week 12

InterventionLetters Correctly Read (Mean)
Low Dose Danazol1.0
High Dose Danazol0.8
Danazol Combined (0.5 mg / BMI and 1.0 mg / BMI Dose)0.9
Placebo2.5

Change in Central Macular Thickness (CMT)

A measured change from baseline to week 12 of central macular thickness of the Intent to Treat population of all treated subjects. A negative difference in Central Macular Thickness constitutes a reduction in retinal thickness. Increase in Central Macular Thickness is caused by diabetic macular edema. A greater negative value indicates a greater reduction in swelling. (NCT01821677)
Timeframe: Determined at Baseline and Week 12

Interventionmicrometers (μm) (Mean)
Low Dose Danazol-6.0
High Dose Danazol-2.8
Danazol Combined (0.5 mg / BMI and 1.0 mg / BMI Dose)-4.4
Placebo-17.5

SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
ethisterone[no description available]high8117beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound;
tertiary alcohol		drug metabolite;
progestin
ethisterone[no description available]high8017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound;
tertiary alcohol		drug metabolite;
progestin
2-(hydroxymethyl)ethisterone[no description available]medium50
2-(hydroxymethyl)ethisterone[no description available]medium51
dehydroepiandrosterone sulfate[no description available]medium12017-oxo steroid;
steroid sulfate		EC 2.7.1.33 (pantothenate kinase) inhibitor;
human metabolite;
mouse metabolite
dehydroepiandrosterone sulfate[no description available]medium12117-oxo steroid;
steroid sulfate		EC 2.7.1.33 (pantothenate kinase) inhibitor;
human metabolite;
mouse metabolite
17-methylestradiol[no description available]medium103-hydroxy steroid
estrone-3-o-sulfamate[no description available]medium20
estrone sulfate[no description available]medium7017-oxo steroid;
steroid sulfate		human metabolite;
mouse metabolite
bupropion[no description available]medium60aromatic ketone;
monochlorobenzenes;
secondary amino compound		antidepressant;
environmental contaminant;
xenobiotic
aminocaproic acid[no description available]medium230amino acid zwitterion;
epsilon-amino acid;
omega-amino fatty acid		antifibrinolytic drug;
hematologic agent;
metabolite
phenytoin[no description available]medium130imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent
tacrine[no description available]medium70acridines;
aromatic amine		EC 3.1.1.7 (acetylcholinesterase) inhibitor
acebutolol[no description available]medium70aromatic amide;
ethanolamines;
ether;
monocarboxylic acid amide;
propanolamine;
secondary amino compound		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympathomimetic agent
acetaminophen[no description available]high150acetamides;
phenols		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
acetohydroxamic acid[no description available]medium40acetohydroxamic acids;
carbohydroximic acid		algal metabolite;
EC 3.5.1.5 (urease) inhibitor
albuterol[no description available]medium100phenols;
phenylethanolamines;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
environmental contaminant;
xenobiotic
alendronate[no description available]medium401,1-bis(phosphonic acid);
primary amino compound		bone density conservation agent;
EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor
alprazolam[no description available]medium30organochlorine compound;
triazolobenzodiazepine		anticonvulsant;
anxiolytic drug;
GABA agonist;
muscle relaxant;
sedative;
xenobiotic
altretamine[no description available]medium60triamino-1,3,5-triazine
amantadine[no description available]medium50adamantanes;
primary aliphatic amine		analgesic;
antiparkinson drug;
antiviral drug;
dopaminergic agent;
NMDA receptor antagonist;
non-narcotic analgesic
amifostine anhydrous[no description available]medium40diamine;
organic thiophosphate		antioxidant;
prodrug;
radiation protective agent
aminoglutethimide[no description available]medium390dicarboximide;
piperidones;
substituted aniline		adrenergic agent;
anticonvulsant;
antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
aminoglutethimide[no description available]medium398dicarboximide;
piperidones;
substituted aniline		adrenergic agent;
anticonvulsant;
antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
theophylline[no description available]medium120dimethylxanthineadenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent
amiodarone[no description available]medium1501-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound		cardiovascular drug
amiodarone[no description available]medium1511-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound		cardiovascular drug
amitriptyline[no description available]medium60carbotricyclic compound;
tertiary amine		adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
tropomyosin-related kinase B receptor agonist;
xenobiotic
amlexanox[no description available]medium20monocarboxylic acid;
pyridochromene		anti-allergic agent;
anti-ulcer drug;
non-steroidal anti-inflammatory drug
amlodipine[no description available]medium80dihydropyridine;
ethyl ester;
methyl ester;
monochlorobenzenes;
primary amino compound		antihypertensive agent;
calcium channel blocker;
vasodilator agent
amoxapine[no description available]medium80dibenzooxazepineadrenergic uptake inhibitor;
antidepressant;
dopaminergic antagonist;
geroprotector;
serotonin uptake inhibitor
anastrozole[no description available]medium50nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
apraclonidine[no description available]medium10dichlorobenzene;
guanidines;
imidazolines		alpha-adrenergic agonist;
antiglaucoma drug;
beta-adrenergic agonist;
diagnostic agent;
ophthalmology drug
aspirin[no description available]high150benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
astemizole[no description available]medium70benzimidazoles;
piperidines		anti-allergic agent;
anticoronaviral agent;
H1-receptor antagonist
atenolol[no description available]medium110ethanolamines;
monocarboxylic acid amide;
propanolamine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
sympatholytic agent;
xenobiotic
azathioprine[no description available]medium230aryl sulfide;
C-nitro compound;
imidazoles;
thiopurine		antimetabolite;
antineoplastic agent;
carcinogenic agent;
DNA synthesis inhibitor;
hepatotoxic agent;
immunosuppressive agent;
prodrug
azathioprine[no description available]medium232aryl sulfide;
C-nitro compound;
imidazoles;
thiopurine		antimetabolite;
antineoplastic agent;
carcinogenic agent;
DNA synthesis inhibitor;
hepatotoxic agent;
immunosuppressive agent;
prodrug
azelaic acid[no description available]medium20alpha,omega-dicarboxylic acid;
dicarboxylic fatty acid		antibacterial agent;
antineoplastic agent;
dermatologic drug;
plant metabolite
azelastine[no description available]medium10monochlorobenzenes;
phthalazines;
tertiary amino compound		anti-allergic agent;
anti-asthmatic drug;
bronchodilator agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
H1-receptor antagonist;
platelet aggregation inhibitor
baclofen[no description available]medium60amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid;
monochlorobenzenes;
primary amino compound		central nervous system depressant;
GABA agonist;
muscle relaxant
bepridil[no description available]medium50pyrrolidines;
tertiary amine		anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent
betaxolol[no description available]medium40propanolamineantihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
bicalutamide[no description available]medium80(trifluoromethyl)benzenes;
monocarboxylic acid amide;
monofluorobenzenes;
nitrile;
sulfone;
tertiary alcohol
bisoprolol[no description available]medium60secondary alcohol;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
brimonidine[no description available]medium30imidazoles;
quinoxaline derivative;
secondary amine		adrenergic agonist;
alpha-adrenergic agonist;
antihypertensive agent
bumetanide[no description available]medium100amino acid;
benzoic acids;
sulfonamide		diuretic;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
buspirone[no description available]medium90azaspiro compound;
N-alkylpiperazine;
N-arylpiperazine;
organic heteropolycyclic compound;
piperidones;
pyrimidines		anxiolytic drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
sedative;
serotonergic agonist
busulfan[no description available]medium110methanesulfonate esteralkylating agent;
antineoplastic agent;
carcinogenic agent;
insect sterilant;
teratogenic agent
busulfan[no description available]medium111methanesulfonate esteralkylating agent;
antineoplastic agent;
carcinogenic agent;
insect sterilant;
teratogenic agent
butenafine[no description available]medium10naphthalenes;
tertiary amine		antifungal drug;
EC 1.14.13.132 (squalene monooxygenase) inhibitor
verapamil[no description available]medium110aromatic ether;
nitrile;
polyether;
tertiary amino compound
carbamazepine[no description available]medium180dibenzoazepine;
ureas		analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic
carmustine[no description available]medium90N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
carteolol[no description available]medium40quinolone;
secondary alcohol		anti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
carvedilol[no description available]medium50carbazoles;
secondary alcohol;
secondary amino compound		alpha-adrenergic antagonist;
antihypertensive agent;
beta-adrenergic antagonist;
cardiovascular drug;
vasodilator agent
cetirizine[no description available]medium40ether;
monocarboxylic acid;
monochlorobenzenes;
piperazines		anti-allergic agent;
environmental contaminant;
H1-receptor antagonist;
xenobiotic
chlormezanone[no description available]medium501,3-thiazine;
lactam;
monochlorobenzenes;
sulfone		antipsychotic agent;
anxiolytic drug;
muscle relaxant
ciclopirox[no description available]medium40cyclic hydroxamic acid;
hydroxypyridone antifungal drug;
pyridone		antibacterial agent;
antiseborrheic
cinoxacin[no description available]medium40cinnolines;
oxacycle;
oxo carboxylic acid		antibacterial drug;
antiinfective agent
ciprofloxacin[no description available]medium80aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
cisapride[no description available]medium70benzamides
clofazimine[no description available]medium40monochlorobenzenes;
phenazines		dye;
leprostatic drug;
non-steroidal anti-inflammatory drug
clomipramine[no description available]medium70dibenzoazepineanticoronaviral agent;
antidepressant;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
serotonergic antagonist;
serotonergic drug;
serotonin uptake inhibitor
clonidine[no description available]medium70clonidine;
imidazoline
chlorazepate[no description available]medium301,4-benzodiazepinoneanticonvulsant;
anxiolytic drug;
GABA modulator;
prodrug
cyclobenzaprine[no description available]medium40carbotricyclic compoundantidepressant;
muscle relaxant;
tranquilizing drug
diazepam[no description available]medium1001,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
diclofenac[no description available]medium110amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
diflunisal[no description available]medium70monohydroxybenzoic acid;
organofluorine compound		non-narcotic analgesic;
non-steroidal anti-inflammatory drug
dipivefrin[no description available]medium10ethanolamines;
pivalate ester		adrenergic agonist;
antiglaucoma drug;
ophthalmology drug;
prodrug;
sympathomimetic agent
disopyramide[no description available]medium60monocarboxylic acid amide;
pyridines;
tertiary amino compound		anti-arrhythmia drug
disulfiram[no description available]medium110organic disulfide;
organosulfur acaricide		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
EC 3.1.1.1 (carboxylesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
ferroptosis inducer;
fungicide;
NF-kappaB inhibitor
valproic acid[no description available]medium100branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent
doxazosin[no description available]medium20aromatic amine;
benzodioxine;
monocarboxylic acid amide;
N-acylpiperazine;
N-arylpiperazine;
quinazolines		alpha-adrenergic antagonist;
antihyperplasia drug;
antihypertensive agent;
antineoplastic agent;
vasodilator agent
doxepin[no description available]medium40dibenzooxepine;
tertiary amino compound		antidepressant
droperidol[no description available]medium60aromatic ketone;
benzimidazoles;
organofluorine compound		anaesthesia adjuvant;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic
econazole[no description available]medium40dichlorobenzene;
ether;
imidazoles;
monochlorobenzenes
enflurane[no description available]medium20ether;
organochlorine compound;
organofluorine compound		anaesthetic
enoxacin[no description available]medium301,8-naphthyridine derivative;
amino acid;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-arylpiperazine;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor
estazolam[no description available]medium30triazoles;
triazolobenzodiazepine		anticonvulsant;
anxiolytic drug;
GABA modulator
etidronate[no description available]medium601,1-bis(phosphonic acid)antineoplastic agent;
bone density conservation agent;
chelator
etodolac[no description available]medium50monocarboxylic acid;
organic heterotricyclic compound		antipyretic;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
brl 42810[no description available]medium402-aminopurines;
acetate ester		antiviral drug;
prodrug
felbamate[no description available]medium90carbamate esteranticonvulsant;
neuroprotective agent
felodipine[no description available]medium120dichlorobenzene;
dihydropyridine;
ethyl ester;
methyl ester		anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent
fenfluramine[no description available]medium10(trifluoromethyl)benzenes;
secondary amino compound		appetite depressant;
serotonergic agonist;
serotonin uptake inhibitor
fentanyl[no description available]medium30anilide;
monocarboxylic acid amide;
piperidines		adjuvant;
anaesthesia adjuvant;
anaesthetic;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic
fexofenadine[no description available]medium50piperidines;
tertiary amine		anti-allergic agent;
H1-receptor antagonist
flecainide[no description available]medium60aromatic ether;
monocarboxylic acid amide;
organofluorine compound;
piperidines		anti-arrhythmia drug
fluconazole[no description available]medium90conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug		environmental contaminant;
P450 inhibitor;
xenobiotic
flucytosine[no description available]medium70aminopyrimidine;
nucleoside analogue;
organofluorine compound;
pyrimidine antifungal drug;
pyrimidone		prodrug
fluphenazine[no description available]medium50N-alkylpiperazine;
organofluorine compound;
phenothiazines		anticoronaviral agent;
dopaminergic antagonist;
phenothiazine antipsychotic drug
flumazenil[no description available]medium100ethyl ester;
imidazobenzodiazepine;
organofluorine compound		antidote to benzodiazepine poisoning;
GABA antagonist
fluorouracil[no description available]medium110nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
fluoxetine[no description available]medium110(trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound
fluphenazine depot[no description available]medium10decanoate ester;
N-alkylpiperazine;
organofluorine compound;
phenothiazines		dopaminergic antagonist;
phenothiazine antipsychotic drug;
prodrug
fluphenazine enanthate[no description available]medium10phenothiazines
flurbiprofen[no description available]medium90fluorobiphenyl;
monocarboxylic acid		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
flutamide[no description available]medium190(trifluoromethyl)benzenes;
monocarboxylic acid amide		androgen antagonist;
antineoplastic agent
foscarnet[no description available]medium40carboxylic acid;
one-carbon compound;
phosphonic acids		antiviral drug;
geroprotector;
HIV-1 reverse transcriptase inhibitor;
sodium-dependent Pi-transporter inhibitor
furosemide[no description available]medium170chlorobenzoic acid;
furans;
sulfonamide		environmental contaminant;
loop diuretic;
xenobiotic
gabapentin[no description available]medium80gamma-amino acidanticonvulsant;
calcium channel blocker;
environmental contaminant;
xenobiotic
gemfibrozil[no description available]medium80aromatic etherantilipemic drug
glimepiride[no description available]medium90sulfonamide
glipizide[no description available]medium40aromatic amide;
monocarboxylic acid amide;
N-sulfonylurea;
pyrazines		EC 2.7.1.33 (pantothenate kinase) inhibitor;
hypoglycemic agent;
insulin secretagogue
glyburide[no description available]medium100monochlorobenzenes;
N-sulfonylurea		anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent
granisetron[no description available]medium20aromatic amide;
indazoles
guanfacine[no description available]medium30acetamides
haloperidol[no description available]medium100aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
halothane[no description available]medium30haloalkane;
organobromine compound;
organochlorine compound;
organofluorine compound		inhalation anaesthetic
hydrochlorothiazide[no description available]medium130benzothiadiazine;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic
hydroxyurea[no description available]medium130one-carbon compound;
ureas		antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent
hydroxyurea[no description available]medium131one-carbon compound;
ureas		antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent
hydroxyzine[no description available]medium80hydroxyether;
monochlorobenzenes;
N-alkylpiperazine		anticoronaviral agent;
antipruritic drug;
anxiolytic drug;
dermatologic drug;
H1-receptor antagonist
ibuprofen[no description available]high140monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic
phenelzine[no description available]medium90primary amine
ifosfamide[no description available]medium70ifosfamidesalkylating agent;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
xenobiotic
amrinone[no description available]medium90bipyridinesEC 3.1.4.* (phosphoric diester hydrolase) inhibitor
indapamide[no description available]medium70indoles;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic
indomethacin[no description available]medium180aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
iodixanol[no description available]medium10organoiodine compoundradioopaque medium
iohexol[no description available]medium30benzenedicarboxamide;
organoiodine compound		environmental contaminant;
radioopaque medium;
xenobiotic
iopromide[no description available]medium10dicarboxylic acid diamide;
organoiodine compound		environmental contaminant;
nephrotoxic agent;
radioopaque medium;
xenobiotic
ioversol[no description available]medium20amidobenzoic acid
isoflurane[no description available]medium20organofluorine compoundinhalation anaesthetic
isoniazid[no description available]medium100carbohydrazideantitubercular agent;
drug allergen
isradipine[no description available]medium50benzoxadiazole;
dihydropyridine;
isopropyl ester;
methyl ester
itraconazole[no description available]medium50piperazines
ketoconazole[no description available]medium180dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine
ketoprofen[no description available]medium110benzophenones;
oxo monocarboxylic acid		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
ketorolac[no description available]medium40amino acid;
aromatic ketone;
monocarboxylic acid;
pyrrolizines;
racemate		analgesic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
labetalol[no description available]medium120benzamides;
benzenes;
phenols;
primary carboxamide;
salicylamides;
secondary alcohol;
secondary amino compound
lamotrigine[no description available]medium601,2,4-triazines;
dichlorobenzene;
primary arylamine		anticonvulsant;
antidepressant;
antimanic drug;
calcium channel blocker;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
excitatory amino acid antagonist;
geroprotector;
non-narcotic analgesic;
xenobiotic
lansoprazole[no description available]medium80benzimidazoles;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
lomefloxacin[no description available]medium20fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antimicrobial agent;
antitubercular agent;
photosensitizing agent
loratadine[no description available]high70benzocycloheptapyridine;
ethyl ester;
N-acylpiperidine;
organochlorine compound;
tertiary carboxamide		anti-allergic agent;
cholinergic antagonist;
geroprotector;
H1-receptor antagonist
losartan[no description available]medium80biphenylyltetrazole;
imidazoles		angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist
loxapine[no description available]medium20dibenzooxazepineantipsychotic agent;
dopaminergic antagonist
maprotiline[no description available]medium80anthracenes
mebendazole[no description available]medium70aromatic ketone;
benzimidazoles;
carbamate ester		antinematodal drug;
microtubule-destabilising agent;
tubulin modulator
meclofenamic acid[no description available]medium30aminobenzoic acid;
organochlorine compound;
secondary amino compound		analgesic;
anticonvulsant;
antineoplastic agent;
antipyretic;
antirheumatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
mefenamic acid[no description available]medium180aminobenzoic acid;
secondary amino compound		analgesic;
antipyretic;
antirheumatic drug;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
mefenamic acid[no description available]medium183aminobenzoic acid;
secondary amino compound		analgesic;
antipyretic;
antirheumatic drug;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
mefloquine hydrochloride[no description available]medium20organofluorine compound;
piperidines;
quinolines;
secondary alcohol
mesalamine[no description available]medium40amino acid;
aromatic amine;
monocarboxylic acid;
monohydroxybenzoic acid;
phenols		non-steroidal anti-inflammatory drug
metformin[no description available]medium70guanidinesenvironmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic
metoclopramide[no description available]medium70benzamides;
monochlorobenzenes;
substituted aniline;
tertiary amino compound		antiemetic;
dopaminergic antagonist;
environmental contaminant;
gastrointestinal drug;
xenobiotic
metoprolol[no description available]high80aromatic ether;
propanolamine;
secondary alcohol;
secondary amino compound		antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
geroprotector;
xenobiotic
metronidazole[no description available]medium100C-nitro compound;
imidazoles;
primary alcohol		antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic
mexiletine[no description available]medium60aromatic ether;
primary amino compound		anti-arrhythmia drug
midazolam[no description available]medium60imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound		anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative
midodrine[no description available]medium30amino acid amide;
aromatic ether;
secondary alcohol		alpha-adrenergic agonist;
prodrug;
sympathomimetic agent;
vasoconstrictor agent
minoxidil[no description available]medium110dialkylarylamine;
tertiary amino compound
mirtazapine[no description available]medium40benzazepine;
tetracyclic antidepressant		alpha-adrenergic antagonist;
anxiolytic drug;
H1-receptor antagonist;
histamine antagonist;
oneirogen;
serotonergic antagonist
mitoxantrone[no description available]medium90dihydroxyanthraquinoneanalgesic;
antineoplastic agent
mitoxantrone[no description available]medium91dihydroxyanthraquinoneanalgesic;
antineoplastic agent
nabumetone[no description available]medium40methoxynaphthalene;
methyl ketone		cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug
nefazodone[no description available]medium100aromatic ether;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazoles		alpha-adrenergic antagonist;
analgesic;
antidepressant;
serotonergic antagonist;
serotonin uptake inhibitor
nevirapine[no description available]medium90cyclopropanes;
dipyridodiazepine		antiviral drug;
HIV-1 reverse transcriptase inhibitor
nicardipine[no description available]medium60benzenes;
C-nitro compound;
diester;
dihydropyridine;
methyl ester;
tertiary amino compound
nifedipine[no description available]medium180C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent
nilutamide[no description available]medium50(trifluoromethyl)benzenes;
C-nitro compound;
imidazolidinone		androgen antagonist;
antineoplastic agent
nimodipine[no description available]medium1002-methoxyethyl ester;
C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
isopropyl ester		antihypertensive agent;
calcium channel blocker;
cardiovascular drug;
vasodilator agent
nisoldipine[no description available]medium80C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
methyl ester
nizatidine[no description available]medium401,3-thiazoles;
C-nitro compound;
carboxamidine;
organic sulfide;
tertiary amino compound		anti-ulcer drug;
cholinergic drug;
H2-receptor antagonist
masoprocol[no description available]medium40catechols;
lignan;
tetrol		antioxidant;
ferroptosis inhibitor;
geroprotector;
plant metabolite
norfloxacin[no description available]medium50fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug;
DNA synthesis inhibitor;
environmental contaminant;
xenobiotic
nortriptyline[no description available]medium70organic tricyclic compound;
secondary amine		adrenergic uptake inhibitor;
analgesic;
antidepressant;
antineoplastic agent;
apoptosis inducer;
drug metabolite
ofloxacin[no description available]medium703-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline
omeprazole[no description available]medium80aromatic ether;
benzimidazoles;
pyridines;
sulfoxide
ondansetron[no description available]medium50carbazoles
oxaprozin[no description available]medium801,3-oxazoles;
monocarboxylic acid		analgesic;
non-steroidal anti-inflammatory drug
pamidronate[no description available]medium60phosphonoacetic acid
pemoline[no description available]medium701,3-oxazolescentral nervous system stimulant
pentamidine[no description available]medium70aromatic ether;
carboxamidine;
diether		anti-inflammatory agent;
antifungal agent;
calmodulin antagonist;
chemokine receptor 5 antagonist;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
NMDA receptor antagonist;
S100 calcium-binding protein B inhibitor;
trypanocidal drug;
xenobiotic
pentoxifylline[no description available]medium70oxopurine
pentoxifylline[no description available]medium71oxopurine
perphenazine[no description available]medium90N-(2-hydroxyethyl)piperazine;
N-alkylpiperazine;
organochlorine compound;
phenothiazines		antiemetic;
dopaminergic antagonist;
phenothiazine antipsychotic drug
pindolol[no description available]medium80indoles;
secondary amine		antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist;
serotonergic antagonist;
vasodilator agent
pirbuterol[no description available]medium10pyridines
prazepam[no description available]medium10benzodiazepine
praziquantel[no description available]medium90isoquinolines
prazosin[no description available]medium80aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
primidone[no description available]medium90pyrimidoneanticonvulsant;
environmental contaminant;
xenobiotic
probenecid[no description available]medium90benzoic acids;
sulfonamide		uricosuric drug
procainamide[no description available]medium60benzamidesanti-arrhythmia drug;
platelet aggregation inhibitor;
sodium channel blocker
procarbazine[no description available]medium70benzamides;
hydrazines		antineoplastic agent
propafenone[no description available]medium40aromatic ketone;
secondary alcohol;
secondary amino compound		anti-arrhythmia drug
propofol[no description available]medium70phenolsanticonvulsant;
antiemetic;
intravenous anaesthetic;
radical scavenger;
sedative
sch 16134[no description available]medium20benzodiazepine
ranitidine[no description available]medium110aralkylamine
riluzole[no description available]medium90benzothiazoles
rimantadine[no description available]medium20alkylamine
risperidone[no description available]medium901,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
psychotropic drug;
second generation antipsychotic;
serotonergic antagonist
salmeterol xinafoate[no description available]medium20ether;
phenols;
primary alcohol;
secondary alcohol;
secondary amino compound
sevoflurane[no description available]medium20ether;
organofluorine compound		central nervous system depressant;
inhalation anaesthetic;
platelet aggregation inhibitor
sulfadiazine[no description available]medium60pyrimidines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
antimicrobial agent;
antiprotozoal drug;
coccidiostat;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
xenobiotic
sotalol[no description available]medium60ethanolamines;
secondary alcohol;
secondary amino compound;
sulfonamide		anti-arrhythmia drug;
beta-adrenergic antagonist;
environmental contaminant;
xenobiotic
sulconazole[no description available]medium10dichlorobenzene;
imidazoles;
monochlorobenzenes;
organic sulfide
sulfasalazine[no description available]medium120
sulfasalazine[no description available]medium121
sumatriptan[no description available]medium60sulfonamide;
tryptamines		serotonergic agonist;
vasoconstrictor agent
suprofen[no description available]medium20aromatic ketone;
monocarboxylic acid;
thiophenes		antirheumatic drug;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug
tazarotene[no description available]medium20acetylenic compound;
ethyl ester;
pyridines;
retinoid;
thiochromane		keratolytic drug;
prodrug;
teratogenic agent
temazepam[no description available]medium30benzodiazepine
terazosin[no description available]medium40furans;
piperazines;
primary amino compound;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent
terfenadine[no description available]medium110diarylmethane
thioridazine[no description available]medium60phenothiazines;
piperidines		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
thiotepa[no description available]medium50aziridines
ticlopidine[no description available]medium100monochlorobenzenes;
thienopyridine		anticoagulant;
fibrin modulating drug;
hematologic agent;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
tioconazole[no description available]medium10dichlorobenzene;
ether;
imidazoles;
thiophenes
tiopronin[no description available]medium30N-acyl-amino acid
tizanidine[no description available]medium40benzothiadiazole;
imidazoles		alpha-adrenergic agonist;
muscle relaxant
ultram[no description available]medium30aromatic ether;
tertiary alcohol;
tertiary amino compound
trazodone[no description available]medium60monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazolopyridine		adrenergic antagonist;
antidepressant;
anxiolytic drug;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor
triazolam[no description available]medium30triazolobenzodiazepinesedative
trientine[no description available]medium10polyazaalkane;
tetramine		copper chelator
trifluoperazine[no description available]medium80N-alkylpiperazine;
N-methylpiperazine;
organofluorine compound;
phenothiazines		antiemetic;
calmodulin antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor;
phenothiazine antipsychotic drug
trimethadione[no description available]medium70oxazolidinoneanticonvulsant;
geroprotector
trimetrexate[no description available]medium30
trimipramine[no description available]medium20dibenzoazepine;
tertiary amino compound		antidepressant;
environmental contaminant;
xenobiotic
venlafaxine[no description available]medium70cyclohexanols;
monomethoxybenzene;
tertiary alcohol;
tertiary amino compound		adrenergic uptake inhibitor;
analgesic;
antidepressant;
dopamine uptake inhibitor;
environmental contaminant;
serotonin uptake inhibitor;
xenobiotic
ici 204,219[no description available]medium90carbamate ester;
indoles;
N-sulfonylcarboxamide		anti-asthmatic agent;
leukotriene antagonist
zolpidem[no description available]medium60imidazopyridinecentral nervous system depressant;
GABA agonist;
sedative
zomepirac[no description available]medium40aromatic ketone;
monocarboxylic acid;
monochlorobenzenes;
pyrroles		cardiovascular drug;
non-steroidal anti-inflammatory drug
floxuridine[no description available]medium60nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
radiosensitizing agent
spironolactone[no description available]medium1403-oxo-Delta(4) steroid;
oxaspiro compound;
steroid lactone;
thioester		aldosterone antagonist;
antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic
penicillamine[no description available]medium120non-proteinogenic alpha-amino acid;
penicillamine		antirheumatic drug;
chelator;
copper chelator;
drug allergen
prednisone[no description available]medium43011-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug
prednisone[no description available]medium43411-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug
pilocarpine[no description available]medium50pilocarpineantiglaucoma drug
vincristine[no description available]medium50acetate ester;
formamides;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid		antineoplastic agent;
drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
testosterone propionate[no description available]medium20steroid ester
bretylium tosylate[no description available]medium30organosulfonate salt;
quaternary ammonium salt		adrenergic antagonist;
anti-arrhythmia drug;
antihypertensive agent
cytarabine[no description available]medium190beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent
cytarabine[no description available]medium193beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent
trifluridine[no description available]medium30nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
EC 2.1.1.45 (thymidylate synthase) inhibitor
medroxyprogesterone acetate[no description available]medium60020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
corticosteroid;
steroid ester		adjuvant;
androgen;
antineoplastic agent;
antioxidant;
female contraceptive drug;
inhibitor;
progestin;
synthetic oral contraceptive
medroxyprogesterone acetate[no description available]medium60920-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
corticosteroid;
steroid ester		adjuvant;
androgen;
antineoplastic agent;
antioxidant;
female contraceptive drug;
inhibitor;
progestin;
synthetic oral contraceptive
mestranol[no description available]high10217beta-hydroxy steroid;
aromatic ether;
terminal acetylenic compound		prodrug;
xenoestrogen
mestranol[no description available]high10017beta-hydroxy steroid;
aromatic ether;
terminal acetylenic compound		prodrug;
xenoestrogen
methylprednisolone[no description available]medium2006-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic
methylprednisolone[no description available]medium2036-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic
estradiol dipropionate[no description available]medium10steroid ester
nafcillin[no description available]medium20penicillin allergen;
penicillin		antibacterial drug
methohexital[no description available]medium20acetylenic compound;
barbiturates		drug allergen;
intravenous anaesthetic
estradiol 17 beta-cypionate[no description available]medium10steroid ester
testosterone enanthate[no description available]medium90heptanoate ester;
sterol ester		androgen
betamethasone[no description available]medium11011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-asthmatic agent;
anti-inflammatory drug;
immunosuppressive agent
chenodeoxycholic acid[no description available]medium60bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite
podophyllotoxin[no description available]medium40furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
levocarnitine[no description available]medium30carnitineantilipemic drug;
nootropic agent;
nutraceutical;
Saccharomyces cerevisiae metabolite;
water-soluble vitamin (role)
megestrol acetate[no description available]medium6020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
steroid ester		antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive
acetylcysteine[no description available]medium60acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
erythromycin[no description available]medium130cyclic ketone;
erythromycin
erythromycin[no description available]medium131cyclic ketone;
erythromycin
levonorgestrel[no description available]high38217beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound		contraceptive drug;
female contraceptive drug;
progestin;
synthetic oral contraceptive
levonorgestrel[no description available]high38017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound		contraceptive drug;
female contraceptive drug;
progestin;
synthetic oral contraceptive
estradiol valerate[no description available]medium20steroid ester
ethambutol[no description available]medium40ethanolamines;
ethylenediamine derivative		antitubercular agent;
environmental contaminant;
xenobiotic
dronabinol[no description available]medium30benzochromene;
diterpenoid;
phytocannabinoid;
polyketide		cannabinoid receptor agonist;
epitope;
hallucinogen;
metabolite;
non-narcotic analgesic
pimozide[no description available]medium90benzimidazoles;
heteroarylpiperidine;
organofluorine compound		antidyskinesia agent;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
betamethasone valerate[no description available]medium1011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
primary alpha-hydroxy ketone;
steroid ester		anti-inflammatory drug
methylprednisolone hemisuccinate[no description available]medium20corticosteroid hormone;
hemisuccinate
stavudine[no description available]medium80dihydrofuran;
nucleoside analogue;
organic molecular entity		antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
cyclacillin[no description available]medium10penicillinantibacterial drug
tranylcypromine[no description available]medium202-phenylcyclopropan-1-amine
cladribine[no description available]medium60organochlorine compound;
purine 2'-deoxyribonucleoside		antineoplastic agent;
immunosuppressive agent
beclomethasone[no description available]medium8011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
corticosteroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-asthmatic drug;
anti-inflammatory drug
estradiol enanthate[no description available]medium10steroid ester
betamethasone-17,21-dipropionate[no description available]medium1011beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
propanoate ester;
steroid ester		antipsoriatic
olsalazine[no description available]medium40azobenzenes;
dicarboxylic acid		non-steroidal anti-inflammatory drug;
prodrug
zalcitabine[no description available]medium80pyrimidine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
selegiline[no description available]high60selegiline;
terminal acetylenic compound		geroprotector
levamisole[no description available]medium706-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazoleantinematodal drug;
antirheumatic drug;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
immunological adjuvant;
immunomodulator
cephalexin[no description available]medium40beta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative		antibacterial drug
isosorbide-5-mononitrate[no description available]medium30glucitol derivative;
nitrate ester		nitric oxide donor;
vasodilator agent
daunorubicin[no description available]medium60aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones		antineoplastic agent;
bacterial metabolite
cephapirin[no description available]medium20cephalosporinantibacterial drug
bromocriptine[no description available]medium390indole alkaloidantidyskinesia agent;
antiparkinson drug;
dopamine agonist;
hormone antagonist
bromocriptine[no description available]medium396indole alkaloidantidyskinesia agent;
antiparkinson drug;
dopamine agonist;
hormone antagonist
ursodeoxycholic acid[no description available]medium70bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite
metipranolol[no description available]medium10acetate ester;
aromatic ether;
propanolamine;
secondary amino compound		anti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist
halazepam[no description available]medium20organic molecular entity
du-21220[no description available]medium10benzyl alcohols;
polyphenol;
secondary alcohol;
secondary amino compound
cefazolin[no description available]medium40beta-lactam antibiotic allergen;
cephalosporin;
tetrazoles;
thiadiazoles		antibacterial drug
amoxicillin[no description available]medium120penicillin allergen;
penicillin		antibacterial drug
timolol[no description available]medium80timololanti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist
moricizine[no description available]medium20carbamate ester;
morpholines;
phenothiazines		anti-arrhythmia drug
bitolterol[no description available]medium10carboxylic ester;
diester;
ethanolamines;
secondary alcohol;
secondary amino compound		anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
prodrug
zidovudine[no description available]medium150azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
zidovudine[no description available]medium151azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
tobramycin[no description available]medium60amino cyclitol glycosideantibacterial agent;
antimicrobial agent;
toxin
paclitaxel[no description available]medium100taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
etoposide[no description available]medium150beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
dobutamine[no description available]medium70catecholamine;
secondary amine		beta-adrenergic agonist;
cardiotonic drug;
sympathomimetic agent
penbutolol[no description available]medium30ethanolamines
ribavirin[no description available]medium1201-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide		anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
guanadrel[no description available]medium10guanidines;
spiroketal		adrenergic antagonist;
antihypertensive agent
methyldopa[no description available]medium120L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		alpha-adrenergic agonist;
antihypertensive agent;
hapten;
peripheral nervous system drug;
sympatholytic agent
tocainide[no description available]medium30monocarboxylic acid amideanti-arrhythmia drug;
local anaesthetic;
sodium channel blocker
sq-11725[no description available]medium80
diltiazem[no description available]medium805-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetateantihypertensive agent;
calcium channel blocker;
vasodilator agent
levobunolol[no description available]medium10aromatic ether;
cyclic ketone;
propanolamine		antiglaucoma drug;
beta-adrenergic antagonist
vecuronium bromide[no description available]medium20organic bromide salt;
quaternary ammonium salt		muscle relaxant;
neuromuscular agent;
nicotinic antagonist
permethrin[no description available]medium40cyclopropanecarboxylate ester;
cyclopropanes		agrochemical;
ectoparasiticide;
pyrethroid ester acaricide;
pyrethroid ester insecticide;
scabicide
sufentanil[no description available]medium20anilide;
ether;
piperidines;
thiophenes		anaesthesia adjuvant;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic
torsemide[no description available]medium40aminopyridine;
N-sulfonylurea;
secondary amino compound		antihypertensive agent;
loop diuretic
cefmetazole[no description available]medium10cephalosporinantibacterial drug
desflurane[no description available]medium20organofluorine compoundinhalation anaesthetic
idarubicin[no description available]medium60anthracycline antibiotic;
deoxy hexoside;
monosaccharide derivative
idarubicin[no description available]medium61anthracycline antibiotic;
deoxy hexoside;
monosaccharide derivative
cefonicid[no description available]medium20cephalosporinantibacterial drug
piperacillin[no description available]medium50penicillin allergen;
penicillin		antibacterial drug
paroxetine[no description available]medium80aromatic ether;
benzodioxoles;
organofluorine compound;
piperidines		antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor
captopril[no description available]medium100alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
cefoperazone[no description available]medium40cephalosporinantibacterial drug
lodoxamide[no description available]medium10organonitrogen compound;
organooxygen compound
atracurium[no description available]medium30diester;
quaternary ammonium ion		muscle relaxant;
nicotinic antagonist
butoconazole[no description available]medium10aryl sulfide;
conazole antifungal drug;
dichlorobenzene;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes
naftifine[no description available]medium10allylamine antifungal drug;
naphthalenes;
tertiary amine		EC 1.14.13.132 (squalene monooxygenase) inhibitor;
sterol biosynthesis inhibitor
pergolide[no description available]medium20diamine;
methyl sulfide;
organic heterotetracyclic compound		antiparkinson drug;
dopamine agonist
cefadroxil anhydrous[no description available]medium60cephalosporinantibacterial drug
encainide[no description available]medium20benzamides;
piperidines		anti-arrhythmia drug;
sodium channel blocker
nedocromil[no description available]medium20dicarboxylic acid;
organic heterotricyclic compound		anti-allergic agent;
anti-asthmatic drug;
non-steroidal anti-inflammatory drug
cefaclor anhydrous[no description available]medium60cephalosporinantibacterial drug;
drug allergen
alfentanil[no description available]medium50monocarboxylic acid amide;
piperidines		central nervous system depressant;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
peripheral nervous system drug
cefotetan[no description available]medium60
lovastatin[no description available]medium120delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug
levocabastine[no description available]medium10piperidines
simvastatin[no description available]high120delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic)		EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug
pravastatin[no description available]medium603-hydroxy carboxylic acid;
carbobicyclic compound;
carboxylic ester;
hydroxy monocarboxylic acid;
secondary alcohol;
statin (semi-synthetic)		anticholesteremic drug;
environmental contaminant;
metabolite;
xenobiotic
cabergoline[no description available]medium40N-acylureaantineoplastic agent;
antiparkinson drug;
dopamine agonist
quinapril[no description available]medium90dicarboxylic acid monoester;
ethyl ester;
isoquinolines;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
fosphenytoin[no description available]medium20imidazolidine-2,4-dione
finasteride[no description available]medium603-oxo steroid;
aza-steroid;
delta-lactam		androgen antagonist;
antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
esmolol[no description available]medium30aromatic ether;
ethanolamines;
methyl ester;
secondary alcohol;
secondary amino compound
adapalene[no description available]medium20adamantanes;
monocarboxylic acid;
naphthoic acid		dermatologic drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
non-steroidal anti-inflammatory drug
sparfloxacin[no description available]medium30fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone
zileuton[no description available]medium901-benzothiophenes;
ureas		anti-asthmatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor;
leukotriene antagonist;
non-steroidal anti-inflammatory drug
cidofovir anhydrous[no description available]medium40phosphonic acids;
pyrimidone		anti-HIV agent;
antineoplastic agent;
antiviral drug;
photosensitizing agent
topotecan[no description available]medium20pyranoindolizinoquinolineantineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
gemcitabine[no description available]medium20organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
ibutilide[no description available]medium20benzenes;
organic amino compound
remifentanil[no description available]medium20alpha-amino acid ester;
anilide;
monocarboxylic acid amide;
piperidinecarboxylate ester		intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
sedative
atorvastatin[no description available]medium40aromatic amide;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrroles;
statin (synthetic)		environmental contaminant;
xenobiotic
lamivudine[no description available]medium70monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol		allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug
irinotecan[no description available]medium30carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
valsartan[no description available]medium80biphenylyltetrazole;
monocarboxylic acid amide;
monocarboxylic acid		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
adenosine[no description available]medium60adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
cefprozil[no description available]medium30cephalosporin;
semisynthetic derivative		antibacterial drug
methylprednisolone aceponate[no description available]medium10corticosteroid hormone
dexamethasone 17-valerate[no description available]medium1021-hydroxy steroid
dexamethasone dipropionate[no description available]medium10corticosteroid hormone
iopamidol[no description available]medium30benzenedicarboxamide;
organoiodine compound;
pentol		environmental contaminant;
radioopaque medium;
xenobiotic
dexfenfluramine[no description available]medium40fenfluramineappetite depressant;
serotonergic agonist;
serotonin uptake inhibitor
sertraline[no description available]medium80dichlorobenzene;
secondary amino compound;
tetralins		antidepressant;
serotonin uptake inhibitor
erythromycin propionate[no description available]medium10erythromycin derivative
dexrazoxane[no description available]medium30razoxaneantineoplastic agent;
cardiovascular drug;
chelator;
immunosuppressive agent
antebate[no description available]medium10corticosteroid hormone
atovaquone[no description available]medium30hydroxy-1,2-naphthoquinone
flunisolide[no description available]medium3011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic ketal;
fluorinated steroid;
primary alpha-hydroxy ketone		anti-asthmatic drug;
anti-inflammatory drug;
immunosuppressive agent
clarithromycin[no description available]medium70macrolide antibioticantibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic
nicotine[no description available]medium603-(1-methylpyrrolidin-2-yl)pyridineanxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic
moexipril[no description available]medium20peptide
methotrexate[no description available]medium190dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
docetaxel[no description available]medium30hydrate;
secondary alpha-hydroxy ketone		antineoplastic agent
levofloxacin[no description available]medium809-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
naproxen[no description available]medium170methoxynaphthalene;
monocarboxylic acid		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
naproxen[no description available]medium171methoxynaphthalene;
monocarboxylic acid		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
ropivacaine[no description available]medium20piperidinecarboxamide;
ropivacaine		local anaesthetic
estradiol 3-benzoate[no description available]medium2017beta-hydroxy steroid;
benzoate ester		estrogen receptor agonist;
xenoestrogen
estramustine[no description available]medium5017beta-hydroxy steroid;
carbamate ester;
organochlorine compound		alkylating agent;
antineoplastic agent;
radiation protective agent
ritonavir[no description available]medium901,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas		antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic
pentostatin[no description available]medium40coformycinsantimetabolite;
antineoplastic agent;
Aspergillus metabolite;
bacterial metabolite;
EC 3.5.4.4 (adenosine deaminase) inhibitor
quinidine[no description available]medium100cinchona alkaloidalpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker
meropenem[no description available]medium50alpha,beta-unsaturated monocarboxylic acid;
carbapenemcarboxylic acid;
organic sulfide;
pyrrolidinecarboxamide		antibacterial agent;
antibacterial drug;
drug allergen
griseofulvin[no description available]medium1501-benzofurans;
antibiotic antifungal drug;
benzofuran antifungal drug;
organochlorine compound;
oxaspiro compound		antibacterial agent;
Penicillium metabolite
cefoxitin[no description available]medium50beta-lactam antibiotic allergen;
cephalosporin;
cephamycin;
semisynthetic derivative		antibacterial drug
saquinavir[no description available]medium80L-asparagine derivative;
quinolines		antiviral drug;
HIV protease inhibitor
netilmicin[no description available]medium30
metyrosine[no description available]medium50L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		antihypertensive agent;
EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor
rocuronium bromide[no description available]medium20organic bromide salt;
quaternary ammonium salt		muscle relaxant;
neuromuscular agent
terconazole[no description available]medium101-(4-{[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-isopropylpiperazine
bacampicillin[no description available]medium20penicillanic acid esterprodrug
erythromycin ethylsuccinate[no description available]medium20cyclic ketone;
erythromycin derivative;
ethyl ester;
succinate ester
amcinonide[no description available]medium1011beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
acetate ester;
corticosteroid;
fluorinated steroid;
spiroketal		anti-inflammatory drug
betamethasone acetate[no description available]medium1011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
acetate ester;
fluorinated steroid;
steroid ester;
tertiary alpha-hydroxy ketone
acarbose[no description available]medium30amino cyclitol;
glycoside
tretinoin[no description available]medium180retinoic acid;
vitamin A		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule
tretinoin[no description available]medium182retinoic acid;
vitamin A		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule
mycophenolic acid[no description available]medium502-benzofurans;
gamma-lactone;
monocarboxylic acid;
phenols		anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
environmental contaminant;
immunosuppressive agent;
mycotoxin;
Penicillium metabolite;
xenobiotic
mupirocin[no description available]medium20alpha,beta-unsaturated carboxylic ester;
epoxide;
monocarboxylic acid;
oxanes;
secondary alcohol;
triol		antibacterial drug;
bacterial metabolite;
protein synthesis inhibitor
fosfomycin[no description available]medium50epoxide;
phosphonic acids		antimicrobial agent;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor
fosfomycin[no description available]medium51epoxide;
phosphonic acids		antimicrobial agent;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor
zithromax[no description available]medium70macrolide antibioticantibacterial drug;
environmental contaminant;
xenobiotic
teniposide[no description available]medium50aromatic ether;
beta-D-glucoside;
cyclic acetal;
furonaphthodioxole;
gamma-lactone;
monosaccharide derivative;
phenols;
thiophenes		antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
cefamandole[no description available]medium20cephalosporin;
semisynthetic derivative		antibacterial drug
dactinomycin[no description available]medium60actinomycinmutagen
melphalan[no description available]medium90L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
sch 22219[no description available]medium1011beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
glucocorticoid;
propanoate ester;
steroid ester		anti-inflammatory drug
mezlocillin[no description available]medium10penicillin allergen;
penicillin		antibacterial drug
cholinophyllin[no description available]medium10
fludarabine[no description available]medium20purine nucleoside
propylthiouracil[no description available]medium80pyrimidinethioneantidote to paracetamol poisoning;
antimetabolite;
antioxidant;
antithyroid drug;
carcinogenic agent;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
hormone antagonist
ipratropium bromide anhydrous[no description available]medium30
etomidate[no description available]medium40ethyl ester;
imidazoles		intravenous anaesthetic;
sedative
mercaptopurine[no description available]medium100aryl thiol;
purines;
thiocarbonyl compound		anticoronaviral agent;
antimetabolite;
antineoplastic agent
thiothixene[no description available]medium50N-methylpiperazineanticoronaviral agent
benztropine[no description available]medium40diarylmethane
sulindac[no description available]medium120monocarboxylic acid;
organofluorine compound;
sulfoxide		analgesic;
antineoplastic agent;
antipyretic;
apoptosis inducer;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug;
tocolytic agent
enclomiphene[no description available]medium80
enclomiphene[no description available]medium81
terbinafine[no description available]medium40acetylenic compound;
allylamine antifungal drug;
enyne;
naphthalenes;
tertiary amine		EC 1.14.13.132 (squalene monooxygenase) inhibitor;
P450 inhibitor;
sterol biosynthesis inhibitor
thioguanine anhydrous[no description available]medium702-aminopurinesanticoronaviral agent;
antimetabolite;
antineoplastic agent
succimer[no description available]medium20dicarboxylic acid;
dithiol;
sulfur-containing carboxylic acid		chelator
streptozocin[no description available]medium70
tamoxifen[no description available]high7810stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
tamoxifen[no description available]high780stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
ethionamide[no description available]medium60pyridines;
thiocarboxamide		antilipemic drug;
antitubercular agent;
fatty acid synthesis inhibitor;
leprostatic drug;
prodrug
dezocine[no description available]medium10phenols;
primary amino compound		opioid analgesic
dapiprazole[no description available]medium10N-alkylpiperazine;
N-arylpiperazine;
pyridines		alpha-adrenergic antagonist;
antipsychotic agent;
miotic;
ophthalmology drug
flosequinan[no description available]medium20quinolines
calcitriol[no description available]medium60D3 vitamins;
hydroxycalciol;
triol		antineoplastic agent;
antipsoriatic;
bone density conservation agent;
calcium channel agonist;
calcium channel modulator;
hormone;
human metabolite;
immunomodulator;
metabolite;
mouse metabolite;
nutraceutical
alprostadil[no description available]medium60prostaglandins Eanticoagulant;
human metabolite;
platelet aggregation inhibitor;
vasodilator agent
amphotericin b[no description available]medium80antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
pulmicort[no description available]medium8011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic acetal;
glucocorticoid;
primary alpha-hydroxy ketone		anti-inflammatory drug;
bronchodilator agent;
drug allergen
olopatadine[no description available]medium20
bw b1090u[no description available]medium10isoquinolines
7432 s[no description available]medium30cephalosporin;
dicarboxylic acid		antibacterial drug
etretinate[no description available]medium30enoate ester;
ethyl ester;
retinoid		keratolytic drug
isotretinoin[no description available]medium130retinoic acidantineoplastic agent;
keratolytic drug;
teratogenic agent
misoprostol[no description available]medium40
misoprostol[no description available]medium42
epoprostenol[no description available]medium20prostaglandins Imouse metabolite
betamethasone benzoate[no description available]medium1021-hydroxy steroid
dorzolamide[no description available]medium10sulfonamide;
thiophenes		antiglaucoma drug;
antihypertensive agent;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
hydromorphone[no description available]medium30morphinane alkaloid;
organic heteropentacyclic compound		mu-opioid receptor agonist;
opioid analgesic
ly 163892[no description available]medium70carbacephem;
zwitterion		antibacterial drug;
antimicrobial agent
nalmefene[no description available]medium40morphinane alkaloid
topiramate[no description available]medium60cyclic ketal;
ketohexose derivative;
sulfamate ester		anticonvulsant;
sodium channel blocker
calcipotriene[no description available]medium10cyclopropanes;
hydroxy seco-steroid;
seco-cholestane;
secondary alcohol;
triol		antipsoriatic;
drug allergen
clobetasol[no description available]medium1011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
fluorinated steroid;
glucocorticoid;
tertiary alpha-hydroxy ketone		anti-inflammatory drug;
SMO receptor agonist
fluticasone[no description available]medium1011beta-hydroxy steroid;
17alpha-hydroxy steroid;
3-oxo-Delta(4) steroid;
corticosteroid;
fluorinated steroid;
thioester		anti-allergic agent;
anti-asthmatic drug
halobetasol[no description available]medium10corticosteroid hormone
latanoprost[no description available]medium20isopropyl ester;
prostaglandins Falpha;
triol		antiglaucoma drug;
antihypertensive agent;
EC 4.2.1.1 (carbonic anhydrase) inhibitor;
prodrug
nalbuphine[no description available]medium30organic heteropentacyclic compoundmu-opioid receptor antagonist;
opioid analgesic
rimexolone[no description available]medium1020-oxo steroid
vinorelbine[no description available]medium50acetate ester;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
ring assembly;
vinca alkaloid		antineoplastic agent;
photosensitizing agent
fluvoxamine[no description available]medium70(trifluoromethyl)benzenes;
5-methoxyvalerophenone O-(2-aminoethyl)oxime		antidepressant;
anxiolytic drug;
serotonin uptake inhibitor
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid[no description available]medium70dihydroxy monocarboxylic acid;
indoles;
organofluorine compound
oxiconazole[no description available]medium10conazole antifungal drug;
dichlorobenzene;
imidazole antifungal drug;
imidazoles;
oxime O-ether		antiinfective agent
naltrexone[no description available]medium70cyclopropanes;
morphinane-like compound;
organic heteropentacyclic compound		antidote to opioid poisoning;
central nervous system depressant;
environmental contaminant;
mu-opioid receptor antagonist;
xenobiotic
butorphanol[no description available]medium40morphinane alkaloidantitussive;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic
cefixime[no description available]medium60cephalosporinantibacterial drug;
drug allergen
lisinopril[no description available]medium70dipeptideEC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
benazepril[no description available]medium40benzazepine;
dicarboxylic acid monoester;
ethyl ester;
lactam		EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
ramipril[no description available]medium50azabicycloalkane;
cyclopentapyrrole;
dicarboxylic acid monoester;
dipeptide;
ethyl ester		bradykinin receptor B2 agonist;
cardioprotective agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
matrix metalloproteinase inhibitor;
prodrug
indinavir sulfate[no description available]medium70dicarboxylic acid diamide;
N-(2-hydroxyethyl)piperazine;
piperazinecarboxamide		HIV protease inhibitor
enalapril[no description available]medium70dicarboxylic acid monoester;
dipeptide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
geroprotector;
prodrug
cefuroxime[no description available]medium403-(carbamoyloxymethyl)cephalosporin;
furans;
oxime O-ether		drug allergen
ceftriaxone[no description available]medium701,2,4-triazines;
1,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen;
EC 3.5.2.6 (beta-lactamase) inhibitor
cefepime[no description available]medium20cephalosporin;
oxime O-ether		antibacterial drug
ceftazidime[no description available]medium60cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
trandolapril[no description available]medium40dicarboxylic acid monoester;
dipeptide;
ethyl ester;
organic heterobicyclic compound;
secondary amino compound;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
guanabenz[no description available]medium40dichlorobenzene
famotidine[no description available]medium801,3-thiazoles;
guanidines;
sulfonamide		anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
cefotaxime[no description available]medium301,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen
aztreonam[no description available]medium60beta-lactam antibiotic allergen;
monobactam		antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
cci 15641[no description available]medium20cephalosporin
cefpodoxime[no description available]medium20carboxylic acid;
cephalosporin		antibacterial drug
dirithromycin[no description available]medium10macrolide antibioticprodrug
cefpodoxime proxetil[no description available]medium20carboxylic acid;
carboxylic ester;
cephalosporin		antibacterial drug;
prodrug
ceftizoxime[no description available]medium30cephalosporinantibacterial drug
nitrofurantoin[no description available]medium100imidazolidine-2,4-dione;
nitrofuran antibiotic;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic		antibacterial drug;
antiinfective agent;
hepatotoxic agent
dantrolene[no description available]medium50
fosinopril[no description available]medium30
nystatin a1[no description available]medium30nystatins
mesna[no description available]medium40organosulfonic acid
cefamandole nafate[no description available]medium10organic sodium saltantibacterial drug;
prodrug
tetracycline[no description available]medium100
minocycline[no description available]medium70
piroxicam[no description available]medium130benzothiazine;
monocarboxylic acid amide;
pyridines		analgesic;
antirheumatic drug;
cyclooxygenase 1 inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
meclocycline[no description available]medium10
warfarin[no description available]medium210benzenes;
hydroxycoumarin;
methyl ketone
acyclovir[no description available]medium1002-aminopurines;
oxopurine		antimetabolite;
antiviral drug
rifampin[no description available]medium110cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
clozapine[no description available]medium130benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound		adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic
didanosine[no description available]medium80purine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor;
geroprotector;
HIV-1 reverse transcriptase inhibitor
ganciclovir[no description available]medium902-aminopurines;
oxopurine		antiinfective agent;
antiviral drug
valacyclovir[no description available]medium30L-valyl esterantiviral drug
olanzapine[no description available]medium60benzodiazepine;
N-arylpiperazine;
N-methylpiperazine		antiemetic;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
serotonin uptake inhibitor
penciclovir[no description available]medium202-aminopurines;
propane-1,3-diols		antiviral drug
allopurinol[no description available]medium130nucleobase analogue;
organic heterobicyclic compound		antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger
rifabutin[no description available]medium70
gamma-aminobutyric acid[no description available]medium20amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule
acetamide[no description available]medium20acetamides;
carboximidic acid;
monocarboxylic acid amide;
N-acylammonia
quinacrine[no description available]medium50acridines;
aromatic ether;
organochlorine compound;
tertiary amino compound		antimalarial;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
catechol[no description available]medium20catecholsallelochemical;
genotoxin;
plant metabolite
taxifolin[no description available]medium203'-hydroxyflavanones;
4'-hydroxyflavanones;
dihydroflavonols;
pentahydroxyflavanone;
secondary alpha-hydroxy ketone
phosphonoacetic acid[no description available]medium20monocarboxylic acid;
phosphonic acids		antiviral agent;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor
3,4-dihydroxyphenylacetic acid[no description available]medium20catechols;
dihydroxyphenylacetic acid		human metabolite
diacetyl[no description available]medium10alpha-diketoneEscherichia coli metabolite;
Saccharomyces cerevisiae metabolite
hydroquinone[no description available]medium30benzenediol;
hydroquinones		antioxidant;
carcinogenic agent;
cofactor;
Escherichia coli metabolite;
human xenobiotic metabolite;
mouse metabolite;
skin lightening agent
melatonin[no description available]medium40acetamides;
tryptamines		anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger
n-acetylserotonin[no description available]medium10acetamides;
N-acylserotonin;
phenols		antioxidant;
human metabolite;
mouse metabolite;
tropomyosin-related kinase B receptor agonist
pyrazinamide[no description available]medium90monocarboxylic acid amide;
N-acylammonia;
pyrazines		antitubercular agent;
prodrug
quinolinic acid[no description available]medium10pyridinedicarboxylic acidEscherichia coli metabolite;
human metabolite;
mouse metabolite;
NMDA receptor agonist
taurine[no description available]medium10amino sulfonic acid;
zwitterion		antioxidant;
Escherichia coli metabolite;
glycine receptor agonist;
human metabolite;
mouse metabolite;
nutrient;
radical scavenger;
Saccharomyces cerevisiae metabolite
2-amino-5-phosphonovalerate[no description available]medium10non-proteinogenic alpha-amino acidNMDA receptor antagonist
alpha-methyl-4-carboxyphenylglycine[no description available]medium10
3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid[no description available]medium10
1-hydroxy-3-amino-2-pyrrolidone[no description available]medium10
ibotenic acid[no description available]medium10non-proteinogenic alpha-amino acidneurotoxin
n(8)-bromoacetyl-n(1)-3'-(4-indolyloxy)-2'-hydroxypropyl-1,8-diamino-4-menthane[no description available]medium10
sk&f-38393[no description available]medium20benzazepine;
catechols;
secondary amino compound
vanilmandelic acid[no description available]medium102-hydroxy monocarboxylic acid;
aromatic ether;
phenols		human metabolite
1,10-diaminodecane[no description available]medium20
1,3-diethyl-8-phenylxanthine[no description available]medium10
1,3-dipropyl-8-cyclopentylxanthine[no description available]medium20oxopurineadenosine A1 receptor antagonist;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
1,3-dipropyl-8-(4-sulfophenyl)xanthine[no description available]medium10
1,5-dihydroxyisoquinoline[no description available]medium10isoquinolinolEC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
pk 11195[no description available]medium20aromatic amide;
isoquinolines;
monocarboxylic acid amide;
monochlorobenzenes		antineoplastic agent
1-(2-trifluoromethylphenyl)imidazole[no description available]medium10imidazoles
1-aminobenzotriazole[no description available]medium30
1-methylimidazole[no description available]medium10imidazoles
edelfosine[no description available]medium10glycerophosphocholine
1h-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one[no description available]medium20oxadiazoloquinoxalineEC 4.6.1.2 (guanylate cyclase) inhibitor
2,2'-dipyridyl[no description available]medium20bipyridinechelator;
ferroptosis inhibitor
2-hydroxysaclofen[no description available]medium10organochlorine compound
3,4-dichloroisocoumarin[no description available]medium20isocoumarins;
organochlorine compound		geroprotector;
serine protease inhibitor
phaclofen[no description available]medium10organophosphate oxoanion;
zwitterion
3-aminobenzamide[no description available]medium10benzamides;
substituted aniline		EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
3-bromo-7-nitroindazole[no description available]medium10
enprofylline[no description available]medium20oxopurineanti-arrhythmia drug;
anti-asthmatic drug;
bronchodilator agent;
non-steroidal anti-inflammatory drug
3-nitropropionic acid[no description available]medium10C-nitro compoundantimycobacterial drug;
EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor;
mycotoxin;
neurotoxin
4-amino-1,8-naphthalimide[no description available]medium20benzoisoquinoline;
dicarboximide
4-aminopyridine[no description available]medium10aminopyridine;
aromatic amine		avicide;
orphan drug;
potassium channel blocker
homovanillic acid[no description available]medium20guaiacols;
monocarboxylic acid		human metabolite;
mouse metabolite
4-hydroxybenzoic acid hydrazide[no description available]medium10carbohydrazide;
phenols
4-phenyl-3-furoxancarbonitrile[no description available]medium201,2,5-oxadiazole;
benzenes;
N-oxide;
nitrile		geroprotector;
nitric oxide donor;
platelet aggregation inhibitor;
soluble guanylate cyclase activator;
vasodilator agent
5,5-dimethyl-1-pyrroline-1-oxide[no description available]medium101-pyrroline nitronesneuroprotective agent;
spin trapping reagent
5,7-dichlorokynurenic acid[no description available]medium10quinolines
5-(n,n-hexamethylene)amiloride[no description available]medium20aromatic amine;
azepanes;
guanidines;
monocarboxylic acid amide;
organochlorine compound;
pyrazines		antineoplastic agent;
apoptosis inducer;
odorant receptor antagonist;
sodium channel blocker
ethylisopropylamiloride[no description available]medium20aromatic amine;
guanidines;
monocarboxylic acid amide;
organochlorine compound;
pyrazines;
tertiary amino compound		anti-arrhythmia drug;
neuroprotective agent;
sodium channel blocker
5-fluoroindole-2-carboxylic acid[no description available]medium20indolyl carboxylic acid
hydroxyindoleacetic acid[no description available]medium10indole-3-acetic acidsdrug metabolite;
human metabolite;
mouse metabolite
phenanthridone[no description available]medium20lactam;
phenanthridines		EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
immunosuppressive agent;
mutagen
6-chloromelatonin[no description available]medium10acetamides
6-hydroxymelatonin[no description available]medium10acetamides;
tryptamines		metabolite;
mouse metabolite
6-methoxytryptoline[no description available]medium10
6-nitroso-1,2-benzopyrone[no description available]medium20
7-chlorokynurenic acid[no description available]medium10organochlorine compound;
quinolinemonocarboxylic acid		neuroprotective agent;
NMDA receptor antagonist
7-nitroindazole[no description available]medium10
8-(4-sulfophenyl)theophylline[no description available]medium20
8-cyclopentyl-1,3-dimethylxanthine[no description available]medium10oxopurine
8-phenyltheophylline[no description available]medium10
acetazolamide[no description available]medium90monocarboxylic acid amide;
sulfonamide;
thiadiazoles		anticonvulsant;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
acetazolamide[no description available]medium91monocarboxylic acid amide;
sulfonamide;
thiadiazoles		anticonvulsant;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
acetohexamide[no description available]medium50acetophenones;
N-sulfonylurea		hypoglycemic agent;
insulin secretagogue
ag 127[no description available]medium20nitrophenol
rtki cpd[no description available]medium20aromatic ether;
monochlorobenzenes;
quinazolines		antineoplastic agent;
antiviral agent;
epidermal growth factor receptor antagonist;
geroprotector
tyrphostin a23[no description available]medium20catechols
tyrphostin 25[no description available]medium20benzenetriol
tyrphostin a1[no description available]medium10methoxybenzenesgeroprotector
1-aminoindan-1,5-dicarboxylic acid[no description available]medium10
alpha-methyltyrosine methyl ester[no description available]medium10
amfonelic acid[no description available]medium10
aniracetam[no description available]medium10N-acylpyrrolidine;
pyrrolidin-2-ones
2-amino-4-phosphonobutyric acid[no description available]medium10
alpha-amino-3-hydroxy-5-tert-butyl-4-isoxazolepropionate[no description available]medium10alpha-amino acid
aurintricarboxylic acid[no description available]medium20monohydroxybenzoic acid;
quinomethanes;
tricarboxylic acid		fluorochrome;
histological dye;
insulin-like growth factor receptor 1 antagonist
bay-k-8644[no description available]medium20(trifluoromethyl)benzenes;
C-nitro compound;
dihydropyridine;
methyl ester
benzamide[no description available]medium10benzamides
bml 190[no description available]medium20N-acylindole
caffeine[no description available]medium110purine alkaloid;
trimethylxanthine		adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic
carbetapentane[no description available]medium10benzenes
carisoprodol[no description available]medium30carbamate estermuscle relaxant
cgs 12066[no description available]medium10N-arylpiperazine;
organofluorine compound;
pyrroloquinoxaline		serotonergic agonist
cgs 15943[no description available]medium20aromatic amine;
biaryl;
furans;
organochlorine compound;
primary amino compound;
quinazolines;
triazoloquinazoline		adenosine A1 receptor antagonist;
adenosine A2A receptor antagonist;
antineoplastic agent;
central nervous system stimulant
chlorambucil[no description available]medium70aromatic amine;
monocarboxylic acid;
nitrogen mustard;
organochlorine compound;
tertiary amino compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
chlorothiazide[no description available]medium40benzothiadiazineantihypertensive agent;
diuretic
chlorpropamide[no description available]medium110monochlorobenzenes;
N-sulfonylurea		hypoglycemic agent;
insulin secretagogue
chlorzoxazone[no description available]medium701,3-benzoxazoles;
heteroaryl hydroxy compound;
organochlorine compound		muscle relaxant;
sedative
cilostamide[no description available]medium20quinolines
cilostazol[no description available]medium50lactam;
tetrazoles		anticoagulant;
bronchodilator agent;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
fibrin modulating drug;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent
cimetidine[no description available]medium150aliphatic sulfide;
guanidines;
imidazoles;
nitrile		adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
ciprofibrate[no description available]medium50cyclopropanes;
monocarboxylic acid;
organochlorine compound		antilipemic drug
clofibrate[no description available]medium90aromatic ether;
ethyl ester;
monochlorobenzenes		anticholesteremic drug;
antilipemic drug;
geroprotector;
PPARalpha agonist
clotrimazole[no description available]medium110conazole antifungal drug;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes		antiinfective agent;
environmental contaminant;
xenobiotic
cx546[no description available]medium10
cyclothiazide[no description available]medium10benzothiadiazineantihypertensive agent;
diuretic
dephostatin[no description available]medium10
nonivamide[no description available]medium10capsaicinoid;
phenols		lachrymator
r 59022[no description available]medium10diarylmethane
diazoxide[no description available]medium70benzothiadiazine;
organochlorine compound;
sulfone		antihypertensive agent;
beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
diuretic;
K-ATP channel agonist;
sodium channel blocker;
sympathomimetic agent;
vasodilator agent
pentetic acid[no description available]medium20pentacarboxylic acidcopper chelator
diphenyleneiodonium[no description available]medium10organic cation
dipyridamole[no description available]medium100piperidines;
pyrimidopyrimidine;
tertiary amino compound;
tetrol		adenosine phosphodiesterase inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
dipyridamole[no description available]medium101piperidines;
pyrimidopyrimidine;
tertiary amino compound;
tetrol		adenosine phosphodiesterase inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
2-amino-7-phosphonoheptanoic acid[no description available]medium10
thiorphan[no description available]medium10N-acyl-amino acid
2,3-dimethoxy-1,4-naphthoquinone[no description available]medium201,4-naphthoquinones
domperidone[no description available]medium70benzimidazoles;
heteroarylpiperidine		antiemetic;
dopaminergic antagonist
ebselen[no description available]medium30benzoselenazoleanti-inflammatory drug;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 3.5.4.1 (cytosine deaminase) inhibitor;
EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor;
enzyme mimic;
ferroptosis inhibitor;
genotoxin;
hepatoprotective agent;
neuroprotective agent;
radical scavenger
ellipticine[no description available]medium20indole alkaloid;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound;
polycyclic heteroarene		antineoplastic agent;
plant metabolite
emodin[no description available]medium20trihydroxyanthraquinoneantineoplastic agent;
laxative;
plant metabolite;
tyrosine kinase inhibitor
ethosuximide[no description available]medium80dicarboximide;
pyrrolidinone		anticonvulsant;
geroprotector;
T-type calcium channel blocker
fenofibrate[no description available]high210aromatic ether;
chlorobenzophenone;
isopropyl ester;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
fluspirilene[no description available]medium40diarylmethane
formoterol fumarate[no description available]medium20formamides;
phenols;
phenylethanolamines;
secondary alcohol;
secondary amino compound
fpl 64176[no description available]medium20carboxylic ester;
pyrroles		calcium channel agonist
furafylline[no description available]medium10oxopurine
fusaric acid[no description available]medium10aromatic carboxylic acid;
pyridines
4-amino-5-hexynoic acid[no description available]medium10
1-(5-isoquinolinesulfonyl)piperazine[no description available]medium10isoquinolines
hemicholinium 3[no description available]medium10morpholines
4-fluorohexahydrosiladifenidol[no description available]medium10
ibudilast[no description available]medium10pyrazolopyridine
ic 261[no description available]medium20indoles
ifenprodil[no description available]medium10piperidines
indirubin-3'-monoxime[no description available]medium20
iodoacetamide[no description available]medium10
1-methyl-3-isobutylxanthine[no description available]medium103-isobutyl-1-methylxanthine
4-piperidinecarboxylic acid[no description available]medium20
4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline[no description available]medium10
jl 18[no description available]medium20
nsc 664704[no description available]medium30indolobenzazepine;
lactam;
organobromine compound		cardioprotective agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
geroprotector
kynurenic acid[no description available]medium10monohydroxyquinoline;
quinolinemonocarboxylic acid		G-protein-coupled receptor agonist;
human metabolite;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist;
Saccharomyces cerevisiae metabolite
2-amino-3-phosphonopropionic acid[no description available]medium10alanine derivative;
non-proteinogenic alpha-amino acid;
phosphonic acids		human metabolite;
metabotropic glutamate receptor antagonist
beta-lapachone[no description available]medium30benzochromenone;
orthoquinones		anti-inflammatory agent;
antineoplastic agent;
plant metabolite
leflunomide[no description available]medium80(trifluoromethyl)benzenes;
isoxazoles;
monocarboxylic acid amide		antineoplastic agent;
antiparasitic agent;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
hepatotoxic agent;
immunosuppressive agent;
non-steroidal anti-inflammatory drug;
prodrug;
pyrimidine synthesis inhibitor;
tyrosine kinase inhibitor
linopirdine[no description available]medium20indoles
loxoprofen[no description available]medium20cyclopentanones;
monocarboxylic acid		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one[no description available]medium10chromones;
morpholines;
organochlorine compound		autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector
meclofenamate sodium anhydrous[no description available]medium30organic sodium salt
methiothepin[no description available]medium10aryl sulfide;
dibenzothiepine;
N-alkylpiperazine;
tertiary amino compound		antipsychotic agent;
dopaminergic antagonist;
geroprotector;
serotonergic antagonist
methoctramine[no description available]medium10aromatic ether;
tetramine		muscarinic antagonist
nocodazole[no description available]medium40aromatic ketone;
benzimidazoles;
carbamate ester;
thiophenes		antimitotic;
antineoplastic agent;
microtubule-destabilising agent;
tubulin modulator
3-Hydroxy-alpha-methyl-DL-tyrosine[no description available]medium10benzenes;
monocarboxylic acid
metolazone[no description available]medium60organochlorine compound;
quinazolines;
sulfonamide		antihypertensive agent;
diuretic;
ion transport inhibitor
milrinone[no description available]medium20bipyridines;
nitrile;
pyridone		cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
mitotane[no description available]medium40diarylmethane
ml 7[no description available]medium20N-sulfonyldiazepane;
organoiodine compound		EC 2.7.11.18 (myosin-light-chain kinase) inhibitor
n-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide[no description available]medium10naphthalenes;
organochlorine compound;
primary amino compound;
sulfonamide
n-bromoacetamide[no description available]medium10
ethylmaleimide[no description available]medium10maleimidesanticoronaviral agent;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.1.1 (hexokinase) inhibitor
fg 7142[no description available]medium20beta-carbolines
fenamic acid[no description available]medium10aminobenzoic acid;
secondary amino compound		membrane transport modulator
n 0840[no description available]medium20
nialamide[no description available]medium50organonitrogen compound;
organooxygen compound
niclosamide[no description available]medium20benzamides;
C-nitro compound;
monochlorobenzenes;
salicylanilides;
secondary carboxamide		anthelminthic drug;
anticoronaviral agent;
antiparasitic agent;
apoptosis inducer;
molluscicide;
piscicide;
STAT3 inhibitor
niflumic acid[no description available]medium20aromatic carboxylic acid;
pyridines
nimesulide[no description available]medium80aromatic ether;
C-nitro compound;
sulfonamide		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
nipecotic acid[no description available]medium10beta-amino acid;
piperidinemonocarboxylic acid
nitrendipine[no description available]medium80C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
ethyl ester;
methyl ester		antihypertensive agent;
calcium channel blocker;
geroprotector;
vasodilator agent
5-nitro-2-(3-phenylpropylamino)benzoic acid[no description available]medium20nitrobenzoic acid
ns 2028[no description available]medium10
ns 1619[no description available]medium20(trifluoromethyl)benzenes;
benzimidazoles;
phenols		potassium channel opener
o(6)-benzylguanine[no description available]medium10
olomoucine[no description available]medium302,6-diaminopurines;
ethanolamines		EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
oxatomide[no description available]medium30benzimidazoles;
diarylmethane;
N-alkylpiperazine		anti-allergic agent;
anti-inflammatory agent;
geroprotector;
H1-receptor antagonist;
serotonergic antagonist
oxiracetam[no description available]medium10organonitrogen compound;
organooxygen compound
oxolinic acid[no description available]medium10aromatic carboxylic acid;
organic heterotricyclic compound;
oxacycle;
quinolinemonocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antifungal agent;
antiinfective agent;
antimicrobial agent;
enzyme inhibitor
quinone[no description available]medium101,4-benzoquinonescofactor;
human xenobiotic metabolite;
mouse metabolite
fenclonine[no description available]medium10phenylalanine derivative
palmidrol[no description available]medium20endocannabinoid;
N-(long-chain-acyl)ethanolamine;
N-(saturated fatty acyl)ethanolamine		anti-inflammatory drug;
anticonvulsant;
antihypertensive agent;
neuroprotective agent
1,7-dimethylxanthine[no description available]medium10dimethylxanthinecentral nervous system stimulant;
human blood serum metabolite;
human xenobiotic metabolite;
mouse metabolite
pd 98059[no description available]medium20aromatic amine;
monomethoxyflavone		EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
phenyl biguanide[no description available]medium20guanidinescentral nervous system drug
phenylbutazone[no description available]medium70pyrazolidinesantirheumatic drug;
EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor;
metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug
phloretin[no description available]medium20dihydrochalconesantineoplastic agent;
plant metabolite
picotamide[no description available]medium20benzamides
pinacidil[no description available]medium60pyridines
piperidine-4-sulfonic acid[no description available]medium10
piracetam[no description available]medium30organonitrogen compound;
organooxygen compound
pirenperone[no description available]medium20aromatic ketone
proglumide[no description available]medium10benzamides;
dicarboxylic acid monoamide;
glutamine derivative;
racemate		anti-ulcer drug;
cholecystokinin antagonist;
cholinergic antagonist;
delta-opioid receptor agonist;
drug metabolite;
gastrointestinal drug;
opioid analgesic;
xenobiotic metabolite
propentofylline[no description available]medium20oxopurine
pf 5901[no description available]medium20quinolines
ritanserin[no description available]medium20organofluorine compound;
piperidines;
thiazolopyrimidine		antidepressant;
antipsychotic agent;
anxiolytic drug;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist
4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone[no description available]medium10methoxybenzenes
rolipram[no description available]medium10pyrrolidin-2-onesantidepressant;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
sb 202190[no description available]medium20imidazoles;
organofluorine compound;
phenols;
pyridines		apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
sobuzoxane[no description available]medium10organic molecular entity
spiroxatrine[no description available]medium20imidazolidines
sq 22536[no description available]medium10nucleoside analogue;
oxolanes		EC 4.6.1.1 (adenylate cyclase) inhibitor
sulfaphenazole[no description available]medium30primary amino compound;
pyrazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 1.14.13.67 (quinine 3-monooxygenase) inhibitor;
P450 inhibitor
sulpiride[no description available]medium70benzamides;
N-alkylpyrrolidine;
sulfonamide		antidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist
t0156[no description available]medium20naphthyridine derivative
1,4-bis(2-(3,5-dichloropyridyloxy))benzene[no description available]medium10
tetraisopropylpyrophosphamide[no description available]medium20phosphoramide
thalidomide[no description available]medium100phthalimides;
piperidones
thalidomide[no description available]medium101phthalimides;
piperidones
theobromine[no description available]medium10dimethylxanthineadenosine receptor antagonist;
bronchodilator agent;
food component;
human blood serum metabolite;
mouse metabolite;
plant metabolite;
vasodilator agent
8-(n,n-diethylamino)octyl-3,4,5-trimethoxybenzoate[no description available]medium10trihydroxybenzoic acid
tolazamide[no description available]medium70N-sulfonylureahypoglycemic agent;
potassium channel blocker
tolbutamide[no description available]medium100N-sulfonylureahuman metabolite;
hypoglycemic agent;
insulin secretagogue;
potassium channel blocker
(1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid[no description available]medium10
ici 136,753[no description available]medium20pyrazolopyridine
triamterene[no description available]medium60pteridinesdiuretic;
sodium channel blocker
trimethoprim[no description available]medium120aminopyrimidine;
methoxybenzenes		antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic
tropicamide[no description available]medium20acetamides
tyrphostin a9[no description available]medium20alkylbenzenegeroprotector
vigabatrin[no description available]medium40gamma-amino acidanticonvulsant;
EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor
8-(4-((2-aminoethyl)aminocarbonylmethyloxy)phenyl)-1,3-dipropylxanthine[no description available]medium20
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole[no description available]medium20aromatic primary alcohol;
furans;
indazoles		antineoplastic agent;
apoptosis inducer;
platelet aggregation inhibitor;
soluble guanylate cyclase activator;
vasodilator agent
zardaverine[no description available]medium10organofluorine compound;
pyridazinone		anti-asthmatic drug;
bronchodilator agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
peripheral nervous system drug
cortisone acetate[no description available]medium30corticosteroid hormone
corticosterone[no description available]medium5011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite
reserpine[no description available]medium80alkaloid ester;
methyl ester;
yohimban alkaloid		adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic
procaine hydrochloride[no description available]medium10organic molecular entity
isoproterenol hydrochloride[no description available]medium40catechols
histamine dihydrochloride[no description available]medium20
carbachol[no description available]medium20ammonium salt;
carbamate ester		cardiotonic drug;
miotic;
muscarinic agonist;
nicotinic acetylcholine receptor agonist;
non-narcotic analgesic
estrone[no description available]medium20017-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols		antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite
estrone[no description available]medium20117-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols		antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite
androsterone[no description available]medium3017-oxo steroid;
3alpha-hydroxy steroid;
androstanoid;
C19-steroid		androgen;
anticonvulsant;
human blood serum metabolite;
human metabolite;
human urinary metabolite;
mouse metabolite;
pheromone
promazine hydrochloride[no description available]medium40hydrochloride
pilocarpine hydrochloride[no description available]medium10hydrochloride
dimethylphenylpiperazinium iodide[no description available]medium20N-arylpiperazine;
organic iodide salt;
piperazinium salt;
quaternary ammonium salt		nicotinic acetylcholine receptor agonist
pentylenetetrazole[no description available]medium20organic heterobicyclic compound;
organonitrogen heterocyclic compound
racepinephrine hydrochloride[no description available]medium20
(4-(m-chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium chloride[no description available]medium20
hexamethonium bromide[no description available]medium10
cystamine dihydrochloride[no description available]medium10
cantharidin[no description available]medium20cyclic dicarboxylic anhydride;
monoterpenoid		EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
herbicide
tetraethylammonium chloride[no description available]medium20organic chloride salt;
quaternary ammonium salt		potassium channel blocker
aspartic acid[no description available]medium10aspartate family amino acid;
aspartic acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
mouse metabolite;
neurotransmitter
glutamine[no description available]medium30amino acid zwitterion;
glutamine family amino acid;
glutamine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
physostigmine[no description available]medium70carbamate ester;
indole alkaloid		antidote to curare poisoning;
EC 3.1.1.8 (cholinesterase) inhibitor;
miotic
apomorphine[no description available]medium50aporphine alkaloidalpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug
promethazine hydrochloride[no description available]medium40hydrochlorideanti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
geroprotector;
H1-receptor antagonist;
local anaesthetic;
sedative
bromodeoxyuridine[no description available]medium50pyrimidine 2'-deoxyribonucleosideantimetabolite;
antineoplastic agent
levodopa[no description available]medium80amino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug
methoxamine hydrochloride[no description available]medium40dimethoxybenzene
papaverine hydrochloride[no description available]medium20
berlition[no description available]medium20dithiolanes;
heterocyclic fatty acid;
lipoic acid;
thia fatty acid		cofactor;
nutraceutical;
prosthetic group
methacholine chloride[no description available]medium10quaternary ammonium salt
androstenedione[no description available]medium20017-oxo steroid;
3-oxo-Delta(4) steroid;
androstanoid		androgen;
Daphnia magna metabolite;
human metabolite;
mouse metabolite
androstenedione[no description available]medium20117-oxo steroid;
3-oxo-Delta(4) steroid;
androstanoid		androgen;
Daphnia magna metabolite;
human metabolite;
mouse metabolite
colchicine[no description available]medium150alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
yohimbine hydrochloride[no description available]medium20
gallamine triethiodide[no description available]medium30
cycloheximide[no description available]medium60antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol		anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor
egtazic acid[no description available]medium10diether;
tertiary amino compound;
tetracarboxylic acid		chelator
cycloserine[no description available]medium304-amino-1,2-oxazolidin-3-one;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic;
zwitterion		antiinfective agent;
antimetabolite;
antitubercular agent;
metabolite;
NMDA receptor agonist
17-alpha-hydroxyprogesterone[no description available]medium4017alpha-hydroxy-C21-steroid;
17alpha-hydroxy steroid;
tertiary alpha-hydroxy ketone		human metabolite;
metabolite;
mouse metabolite;
progestin
quinacrine monohydrochloride[no description available]medium20
chlorpromazine hydrochloride[no description available]medium20hydrochloride;
phenothiazines		anticoronaviral agent;
phenothiazine antipsychotic drug
cytarabine hydrochloride[no description available]medium10
tryptophan[no description available]medium30erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
tryptophan zwitterion;
tryptophan		antidepressant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
lidocaine hydrochloride[no description available]medium20hydrochlorideanti-arrhythmia drug;
local anaesthetic
arginine[no description available]medium50arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
rotenone[no description available]medium50organic heteropentacyclic compound;
rotenones		antineoplastic agent;
metabolite;
mitochondrial NADH:ubiquinone reductase inhibitor;
phytogenic insecticide;
piscicide;
toxin
synephrine[no description available]medium30ethanolamines;
phenethylamine alkaloid;
phenols		alpha-adrenergic agonist;
plant metabolite
pyridostigmine bromide[no description available]medium40pyridinium salt
imipramine hydrochloride[no description available]medium40hydrochlorideantidepressant
neostigmine bromide[no description available]medium30bromide salt
edrophonium chloride[no description available]medium30chloride salt;
quaternary ammonium salt		antidote;
diagnostic agent;
EC 3.1.1.8 (cholinesterase) inhibitor
suramin sodium[no description available]medium20organic sodium saltangiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug
pyrazolanthrone[no description available]medium30anthrapyrazole;
aromatic ketone;
cyclic ketone		antineoplastic agent;
c-Jun N-terminal kinase inhibitor;
geroprotector
methapyrilene hydrochloride[no description available]medium20hydrochlorideanti-allergic agent;
carcinogenic agent;
H1-receptor antagonist;
sedative
tetrracaine hydrochloride[no description available]medium30benzoate ester
chelidamic acid[no description available]medium10
2-chloroadenosine[no description available]medium20purine nucleoside
diphenhydramine hydrochloride[no description available]medium40hydrochloride;
organoammonium salt		anti-allergic agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
sedative
cysteamine hydrochloride[no description available]medium10
propantheline bromide[no description available]medium30xanthenes
hydralazine hydrochloride[no description available]medium10hydrochlorideantihypertensive agent;
vasodilator agent
ethamivan[no description available]medium10methoxybenzenes;
phenols
pargyline hydrochloride[no description available]medium20
aminophylline[no description available]medium40mixturebronchodilator agent;
cardiotonic drug
azacitidine[no description available]medium70N-glycosyl-1,3,5-triazine;
nucleoside analogue		antineoplastic agent
orphenadrine hydrochloride[no description available]medium20hydrochlorideantiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist;
muscle relaxant;
NMDA receptor antagonist;
parasympatholytic
benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(n,n-dimethyl-n-2-propenyl-), dibromide[no description available]medium20
cyproterone acetate[no description available]high10120-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
chlorinated steroid;
steroid ester		androgen antagonist;
geroprotector;
progestin
cyproterone acetate[no description available]high10020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
chlorinated steroid;
steroid ester		androgen antagonist;
geroprotector;
progestin
bicuculline[no description available]medium10benzylisoquinoline alkaloid;
isoquinoline alkaloid;
isoquinolines		agrochemical;
central nervous system stimulant;
GABA-gated chloride channel antagonist;
GABAA receptor antagonist;
neurotoxin
kainic acid[no description available]medium10dicarboxylic acid;
L-proline derivative;
non-proteinogenic L-alpha-amino acid;
pyrrolidinecarboxylic acid		antinematodal drug;
excitatory amino acid agonist
tetrahydrozoline hydrochloride[no description available]medium20hydrochloridenasal decongestant;
sympathomimetic agent;
vasoconstrictor agent
dequalinium chloride[no description available]medium20organic chloride saltantifungal agent;
antineoplastic agent;
antiseptic drug;
mitochondrial NADH:ubiquinone reductase inhibitor
decamethonium dibromide[no description available]medium20
amitriptyline hydrochloride[no description available]medium40organic tricyclic compound
naphazoline hydrochloride[no description available]medium20organic molecular entity
doxylamine succinate[no description available]medium20organic molecular entity
carbamylhydrazine monohydrochloride[no description available]medium10organic molecular entity
formestane[no description available]medium5017-oxo steroid;
3-oxo-Delta(4) steroid;
enol;
hydroxy steroid		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
debrisoquin sulfate[no description available]medium10organic sulfate salt
betaine hydrochloride[no description available]medium30
bethanechol chloride[no description available]medium10carbamate ester;
chloride salt;
quaternary ammonium salt		muscarinic agonist
Mecamylamine hydrochloride[no description available]medium20monoterpenoid
vinblastine[no description available]medium30
cyproheptadine hydrochloride (anhydrous)[no description available]medium40hydrochloride
5 alpha-androstane-3 alpha,17 beta-diol[no description available]medium20androstane-3alpha,17beta-diolDaphnia magna metabolite;
human metabolite
azetidyl-2-carboxylic acid[no description available]medium10azetidine-2-carboxylic acid
muscarine[no description available]medium10
antazoline hydrochloride[no description available]medium20
doxifluridine[no description available]medium30organofluorine compound;
pyrimidine 5'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
prodrug
meclofenoxate hydrochloride[no description available]medium10
clonidine hydrochloride[no description available]medium30dichlorobenzene
buthionine sulfoximine[no description available]medium20diastereoisomeric mixture;
homocysteines;
non-proteinogenic alpha-amino acid;
sulfoximide		EC 6.3.2.2 (glutamate--cysteine ligase) inhibitor;
ferroptosis inducer
mexiletine hydrochloride[no description available]medium40hydrochlorideanti-arrhythmia drug
cyclophosphamide[no description available]medium10hydratealkylating agent;
antineoplastic agent;
carcinogenic agent;
immunosuppressive agent
suxamethonium chloride[no description available]medium10chloride saltmuscle relaxant
cyclobenzaprine hydrochloride[no description available]medium20hydrochlorideantidepressant;
muscle relaxant
n-methylaspartate[no description available]medium10amino dicarboxylic acid;
D-alpha-amino acid;
D-aspartic acid derivative;
secondary amino compound		neurotransmitter agent
3-deazaadenosine[no description available]medium20
metoclopramide hydrochloride[no description available]medium40
isoetharine mesylate[no description available]medium20
propionylpromazine hydrochloride[no description available]medium20
camptothecin[no description available]medium40delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
nsc-145,668[no description available]medium10hydrochlorideantimetabolite;
antineoplastic agent
clodronic acid[no description available]medium201,1-bis(phosphonic acid);
one-carbon compound;
organochlorine compound		antineoplastic agent;
bone density conservation agent
benserazide hydrochloride[no description available]medium20hydrochlorideantiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
pancuronium bromide[no description available]medium30bromide saltcholinergic antagonist;
muscle relaxant;
nicotinic antagonist
tetradecanoylphorbol acetate[no description available]medium20acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester		antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator
metergoline[no description available]medium30carbamate ester;
ergoline alkaloid		dopamine agonist;
geroprotector;
serotonergic antagonist
lisuride[no description available]medium20monocarboxylic acid amideantidyskinesia agent;
antiparkinson drug;
dopamine agonist;
serotonergic agonist
disopyramide phosphate[no description available]medium40organoammonium phosphate
ergocristine[no description available]medium10ergot alkaloid
triamcinolone[no description available]medium7011beta-hydroxy steroid;
16alpha-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-allergic agent;
anti-inflammatory drug
buspirone hydrochloride[no description available]medium20hydrochlorideanxiolytic drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
sedative;
serotonergic agonist
propafenone hydrochloride[no description available]medium40hydrochlorideanti-arrhythmia drug
etazolate hydrochloride[no description available]medium20
butaclamol[no description available]medium10amino alcohol;
organic heteropentacyclic compound;
tertiary alcohol;
tertiary amino compound		dopaminergic antagonist
carbidopa[no description available]medium50catechols;
hydrate;
hydrazines;
monocarboxylic acid		antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
cephradine[no description available]medium50beta-lactam antibiotic allergen;
cephalosporin		antibacterial drug
lonidamine[no description available]medium10dichlorobenzene;
indazoles;
monocarboxylic acid		antineoplastic agent;
antispermatogenic agent;
EC 2.7.1.1 (hexokinase) inhibitor;
geroprotector
dexibuprofen[no description available]medium10ibuprofennon-narcotic analgesic;
non-steroidal anti-inflammatory drug
quisqualic acid[no description available]medium10non-proteinogenic alpha-amino acid
pirfenidone[no description available]medium20pyridoneantipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
flecainide acetate[no description available]medium40acetate saltanti-arrhythmia drug
nicardipine hydrochloride[no description available]medium40dihydropyridinegeroprotector
terazosin hydrochloride anhydrous[no description available]medium20
pergolide mesylate[no description available]medium30methanesulfonate saltantiparkinson drug;
dopamine agonist;
geroprotector
ranitidine hydrochloride[no description available]medium10
colforsin[no description available]medium20acetate ester;
cyclic ketone;
labdane diterpenoid;
organic heterotricyclic compound;
tertiary alpha-hydroxy ketone;
triol		adenylate cyclase agonist;
anti-HIV agent;
antihypertensive agent;
plant metabolite;
platelet aggregation inhibitor;
protein kinase A agonist
alo 2145[no description available]medium10hydrochloridealpha-adrenergic agonist;
antiglaucoma drug
enoximone[no description available]medium30aromatic ketone
atomoxetine[no description available]medium50aromatic ether;
secondary amino compound;
toluenes		adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
xenobiotic
raloxifene hydrochloride[no description available]high50hydrochloridebone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
mifepristone[no description available]medium3503-oxo-Delta(4) steroid;
acetylenic compound;
tertiary amino compound		abortifacient;
contraceptive drug;
hormone antagonist;
synthetic oral contraceptive
mifepristone[no description available]medium3533-oxo-Delta(4) steroid;
acetylenic compound;
tertiary amino compound		abortifacient;
contraceptive drug;
hormone antagonist;
synthetic oral contraceptive
quinpirole hydrochloride[no description available]medium10
imazodan[no description available]medium10
mibefradil dihydrochloride[no description available]medium20
aptiganel hydrochloride[no description available]medium20
phenelzine sulfate[no description available]medium20organic molecular entity
fluoxetine hydrochloride[no description available]medium20hydrochloride;
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
propranolol hydrochloride[no description available]medium20hydrochloride
bupropion hydrochloride[no description available]medium50aromatic ketone
diltiazem hydrochloride[no description available]medium20hydrochlorideantihypertensive agent;
calcium channel blocker;
vasodilator agent
trazodone hydrochloride[no description available]medium50hydrochlorideadrenergic antagonist;
antidepressant;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor
verapamil hydrochloride[no description available]medium50
doxazosin mesylate[no description available]medium30methanesulfonate saltgeroprotector
terfenadine[no description available]medium20diarylmethane
amantadine hydrochloride[no description available]medium40hydrochlorideantiviral agent;
dopamine agonist;
NMDA receptor antagonist
mevastatin[no description available]medium202-pyranones;
carboxylic ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		antifungal agent;
apoptosis inducer;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
fungal metabolite;
Penicillium metabolite
chloroquine diphosphate[no description available]medium20
dobutamine hydrochloride[no description available]medium40hydrochloridebeta-adrenergic agonist;
cardiotonic drug;
sympathomimetic agent
desipramine hydrochloride[no description available]medium20hydrochloridedrug allergen
dopamine hydrochloride[no description available]medium20catecholamine
proadifen hydrochloride[no description available]medium20
4-nitrobenzylthioinosine[no description available]medium20purine nucleoside
metrifudil[no description available]medium10
rutecarpine[no description available]medium20beta-carbolines
trihexyphenidyl hydrochloride[no description available]medium20aralkylamine
thioridazine hydrochloride[no description available]medium20hydrochloridefirst generation antipsychotic;
geroprotector
procainamide hydrochloride[no description available]medium10hydrochlorideanti-arrhythmia drug
siquil[no description available]medium20hydrochlorideanticoronaviral agent
sotalol hydrochloride[no description available]medium10hydrochlorideanti-arrhythmia drug;
beta-adrenergic antagonist
oxymetazoline hydrochloride[no description available]medium20hydrochloridealpha-adrenergic agonist;
nasal decongestant;
sympathomimetic agent;
vasoconstrictor agent
alprenolol hydrochloride[no description available]medium20hydrochloride
2-methoxyestradiol[no description available]medium4017beta-hydroxy steroid;
3-hydroxy steroid		angiogenesis modulating agent;
antimitotic;
antineoplastic agent;
human metabolite;
metabolite;
mouse metabolite
fluphenazine hydrochloride[no description available]medium20phenothiazinesanticoronaviral agent
tryptamine monohydrochloride[no description available]medium20
clomipramine hydrochloride[no description available]medium20hydrochlorideanticoronaviral agent;
antidepressant;
serotonergic antagonist;
serotonergic drug
amiloride hydrochloride[no description available]medium40hydratediuretic;
sodium channel blocker
prazosin hydrochloride[no description available]medium20hydrochloride
mianserin hydrochloride[no description available]medium20hydrochloridegeroprotector
lomefloxacin hydrochloride[no description available]medium40hydrochlorideantimicrobial agent;
antitubercular agent;
photosensitizing agent
fenspiride hydrochloride[no description available]medium20
nilverm[no description available]medium20organic molecular entity
sanguinarine chloride[no description available]medium20
ropinirole hydrochloride[no description available]medium20indoles
plasmenylserine[no description available]medium10O-phosphoserineEC 1.4.7.1 [glutamate synthase (ferredoxin)] inhibitor;
EC 2.5.1.49 (O-acetylhomoserine aminocarboxypropyltransferase) inhibitor;
EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
5-aminovaleric acid hydrochloride[no description available]medium10
n-acetyltryptamine[no description available]medium10acetamides;
indoles
D-serine[no description available]medium10D-alpha-amino acid;
serine zwitterion;
serine		Escherichia coli metabolite;
human metabolite;
NMDA receptor agonist
dihydroergotamine mesylate[no description available]medium20methanesulfonate saltnon-narcotic analgesic;
serotonergic agonist;
vasoconstrictor agent
ranolazine hydrochloride[no description available]medium20
loxapine succinate[no description available]medium30succinate saltgeroprotector
guanfacine hydrochloride[no description available]medium20acetamidesgeroprotector
pirenzepine dihydrochloride[no description available]medium10hydrochloride
labetalol hydrochloride[no description available]medium20salicylamides
acecainide hydrochloride[no description available]medium10
loperamide hydrochloride[no description available]medium40hydrochlorideanticoronaviral agent;
antidiarrhoeal drug;
mu-opioid receptor agonist
maprotiline hydrochloride[no description available]medium20anthracenes
protoporphyrin ix, disodium salt[no description available]medium10
siguazodan[no description available]medium10pyridazinone
3-octadecanamido-2-ethoxypropylphosphocholine[no description available]medium10
chelerythrine chloride[no description available]medium20
tosyllysine chloromethyl ketone[no description available]medium20
5-(n-methyl-n-isobutyl)amiloride[no description available]medium20
1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride[no description available]medium20hydrochlorideEC 2.7.11.13 (protein kinase C) inhibitor
amperozide hydrochloride[no description available]medium20hydrochlorideanxiolytic drug;
dopamine uptake inhibitor;
geroprotector;
second generation antipsychotic;
serotonergic antagonist
pyrrolidine dithiocarbamic acid[no description available]medium20
agroclavine[no description available]medium10ergot alkaloid
s-methylisothiourea sulfate[no description available]medium10
p-Aminobenzamidine dihydrochloride[no description available]medium20organic molecular entity
benzamidine hydrochloride[no description available]medium10
ketorolac tromethamine[no description available]medium40organoammonium saltanalgesic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor
methionine sulfoximine[no description available]medium10L-alpha-amino acid zwitterion;
L-methionine derivative;
methionine sulfoximine;
non-proteinogenic L-alpha-amino acid		EC 6.3.1.2 (glutamate--ammonia ligase) inhibitor;
geroprotector
tretazicar[no description available]medium20
carbetapentane citrate[no description available]medium20carbonyl compound
phentolamine mesylate[no description available]medium40
mephentermine[no description available]medium202-aminooctadecane-1,3-diolEC 2.7.11.13 (protein kinase C) inhibitor;
human metabolite;
mouse metabolite
oxybutynin hydrochloride[no description available]medium40hydrochloride
nimustine[no description available]medium10hydrochlorideantineoplastic agent
cordium[no description available]medium30hydrate;
hydrochloride
L-2-aminoadipic acid[no description available]medium102-aminoadipic acidEscherichia coli metabolite;
human metabolite
prilocaine hydrochloride[no description available]medium20hydrochloridelocal anaesthetic
mor-14[no description available]medium10hydroxypiperidine;
piperidine alkaloid;
tertiary amino compound		anti-HIV agent;
cardioprotective agent;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
plant metabolite
brexanolone[no description available]medium203-hydroxy-5alpha-pregnan-20-oneantidepressant;
GABA modulator;
human metabolite;
intravenous anaesthetic;
sedative
phenylisopropyladenosine[no description available]medium10aromatic amine;
benzenes;
hydrocarbyladenosine;
purine nucleoside;
secondary amino compound		adenosine A1 receptor agonist;
neuroprotective agent
hexamethonium chloride[no description available]medium10
6-(4-nitrobenzylthio)guanosine[no description available]medium20
3-aminopropylphosphonic acid[no description available]medium10phosphonic acids;
primary amino compound;
zwitterion		GABAB receptor agonist
5'-n-methylcarboxamideadenosine[no description available]medium10
3,7-dimethyl-1-propargylxanthine[no description available]medium10
zpck[no description available]medium20
n(6)-phenyladenosine[no description available]medium10purine nucleoside
tetrahydrodeoxycorticosterone[no description available]medium2021-hydroxy steroid
n-methyladenosine[no description available]medium10methyladenosine
mizoribine[no description available]medium30imidazolesanticoronaviral agent
mizoribine[no description available]medium31imidazolesanticoronaviral agent
1-amino-1,3-dicarboxycyclopentane[no description available]medium10
u 73122[no description available]medium10aromatic ether;
aza-steroid;
maleimides		EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor
alphaxalone[no description available]medium10corticosteroid hormone
s-nitrosoglutathione[no description available]medium10glutathione derivative;
nitrosothio compound		bronchodilator agent;
nitric oxide donor;
platelet aggregation inhibitor;
signalling molecule
cp-55,940[no description available]medium20
vanoxerine[no description available]medium20hydrochloridedopamine uptake inhibitor
methyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate[no description available]medium20beta-carbolines
u 69593[no description available]medium20monocarboxylic acid amide;
N-alkylpyrrolidine;
organic heterobicyclic compound;
oxaspiro compound		anti-inflammatory agent;
diuretic;
kappa-opioid receptor agonist
cv 3988[no description available]medium20
beta-carboline-3-carboxylic acid methyl ester[no description available]medium20beta-carbolines
methoctramine[no description available]medium20hydrochloridemuscarinic antagonist
hypotaurine[no description available]medium10aminosulfinic acid;
zwitterion		human metabolite;
metabolite;
mouse metabolite
dihydrokainate[no description available]medium10dicarboxylic acid
gabazine[no description available]medium10
cl 218872[no description available]medium10pyridazines;
ring assembly
betaxolol hydrochloride[no description available]medium20hydrochlorideantihypertensive agent;
beta-adrenergic antagonist
catechin[no description available]medium10hydrategeroprotector
1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine[no description available]medium20hydrobromideserotonergic antagonist
s-methylthiocitrulline[no description available]medium10imidothiocarbamic ester;
L-arginine derivative;
L-ornithine derivative;
non-proteinogenic L-alpha-amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
neuroprotective agent
dihydrocapsaicin[no description available]medium10capsaicinoid
ml 9[no description available]medium10
parthenolide[no description available]medium20germacranolide
3',4'-dichlorobenzamil[no description available]medium20guanidines;
pyrazines
1-(carboxymethylthio)tetradecane[no description available]medium10straight-chain fatty acid
2-iodomelatonin[no description available]medium10acetamides
arcaine, sulfate[no description available]medium10
gr 113808[no description available]medium20indolyl carboxylate ester;
piperidines;
sulfonamide		serotonergic antagonist
gallopamil hydrochloride[no description available]medium20
gamma-glutamylaminomethylsulfonic acid[no description available]medium10
buthionine sulfoximine[no description available]medium202-amino-4-(S-butylsulfonimidoyl)butanoic acidEC 6.3.2.2 (glutamate--cysteine ligase) inhibitor;
ferroptosis inducer
sb 204070a[no description available]medium20
1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine[no description available]medium20(trifluoromethyl)benzenes;
N-alkylpiperazine;
N-arylpiperazine;
primary arylamine;
substituted aniline		geroprotector;
serotonergic agonist
l 655240[no description available]medium10methylindole
san 58035[no description available]medium20
nnc 711[no description available]medium10
4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide[no description available]medium20diarylmethane
e 64[no description available]medium20dicarboxylic acid monoamide;
epoxy monocarboxylic acid;
guanidines;
L-leucine derivative;
zwitterion		antimalarial;
antiparasitic agent;
protease inhibitor
azetidine-2,4-dicarboxylic acid[no description available]medium10
pre 084[no description available]medium20morpholines
1-(2-allylphenoxy)-3-((8-bromoacetylamino-4-menthane-1-yl)amino)-1-propanol[no description available]medium20
sr 2640[no description available]medium20quinolines
ici 204448[no description available]medium10
4-amino-1-(6-chloro-2-pyridyl)piperidine hydrochloride[no description available]medium10
n,n-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide[no description available]medium20phenylindole
3,5-bis(trifluoromethyl)benzyl n-acetyltryptophan[no description available]medium10
8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine[no description available]medium20
l 741626[no description available]medium20piperidines
nisoxetine hydrochloride[no description available]medium20
ng-nitroarginine methyl ester[no description available]medium10hydrochlorideEC 1.14.13.39 (nitric oxide synthase) inhibitor
tilarginine acetate[no description available]medium10
alpha-guanidinoglutaric acid[no description available]medium10L-glutamic acid derivative
3,4-dichloro-n-methyl-n-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide, (trans)-(+-)-isomer[no description available]medium20
imidazole-4-acetic acid hydrochloride[no description available]medium10
nsc-141549[no description available]medium40
2-chloro-2-deoxyglucose[no description available]medium10
idazoxan hydrochloride[no description available]medium20
isoguvacine hydrochloride[no description available]medium10
8-methoxymethyl-3-isobutyl-1-methylxanthine[no description available]medium10oxopurine
cyc 202[no description available]medium402,6-diaminopurinesantiviral drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
Serotonin hydrochloride[no description available]medium10tryptamines
n-phthaloylglutamic acid[no description available]medium10L-glutamic acid derivative;
phthalimides
1,3-dipropyl-7-methylxanthine[no description available]medium10
ag 3-5[no description available]medium10C-nitro compound
n-n-propylnorapomorphine[no description available]medium10aporphine alkaloid
urapidil monohydrochloride[no description available]medium20
aminopterin[no description available]medium30dicarboxylic acidEC 1.5.1.3 (dihydrofolate reductase) inhibitor;
mutagen
azepexole, dihydrochloride[no description available]medium10
2,5-dimethoxy-4-iodoamphetamine hydrochloride[no description available]medium10
abt 980[no description available]medium20
sk&f 75670[no description available]medium20
esatenolol[no description available]medium10atenololbeta-adrenergic antagonist
nbi 27914[no description available]medium20dialkylarylamine;
tertiary amino compound
sb 216763[no description available]medium20indoles;
maleimides
(R)-atenolol[no description available]medium10atenolol
memantine hydrochloride[no description available]medium20hydrochlorideantidepressant;
antiparkinson drug;
dopaminergic agent;
neuroprotective agent;
NMDA receptor antagonist
pefabloc[no description available]medium10
pongidae[no description available]medium20
succinylproline[no description available]medium10N-acyl-amino acid
sb 205384[no description available]medium20thienopyridine
hydrastine[no description available]medium20isoquinolinesmetabolite
gabaculine hydrochloride[no description available]medium10
etiron monohydrobromide[no description available]medium10
bmy 7378[no description available]medium10
vesamicol[no description available]medium10
cortisone[no description available]medium5011-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		human metabolite;
mouse metabolite
vincristine sulfate[no description available]medium50organic sulfate saltantineoplastic agent;
geroprotector
n-methylserotonin oxalate salt[no description available]medium10
nsc 95397[no description available]medium201,4-naphthoquinones
wortmannin[no description available]medium30acetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound		anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent
lithium chloride[no description available]medium10inorganic chloride;
lithium salt		antimanic drug;
geroprotector
canavanine[no description available]medium10amino acid zwitterion;
non-proteinogenic L-alpha-amino acid		phytogenic insecticide;
plant metabolite
5-hydroxytryptophan[no description available]medium105-hydroxytryptophan;
amino acid zwitterion;
hydroxy-L-tryptophan;
non-proteinogenic L-alpha-amino acid		human metabolite;
mouse metabolite;
plant metabolite
ouabain[no description available]medium5011alpha-hydroxy steroid;
14beta-hydroxy steroid;
5beta-hydroxy steroid;
alpha-L-rhamnoside;
cardenolide glycoside;
steroid hormone		anti-arrhythmia drug;
cardiotonic drug;
EC 2.3.3.1 [citrate (Si)-synthase] inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
ion transport inhibitor;
plant metabolite
tosylphenylalanyl chloromethyl ketone[no description available]medium10alpha-chloroketone;
sulfonamide		alkylating agent;
serine proteinase inhibitor
monoiodotyrosine[no description available]medium10amino acid zwitterion;
L-tyrosine derivative;
monoiodotyrosine;
non-proteinogenic L-alpha-amino acid		EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor;
human metabolite;
mouse metabolite
nitroarginine[no description available]medium10guanidines;
L-arginine derivative;
N-nitro compound;
non-proteinogenic L-alpha-amino acid
willardiine[no description available]medium10amino acid zwitterion;
L-alanine derivative;
non-proteinogenic L-alpha-amino acid
cortodoxone[no description available]medium70deoxycortisol;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		human metabolite;
mouse metabolite
amiodarone hydrochloride[no description available]medium20aromatic ketone
dicyclomine hydrochloride[no description available]medium20hydrochlorideantispasmodic drug;
muscarinic antagonist
nortriptyline hydrochloride[no description available]medium40organic tricyclic compoundgeroprotector
paromomycin sulfate[no description available]medium30
Dubinidine[no description available]medium10organic heterotricyclic compound;
organonitrogen heterocyclic compound;
oxacycle
cyclopamine[no description available]medium20piperidinesglioma-associated oncogene inhibitor
s-(4-azidophenacyl)glutathione[no description available]medium10peptide
hydroxylamine hydrochloride[no description available]medium20organic molecular entity
sb 228357[no description available]medium20indolyl carboxylic acid
3,5-dihydroxyphenylglycine[no description available]medium10amino acid zwitterion;
non-proteinogenic L-alpha-amino acid;
resorcinols
actinonin[no description available]medium20
vinpocetine[no description available]medium20alkaloidgeroprotector
dihydroergocristine monomesylate[no description available]medium20methanesulfonate saltalpha-adrenergic antagonist;
geroprotector;
vasodilator agent
resveratrol[no description available]medium20resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger
oleic acid[no description available]medium20octadec-9-enoic acidantioxidant;
Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
Escherichia coli metabolite;
mouse metabolite;
plant metabolite;
solvent
thapsigargin[no description available]medium20butyrate ester;
organic heterotricyclic compound;
sesquiterpene lactone		calcium channel blocker;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor
brivudine[no description available]medium10
5,11-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol[no description available]medium20carbotetracyclic compound;
polyphenol		estrogen receptor agonist;
estrogen receptor antagonist;
geroprotector;
neuroprotective agent
2-amino-3-(5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl)propionic acid[no description available]medium10
adenosine-5'-(n-ethylcarboxamide)[no description available]medium10adenosines;
monocarboxylic acid amide		adenosine A1 receptor agonist;
adenosine A2A receptor agonist;
antineoplastic agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
L-cycloserine[no description available]medium104-amino-1,2-oxazolidin-3-oneanti-HIV agent;
anticonvulsant;
EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitor
1,4-dideoxy-1,4-imino-d-arabinitol[no description available]medium10
purvalanol a[no description available]medium20purvalanol
isoliquiritigenin[no description available]medium20chalconesantineoplastic agent;
biological pigment;
EC 1.14.18.1 (tyrosinase) inhibitor;
GABA modulator;
geroprotector;
metabolite;
NMDA receptor antagonist
rauwolscine[no description available]medium10methyl 17-hydroxy-20xi-yohimban-16-carboxylate
gw9662[no description available]medium20benzamides
calmidazolium[no description available]medium20organic chloride saltapoptosis inducer;
calmodulin antagonist
tropisetron hydrochloride[no description available]medium20
Reactive blue 2[no description available]medium10anthraquinone
5,6-dichloro-1-ethyl-1,3-dihydro-2h-benzimidazol-2-one[no description available]medium10dichlorobenzene
quinidine sulfate[no description available]medium20
methamilane methiodide[no description available]medium10
pilocarpine nitrate[no description available]medium10
r 59949[no description available]medium20diarylmethane
n(6)-cyclopentyladenosine[no description available]medium20
methylatropine nitrate[no description available]medium20
sb 366791[no description available]medium20
ag-213[no description available]medium20
3,3',4,5'-tetrahydroxystilbene[no description available]medium20catechols;
polyphenol;
resorcinols;
stilbenol		antineoplastic agent;
apoptosis inducer;
geroprotector;
hypoglycemic agent;
plant metabolite;
protein kinase inhibitor;
tyrosine kinase inhibitor
bemesetron[no description available]medium20
(S)-(-)-pindolol[no description available]medium10pindolol
levosulpiride[no description available]medium20sulpirideantidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist
caffeic acid[no description available]medium10caffeic acidgeroprotector;
mouse metabolite
4-fluorophenyl-L-alanine[no description available]medium204-fluorophenylalanine;
L-phenylalanine derivative;
non-proteinogenic L-alpha-amino acid
urocanic acid[no description available]medium10urocanic acidhuman metabolite
cotinine[no description available]medium20N-alkylpyrrolidine;
pyridines;
pyrrolidin-2-ones;
pyrrolidine alkaloid		antidepressant;
biomarker;
human xenobiotic metabolite;
plant metabolite
cinnarizine[no description available]high140diarylmethane;
N-alkylpiperazine;
olefinic compound		anti-allergic agent;
antiemetic;
calcium channel blocker;
geroprotector;
H1-receptor antagonist;
histamine antagonist;
muscarinic antagonist
cysteine sulfinic acid[no description available]medium10organosulfinic acid;
S-substituted L-cysteine		Escherichia coli metabolite;
human metabolite;
metabotropic glutamate receptor agonist;
mouse metabolite
d-ap7[no description available]medium10
(1R,2S)-tranylcypromine hydrochloride[no description available]medium40hydrochloride
tacrine hydrochloride[no description available]medium30
4-bromotetramisole, oxalate (1:1), salt(s)-isomer[no description available]medium20
3-hydroxybenzylhydrazine hydrochloride[no description available]medium20
1-(3-chlorophenyl)biguanide hydrochloride[no description available]medium20
4-chlorophenylalanine methyl ester, hydrochloride, (dl)-isomer[no description available]medium10
capsazepine[no description available]medium20benzazepine;
catechols;
monochlorobenzenes;
thioureas		capsaicin receptor antagonist
diphenyleneiodium chloride[no description available]medium20organic chloride saltEC 1.6.3.1. [NAD(P)H oxidase (H2O2-forming)] inhibitor;
G-protein-coupled receptor agonist
azetidine-2,4-dicarboxylic acid, (cis)-isomer[no description available]medium10
tamoxifen citrate[no description available]medium20citrate saltangiogenesis inhibitor;
anticoronaviral agent
pimagedine hydrochloride[no description available]medium10
Betaine Aldehyde Chloride[no description available]medium10quaternary ammonium salt
eskazine[no description available]medium20
monastrol[no description available]medium10enoate ester;
ethyl ester;
phenols;
racemate;
thioureas		antileishmanial agent;
antimitotic;
antineoplastic agent;
EC 3.5.1.5 (urease) inhibitor
u 0126[no description available]medium20aryl sulfide;
dinitrile;
enamine;
substituted aniline		antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
osteogenesis regulator;
vasoconstrictor agent
4-diphenylacetoxy-n-methylpiperidine methiodide[no description available]medium20iodide salt;
quaternary ammonium salt		cholinergic antagonist;
muscarinic antagonist
1-(4-hydroxybenzyl)imidazole-2-thiol[no description available]medium10
2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide[no description available]medium20
bp 897[no description available]medium20naphthalenecarboxamide
trequinsin hydrochloride[no description available]medium20
neboglamine[no description available]medium10
benzatropine methanesulfonate[no description available]medium20
sb 203186[no description available]medium10indolyl carboxylic acid
n-(1-methyl-5-indolyl)-n'-(3-methyl-5-isothiazolyl)urea[no description available]medium201,2-thiazoles;
indoles;
ureas		receptor modulator;
serotonergic antagonist
gw 7647[no description available]medium20aryl sulfide;
monocarboxylic acid;
ureas		PPARalpha agonist
ro 41-0960[no description available]medium20
cgp 13501[no description available]medium10alkylbenzene
n-(2-(4-(4-chlorophenyl)piperazin-1-yl)ethyl)-3-methoxybenzamide[no description available]medium20
brl 15572[no description available]medium20monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
secondary alcohol		geroprotector;
serotonergic antagonist
mrs 1523[no description available]medium20
or486[no description available]medium10
fg 9041[no description available]medium20quinoxaline derivative
iik7[no description available]medium10
sb 415286[no description available]medium20C-nitro compound;
maleimides;
monochlorobenzenes;
phenols;
secondary amino compound;
substituted aniline		antioxidant;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent
dm 235[no description available]medium20
jhw 015[no description available]medium20indolecarboxamide
bw 723c86[no description available]medium20tryptamines
sc 560[no description available]medium20aromatic ether;
monochlorobenzenes;
organofluorine compound;
pyrazoles		angiogenesis modulating agent;
antineoplastic agent;
apoptosis inducer;
cyclooxygenase 1 inhibitor;
non-steroidal anti-inflammatory drug
sc-19220[no description available]medium10aromatic ether
le 300[no description available]medium20indoles
ly 367265[no description available]medium20dihydropyridine;
fluoroindole;
tertiary amino compound;
thiadiazoloquinoline		antidepressant;
geroprotector;
serotonergic antagonist;
serotonin uptake inhibitor
diclofenac sodium[no description available]medium10organic sodium salt
cgp 7930[no description available]medium20alkylbenzene
1,3,5-tris(4-hydroxyphenyl)-4-propyl-1h-pyrazole[no description available]medium20phenols;
pyrazoles		estrogen receptor agonist
sib 1757[no description available]medium20
sphingosine[no description available]medium10sphing-4-eninehuman metabolite;
mouse metabolite
apigenin[no description available]medium20trihydroxyflavoneantineoplastic agent;
metabolite
luteolin[no description available]medium103'-hydroxyflavonoid;
tetrahydroxyflavone		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist
daphnetin[no description available]medium20hydroxycoumarin
genistein[no description available]medium207-hydroxyisoflavonesantineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
timolol maleate[no description available]medium40maleate saltanti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist
brompheniramine maleate[no description available]medium50maleate saltanti-allergic agent
chlorpheniramine maleate[no description available]medium40organic molecular entity
clemastine fumarate[no description available]medium40fumarate saltanti-allergic agent;
antipruritic drug;
H1-receptor antagonist;
muscarinic antagonist
methylergonovine maleate[no description available]medium40ergoline alkaloidgeroprotector
astaxanthine[no description available]medium30carotenol;
carotenone		animal metabolite;
anticoagulant;
antioxidant;
food colouring;
plant metabolite
harman[no description available]medium20harmala alkaloid;
indole alkaloid fundamental parent;
indole alkaloid		anti-HIV agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
plant metabolite
morin[no description available]medium107-hydroxyflavonol;
pentahydroxyflavone		angiogenesis modulating agent;
anti-inflammatory agent;
antibacterial agent;
antihypertensive agent;
antineoplastic agent;
antioxidant;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
hepatoprotective agent;
metabolite;
neuroprotective agent
myricetin[no description available]medium207-hydroxyflavonol;
hexahydroxyflavone		antineoplastic agent;
antioxidant;
cyclooxygenase 1 inhibitor;
food component;
geroprotector;
hypoglycemic agent;
plant metabolite
daidzein[no description available]medium107-hydroxyisoflavonesantineoplastic agent;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
phytoestrogen;
plant metabolite
caffeic acid phenethyl ester[no description available]medium20alkyl caffeate esteranti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
antioxidant;
antiviral agent;
immunomodulator;
metabolite;
neuroprotective agent
rottlerin[no description available]medium20aromatic ketone;
benzenetriol;
chromenol;
enone;
methyl ketone		anti-allergic agent;
antihypertensive agent;
antineoplastic agent;
apoptosis inducer;
K-ATP channel agonist;
metabolite
flupenthixol[no description available]medium20flupenthixoldopaminergic antagonist
n-oleoyldopamine[no description available]medium20catechols;
fatty amide;
N-(fatty acyl)-dopamine;
secondary carboxamide		TRPV1 agonist
pheniramine maleate[no description available]medium30organic molecular entity
tranilast[no description available]medium50amidobenzoic acid;
cinnamamides;
dimethoxybenzene;
secondary carboxamide		anti-allergic agent;
anti-asthmatic drug;
antineoplastic agent;
aryl hydrocarbon receptor agonist;
calcium channel blocker;
hepatoprotective agent;
nephroprotective agent
trimipramine maleate[no description available]medium20maleate saltantidepressant
xylometazoline hydrochloride[no description available]medium20
flunarizine hydrochloride[no description available]medium20diarylmethane
ketotifen fumarate[no description available]medium30organoammonium saltanti-asthmatic drug;
H1-receptor antagonist
cis-flupenthixol dihydrochloride[no description available]medium30hydrochloridegeroprotector
n-arachidonylglycine[no description available]medium20fatty amide;
N-acylglycine
n-oleoylethanolamine[no description available]medium20endocannabinoid;
N-(long-chain-acyl)ethanolamine;
N-acylethanolamine 18:1		EC 3.5.1.23 (ceramidase) inhibitor;
geroprotector;
PPARalpha agonist
cyclosporine[no description available]medium130homodetic cyclic peptideanti-asthmatic drug;
anticoronaviral agent;
antifungal agent;
antirheumatic drug;
carcinogenic agent;
dermatologic drug;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
geroprotector;
immunosuppressive agent;
metabolite
phenoxybenzamine hydrochloride[no description available]medium40organic molecular entity
phenylephrine hydrochloride[no description available]medium10hydrochloride
mepyramine maleate[no description available]medium20
brefeldin a[no description available]medium20macrolide antibioticPenicillium metabolite
fenretinide[no description available]medium30monocarboxylic acid amide;
retinoid		antineoplastic agent;
antioxidant
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid[no description available]medium20benzoic acids;
naphthalenes;
retinoid		antineoplastic agent;
retinoic acid receptor agonist;
teratogenic agent
l-2-(carboxypropyl)glycine[no description available]medium10
4-aminocrotonic acid[no description available]medium10
denopamine[no description available]medium10dimethoxybenzene
l 655,708[no description available]medium20
ro 41-1049[no description available]medium10
sb 200646a[no description available]medium20
seglitide[no description available]medium10
sib 1893[no description available]medium10
su 6656[no description available]medium20
tyrphostin ag 555[no description available]medium20
tyrphostin ag-494[no description available]medium10
tyrphostin b44[no description available]medium20
ag-490[no description available]medium20catechols;
enamide;
monocarboxylic acid amide;
nitrile;
secondary carboxamide		anti-inflammatory agent;
antioxidant;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector;
STAT3 inhibitor
ag 112[no description available]medium20
ag 183[no description available]medium20
semaxinib[no description available]medium30olefinic compound;
oxindoles;
pyrroles		angiogenesis modulating agent;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist
8-(3-chlorostyryl)caffeine[no description available]medium20monochlorobenzenes;
trimethylxanthine		adenosine A2A receptor antagonist;
EC 1.4.3.4 (monoamine oxidase) inhibitor
bay 11-7085[no description available]medium20benzenes;
nitrile;
sulfone		anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
ferroptosis inducer;
NF-kappaB inhibitor
molsidomine[no description available]medium30ethyl ester;
morpholines;
oxadiazole;
zwitterion		antioxidant;
apoptosis inhibitor;
cardioprotective agent;
nitric oxide donor;
vasodilator agent
diamide[no description available]medium101,1'-azobis(N,N-dimethylformamide)
nomifensine maleate[no description available]medium20
nalbuphine hydrochloride[no description available]medium20hydrochloride
isoalloxazine[no description available]medium10benzo[g]pteridine-2,4-dione
vinblastine sulfate[no description available]medium40
n-methylscopolamine bromide[no description available]medium20
dextromethorphan hydrobromide[no description available]medium40hydrate;
hydrobromide
naloxone hydrochloride[no description available]medium10hydrochlorideantidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist
s-trans,trans-farnesylthiosalicylic acid[no description available]medium20sesquiterpenoid
sulindac sulfone[no description available]medium20monocarboxylic acid;
organofluorine compound;
sulfone		apoptosis inducer;
cyclooxygenase 2 inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor
naltrexone hydrochloride[no description available]medium20hydrochlorideantidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist
guanabenz acetate[no description available]medium30dichlorobenzenegeroprotector
nylidrin hydrochloride[no description available]medium20alkylbenzene
triprolidine hydrochloride anhydrous[no description available]medium20hydrochlorideH1-receptor antagonist
fenoterol[no description available]medium30hydrobromidebeta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent
tiapridex[no description available]medium10benzamides
quipazine maleate[no description available]medium20
n-(2-aminoethyl)-4-chlorobenzamide hydrochloride[no description available]medium10
tulobuterol hydrochloride[no description available]medium20organic molecular entity
hp 029[no description available]medium20
n,n,n-trimethyl-1-(4-stilbenoxy)-2-propylammonium iodide[no description available]medium10
6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2h-pyran-2-one[no description available]medium20naphthalenes
nf023[no description available]medium10
nf 449[no description available]medium20
7-chloro-4-hydroxy-2-phenyl-1,8-naphthyridine[no description available]medium20
gr 46611[no description available]medium10
diacetylmonoxime[no description available]medium10
homatropine hydrobromide, (endo-(+-)-isomer)[no description available]medium20
vancomycin hydrochloride[no description available]medium10
moxisylyte hydrochloride[no description available]medium10monoterpenoid
dizocilpine maleate[no description available]medium20maleate salt;
tetracyclic antidepressant		anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist
beta-aminopropionitrile fumarate[no description available]medium10
flupirtine[no description available]medium20
zimelidine hydrochloride[no description available]medium20
pregna-4,17-diene-3,16-dione, (17z)-isomer[no description available]medium20
su 4312[no description available]medium20
gw 1929[no description available]medium20benzophenones
protriptyline hydrochloride[no description available]medium20hydrochlorideantidepressant
n(4)-chloroacetylcytosine arabinoside[no description available]medium10
n-(3-(cyclohexylidene-(1h-imidazol-4-ylmethyl))phenyl)ethanesulfonamide[no description available]medium20
n-(4-amino-2-chlorophenyl)phthalimide[no description available]medium10
cb 34[no description available]medium10
b 43[no description available]medium20aromatic amine;
aromatic ether;
cyclopentanes;
primary amino compound;
pyrrolopyrimidine		EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector
(8R)-7-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,13,14-triol[no description available]medium10aporphine alkaloid
(8R)-7-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,13,14-triol[no description available]medium10aporphine alkaloid
3-(6-chloro-3-pyridazinyl)-3,8-diazabicyclo(3.2.1)octane[no description available]medium10
2-(3,3-diphenylpropylamino)acetamide[no description available]medium20diarylmethane
4-(2-(phenylsulfonylamino)ethylthio)-2,6-difluorophenoxyacetamide[no description available]medium10
gw2974[no description available]medium10pyridopyrimidine
l 162313[no description available]medium20
l-165041[no description available]medium10aromatic ketone
mrs 1754[no description available]medium10oxopurine
s-nitroso-n-acetylpenicillamine[no description available]medium10nitroso compound;
nitrosothio compound		nitric oxide donor;
vasodilator agent
pd 404182[no description available]medium10
sb 222200[no description available]medium20quinolines
dantrolene sodium[no description available]medium50
cr 2945[no description available]medium20
sb 218795[no description available]medium20quinolines
dihydroceramide[no description available]medium10N-acylsphinganine
epinephrine bitartrate[no description available]medium20
bicuculline methobromide[no description available]medium20
butylscopolammonium bromide[no description available]medium30
butaclamol hydrochloride[no description available]medium20
a 38503[no description available]medium20
8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide[no description available]medium10
sk&f 89976-a[no description available]medium10
cv 1808[no description available]medium20purine nucleoside
fluvoxamine maleate[no description available]medium30(trifluoromethyl)benzenes
naloxone benzoylhydrazone[no description available]medium20
2-methyl-6-(phenylethynyl)pyridine hydrochloride[no description available]medium20hydrochlorideanxiolytic drug;
metabotropic glutamate receptor antagonist
amiprilose[no description available]medium10
(R)-fluoxetine hydrochloride[no description available]medium20hydrochlorideantidepressant;
serotonin uptake inhibitor
desmethylselegiline hydrochloride[no description available]medium10
3-morpholino-sydnonimine monohydrochloride[no description available]medium20
t 1032[no description available]medium20
qx-314 bromide[no description available]medium10
(S)-fluoxetine hydrochloride[no description available]medium20hydrochlorideantidepressant;
serotonin uptake inhibitor
sr 59230a[no description available]medium20
u 74389g[no description available]medium20
1-(2-methoxyphenyl)piperazine hydrochloride[no description available]medium20
y 27632, dihydrochloride, (4(r)-trans)-isomer[no description available]medium10
noscapine hydrochloride[no description available]medium20
a 77636[no description available]medium20hydrochlorideantiparkinson drug;
dopamine agonist
cgp 20712a[no description available]medium20
levodopa methyl ester hydrochloride[no description available]medium20
benalfocin hydrochloride[no description available]medium10
lu 19005[no description available]medium20
benoxathian hydrochloride[no description available]medium20
((2-n-butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-oxo-1h-inden-5-yl)oxy)acetic acid, (+)-isomer[no description available]medium20
n-cyclopropyl adenosine-5'-carboxamide[no description available]medium10
cefotaxime sodium[no description available]medium20organic sodium salt
calpain inhibitor iii[no description available]medium20
GR 127935 hydrochloride[no description available]medium20hydrochlorideserotonergic antagonist
mrs 1845[no description available]medium20
1-aminocyclopropane-1-carboxylic acid hydrochloride[no description available]medium20
alaproclate hydrochloride[no description available]medium20
ubenimex[no description available]medium20peptide
3-chloroalanine hydrochloride, (l-ala)-isomer[no description available]medium10
dsp 4 hydrochloride[no description available]medium20
calcimycin[no description available]medium20benzoxazole
(2-(2',6'-dimethoxy)phenoxyethylamino)methylbenzodioxan hydrochloride[no description available]medium20hydrochloridealpha-adrenergic antagonist
2-cyclooctyl-2-hydroxyethylamine hydrochloride[no description available]medium20
cirazoline monohydrochloride[no description available]medium20
adtn[no description available]medium20
apocodeine hydrochloride, (r)-isomer[no description available]medium20
Dihydro-beta-erythroidine hydrobromide[no description available]medium10indoles
lilly 78335[no description available]medium20
efaroxan hydrochloride[no description available]medium20
fenoldopam hydrobromide[no description available]medium20
1-[2-(benzhydryloxy)ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride[no description available]medium20hydrochloridedopamine uptake inhibitor
guvacine hydrochloride[no description available]medium10
7-hydroxy-2-n,n-dipropylaminotetralin hydrobromide[no description available]medium20
8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide, (r)-isomer,[no description available]medium20organic molecular entity
1-(2-(4-(4-fluoro-benzoyl)-piperidin-1-yl)-ethyl)-3,3-dimethyl-1,2-dihydro-indol-2-one[no description available]medium20hydrochloridereceptor modulator;
serotonergic antagonist
4-iodoclonidine[no description available]medium20
4-methylpyrazole monohydrochloride[no description available]medium10
tele-methylhistamine[no description available]medium10
alpha-methyltyrosine methyl ester, monohydrochloride[no description available]medium20
octoclothepine maleate[no description available]medium20
2-(n-phenethyl-n-propyl)amino-5-hydroxytetralin hydrochloride[no description available]medium20
du 24565[no description available]medium20
2-methoxyidazoxan hydrochloride[no description available]medium20
ro 25-6981[no description available]medium20
sk&f 77434[no description available]medium20hydrobromidedopamine agonist;
prodrug
3-[(6aR,9R,10aR)-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-yl]-1,1-diethylurea[no description available]medium20organic heterotetracyclic compound;
organonitrogen heterocyclic compound
demethylcantharidin[no description available]medium20
atropine sulfate[no description available]medium20
1-deoxynojirimycin hydrochloride[no description available]medium10
win 62577[no description available]medium20
quinine sulfate[no description available]medium40hydrate
quercetin[no description available]medium20
rv 538, (r-(r*,r*))-isomer[no description available]medium20
3,4-dichloro-n-methyl-n-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide, (1s-cis)-isomer[no description available]medium20
valproate sodium[no description available]medium20organic sodium saltgeroprotector
u 63557a[no description available]medium10
taurocholic acid, monosodium salt[no description available]medium20bile salt
cefmetazole sodium[no description available]medium10organic sodium saltantimicrobial agent
fusidate sodium[no description available]medium20
cephapirin sodium[no description available]medium30cephalosporin;
organic sodium salt		antibacterial drug
sodium cephalothin[no description available]medium30organic sodium salt
cefazolin sodium[no description available]medium30organic sodium salt
5-hydroxydecanoic acid, monosodium salt[no description available]medium10
ro13-9904[no description available]medium10
phenytoin sodium[no description available]medium10
cr 1409[no description available]medium10
cortisol succinate, sodium salt[no description available]medium20organic molecular entity
lfm a13[no description available]medium10aromatic amide;
dibromobenzene;
enamide;
enol;
nitrile;
secondary carboxamide		antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 2.7.11.21 (polo kinase) inhibitor;
geroprotector;
platelet aggregation inhibitor
l 701324[no description available]medium10quinolines
hispidin[no description available]medium202-pyranones;
catechols		antioxidant;
EC 2.7.11.13 (protein kinase C) inhibitor;
fungal metabolite
minocycline hydrochloride[no description available]medium50
demeclocycline hydrochloride[no description available]medium40
sepiapterin[no description available]medium10sepiapterin
isoxanthopterin[no description available]medium10dihydroxypteridine
zaprinast[no description available]medium20triazolopyrimidines
thiolactomycin[no description available]medium20
2,4-diaminohypoxanthine[no description available]medium10hydroxypyrimidine
quazinone[no description available]medium10
8-bromocyclic gmp, sodium salt[no description available]medium20organic sodium saltmuscle relaxant;
protein kinase G agonist
ag-879[no description available]medium20
albendazole[no description available]medium90aryl sulfide;
benzimidazoles;
benzimidazolylcarbamate fungicide;
carbamate ester		anthelminthic drug;
microtubule-destabilising agent;
tubulin modulator
troglitazone[no description available]medium100chromanes;
thiazolidinone		anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent
sr141716[no description available]medium40amidopiperidine;
carbohydrazide;
dichlorobenzene;
monochlorobenzenes;
pyrazoles		anti-obesity agent;
appetite depressant;
CB1 receptor antagonist
tolfenamic acid[no description available]medium10aminobenzoic acid;
organochlorine compound;
secondary amino compound		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
emetine[no description available]medium40isoquinoline alkaloid;
pyridoisoquinoline		antiamoebic agent;
anticoronaviral agent;
antiinfective agent;
antimalarial;
antineoplastic agent;
antiprotozoal drug;
antiviral agent;
autophagy inhibitor;
emetic;
expectorant;
plant metabolite;
protein synthesis inhibitor
clobetasol propionate[no description available]medium2011beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
fluorinated steroid;
glucocorticoid		anti-inflammatory drug
digoxin[no description available]medium110cardenolide glycoside;
steroid saponin		anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope
digitoxigenin[no description available]medium1014beta-hydroxy steroid;
3beta-hydroxy steroid
kendomycin[no description available]medium10benzofurans
4-nonylphenol[no description available]medium10phenolsenvironmental contaminant
estriol[no description available]high5016alpha-hydroxy steroid;
17beta-hydroxy steroid;
3-hydroxy steroid		estrogen;
human metabolite;
human xenobiotic metabolite;
mouse metabolite
aldosterone[no description available]medium2011beta-hydroxy steroid;
18-oxo steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
mineralocorticoid;
primary alpha-hydroxy ketone;
steroid aldehyde		human metabolite;
mouse metabolite
etiocholanolone[no description available]medium1017-oxo steroid;
3alpha-hydroxy steroid;
androstanoid		human metabolite;
mouse metabolite
dehydroepiandrosterone[no description available]medium15017-oxo steroid;
3beta-hydroxy-Delta(5)-steroid;
androstanoid		androgen;
human metabolite;
mouse metabolite
dehydroepiandrosterone[no description available]medium15117-oxo steroid;
3beta-hydroxy-Delta(5)-steroid;
androstanoid		androgen;
human metabolite;
mouse metabolite
17-desoxyestradiol[no description available]medium103-hydroxy steroid;
phenolic steroid;
phenols		estrogen
ethinyl estradiol[no description available]high29517-hydroxy steroid;
3-hydroxy steroid;
terminal acetylenic compound		xenoestrogen
ethinyl estradiol[no description available]high29017-hydroxy steroid;
3-hydroxy steroid;
terminal acetylenic compound		xenoestrogen
methyltestosterone[no description available]high17017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
enone		anabolic agent;
androgen;
antineoplastic agent
desoxycorticosterone[no description available]medium5020-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
mineralocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite
norethindrone[no description available]high20317beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound;
tertiary alcohol		progestin;
synthetic oral contraceptive
norethindrone[no description available]high20017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound;
tertiary alcohol		progestin;
synthetic oral contraceptive
4-tert-octylphenol[no description available]medium10alkylbenzene
pregnenolone[no description available]medium3020-oxo steroid;
3beta-hydroxy-Delta(5)-steroid;
C21-steroid		human metabolite;
mouse metabolite
nandrolone[no description available]high16117beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
anabolic androgenic steroid		human metabolite
nandrolone[no description available]high16017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
anabolic androgenic steroid		human metabolite
mestanolone[no description available]medium103-oxo-5alpha-steroid
androstenediol[no description available]medium1017beta-hydroxy steroid;
3beta-hydroxy-Delta(5)-steroid		androgen;
human metabolite;
mouse metabolite;
radiation protective agent
dihydrotestosterone[no description available]high22217beta-hydroxy steroid;
17beta-hydroxyandrostan-3-one;
3-oxo-5alpha-steroid		androgen;
Daphnia magna metabolite;
human metabolite;
mouse metabolite
dihydrotestosterone[no description available]high22017beta-hydroxy steroid;
17beta-hydroxyandrostan-3-one;
3-oxo-5alpha-steroid		androgen;
Daphnia magna metabolite;
human metabolite;
mouse metabolite
mesterolone[no description available]medium303-oxo-5alpha-steroid
gestrinone[no description available]medium660oxo steroid
gestrinone[no description available]medium6610oxo steroid
desogestrel[no description available]high3117beta-hydroxy steroid;
terminal acetylenic compound		contraceptive drug;
progestin;
synthetic oral contraceptive
desogestrel[no description available]high3017beta-hydroxy steroid;
terminal acetylenic compound		contraceptive drug;
progestin;
synthetic oral contraceptive
16-hydroxytestosterone[no description available]medium1016alpha-hydroxy steroid;
17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
androstanoid;
C19-steroid;
diol;
secondary alcohol		androgen
2-iodoestradiol[no description available]medium10
17-alpha-hydroxypregnenolone[no description available]medium2017alpha-hydroxy-C21-steroid;
17alpha-hydroxy steroid;
3beta-hydroxy-Delta(5)-steroid;
hydroxypregnenolone;
tertiary alpha-hydroxy ketone		human metabolite;
mouse metabolite
bolasterone[no description available]medium103-hydroxy steroidandrogen
matairesinol[no description available]medium10gamma-lactone;
lignan;
polyphenol		angiogenesis inhibitor;
anti-asthmatic agent;
phytoestrogen;
plant metabolite
4-androstene-3,17-diol[no description available]medium103-hydroxy steroidandrogen
3,4-divanillyltetrahydrofuran[no description available]medium10
equilin[no description available]medium1017-oxo steroid;
3-hydroxy steroid
naringenin[no description available]medium10(2S)-flavan-4-one;
naringenin		expectorant;
plant metabolite
equilenin[no description available]medium1017-oxo steroid;
3-hydroxy steroid		antioxidant;
mammalian metabolite
etonogestrel[no description available]medium2017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound		contraceptive drug;
female contraceptive drug;
progestin
chlordecone[no description available]medium10cyclic ketone;
organochlorine compound		insecticide;
persistent organic pollutant
5,6-dimethylbenzimidazole[no description available]medium10dimethylbenzimidazoleEscherichia coli metabolite;
human metabolite
hexachlorocyclohexane[no description available]medium30chlorocyclohexane
parathion[no description available]medium10C-nitro compound;
organic thiophosphate;
organothiophosphate insecticide		acaricide;
agrochemical;
avicide;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
mouse metabolite
pentachlorophenol[no description available]medium10aromatic fungicide;
chlorophenol;
organochlorine pesticide;
pentachlorobenzenes		human xenobiotic metabolite
amitrole[no description available]medium10aromatic amine;
triazoles		carotenoid biosynthesis inhibitor;
EC 1.11.1.6 (catalase) inhibitor;
herbicide
ametantrone[no description available]medium10
2-aminothiazole[no description available]medium101,3-thiazoles;
primary amino compound
azinphosmethyl[no description available]medium10benzotriazines;
organic thiophosphate;
organothiophosphate insecticide		agrochemical;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor
bromhexine[no description available]medium30organobromine compound;
substituted aniline;
tertiary amino compound		mucolytic
bupivacaine[no description available]medium40aromatic amide;
piperidinecarboxamide;
tertiary amino compound
carbazilquinone[no description available]medium10organic molecular entity
carmofur[no description available]medium10organohalogen compound;
pyrimidines
celiprolol[no description available]medium10aromatic ketone
chloral hydrate[no description available]medium20aldehyde hydrate;
ethanediol;
organochlorine compound		general anaesthetic;
mouse metabolite;
sedative;
xenobiotic
chloroquine[no description available]medium80aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
chlorthalidone[no description available]medium40isoindoles;
monochlorobenzenes;
sulfonamide
clenbuterol[no description available]medium20amino alcohol;
dichlorobenzene;
ethanolamines;
primary arylamine;
secondary amino compound;
substituted aniline		beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent
clioquinol[no description available]medium40monohydroxyquinoline;
organochlorine compound;
organoiodine compound		antibacterial agent;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
antiprotozoal drug;
chelator;
copper chelator
cycloleucine[no description available]medium10non-proteinogenic alpha-amino acidEC 2.5.1.6 (methionine adenosyltransferase) inhibitor
dapsone[no description available]medium140substituted aniline;
sulfone		anti-inflammatory drug;
antiinfective agent;
antimalarial;
leprostatic drug
dapsone[no description available]medium141substituted aniline;
sulfone		anti-inflammatory drug;
antiinfective agent;
antimalarial;
leprostatic drug
debrisoquin[no description available]medium30carboxamidine;
isoquinolines		adrenergic agent;
antihypertensive agent;
human metabolite;
sympatholytic agent
dicamba[no description available]medium10dichlorobenzene;
methoxybenzoic acid		agrochemical;
environmental contaminant;
herbicide;
synthetic auxin;
xenobiotic
dichlorphenamide[no description available]medium30dichlorobenzene;
sulfonamide		antiglaucoma drug;
EC 4.2.1.1 (carbonic anhydrase) inhibitor;
ophthalmology drug
dicyclomine[no description available]medium30carboxylic ester;
tertiary amine		antispasmodic drug;
muscarinic antagonist;
parasympatholytic
diethylcarbamazine[no description available]medium30N-carbamoylpiperazine;
N-methylpiperazine
dimercaprol[no description available]medium50dithiol;
primary alcohol		chelator
dinitolmide[no description available]medium10dinitrotoluene
dipyrone[no description available]medium10amino sulfonic acid;
pyrazoles		anti-inflammatory agent;
antipyretic;
antirheumatic drug;
cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug;
prodrug
ethinamate[no description available]medium10carbamate ester;
terminal acetylenic compound		sedative
berotek[no description available]medium30resorcinols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent;
tocolytic agent
glutethimide[no description available]medium50piperidines
guanethidine[no description available]medium50azocanes;
guanidines		adrenergic antagonist;
antihypertensive agent;
sympatholytic agent
hydralazine[no description available]medium50azaarene;
hydrazines;
ortho-fused heteroarene;
phthalazines		antihypertensive agent;
vasodilator agent
lidocaine[no description available]medium90benzenes;
monocarboxylic acid amide;
tertiary amino compound		anti-arrhythmia drug;
drug allergen;
environmental contaminant;
local anaesthetic;
xenobiotic
iproniazid[no description available]medium90carbohydrazide;
pyridines
isoproterenol[no description available]medium50catechols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent
lomustine[no description available]medium60N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
mechlorethamine[no description available]medium40nitrogen mustard;
organochlorine compound		alkylating agent
mephenytoin[no description available]medium50imidazolidine-2,4-dioneanticonvulsant
mepivacaine[no description available]medium40piperidinecarboxamidedrug allergen;
local anaesthetic
meprobamate[no description available]medium50organic molecular entity
methoxyflurane[no description available]medium30ether;
organochlorine compound;
organofluorine compound		hepatotoxic agent;
inhalation anaesthetic;
nephrotoxic agent;
non-narcotic analgesic
methyclothiazide[no description available]medium20benzothiadiazine
methyl salicylate[no description available]medium20benzoate ester;
methyl ester;
salicylates		flavouring agent;
insect attractant;
metabolite
methylphenidate[no description available]medium60beta-amino acid ester;
methyl ester;
piperidines
moclobemide[no description available]medium20benzamides;
monochlorobenzenes;
morpholines		antidepressant;
environmental contaminant;
xenobiotic
clorgyline[no description available]medium10aromatic ether;
dichlorobenzene;
terminal acetylenic compound;
tertiary amino compound		antidepressant;
EC 1.4.3.4 (monoamine oxidase) inhibitor
nalidixic acid[no description available]medium601,8-naphthyridine derivative;
monocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antimicrobial agent;
DNA synthesis inhibitor
nitroglycerin[no description available]medium40nitroglycerolexplosive;
muscle relaxant;
nitric oxide donor;
prodrug;
tocolytic agent;
vasodilator agent;
xenobiotic
nylidrin[no description available]medium20alkylbenzene
oxprenolol[no description available]medium60aromatic ether
4-dichlorobenzene[no description available]medium30dichlorobenzeneinsecticide
phenacemide[no description available]medium20acetamides
phenacetin[no description available]medium70acetamides;
aromatic ether		cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug
phenazopyridine[no description available]medium10diaminopyridine;
monoazo compound		anticoronaviral agent;
carcinogenic agent;
local anaesthetic;
non-narcotic analgesic
phenobarbital[no description available]medium50barbituratesanticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative
phentermine[no description available]medium50primary amineadrenergic agent;
appetite depressant;
central nervous system drug;
central nervous system stimulant;
dopaminergic agent;
sympathomimetic agent
pipobroman[no description available]medium10N-acylpiperazine;
organobromine compound;
tertiary carboxamide		alkylating agent;
antineoplastic agent
polythiazide[no description available]medium20benzothiadiazine
prilocaine[no description available]medium10amino acid amide;
monocarboxylic acid amide		anticonvulsant;
local anaesthetic
primaquine[no description available]medium70aminoquinoline;
aromatic ether;
N-substituted diamine		antimalarial
probucol[no description available]medium70dithioketal;
polyphenol		anti-inflammatory drug;
anticholesteremic drug;
antilipemic drug;
antioxidant;
cardiovascular drug
procaine[no description available]medium30benzoate ester;
substituted aniline;
tertiary amino compound		central nervous system depressant;
drug allergen;
local anaesthetic;
peripheral nervous system drug
resorcinol[no description available]medium10benzenediol;
phenolic donor;
resorcinols		erythropoietin inhibitor;
sensitiser
semustine[no description available]medium10N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent;
carcinogenic agent
streptonigrin[no description available]medium10pyridines;
quinolone		antimicrobial agent;
antineoplastic agent
sulfacetamide[no description available]medium20N-sulfonylcarboxamide;
substituted aniline		antibacterial drug;
antiinfective agent;
antimicrobial agent;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfaguanidine[no description available]medium10sulfonamide antibioticantiinfective agent
sulfamethazine[no description available]medium30pyrimidines;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
antiinfective agent;
antimicrobial agent;
carcinogenic agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
ligand;
xenobiotic
sulfamethoxazole[no description available]medium50isoxazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial agent;
antiinfective agent;
antimicrobial agent;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
epitope;
P450 inhibitor;
xenobiotic
sulfamethoxypyridazine[no description available]medium10pyridazines;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfanilamide[no description available]medium70substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial agent;
drug allergen;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
sulfapyridine[no description available]medium20pyridines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
dermatologic drug;
drug allergen;
environmental contaminant;
xenobiotic
sulfathiazole[no description available]medium301,3-thiazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
xenobiotic
sulfisoxazole[no description available]medium30isoxazoles;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
drug allergen
sulfoxone[no description available]medium10sulfonamide
tegafur[no description available]medium20organohalogen compound;
pyrimidines
terbutaline[no description available]medium70phenylethanolamines;
resorcinols		anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
hypoglycemic agent;
sympathomimetic agent;
tocolytic agent
tetracaine[no description available]medium30benzoate ester;
tertiary amino compound		local anaesthetic
thiabendazole[no description available]medium401,3-thiazoles;
benzimidazole fungicide;
benzimidazoles		antifungal agrochemical;
antinematodal drug
2,2'-thiodiethanol[no description available]medium10aliphatic sulfide;
diol		antineoplastic agent;
antioxidant;
metabolite;
solvent
trichlormethiazide[no description available]medium10benzothiadiazine;
sulfonamide antibiotic		antihypertensive agent;
diuretic
2,2',2''-trichlorotriethylamine[no description available]medium10
urethane[no description available]medium20carbamate esterfungal metabolite;
mutagen
vesamicol[no description available]medium10piperidines
triethylenemelamine[no description available]medium101,3,5-triazinesalkylating agent;
insect sterilant
allobarbital[no description available]medium20barbiturates
paramethasone[no description available]medium20fluorinated steroid
azauridine[no description available]medium10N-glycosyl-1,2,4-triazineantimetabolite;
antineoplastic agent;
drug metabolite
penicillin g[no description available]medium50penicillin allergen;
penicillin		antibacterial drug;
drug allergen;
epitope
idoxuridine[no description available]medium30organoiodine compound;
pyrimidine 2'-deoxyribonucleoside		antiviral drug;
DNA synthesis inhibitor
chloramphenicol[no description available]medium70C-nitro compound;
carboxamide;
diol;
organochlorine compound		antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor
dromostanolone[no description available]medium1017beta-hydroxy steroid;
3-oxo-5alpha-steroid;
anabolic androgenic steroid		anabolic agent;
antineoplastic agent
cephalothin[no description available]medium30azabicycloalkene;
beta-lactam antibiotic allergen;
carboxylic acid;
cephalosporin;
semisynthetic derivative;
thiophenes		antibacterial drug;
antimicrobial agent
thiamine[no description available]medium10organic chloride salt;
vitamin B1
methicillin[no description available]medium10penicillin allergen;
penicillin		antibacterial drug
niridazole[no description available]medium301,3-thiazoles;
C-nitro compound
cloxacillin[no description available]medium30penicillin allergen;
penicillin;
semisynthetic derivative		antibacterial agent;
antibacterial drug
zoxazolamine[no description available]medium30benzoxazole
aniline[no description available]medium10anilines;
primary arylamine
uracil mustard[no description available]medium30aminouracil;
nitrogen mustard
oxacillin[no description available]medium20penicillinantibacterial agent;
antibacterial drug
fluocinolone acetonide[no description available]medium2011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic ketal;
fluorinated steroid;
glucocorticoid;
organic heteropentacyclic compound;
primary alpha-hydroxy ketone		anti-inflammatory drug;
antipruritic drug
triaziquone[no description available]medium101,4-benzoquinones;
aziridines		alkylating agent;
antineoplastic agent
ampicillin[no description available]medium30beta-lactam antibiotic;
penicillin allergen;
penicillin		antibacterial drug
mannitol[no description available]medium80mannitolallergen;
antiglaucoma drug;
compatible osmolytes;
Escherichia coli metabolite;
food anticaking agent;
food bulking agent;
food humectant;
food stabiliser;
food thickening agent;
hapten;
metabolite;
osmotic diuretic;
sweetening agent
sulfobromophthalein sodium[no description available]medium20organic sodium saltdye
dalapon[no description available]medium10carboxylic acid;
organohalogen compound
methylpentynol[no description available]medium10ynone
penicillin v[no description available]medium30penicillin allergen;
penicillin
isosorbide dinitrate[no description available]medium50glucitol derivative;
nitrate ester		nitric oxide donor;
vasodilator agent
pseudoephedrine[no description available]medium30phenylethanolamines;
secondary alcohol;
secondary amino compound		anti-asthmatic drug;
bronchodilator agent;
central nervous system drug;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
fenoprop[no description available]medium10monocarboxylic acidphenoxy herbicide
2-methyl-4-chlorophenoxyacetic acid[no description available]medium10chlorophenoxyacetic acid;
monochlorobenzenes		environmental contaminant;
phenoxy herbicide;
synthetic auxin
dicloran[no description available]medium10aromatic fungicide;
dichlorobenzene;
nitroaniline		antifungal agrochemical
phenylhydrazine[no description available]medium10phenylhydrazinesxenobiotic
dyrene[no description available]medium10monochlorobenzenes;
organochlorine pesticide;
secondary amino compound;
triazines		antifungal agrochemical
acrolein[no description available]medium10enalherbicide;
human xenobiotic metabolite;
toxin
tetraethylenepentamine[no description available]medium10polyazaalkanecopper chelator
ergotamine[no description available]medium20peptide ergot alkaloidalpha-adrenergic agonist;
mycotoxin;
non-narcotic analgesic;
oxytocic;
serotonergic agonist;
vasoconstrictor agent
chloranil[no description available]medium101,4-benzoquinones;
organochlorine compound		EC 2.7.1.33 (pantothenate kinase) inhibitor;
metabolite
amiben[no description available]medium10chlorobenzoic acid
monuron[no description available]medium103-(3,4-substituted-phenyl)-1,1-dimethylurea;
monochlorobenzenes		environmental contaminant;
herbicide;
xenobiotic
iminodiacetic acid[no description available]medium10amino dicarboxylic acid;
glycine derivative;
non-proteinogenic alpha-amino acid		chelator
phenetidine[no description available]medium10aromatic ether;
primary amino compound;
substituted aniline		drug metabolite
diazooxonorleucine[no description available]medium10amino acid zwitterion;
diazo compound;
ketone;
non-proteinogenic L-alpha-amino acid		analgesic;
antibacterial agent;
antimetabolite;
antineoplastic agent;
antiviral agent;
apoptosis inducer;
bacterial metabolite;
EC 2.4.2.14 (amidophosphoribosyltransferase) inhibitor;
EC 3.5.1.2 (glutaminase) inhibitor;
EC 6.3.4.2 [CTP synthase (glutamine hydrolyzing)] inhibitor;
EC 6.3.5.1 [NAD(+) synthase (glutamine-hydrolysing)] inhibitor;
EC 6.3.5.2 [GMP synthase (glutamine-hydrolysing)] inhibitor;
EC 6.3.5.3 (phosphoribosylformylglycinamidine synthase) inhibitor;
EC 6.3.5.4 [asparagine synthase (glutamine-hydrolysing)] inhibitor;
EC 6.3.5.5 [carbamoyl-phosphate synthase (glutamine-hydrolysing)] inhibitor;
glutamine antagonist
methylpentynol carbamate[no description available]medium10
mechlorethamine n-oxide[no description available]medium10nitrogen mustard
linuron[no description available]medium10dichlorobenzene;
phenylureas		agrochemical;
environmental contaminant;
herbicide;
xenobiotic
carbutamide[no description available]medium20benzenes;
sulfonamide
hydantoins[no description available]medium10imidazolidine-2,4-dione
plumbagin[no description available]medium10hydroxy-1,4-naphthoquinone;
phenols		anticoagulant;
antineoplastic agent;
immunological adjuvant;
metabolite
pamaquine[no description available]medium10aminoquinoline
mustard gas[no description available]medium10ethyl sulfide;
organochlorine compound		alkylating agent;
carcinogenic agent;
vesicant
hesperidin[no description available]medium203'-hydroxyflavanones;
4'-methoxyflavanones;
dihydroxyflavanone;
disaccharide derivative;
flavanone glycoside;
monomethoxyflavanone;
rutinoside		mutagen
medroxyprogesterone[no description available]medium47017alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone		contraceptive drug;
progestin;
synthetic oral contraceptive
medroxyprogesterone[no description available]medium47817alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone		contraceptive drug;
progestin;
synthetic oral contraceptive
apronalide[no description available]medium10N-acylurea
4,6-dinitro-o-cresol[no description available]medium10dinitrophenol acaricide;
hydroxytoluene;
nitrotoluene		dinitrophenol insecticide;
fungicide;
herbicide
metahexamide[no description available]medium10benzenes;
sulfonamide
toyocamycin[no description available]medium10antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
nitrile;
ribonucleoside		antimetabolite;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite
hadacidin[no description available]medium10aldehyde;
monocarboxylic acid;
N-hydroxy-alpha-amino-acid		antimicrobial agent;
antineoplastic agent;
Penicillium metabolite;
teratogenic agent
carbophenothion[no description available]medium10organic sulfide
porfiromycin[no description available]medium10
deoxyuridine[no description available]medium10pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
testolactone[no description available]medium103-oxo-Delta(1),Delta(4)-steroid;
seco-androstane
pyrithioxin[no description available]medium10methylpyridines
nsc 65346[no description available]medium10nucleoside analogueprotein kinase inhibitor
guanazole[no description available]medium10aromatic amine;
triazoles		antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor
meturedepa[no description available]medium10phosphoramide
ioxynil[no description available]medium10iodophenol;
nitrile		environmental contaminant;
herbicide;
xenobiotic
bromoxynil[no description available]medium10dibromobenzene;
hydroxynitrile;
phenols		environmental contaminant;
herbicide;
xenobiotic
picloram[no description available]medium10aminopyridine;
chloropyridine;
organochlorine pesticide;
pyridinemonocarboxylic acid		herbicide;
synthetic auxin
ethoglucid[no description available]medium10epoxide
azaribine[no description available]medium10acetate ester;
N-glycosyl-1,2,4-triazine		antipsoriatic;
prodrug
1,3,5-triglycidyl-s-triazinetrione[no description available]medium10
acetophenazine[no description available]medium20N-(2-hydroxyethyl)piperazine;
N-alkylpiperazine;
phenothiazines		phenothiazine antipsychotic drug
dicloxacillin[no description available]medium40dichlorobenzene;
penicillin		antibacterial drug
improsan[no description available]medium10organosulfonic ester
streptomycin[no description available]medium70antibiotic antifungal drug;
antibiotic fungicide;
streptomycins		antibacterial drug;
antifungal agrochemical;
antimicrobial agent;
antimicrobial drug;
bacterial metabolite;
protein synthesis inhibitor
piperacetazine[no description available]medium10phenothiazines
carbenicillin[no description available]medium30penicillin allergen;
penicillin		antibacterial drug
floxacillin[no description available]medium30penicillin allergen;
penicillin		antibacterial drug
pentaquine[no description available]medium10
isopentenyladenosine[no description available]medium10N-ribosyl-N(6)-isopentenyladenine;
nucleoside analogue		antineoplastic agent;
plant growth regulator;
plant metabolite
ancitabine[no description available]medium10diol;
organic heterotricyclic compound		antimetabolite;
antineoplastic agent;
prodrug
phenacid[no description available]medium10
xipamide[no description available]medium30benzamides
pentamethylmelamine[no description available]medium10
calusterone[no description available]medium103-hydroxy steroidandrogen
etoprine[no description available]medium10
razoxane[no description available]medium10N-alkylpiperazine
fludarabine phosphate[no description available]medium30nucleoside analogue;
organofluorine compound;
purine arabinonucleoside monophosphate		antimetabolite;
antineoplastic agent;
antiviral agent;
DNA synthesis inhibitor;
immunosuppressive agent;
prodrug
azetepa[no description available]medium10phosphoramide
ripazepam[no description available]medium10benzenes
prednimustine[no description available]medium10corticosteroid hormone
amygdalin[no description available]medium10cyanogenic glycoside;
disaccharide derivative;
gentiobioside		plant metabolite
amineptin[no description available]medium50amino acid;
carbocyclic fatty acid;
carbotricyclic compound;
secondary amino compound		antidepressant;
dopamine uptake inhibitor
ticarcillin[no description available]medium10penicillin allergen;
penicillin		antibacterial drug
etidocaine[no description available]medium20amino acid amidelocal anaesthetic
nimustine[no description available]medium20aminopyrimidine;
N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
butibufen[no description available]medium20monoterpenoid
spiromustine[no description available]medium10
diaziquone[no description available]medium101,4-benzoquinones;
aziridines;
carbamate ester;
enamine		alkylating agent;
antineoplastic agent
triciribine phosphate[no description available]medium10
bw-755c[no description available]medium10
piritrexim[no description available]medium30
caracemide[no description available]medium10
bambuterol[no description available]medium40carbamate ester;
phenylethanolamines		anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
prodrug;
sympathomimetic agent;
tocolytic agent
cilazapril, anhydrous[no description available]medium20dicarboxylic acid monoester;
ethyl ester;
pyridazinodiazepine		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
2,5-bis(1-aziridinyl)-3,6-bis(2-methoxyethoxy)-4-benzoquinone[no description available]medium101,4-benzoquinones
morzid[no description available]medium10morpholines
febrifugine[no description available]medium10quinazolines
thymine arabinoside[no description available]medium10N-glycosyl compound
psicofuranine[no description available]medium10psicose derivative;
purine nucleoside
triciribine[no description available]medium10nucleoside analogueEC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
5-chloro-2'-deoxyuridine[no description available]medium10
bendamustine[no description available]medium30benzimidazoles
trofosfamide[no description available]medium10ifosfamides
4-aminobenzoic acid-n-xyloside[no description available]medium10
fotrin[no description available]medium10
sufosfamide[no description available]medium10
propatyl nitrate[no description available]medium10nitrate ester
sulfamidochrysoidine[no description available]medium10
ibopamine[no description available]medium20benzoate ester;
phenols
pumitepa[no description available]medium10
elmustine[no description available]medium10
forphenicinol[no description available]medium10
dipropylacetamide[no description available]medium10fatty amidegeroprotector;
metabolite;
teratogenic agent
inproquone[no description available]medium10
neplanocin a[no description available]medium10
1-ethoxysilatrane[no description available]medium10
nsc-172755[no description available]medium10
streptovitacin a[no description available]medium10
cb 10375[no description available]medium10
carbenicillin indanyl[no description available]medium10penicillin
cb 1837[no description available]medium10
hexaphosphamide[no description available]medium10
dipin[no description available]medium10
phosphazine[no description available]medium10
diiodobenzotepa[no description available]medium10
icig 1163[no description available]medium10
bimolane[no description available]medium10
thiodipin[no description available]medium10
fluoxydine[no description available]medium10
imiphos[no description available]medium10
aldophosphamide[no description available]medium10nitrogen mustard
perindopril[no description available]medium30alpha-amino acid ester;
dicarboxylic acid monoester;
ethyl ester;
organic heterobicyclic compound		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione[no description available]medium10
oxymatrine[no description available]medium10alkaloid;
tertiary amine oxide
1,1,2-trichloroethanol[no description available]medium10
iremycin[no description available]medium10
n,n'-bis((2-chloroethyl)nitrosocarbamoyl)cystamine[no description available]medium10
hainanensine[no description available]medium10
ritrosulfan[no description available]medium10
damvar[no description available]medium10
benzo-tepa[no description available]medium10
tevenel[no description available]medium10sulfonamide
tac 278[no description available]medium10
(4r)-3-((2s)-3-mercapto-2-methylpropanoyl)-4- thiazolidinecarboxylic acid[no description available]medium10
atropine[no description available]medium70
deflazacort[no description available]medium20corticosteroid hormone
hexestrol diphosphate[no description available]medium10
carbocysteine[no description available]medium10L-cysteine thioether;
non-proteinogenic L-alpha-amino acid		mucolytic
demecolcine[no description available]medium10alkaloid;
secondary amino compound		antineoplastic agent;
microtubule-destabilising agent
nsc-89199[no description available]medium10carbamate ester;
organochlorine compound;
steroid phosphate
phenethicillin[no description available]medium20penicillin allergen;
penicillin
indicine-n-oxide[no description available]medium10
trimethoprim, sulfamethoxazole drug combination[no description available]medium20
oxytocin[no description available]medium30heterodetic cyclic peptide;
peptide hormone		oxytocic;
vasodilator agent
digitoxin[no description available]medium50cardenolide glycosideEC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor
angustibalin[no description available]medium10sesquiterpene lactone
metrizamide[no description available]medium20amino sugar
retinol[no description available]medium50retinol;
vitamin A		human metabolite;
mouse metabolite;
plant metabolite
clindamycin[no description available]medium30
formycin[no description available]medium10formycinantineoplastic agent
tiazofurin[no description available]medium201,3-thiazoles;
C-glycosyl compound;
monocarboxylic acid amide		antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
prodrug
azaserine[no description available]medium30carboxylic ester;
diazo compound;
L-serine derivative;
non-proteinogenic L-alpha-amino acid		antifungal agent;
antimetabolite;
antimicrobial agent;
antineoplastic agent;
glutamine antagonist;
immunosuppressive agent;
metabolite
dipyrone[no description available]medium20organic sodium saltanti-inflammatory agent;
antipyretic;
antirheumatic drug;
cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug;
prodrug
4-[[bis(2-hydroxyethyl)amino]methyl]-2,6-ditert-butylphenol[no description available]medium10alkylbenzene
aceglatone[no description available]medium10organic molecular entity
carbenoxolone[no description available]medium30
amygdalin[no description available]medium10amygdalinantineoplastic agent;
apoptosis inducer;
plant metabolite
mitobronitol[no description available]medium10alcohol;
organobromine compound
leuprolide[no description available]high6517oligopeptideanti-estrogen;
antineoplastic agent;
gonadotropin releasing hormone agonist
leuprolide[no description available]high650oligopeptideanti-estrogen;
antineoplastic agent;
gonadotropin releasing hormone agonist
octotropine methylbromide[no description available]medium20
thioinosine[no description available]medium10
thiouracil[no description available]medium10nucleobase analogue;
thiocarbonyl compound		antithyroid drug;
metabolite
methimazole[no description available]medium901,3-dihydroimidazole-2-thionesantithyroid drug
6-thioguanosine[no description available]medium10purine nucleoside
lincomycin[no description available]medium20carbohydrate-containing antibiotic;
L-proline derivative;
monocarboxylic acid amide;
pyrrolidinecarboxamide;
S-glycosyl compound		antimicrobial agent;
bacterial metabolite
thiocarlide[no description available]medium10thioureas
mannomustine[no description available]medium10amino alcohol
gestodene[no description available]medium50steroidestrogen
glucametacin[no description available]medium20
1-(2-(2-(4-pyridyl)-2-imidazoline-1-yl)ethyl)-3-(4-carboxyphenyl)urea[no description available]medium10
hymecromone[no description available]medium10hydroxycoumarinantineoplastic agent;
hyaluronic acid synthesis inhibitor
cynarine[no description available]medium30alkyl caffeate ester;
quinic acid		plant metabolite
codeine[no description available]medium40morphinane alkaloid;
organic heteropentacyclic compound		antitussive;
drug allergen;
environmental contaminant;
opioid analgesic;
opioid receptor agonist;
prodrug;
xenobiotic
dihydrocodeine[no description available]medium20morphinane alkaloid
naloxone[no description available]medium80morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol		antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist
naloxone[no description available]medium81morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol		antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist
morphine[no description available]medium60morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic
pactamycin[no description available]medium10
anthramycin[no description available]medium10
lacidipine[no description available]medium20cinnamate ester;
tert-butyl ester
cytochalasin b[no description available]medium10cytochalasin;
lactam;
lactone;
organic heterotricyclic compound		actin polymerisation inhibitor;
metabolite;
mycotoxin;
platelet aggregation inhibitor
irisquinone[no description available]medium10
mitoguazone[no description available]medium10guanidines;
hydrazone		antineoplastic agent;
apoptosis inducer;
EC 4.1.1.50 (adenosylmethionine decarboxylase) inhibitor
nitrofurazone[no description available]medium20
ceftiofur[no description available]medium10
cilastatin[no description available]medium10carboxamide;
L-cysteine derivative;
non-proteinogenic L-alpha-amino acid;
organic sulfide		EC 3.4.13.19 (membrane dipeptidase) inhibitor;
environmental contaminant;
protease inhibitor;
xenobiotic
sibiromycin[no description available]medium10aminoglycoside antibiotic;
hemiaminal;
phenols;
pyrrolobenzodiazepine		antineoplastic agent;
bacterial metabolite
1-methyl-d-lysergic acid butanolamide[no description available]medium50ergot alkaloid;
monocarboxylic acid amide		serotonergic antagonist;
sympatholytic agent;
vasoconstrictor agent
fumagillin[no description available]medium10antibiotic antifungal drug;
carboxylic ester;
dicarboxylic acid monoester;
meroterpenoid;
organooxygen heterocyclic antibiotic;
spiro-epoxide		angiogenesis inhibitor;
antibacterial drug;
antimicrobial agent;
antiprotozoal drug;
fungal metabolite;
methionine aminopeptidase 2 inhibitor
thioacetazone[no description available]medium20
treosulfan[no description available]medium10methanesulfonate ester
gentamicin sulfate[no description available]medium40
nkp 608[no description available]medium10
ganu[no description available]medium10
metamelfalan[no description available]medium10
vindesine[no description available]medium10
diflucortolone[no description available]medium2021-hydroxy steroid
2-((3-chloroethyl)-3-nitrosoureido)glucopyranose[no description available]medium10
ro 6-4563[no description available]medium10monoterpenoid
flucloronide[no description available]medium1021-hydroxy steroid
hainanolide[no description available]medium10
gliocladic acid[no description available]medium10p-menthane monoterpenoid
cleistanthin[no description available]medium10cleistanthins;
xylose derivative		alpha-adrenergic antagonist;
antihypertensive agent;
diuretic
nimorazole[no description available]medium10
ascorbic acid[no description available]high101ascorbic acid;
vitamin C		coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent
ascorbic acid[no description available]high100ascorbic acid;
vitamin C		coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent
novobiocin[no description available]medium40carbamate ester;
ether;
hexoside;
hydroxycoumarin;
monocarboxylic acid amide;
monosaccharide derivative;
phenols		antibacterial agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Escherichia coli metabolite;
hepatoprotective agent
chlortetracycline[no description available]medium20
oxytetracycline, anhydrous[no description available]medium50
bactobolin[no description available]medium10amino acid amide
mobiflex[no description available]medium40heteroaryl hydroxy compound;
monocarboxylic acid amide;
pyridines;
thienothiazine		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
demeclocycline[no description available]medium20
dacarbazine[no description available]medium100dacarbazine
azaguanine[no description available]medium10nucleobase analogue;
triazolopyrimidines		antimetabolite;
antineoplastic agent;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor
alanosine[no description available]medium20
7-deazaguanosine[no description available]medium10
pyrazofurin[no description available]medium10C-glycosyl compound;
pyrazoles		antimetabolite;
antimicrobial agent;
antineoplastic agent;
EC 4.1.1.23 (orotidine-5'-phosphate decarboxylase) inhibitor
n(10)-methylfolate[no description available]medium10folic acids
5-methyltetrahydrohomofolic acid[no description available]medium10
ninopterin[no description available]medium10
coumarin[no description available]medium30coumarinsfluorescent dye;
human metabolite;
plant metabolite
salicylic acid[no description available]medium20monohydroxybenzoic acidalgal metabolite;
antifungal agent;
antiinfective agent;
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor;
keratolytic drug;
plant hormone;
plant metabolite
alanine[no description available]medium10alpha-amino acid;
amino acid zwitterion		fundamental metabolite
uracil[no description available]medium20pyrimidine nucleobase;
pyrimidone		allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
urea[no description available]medium30isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
bremazocine[no description available]medium20
alprenolol[no description available]medium30secondary alcohol;
secondary amino compound		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
antipyrine[no description available]medium40pyrazoloneantipyretic;
cyclooxygenase 3 inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
chlorpromazine[no description available]medium120organochlorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug
desipramine[no description available]medium90dibenzoazepine;
secondary amino compound		adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
cholinergic antagonist;
drug allergen;
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
serotonin uptake inhibitor
fleroxacin[no description available]medium30difluorobenzene;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-alkylpiperazine;
quinolines		antibacterial drug;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
imipramine[no description available]medium80dibenzoazepineadrenergic uptake inhibitor;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
pirenzepine[no description available]medium30pyridobenzodiazepineanti-ulcer drug;
antispasmodic drug;
muscarinic antagonist
practolol[no description available]medium30acetamides;
ethanolamines;
propanolamine;
secondary alcohol;
secondary amino compound		anti-arrhythmia drug;
beta-adrenergic antagonist
propranolol[no description available]medium110naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
imatinib[no description available]medium50aromatic amine;
benzamides;
N-methylpiperazine;
pyridines;
pyrimidines		antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
sucrose[no description available]medium20glycosyl glycosidealgal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent
aminopyrine[no description available]medium40pyrazolone;
tertiary amino compound		antipyretic;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
phencyclidine[no description available]medium20benzenes;
piperidines		anaesthetic;
neurotoxin;
NMDA receptor antagonist;
psychotropic drug
amiloride[no description available]medium40aromatic amine;
guanidines;
organochlorine compound;
pyrazines		diuretic;
sodium channel blocker
guanoxan[no description available]medium20benzodioxine
mibefradil[no description available]medium40tetralinsT-type calcium channel blocker
telmisartan[no description available]medium80benzimidazoles;
biphenyls;
carboxybiphenyl		angiotensin receptor antagonist;
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
environmental contaminant;
xenobiotic
n-methylscopolamine[no description available]medium20
bosentan anhydrous[no description available]medium100primary alcohol;
pyrimidines;
sulfonamide		antihypertensive agent;
endothelin receptor antagonist
erlotinib[no description available]medium30aromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound		antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor
dasatinib[no description available]medium401,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
proscillaridin[no description available]medium20organic molecular entity
ro 42-5892[no description available]medium20cyclopropanes;
diol;
L-histidine derivative;
secondary carboxamide;
sulfone		antihypertensive agent;
EC 3.4.23.15 (renin) inhibitor;
peptidomimetic;
vasodilator agent
tiacrilast[no description available]medium20
artesunate[no description available]medium30artemisinin derivative;
cyclic acetal;
dicarboxylic acid monoester;
hemisuccinate;
semisynthetic derivative;
sesquiterpenoid		antimalarial;
antineoplastic agent;
ferroptosis inducer
scopolamine hydrobromide[no description available]medium40
pht 427[no description available]medium20
mobic[no description available]medium701,3-thiazoles;
benzothiazine;
monocarboxylic acid amide		analgesic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
cgp 52411[no description available]medium10phthalimidesgeroprotector;
tyrosine kinase inhibitor
aa 861[no description available]medium101,4-benzoquinones;
acetylenic compound;
primary alcohol		EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor
bu 224[no description available]medium10quinolines
ml 9[no description available]medium10naphthalenes;
sulfonic acid derivative
pd 169316[no description available]medium10imidazoles
2-bromoergocryptine mesylate[no description available]medium10methanesulfonate saltantiparkinson drug
salmeterol xinafoate[no description available]medium30naphthoic acid
eliprodil[no description available]medium10monochlorobenzenes;
monofluorobenzenes;
piperidines;
secondary alcohol;
tertiary amino compound
sertraline hydrochloride[no description available]medium10hydrochlorideantidepressant;
serotonin uptake inhibitor
opipramol hydrochloride[no description available]medium10
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1h-imidazole[no description available]medium10ether;
imidazoles;
monomethoxybenzene		TRP channel blocker
u 78517f[no description available]medium10
mk 912[no description available]medium10
sk&f 86466[no description available]medium10benzazepine
w 7[no description available]medium10
4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine[no description available]medium10
dizocilpine[no description available]medium10secondary amino compound;
tetracyclic antidepressant		anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist
6-bromoindirubin-3'-oxime[no description available]medium10
h 89[no description available]medium10N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
phenylthiazolylthiourea[no description available]medium10
(2'-(4-aminophenyl)-(2,5'-bi-1h-benzimidazol)-5-amine)[no description available]medium10benzimidazoles
tg 003[no description available]medium10
3-(n,n-dimethylsulfonamido)-4-methyl-nitrobenzene[no description available]medium10C-nitro compound;
sulfonamide;
toluenes		bone density conservation agent;
EC 3.1.4.53 (3',5'-cyclic-AMP phosphodiesterase) inhibitor;
geroprotector
quinine[no description available]medium80cinchona alkaloidantimalarial;
muscle relaxant;
non-narcotic analgesic
quinine[no description available]medium81cinchona alkaloidantimalarial;
muscle relaxant;
non-narcotic analgesic
l 663536[no description available]medium10aryl sulfide;
indoles;
monocarboxylic acid;
monochlorobenzenes		antineoplastic agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
leukotriene antagonist
su 9516[no description available]medium10
ml 10302[no description available]medium10
ag 538[no description available]medium10
bw b70c[no description available]medium10aromatic ether;
hydroxamic acid;
organofluorine compound;
ureas		EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor
mg 624[no description available]medium10
5-(4-phenylbutoxy)psoralen[no description available]medium10aromatic ether;
benzenes;
psoralens		geroprotector;
immunosuppressive agent;
potassium channel blocker
bisoprolol, fumarate (1:1) salt[no description available]medium20
8-(n,n-diethylamino)octyl-3,4,5-trimethoxybenzoate hydrochloride[no description available]medium10
ro 8-4304[no description available]medium10
sb 203186[no description available]medium10
2-hydroxyapomorphine, (r)-isomer[no description available]medium10
N-methyl-6-chloro-1-(3-methylphenyl)-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol hydrobromide[no description available]medium10hydrobromidedopamine agonist;
prodrug
acetic acid[no description available]medium10monocarboxylic acidantimicrobial food preservative;
Daphnia magna metabolite;
food acidity regulator;
protic solvent
adenine[no description available]medium206-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
allantoin[no description available]medium10imidazolidine-2,4-dione;
ureas		Escherichia coli metabolite;
human metabolite;
Saccharomyces cerevisiae metabolite;
vulnerary
betaine[no description available]medium50amino-acid betaine;
glycine derivative		fundamental metabolite
carnitine[no description available]medium20amino-acid betainehuman metabolite;
mouse metabolite
citric acid, anhydrous[no description available]medium50tricarboxylic acidantimicrobial agent;
chelator;
food acidity regulator;
fundamental metabolite
creatine[no description available]high21glycine derivative;
guanidines;
zwitterion		geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent;
nutraceutical
creatine[no description available]high20glycine derivative;
guanidines;
zwitterion		geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent;
nutraceutical
lactic acid[no description available]medium102-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite
dimethyl sulfoxide[no description available]medium10sulfoxide;
volatile organic compound		alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger
formaldehyde[no description available]medium10aldehyde;
one-carbon compound		allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
glycine[no description available]medium30alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
glycerol[no description available]high41alditol;
triol		algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent
glycerol[no description available]high40alditol;
triol		algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent
inositol[no description available]medium30cyclitol;
hexol
niacinamide[no description available]medium10pyridine alkaloid;
pyridinecarboxamide;
vitamin B3		anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor
niacin[no description available]medium60pyridine alkaloid;
pyridinemonocarboxylic acid;
vitamin B3		antidote;
antilipemic drug;
EC 3.5.1.19 (nicotinamidase) inhibitor;
Escherichia coli metabolite;
human urinary metabolite;
metabolite;
mouse metabolite;
plant metabolite;
vasodilator agent
orotic acid[no description available]medium10pyrimidinemonocarboxylic acidEscherichia coli metabolite;
metabolite;
mouse metabolite
4-aminobenzoic acid[no description available]medium10aminobenzoic acid;
aromatic amino-acid zwitterion		allergen;
Escherichia coli metabolite;
plant metabolite
phenol[no description available]medium10phenolsantiseptic drug;
disinfectant;
human xenobiotic metabolite;
mouse metabolite
phenylacetic acid[no description available]medium10benzenes;
monocarboxylic acid;
phenylacetic acids		allergen;
Aspergillus metabolite;
auxin;
EC 6.4.1.1 (pyruvate carboxylase) inhibitor;
Escherichia coli metabolite;
human metabolite;
plant growth retardant;
plant metabolite;
Saccharomyces cerevisiae metabolite;
toxin
pyridoxal phosphate[no description available]medium20methylpyridines;
monohydroxypyridine;
pyridinecarbaldehyde;
vitamin B6 phosphate		coenzyme;
cofactor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
pyridoxine[no description available]medium120hydroxymethylpyridine;
methylpyridines;
monohydroxypyridine;
vitamin B6		cofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
thiamine[no description available]medium40primary alcohol;
vitamin B1		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
catechin[no description available]medium10hydroxyflavan
menthol[no description available]medium10p-menthane monoterpenoid;
secondary alcohol		volatile oil component
alfuzosin[no description available]medium20monocarboxylic acid amide;
quinazolines;
tetrahydrofuranol		alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent
ambroxol[no description available]medium10aromatic amine
pimagedine[no description available]medium10guanidines;
one-carbon compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
EC 1.4.3.4 (monoamine oxidase) inhibitor
amobarbital[no description available]medium10barbiturates
amsacrine[no description available]medium40acridines;
aromatic ether;
sulfonamide		antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
anethole trithione[no description available]medium10methoxybenzenes
anthralin[no description available]medium20anthracenesantipsoriatic
barbital[no description available]medium10barbituratesdrug allergen
bendazac[no description available]medium30indazoles;
monocarboxylic acid		non-steroidal anti-inflammatory drug;
radical scavenger
benzbromarone[no description available]medium801-benzofurans;
aromatic ketone		uricosuric drug
bay h 4502[no description available]medium20biphenyls;
imidazoles
bromisovalum[no description available]medium10N-acylurea;
organobromine compound
brotizolam[no description available]medium10organic molecular entity
butalbital[no description available]medium10barbituratesanalgesic;
sedative
candesartan cilexetil[no description available]medium10biphenyls
carprofen[no description available]medium20carbazoles;
organochlorine compound		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug;
photosensitizing agent
celecoxib[no description available]medium40organofluorine compound;
pyrazoles;
sulfonamide;
toluenes		cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
chlordiazepoxide[no description available]medium40benzodiazepine
chloroxylenol[no description available]medium20monochlorobenzenes;
phenols		antiseptic drug;
disinfectant;
molluscicide
chlorpheniramine[no description available]medium30monochlorobenzenes;
pyridines;
tertiary amino compound		anti-allergic agent;
antidepressant;
antipruritic drug;
H1-receptor antagonist;
histamine antagonist;
serotonin uptake inhibitor
citalopram[no description available]medium602-benzofurans;
cyclic ether;
nitrile;
organofluorine compound;
tertiary amino compound
clobazam[no description available]medium201,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
GABA modulator
clomiphene[no description available]medium60tertiary amineestrogen antagonist;
estrogen receptor modulator
clotiazepam[no description available]medium10organic molecular entity
cyclandelate[no description available]medium20carboxylic ester;
secondary alcohol		vasodilator agent
cyproheptadine[no description available]medium20piperidines;
tertiary amine		anti-allergic agent;
antipruritic drug;
gastrointestinal drug;
H1-receptor antagonist;
serotonergic antagonist
danthron[no description available]medium10dihydroxyanthraquinoneapoptosis inducer;
plant metabolite
deferoxamine[no description available]medium30acyclic desferrioxaminebacterial metabolite;
ferroptosis inhibitor;
iron chelator;
siderophore
amphetamine[no description available]medium20primary amine
eflornithine[no description available]medium10alpha-amino acid;
fluoroamino acid		trypanocidal drug
ddt[no description available]medium10benzenoid aromatic compound;
chlorophenylethane;
monochlorobenzenes;
organochlorine insecticide		bridged diphenyl acaricide;
carcinogenic agent;
endocrine disruptor;
persistent organic pollutant
diphenhydramine[no description available]medium50ether;
tertiary amino compound		anti-allergic agent;
antidyskinesia agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
antitussive;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
oneirogen;
sedative
ethacrynic acid[no description available]medium50aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid		EC 2.5.1.18 (glutathione transferase) inhibitor;
ion transport inhibitor;
loop diuretic
ethoxzolamide[no description available]medium10aromatic ether;
benzothiazoles;
sulfonamide		antiglaucoma drug;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
flufenamic acid[no description available]medium30aromatic amino acid;
organofluorine compound		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
flunitrazepam[no description available]medium101,4-benzodiazepinone;
C-nitro compound;
monofluorobenzenes		anxiolytic drug;
GABAA receptor agonist;
sedative
fomepizole[no description available]medium20pyrazolesantidote;
EC 1.1.1.1 (alcohol dehydrogenase) inhibitor;
protective agent
glafenine[no description available]medium70aminoquinoline;
carboxylic ester;
glycol;
organochlorine compound;
secondary amino compound		inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
gliclazide[no description available]medium50N-sulfonylureahypoglycemic agent;
insulin secretagogue;
radical scavenger
gossypol[no description available]medium30
guaiazulene[no description available]medium10sesquiterpene
fasudil[no description available]medium10isoquinolines;
N-sulfonyldiazepane		antihypertensive agent;
calcium channel blocker;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
geroprotector;
neuroprotective agent;
nootropic agent;
vasodilator agent
hexachlorophene[no description available]medium30bridged diphenyl fungicide;
polyphenol;
trichlorobenzene		acaricide;
antibacterial agent;
antifungal agrochemical;
antiseptic drug
miltefosine[no description available]medium10phosphocholines;
phospholipid		anti-inflammatory agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
apoptosis inducer;
immunomodulator;
protein kinase inhibitor
hexestrol[no description available]medium20stilbenoid
hexetidine[no description available]medium10organic heteromonocyclic compound;
organonitrogen heterocyclic compound
hexobarbital[no description available]medium10barbiturates
alverine[no description available]medium10tertiary amineantispasmodic drug
idebenone[no description available]medium101,4-benzoquinones;
primary alcohol		antioxidant;
ferroptosis inhibitor
iodipamide[no description available]medium10benzoic acids;
organoiodine compound;
secondary carboxamide		radioopaque medium
avapro[no description available]medium60azaspiro compound;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
2-propanol[no description available]medium10secondary alcohol;
secondary fatty alcohol		protic solvent
isoxsuprine[no description available]medium30alkylbenzene
ketamine[no description available]medium50cyclohexanones;
monochlorobenzenes;
secondary amino compound		analgesic;
environmental contaminant;
intravenous anaesthetic;
neurotoxin;
NMDA receptor antagonist;
xenobiotic
ketanserin[no description available]medium30aromatic ketone;
organofluorine compound;
piperidines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
cardiovascular drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist
khellin[no description available]medium10furanochromone;
organic heterotricyclic compound;
oxacycle		anti-asthmatic agent;
bronchodilator agent;
cardiovascular drug;
vasodilator agent
lofepramine[no description available]medium30aromatic ketone;
dibenzoazepine;
monochlorobenzenes;
tertiary amino compound		antidepressant
loperamide[no description available]medium30monocarboxylic acid amide;
monochlorobenzenes;
piperidines;
tertiary alcohol		anticoronaviral agent;
antidiarrhoeal drug;
mu-opioid receptor agonist
malathion[no description available]medium10diester;
ethyl ester;
organic thiophosphate
diisopropyl 1,3-dithiol-2-ylidenemalonate[no description available]medium10isopropyl ester
mazindol[no description available]medium20organic molecular entity
meclizine[no description available]medium40diarylmethane
meclofenoxate[no description available]medium10monocarboxylic acid
vitamin k 3[no description available]medium301,4-naphthoquinones;
vitamin K		angiogenesis inhibitor;
antineoplastic agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
human urinary metabolite;
nutraceutical
meperidine[no description available]medium30ethyl ester;
piperidinecarboxylate ester;
tertiary amino compound		antispasmodic drug;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic
methadone[no description available]medium30benzenes;
diarylmethane;
ketone;
tertiary amino compound
methoxsalen[no description available]medium20aromatic ether;
psoralens		antineoplastic agent;
cross-linking reagent;
dermatologic drug;
photosensitizing agent;
plant metabolite
methyprylon[no description available]medium10organic molecular entity
metyrapone[no description available]medium70aromatic ketoneantimetabolite;
diagnostic agent;
EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor
mianserin[no description available]medium50dibenzoazepineadrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
H1-receptor antagonist;
histamine agonist;
sedative;
serotonergic antagonist
miconazole[no description available]medium50dichlorobenzene;
ether;
imidazoles
modafinil[no description available]medium30monocarboxylic acid amide;
sulfoxide
moxisylyte[no description available]medium30monoterpenoid
deet[no description available]medium10benzamides;
monocarboxylic acid amide		environmental contaminant;
insect repellent;
xenobiotic
niceritrol[no description available]medium10organic molecular entity
nitrazepam[no description available]medium201,4-benzodiazepinone;
C-nitro compound		anticonvulsant;
antispasmodic drug;
drug metabolite;
GABA modulator;
sedative
orphenadrine[no description available]medium50ether;
tertiary amino compound		antidyskinesia agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist;
muscle relaxant;
NMDA receptor antagonist;
parasympatholytic
oxamniquine[no description available]medium10aromatic primary alcohol;
C-nitro compound;
quinolines;
secondary amino compound
oxazepam[no description available]medium501,4-benzodiazepinone;
organochlorine compound		anxiolytic drug;
environmental contaminant;
xenobiotic
oxethazaine[no description available]medium20amino acid amide
oxybenzone[no description available]medium10hydroxybenzophenone;
monomethoxybenzene		dermatologic drug;
environmental contaminant;
protective agent;
ultraviolet filter;
xenobiotic
oxyphenbutazone[no description available]medium30phenols;
pyrazolidines		antimicrobial agent;
antineoplastic agent;
antipyretic;
drug metabolite;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite
aminosalicylic acid[no description available]medium70aminobenzoic acid;
phenols		antitubercular agent
pantoprazole[no description available]medium30aromatic ether;
benzimidazoles;
organofluorine compound;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
environmental contaminant;
xenobiotic
pentobarbital[no description available]medium20barbituratesGABAA receptor agonist
perazine[no description available]medium10N-alkylpiperazine;
N-methylpiperazine;
phenothiazines		dopaminergic antagonist;
phenothiazine antipsychotic drug
phenolphthalein[no description available]medium10phenols
phenoxybenzamine[no description available]medium50aromatic amine
moxonidine[no description available]medium10organohalogen compound;
pyrimidines
pipemidic acid[no description available]medium10amino acid;
monocarboxylic acid;
N-arylpiperazine;
pyridopyrimidine;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor
piperazine[no description available]medium10azacycloalkane;
piperazines;
saturated organic heteromonocyclic parent		anthelminthic drug
prochlorperazine[no description available]medium50N-alkylpiperazine;
N-methylpiperazine;
organochlorine compound;
phenothiazines		alpha-adrenergic antagonist;
antiemetic;
cholinergic antagonist;
dopamine receptor D2 antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic
promethazine[no description available]medium50phenothiazines;
tertiary amine		anti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
sedative
promethazine[no description available]medium51phenothiazines;
tertiary amine		anti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
sedative
pyridinolcarbamate[no description available]medium10pyridines
pyrimethamine[no description available]medium70aminopyrimidine;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
opc 12759[no description available]medium10secondary carboxamide
rofecoxib[no description available]medium30butenolide;
sulfone		analgesic;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
salicylamide[no description available]medium20phenols;
salicylamides		antirheumatic drug;
non-narcotic analgesic
sibutramine[no description available]medium20organochlorine compound;
tertiary amino compound		anti-obesity agent;
serotonin uptake inhibitor
4-phenylbutyric acid, sodium salt[no description available]medium10organic sodium saltEC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector;
neuroprotective agent;
orphan drug;
prodrug
vorinostat[no description available]medium30dicarboxylic acid diamide;
hydroxamic acid		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
sulfadimethoxine[no description available]medium20aromatic ether;
pyrimidines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
antimicrobial agent;
drug allergen;
environmental contaminant;
xenobiotic
sulfamerazine[no description available]medium20pyrimidines;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
drug allergen
sulfameter[no description available]medium10pyrimidines;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
leprostatic drug;
renal agent
sulfamethizole[no description available]medium50sulfonamide antibiotic;
sulfonamide;
thiadiazoles		antiinfective agent;
antimicrobial agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfinpyrazone[no description available]medium40pyrazolidines;
sulfoxide		uricosuric drug
2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol[no description available]medium30alkylbenzene
suramin[no description available]medium10naphthalenesulfonic acid;
phenylureas;
secondary carboxamide		angiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug
gatifloxacin[no description available]medium40N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antiinfective agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
temozolomide[no description available]medium40imidazotetrazine;
monocarboxylic acid amide;
triazene derivative		alkylating agent;
antineoplastic agent;
prodrug
tiaprofenic acid[no description available]medium30aromatic ketone;
monocarboxylic acid;
thiophenes		drug allergen;
non-steroidal anti-inflammatory drug
tolperisone[no description available]medium10aromatic ketone
tranexamic acid[no description available]medium540amino acid
tranexamic acid[no description available]medium541amino acid
triclosan[no description available]medium10aromatic ether;
dichlorobenzene;
monochlorobenzenes;
phenols		antibacterial agent;
antimalarial;
drug allergen;
EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
fungicide;
persistent organic pollutant;
xenobiotic
triflupromazine[no description available]medium20organofluorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic
vesnarinone[no description available]medium10organic molecular entity
guanidine hydrochloride[no description available]medium10one-carbon compound;
organic chloride salt		protein denaturant
hydrocortisone acetate[no description available]medium10cortisol ester;
tertiary alpha-hydroxy ketone
mitomycin[no description available]medium40mitomycinalkylating agent;
antineoplastic agent
prednisolone[no description available]medium32011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic
prednisolone[no description available]medium32211beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic
cephaloridine[no description available]medium30beta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative		antibacterial drug
phentolamine[no description available]medium50imidazoles;
phenols;
substituted aniline;
tertiary amino compound		alpha-adrenergic antagonist;
vasodilator agent
sorbitol[no description available]medium40glucitolcathartic;
Escherichia coli metabolite;
food humectant;
human metabolite;
laxative;
metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite;
sweetening agent
piperonyl butoxide[no description available]medium20benzodioxolespesticide synergist
bromouracil[no description available]medium10nucleobase analogue;
pyrimidines		mutagen
3,3',5-triiodothyroacetic acid[no description available]medium10
thyroxine[no description available]medium1202-halophenol;
iodophenol;
L-phenylalanine derivative;
non-proteinogenic L-alpha-amino acid;
thyroxine zwitterion;
thyroxine		antithyroid drug;
human metabolite;
mouse metabolite;
thyroid hormone
dextroamphetamine[no description available]medium201-phenylpropan-2-amineadrenergic agent;
adrenergic uptake inhibitor;
dopamine uptake inhibitor;
dopaminergic agent;
neurotoxin;
sympathomimetic agent
norethindrone acetate[no description available]high303-oxo-Delta(4) steroid;
acetate ester;
terminal acetylenic compound		progestin;
synthetic oral contraceptive
cyclobarbital[no description available]medium10barbiturates
trichlorfon[no description available]medium10organic phosphonate;
organochlorine compound;
phosphonic ester		agrochemical;
anthelminthic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
insecticide
oxandrolone[no description available]high6017beta-hydroxy steroid;
3-oxo steroid;
anabolic androgenic steroid;
oxa-steroid		anabolic agent;
androgen
nad[no description available]medium10NADgeroprotector
triiodothyronine[no description available]medium1402-halophenol;
amino acid zwitterion;
iodophenol;
iodothyronine		human metabolite;
mouse metabolite;
thyroid hormone
cetrimonium bromide[no description available]medium20organic bromide salt;
quaternary ammonium salt		detergent;
surfactant
tetrabenazine[no description available]medium20benzoquinolizine;
cyclic ketone;
tertiary amino compound
uridine[no description available]medium10uridinesdrug metabolite;
fundamental metabolite;
human metabolite
kanamycin a[no description available]medium50kanamycinsbacterial metabolite
phenylephrine[no description available]medium10phenols;
phenylethanolamines;
secondary amino compound		alpha-adrenergic agonist;
cardiotonic drug;
mydriatic agent;
nasal decongestant;
protective agent;
sympathomimetic agent;
vasoconstrictor agent
carbaryl[no description available]medium10carbamate ester;
naphthalenes		acaricide;
agrochemical;
carbamate insecticide;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant growth retardant
lactose[no description available]medium30lactose
methionine[no description available]medium20aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid		antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical
Mebutamate[no description available]medium10organic molecular entity
norethynodrel[no description available]medium60oxo steroid
norethynodrel[no description available]medium62oxo steroid
benziodarone[no description available]medium30aromatic ketone
methaqualone[no description available]medium10quinazolinesGABA agonist;
sedative
trypan blue[no description available]medium10
cordycepin[no description available]medium103'-deoxyribonucleoside;
adenosines		antimetabolite;
nucleoside antibiotic
trichloroacetic acid[no description available]medium20monocarboxylic acid;
organochlorine compound		carcinogenic agent;
metabolite;
mouse metabolite
trichloroacetic acid[no description available]medium21monocarboxylic acid;
organochlorine compound		carcinogenic agent;
metabolite;
mouse metabolite
triamcinolone acetonide[no description available]medium3011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
cyclic ketal;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone		anti-allergic agent;
anti-inflammatory drug
allylpropymal[no description available]medium10barbiturates
butobarbital[no description available]medium10barbiturates
trichloroethylene[no description available]medium30chloroethenesinhalation anaesthetic;
mouse metabolite
dehydrocholic acid[no description available]medium1012-oxo steroid;
3-oxo-5beta-steroid;
7-oxo steroid;
oxo-5beta-cholanic acid		gastrointestinal drug
benzoyl peroxide[no description available]medium10carbonyl compound
furan[no description available]medium10furans;
mancude organic heteromonocyclic parent;
monocyclic heteroarene		carcinogenic agent;
hepatotoxic agent;
Maillard reaction product
phenformin[no description available]medium40biguanidesantineoplastic agent;
geroprotector;
hypoglycemic agent
mephobarbital[no description available]medium30barbituratesanticonvulsant
hexachlorobenzene[no description available]medium10aromatic fungicide;
chlorobenzenes		antifungal agrochemical;
carcinogenic agent;
persistent organic pollutant
trinitrotoluene[no description available]medium10trinitrotolueneexplosive
framycetin[no description available]medium20aminoglycosideallergen;
antibacterial drug;
Escherichia coli metabolite
meglumine[no description available]medium10hexosamine;
secondary amino compound
cinchophen[no description available]medium60quinolines
yohimbine[no description available]medium20methyl 17-hydroxy-20xi-yohimban-16-carboxylatealpha-adrenergic antagonist;
dopamine receptor D2 antagonist;
serotonergic antagonist
mequinol[no description available]medium10methoxybenzenes;
phenols		metabolite
quinestrol[no description available]high2017-hydroxy steroid;
terminal acetylenic compound		xenoestrogen
dydrogesterone[no description available]medium5020-oxo steroid;
3-oxo-Delta(4) steroid		progestin
dydrogesterone[no description available]medium5220-oxo steroid;
3-oxo-Delta(4) steroid		progestin
ephedrine[no description available]medium20phenethylamine alkaloid;
phenylethanolamines		bacterial metabolite;
environmental contaminant;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
chlormadinone acetate[no description available]medium30corticosteroid hormone
2,3-dimercaptosuccinic acid[no description available]medium10
evans blue[no description available]medium10organic sodium saltfluorochrome;
histological dye;
sodium channel blocker;
teratogenic agent
phenyramidol[no description available]medium10aminopyridine
nandrolone decanoate[no description available]medium30steroid ester
bucladesine[no description available]medium103',5'-cyclic purine nucleotide;
butanamides;
butyrate ester		agonist;
cardiotonic drug;
vasodilator agent
perflubron[no description available]medium10haloalkane;
organobromine compound;
perfluorinated compound		blood substitute;
radioopaque medium
dextropropoxyphene[no description available]medium301-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoatemu-opioid receptor agonist;
opioid analgesic
glycyrrhetinic acid[no description available]medium20cyclic terpene ketone;
hydroxy monocarboxylic acid;
pentacyclic triterpenoid		immunomodulator;
plant metabolite
dihydralazine[no description available]medium20phthalazines
phenylpropanolamine[no description available]medium10amphetamines;
phenethylamine alkaloid		plant metabolite
dihydroergotamine[no description available]medium30ergot alkaloid;
semisynthetic derivative		dopamine agonist;
non-narcotic analgesic;
serotonergic agonist;
sympatholytic agent;
vasoconstrictor agent
chlormethiazole[no description available]medium10thiazoles
methamphetamine[no description available]medium30amphetamines;
secondary amine		central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic
gentian violet[no description available]medium10organic chloride saltanthelminthic drug;
antibacterial agent;
antifungal agent;
antiseptic drug;
histological dye
hematoporphyrin[no description available]medium10
lactulose[no description available]medium40glycosylfructosegastrointestinal drug;
laxative
erythromycin stearate[no description available]medium10aminoglycoside
vancomycin[no description available]medium50glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
d-alpha tocopherol[no description available]medium100alpha-tocopherolalgal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite
sulfadoxine[no description available]medium40pyrimidines;
sulfonamide		antibacterial drug;
antimalarial
acadesine[no description available]medium101-ribosylimidazolecarboxamide;
aminoimidazole;
nucleoside analogue		antineoplastic agent;
platelet aggregation inhibitor
iproclozide[no description available]medium10aromatic ether
carbenicillin disodium[no description available]medium10organic sodium salt
dehydroemetine[no description available]medium10aromatic ether;
isoquinolines;
pyridoisoquinoline		antileishmanial agent;
antimalarial;
antiprotozoal drug
benorilate[no description available]medium10carbonyl compound
trimetazidine[no description available]medium10aromatic amine
vidarabine[no description available]medium40beta-D-arabinoside;
purine nucleoside		antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic
vidarabine[no description available]medium41beta-D-arabinoside;
purine nucleoside		antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic
tiadenol[no description available]medium10aliphatic sulfide
stanozolol[no description available]high31117beta-hydroxy steroid;
anabolic androgenic steroid;
organic heteropentacyclic compound;
tertiary alcohol		anabolic agent;
androgen
stanozolol[no description available]high31017beta-hydroxy steroid;
anabolic androgenic steroid;
organic heteropentacyclic compound;
tertiary alcohol		anabolic agent;
androgen
thiamphenicol[no description available]medium20monocarboxylic acid amide;
sulfone		antimicrobial agent;
immunosuppressive agent
pizotyline[no description available]medium10benzocycloheptathiophenehistamine antagonist;
muscarinic antagonist;
serotonergic antagonist
carbimazole[no description available]medium301,3-dihydroimidazole-2-thiones;
carbamate ester		antithyroid drug;
prodrug
oxyphenisatin[no description available]medium30indoles
tetrachloroethylene[no description available]medium10chlorocarbon;
chloroethenes		nephrotoxic agent
butachlor[no description available]medium10aromatic amide;
organochlorine compound;
tertiary carboxamide		environmental contaminant;
herbicide;
xenobiotic
rose bengal b disodium salt[no description available]medium20
glutamic acid[no description available]medium10glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
nicergoline[no description available]medium10organic heterotetracyclic compound;
organonitrogen heterocyclic compound
oxcarbazepine[no description available]medium30cyclic ketone;
dibenzoazepine		anticonvulsant;
drug allergen
pirprofen[no description available]medium60pyrroline
amikacin[no description available]medium50alpha-D-glucoside;
amino cyclitol glycoside;
aminoglycoside;
carboxamide		antibacterial drug;
antimicrobial agent;
nephrotoxin
ticrynafen[no description available]medium60aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid;
thiophenes		antihypertensive agent;
hepatotoxic agent;
loop diuretic
bezafibrate[no description available]medium40aromatic ether;
monocarboxylic acid amide;
monocarboxylic acid;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
benoxaprofen[no description available]medium601,3-benzoxazoles;
monocarboxylic acid;
monochlorobenzenes		antipsoriatic;
antipyretic;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
hepatotoxic agent;
nephrotoxin;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
protein kinase C agonist
muzolimine[no description available]medium10dichlorobenzene
epirubicin[no description available]medium40aminoglycoside;
anthracycline antibiotic;
anthracycline;
deoxy hexoside;
monosaccharide derivative;
p-quinones;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		antimicrobial agent;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
foscarnet sodium[no description available]medium20one-carbon compound;
organic sodium salt		antiviral drug
moxalactam[no description available]medium10cephalosporin;
oxacephem		antibacterial drug
nicorandil[no description available]medium20nitrate ester;
pyridinecarboxamide		potassium channel opener;
vasodilator agent
miglustat[no description available]medium20piperidines;
tertiary amino compound		anti-HIV agent;
EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor
atomoxetine hydrochloride[no description available]medium20hydrochlorideadrenergic uptake inhibitor;
antidepressant
gepirone[no description available]medium10N-arylpiperazine
clopidogrel[no description available]medium20methyl ester;
monochlorobenzenes;
thienopyridine		anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
bromfenac[no description available]medium70aromatic amino acid;
benzophenones;
organobromine compound;
substituted aniline		non-narcotic analgesic;
non-steroidal anti-inflammatory drug
duloxetine[no description available]medium20duloxetine
adefovir dipivoxil[no description available]medium206-aminopurines;
carbonate ester;
ether;
organic phosphonate		antiviral drug;
DNA synthesis inhibitor;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent;
prodrug
capecitabine[no description available]medium20carbamate ester;
cytidines;
organofluorine compound		antimetabolite;
antineoplastic agent;
prodrug
halofuginone[no description available]medium10quinazolines
ortho-cept[no description available]medium10
4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol[no description available]medium10stilbenoid
efavirenz[no description available]medium30acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound		antiviral drug;
HIV-1 reverse transcriptase inhibitor
nelfinavir[no description available]medium40aryl sulfide;
benzamides;
organic heterobicyclic compound;
phenols;
secondary alcohol;
tertiary amino compound		antineoplastic agent;
HIV protease inhibitor
doxapram hydrochloride[no description available]medium10hydrochloridecentral nervous system stimulant
1,5-anhydroglucitol[no description available]medium10anhydro sugarhuman metabolite
betulinic acid[no description available]medium10hydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-HIV agent;
anti-inflammatory agent;
antimalarial;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
plant metabolite
amprenavir[no description available]medium40carbamate ester;
sulfonamide;
tetrahydrofuryl ester		antiviral drug;
HIV protease inhibitor
glutathione disulfide[no description available]medium10glutathione derivative;
organic disulfide		Escherichia coli metabolite;
mouse metabolite
erdosteine[no description available]medium10N-acyl-amino acid
mizolastine[no description available]medium10benzimidazoles
intoplicine[no description available]medium10pyridoindole
medetomidine[no description available]medium10imidazoles
picosulfate sodium[no description available]medium10aryl sulfate;
pyridines
dienogest[no description available]medium7017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
aliphatic nitrile;
steroid hormone		progesterone receptor agonist;
progestin;
synthetic oral contraceptive
dienogest[no description available]medium7117beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
aliphatic nitrile;
steroid hormone		progesterone receptor agonist;
progestin;
synthetic oral contraceptive
morphazinamide[no description available]medium10morpholines;
pyrazines;
secondary carboxamide
voriconazole[no description available]medium30conazole antifungal drug;
difluorobenzene;
pyrimidines;
tertiary alcohol;
triazole antifungal drug		P450 inhibitor
cyclobutyrol[no description available]medium10hydroxy monocarboxylic acidbile therapy drug
terlipressin[no description available]medium10polypeptide
isoflavone[no description available]medium10isoflavones
clevudine[no description available]medium10
tetrandrine[no description available]medium10bisbenzylisoquinoline alkaloid;
isoquinolines
rosiglitazone[no description available]medium80aminopyridine;
thiazolidinediones		EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug
lopinavir[no description available]medium20amphetamines;
dicarboxylic acid diamide		anticoronaviral agent;
antiviral drug;
HIV protease inhibitor
selenomethionine[no description available]medium10amino acid zwitterion;
selenomethionine		plant metabolite
fingolimod[no description available]medium10aminodiol;
primary amino compound		antineoplastic agent;
CB1 receptor antagonist;
immunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist
ecteinascidin 743[no description available]medium10acetate ester;
azaspiro compound;
bridged compound;
hemiaminal;
isoquinoline alkaloid;
lactone;
organic heteropolycyclic compound;
organic sulfide;
oxaspiro compound;
polyphenol;
tertiary amino compound		alkylating agent;
angiogenesis modulating agent;
anti-inflammatory agent;
antineoplastic agent;
marine metabolite
nitisinone[no description available]medium20(trifluoromethyl)benzenes;
C-nitro compound;
cyclohexanones;
mesotrione		EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor
marimastat[no description available]medium10hydroxamic acid;
secondary carboxamide		antineoplastic agent;
matrix metalloproteinase inhibitor
clofarabine[no description available]medium30adenosines;
organofluorine compound		antimetabolite;
antineoplastic agent
mitiglinide[no description available]medium10benzenes;
monocarboxylic acid
imatinib mesylate[no description available]medium10methanesulfonate saltanticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
gefitinib[no description available]medium50aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine[no description available]medium10adenosines;
monocarboxylic acid amide;
organoiodine compound		adenosine A3 receptor agonist
antiprimod[no description available]medium10
sulbactam[no description available]medium20penicillanic acids
olmesartan medoxomil[no description available]medium30biphenyls
ilomastat[no description available]medium10hydroxamic acid;
L-tryptophan derivative;
N-acyl-amino acid		anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
EC 3.4.24.24 (gelatinase A) inhibitor;
neuroprotective agent
atazanavir[no description available]medium20carbohydrazideantiviral drug;
HIV protease inhibitor
ezetimibe[no description available]medium30azetidines;
beta-lactam;
organofluorine compound		anticholesteremic drug;
antilipemic drug;
antimetabolite
cariporide[no description available]medium10
tezosentan[no description available]medium10
moxifloxacin[no description available]medium30aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug
jtt 501[no description available]medium10
paromomycin[no description available]medium40amino cyclitol glycoside;
aminoglycoside antibiotic		anthelminthic drug;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug
avasimibe[no description available]medium10monoterpenoid
biotin[no description available]medium30biotins;
vitamin B7		coenzyme;
cofactor;
Escherichia coli metabolite;
fundamental metabolite;
human metabolite;
mouse metabolite;
nutraceutical;
prosthetic group;
Saccharomyces cerevisiae metabolite
troleandomycin[no description available]medium40acetate ester;
epoxide;
macrolide antibiotic;
monosaccharide derivative;
polyketide;
semisynthetic derivative		EC 1.14.13.97 (taurochenodeoxycholate 6alpha-hydroxylase) inhibitor;
xenobiotic
deferasirox[no description available]medium40benzoic acids;
monocarboxylic acid;
phenols;
triazoles		iron chelator
tbc-11251[no description available]medium30benzodioxoles
sitosterol, (3beta)-isomer[no description available]medium103beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
C29-steroid;
phytosterols;
stigmastane sterol		anticholesteremic drug;
antioxidant;
mouse metabolite;
plant metabolite;
sterol methyltransferase inhibitor
benzarone[no description available]medium301-benzofurans
noscapine[no description available]medium10aromatic ether;
benzylisoquinoline alkaloid;
cyclic acetal;
isobenzofuranone;
organic heterobicyclic compound;
organic heterotricyclic compound;
tertiary amino compound		antineoplastic agent;
antitussive;
apoptosis inducer;
plant metabolite
homoharringtonine[no description available]medium10alkaloid ester;
enol ether;
organic heteropentacyclic compound;
tertiary alcohol		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
protein synthesis inhibitor
o-(chloroacetylcarbamoyl)fumagillol[no description available]medium10carbamate ester;
organochlorine compound;
semisynthetic derivative;
sesquiterpenoid;
spiro-epoxide		angiogenesis inhibitor;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
methionine aminopeptidase 2 inhibitor;
retinoic acid receptor alpha antagonist
bortezomib[no description available]medium30amino acid amide;
L-phenylalanine derivative;
pyrazines		antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor
nexavar[no description available]medium10organosulfonate salt
glucosamine[no description available]medium30D-glucosamineEscherichia coli metabolite;
geroprotector;
mouse metabolite
trimethaphan camsylate[no description available]medium10
erythromycin estolate[no description available]medium40aminoglycoside sulfate salt;
erythromycin derivative		enzyme inhibitor
devazepide[no description available]medium201,4-benzodiazepinone;
indolecarboxamide		antineoplastic agent;
apoptosis inducer;
cholecystokinin antagonist;
gastrointestinal drug
tolterodine[no description available]medium20tertiary amineantispasmodic drug;
muscarinic antagonist;
muscle relaxant
doxorubicin hydrochloride[no description available]medium30anthracycline
ao 128[no description available]medium20organic molecular entity
alpha-D-fructofuranose 1,6-bisphosphate[no description available]medium10D-fructofuranose 1,6-bisphosphate
docosahexaenoate[no description available]medium10docosahexaenoic acid;
omega-3 fatty acid		algal metabolite;
antineoplastic agent;
Daphnia tenebrosa metabolite;
human metabolite;
mouse metabolite;
nutraceutical
tacrolimus[no description available]medium60macrolide lactambacterial metabolite;
immunosuppressive agent
cerivastatin[no description available]medium30dihydroxy monocarboxylic acid;
pyridines;
statin (synthetic)
rosuvastatin[no description available]medium20dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrimidines;
statin (synthetic);
sulfonamide		anti-inflammatory agent;
antilipemic drug;
cardioprotective agent;
CETP inhibitor;
environmental contaminant;
xenobiotic
cocaine[no description available]medium10benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid		adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
eicosapentaenoic acid[no description available]medium10icosapentaenoic acid;
omega-3 fatty acid		anticholesteremic drug;
antidepressant;
antineoplastic agent;
Daphnia galeata metabolite;
fungal metabolite;
micronutrient;
mouse metabolite;
nutraceutical
drf 2725[no description available]medium30
diethylstilbestrol[no description available]medium60olefinic compound;
polyphenol		antifungal agent;
antineoplastic agent;
autophagy inducer;
calcium channel blocker;
carcinogenic agent;
EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
endocrine disruptor;
xenoestrogen
alitretinoin[no description available]medium10retinoic acidantineoplastic agent;
keratolytic drug;
metabolite;
retinoid X receptor agonist
decitabine[no description available]medium302'-deoxyribonucleoside
tenofovir[no description available]medium30nucleoside analogue;
phosphonic acids		antiviral drug;
drug metabolite;
HIV-1 reverse transcriptase inhibitor
rubitecan[no description available]medium20C-nitro compound;
delta-lactone;
pyranoindolizinoquinoline;
semisynthetic derivative;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
micafungin[no description available]medium20antibiotic antifungal drug;
echinocandin		antiinfective agent
riboflavin[no description available]medium20flavin;
vitamin B2		anti-inflammatory agent;
antioxidant;
cofactor;
Escherichia coli metabolite;
food colouring;
fundamental metabolite;
human urinary metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite
sodium bicarbonate[no description available]medium30one-carbon compound;
organic sodium salt		antacid;
food anticaking agent
sodium acetate, anhydrous[no description available]medium10organic sodium saltNMR chemical shift reference compound
sodium benzoate[no description available]medium10organic sodium saltalgal metabolite;
antimicrobial food preservative;
drug allergen;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
human xenobiotic metabolite;
plant metabolite
ditiocarb sodium[no description available]medium10organic molecular entity
discodermolide[no description available]medium10diterpenoid
cannabidiol[no description available]medium10olefinic compound;
phytocannabinoid;
resorcinols		antimicrobial agent;
plant metabolite
prothionamide[no description available]medium10pyridines
capsaicin[no description available]medium60capsaicinoidnon-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker
sodium propionate[no description available]medium10organic sodium saltantifungal drug;
food preservative
fusidic acid[no description available]medium2011alpha-hydroxy steroid;
3alpha-hydroxy steroid;
alpha,beta-unsaturated monocarboxylic acid;
steroid acid;
steroid antibiotic;
sterol ester		EC 2.7.1.33 (pantothenate kinase) inhibitor;
Escherichia coli metabolite;
protein synthesis inhibitor
hmr 3647[no description available]medium60
toremifene[no description available]medium30aromatic ether;
organochlorine compound;
tertiary amine		antineoplastic agent;
bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
telaprevir[no description available]medium10cyclopentapyrrole;
cyclopropanes;
oligopeptide;
pyrazines		antiviral drug;
hepatitis C protease inhibitor;
peptidomimetic
droloxifene[no description available]medium10stilbenoid
or 1259[no description available]medium10hydrazone;
nitrile;
pyridazinone		anti-arrhythmia drug;
cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
vasodilator agent
orlistat[no description available]medium40beta-lactone;
carboxylic ester;
formamides;
L-leucine derivative		anti-obesity agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor
idoxifene[no description available]medium10stilbenoid
zd 6474[no description available]medium10aromatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine		antineoplastic agent;
tyrosine kinase inhibitor
silybin[no description available]medium10
chloramine-t[no description available]medium10organic sodium saltallergen;
antifouling biocide;
disinfectant
tolcapone[no description available]medium702-nitrophenols;
benzophenones;
catechols		antiparkinson drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
dinoprostone[no description available]medium80prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
dinoprost[no description available]medium70monocarboxylic acid;
prostaglandins Falpha		human metabolite;
mouse metabolite
beta carotene[no description available]medium20carotenoid beta-end derivative;
cyclic carotene		antioxidant;
biological pigment;
cofactor;
ferroptosis inhibitor;
human metabolite;
mouse metabolite;
plant metabolite;
provitamin A
cholecalciferol[no description available]high30D3 vitamins;
hydroxy seco-steroid;
seco-cholestane;
secondary alcohol;
steroid hormone		geroprotector;
human metabolite
clavulanic acid[no description available]medium20oxapenamantibacterial drug;
anxiolytic drug;
bacterial metabolite;
EC 3.5.2.6 (beta-lactamase) inhibitor
oxymetholone[no description available]medium140
montelukast[no description available]medium60aliphatic sulfide;
monocarboxylic acid;
quinolines		anti-arrhythmia drug;
anti-asthmatic drug;
leukotriene antagonist
mycophenolate mofetil[no description available]medium30carboxylic ester;
ether;
gamma-lactone;
phenols;
tertiary amino compound		anticoronaviral agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
immunosuppressive agent;
prodrug
entacapone[no description available]medium502-nitrophenols;
catechols;
monocarboxylic acid amide;
nitrile		antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
diosmin[no description available]medium10dihydroxyflavanone;
disaccharide derivative;
glycosyloxyflavone;
monomethoxyflavone;
rutinoside		anti-inflammatory agent;
antioxidant
sdz psc 833[no description available]medium10homodetic cyclic peptide
coenzyme q10[no description available]medium10ubiquinonesantioxidant;
ferroptosis inhibitor;
human metabolite
ozagrel[no description available]medium10cinnamic acids
pitavastatin[no description available]medium20cyclopropanes;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
quinolines;
statin (synthetic)		antioxidant
alatrofloxacin mesylate[no description available]medium20
natamycin[no description available]medium20antibiotic antifungal drug;
dicarboxylic acid monoester;
epoxide;
macrolide antibiotic;
monosaccharide derivative;
polyene antibiotic		antifungal agrochemical;
antimicrobial food preservative;
apoptosis inducer;
bacterial metabolite;
ophthalmology drug
acitretin[no description available]medium60acitretin;
alpha,beta-unsaturated monocarboxylic acid;
retinoid		keratolytic drug
dothiepin[no description available]medium10dothiepin
levetiracetam[no description available]medium40pyrrolidin-2-onesanticonvulsant;
environmental contaminant;
xenobiotic
nalorphine[no description available]medium10morphinane alkaloid
oxymorphone[no description available]medium30morphinane alkaloid
sirolimus[no description available]medium30antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol		antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
alvocidib[no description available]medium10dihydroxyflavone;
hydroxypiperidine;
monochlorobenzenes;
tertiary amino compound		antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
seocalcitol[no description available]medium10
geldanamycin[no description available]medium101,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound		antimicrobial agent;
antineoplastic agent;
antiviral agent;
cysteine protease inhibitor;
Hsp90 inhibitor
demycarosylturimycin h[no description available]medium20
iloprost[no description available]medium10carbobicyclic compound;
monocarboxylic acid;
secondary alcohol		platelet aggregation inhibitor;
vasodilator agent
furazolidone[no description available]medium30
orantinib[no description available]medium10
dextromethorphan[no description available]medium206-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthreneantitussive;
environmental contaminant;
neurotoxin;
NMDA receptor antagonist;
oneirogen;
prodrug;
xenobiotic
bleomycin[no description available]medium20bleomycinantineoplastic agent;
metabolite
enalaprilat anhydrous[no description available]medium40dicarboxylic acid;
dipeptide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
imidapril[no description available]medium10dicarboxylic acid monoester;
dipeptide;
ethyl ester;
imidazolidines;
N-acylurea;
secondary amino compound		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
ximelagatran[no description available]medium40amidoxime;
azetidines;
carboxamide;
ethyl ester;
hydroxylamines;
secondary amino compound;
secondary carboxamide;
tertiary carboxamide		anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor;
prodrug;
serine protease inhibitor
proguanil[no description available]medium20biguanides;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
rifamycin sv[no description available]medium20acetate ester;
cyclic ketal;
lactam;
macrocycle;
organic heterotetracyclic compound;
polyphenol;
rifamycins		antimicrobial agent;
antitubercular agent;
bacterial metabolite
epoprostenol sodium[no description available]medium10prostanoid
ixabepilone[no description available]medium201,3-thiazoles;
beta-hydroxy ketone;
epoxide;
lactam;
macrocycle		antineoplastic agent;
microtubule-destabilising agent
azlocillin[no description available]medium10penicillin allergen;
penicillin;
semisynthetic derivative		antibacterial drug
nifurtimox[no description available]medium20nitrofuran antibiotic
roxithromycin[no description available]medium30roxithromycinenvironmental contaminant;
xenobiotic
beraprost[no description available]medium10enyne;
monocarboxylic acid;
organic heterotricyclic compound;
secondary alcohol;
secondary allylic alcohol		anti-inflammatory agent;
antihypertensive agent;
platelet aggregation inhibitor;
prostaglandin receptor agonist;
vasodilator agent
lanreotide[no description available]medium10
lu 208075[no description available]medium30diarylmethane
acetylcarnitine[no description available]medium10O-acetylcarnitine;
saturated fatty acyl-L-carnitine		human metabolite;
Saccharomyces cerevisiae metabolite
nifurtoinol[no description available]medium10hydrazone;
imidazolidine-2,4-dione;
nitrofuran antibiotic;
organonitrogen heterocyclic antibiotic		antibacterial drug;
antiinfective agent;
hepatotoxic agent
eflucimibe[no description available]medium10
etomoxir[no description available]medium20aromatic ether
pentagastrin[no description available]medium20organic molecular entity
azd 6244[no description available]medium10benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
vinflunine[no description available]medium10acetate ester;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
semisynthetic derivative;
vinca alkaloid		antineoplastic agent
baci-im[no description available]medium50homodetic cyclic peptide;
polypeptide;
zwitterion		antibacterial agent;
antimicrobial agent
pf 03491390[no description available]medium10
amodiaquine hydrochloride[no description available]medium30
tannins[no description available]medium10tannin
cerivastatin sodium[no description available]medium10organic sodium salt;
statin (synthetic)
monensin[no description available]medium10
oxacillin sodium[no description available]medium20organic sodium salt
sodium diatrizoate[no description available]medium10organic sodium salt;
organoiodine compound		radioopaque medium
dicumarol[no description available]medium20hydroxycoumarinanticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
Hsp90 inhibitor;
vitamin K antagonist
acenocoumarol[no description available]medium40C-nitro compound;
hydroxycoumarin;
methyl ketone		anticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor
phenprocoumon[no description available]medium10hydroxycoumarinanticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor
rolitetracycline[no description available]medium20
lornoxicam[no description available]medium20heteroaryl hydroxy compound;
monocarboxylic acid amide;
organochlorine compound;
pyridines;
thienothiazine		antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
ajmaline[no description available]medium10
entecavir[no description available]medium302-aminopurines;
oxopurine;
primary alcohol;
secondary alcohol		antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
inosine[no description available]medium10inosines;
purines D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
folic acid[no description available]medium100folic acids;
N-acyl-amino acid		human metabolite;
mouse metabolite;
nutrient
sildenafil[no description available]medium40piperazines;
pyrazolopyrimidine;
sulfonamide		EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
oxypurinol[no description available]medium10pyrazolopyrimidinedrug metabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor
raltitrexed[no description available]medium20N-acyl-amino acid
leucovorin[no description available]medium30formyltetrahydrofolic acidEscherichia coli metabolite;
mouse metabolite
tirapazamine[no description available]medium10aromatic amine;
benzotriazines;
N-oxide		antibacterial agent;
antineoplastic agent;
apoptosis inducer
aminooxyacetic acid[no description available]medium10amino acid;
hydroxylamines;
monocarboxylic acid		anticonvulsant;
EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor;
EC 4.2.1.22 (cystathionine beta-synthase) inhibitor;
nootropic agent
aprindine[no description available]medium10indanes
bretylium[no description available]medium20quaternary ammonium ionadrenergic antagonist;
anti-arrhythmia drug;
antihypertensive agent
3,4-dihydroxybenzohydroxamic acid[no description available]medium10benzoic acids
ethyl loflazepate[no description available]medium10organic molecular entity
incadronate[no description available]medium101,1-bis(phosphonic acid)
ketotifen[no description available]medium40cyclic ketone;
olefinic compound;
organic heterotricyclic compound;
organosulfur heterocyclic compound;
piperidines;
tertiary amino compound		anti-asthmatic drug;
H1-receptor antagonist
lorazepam[no description available]medium20benzodiazepine
methoxyamine[no description available]medium10organooxygen compound
nomifensine[no description available]medium60isoquinolinesdopamine uptake inhibitor
papaverine[no description available]medium50benzylisoquinoline alkaloid;
dimethoxybenzene;
isoquinolines		antispasmodic drug;
vasodilator agent
phenindione[no description available]medium10aromatic ketone;
beta-diketone		anticoagulant
rabeprazole[no description available]medium20benzimidazoles;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
risedronic acid[no description available]medium30pyridines
sulforaphane[no description available]medium10isothiocyanate;
sulfoxide		antineoplastic agent;
antioxidant;
EC 3.5.1.98 (histone deacetylase) inhibitor;
plant metabolite
zopiclone[no description available]medium20monochloropyridine;
pyrrolopyrazine		central nervous system depressant;
sedative
sterogenol[no description available]medium10bromide salt;
pyridinium salt		antiseptic drug;
EC 2.7.11.18 (myosin-light-chain kinase) inhibitor;
surfactant
cycloguanil[no description available]medium10triazinesantifolate;
antiinfective agent;
antimalarial;
antiparasitic agent;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
benzohydroxamic acid[no description available]medium10
pyrodifenium bromide[no description available]medium10organic molecular entity
amopyroquine[no description available]medium10
benzonidazole[no description available]medium20C-nitro compound;
imidazoles;
monocarboxylic acid amide		antiprotozoal drug
dexchlorpheniramine[no description available]medium20chlorphenamine
halofantrine[no description available]medium50phenanthrenes
hydroxymaprotilin[no description available]medium10
pinazepam[no description available]medium10benzodiazepine
staurosporine[no description available]medium20indolocarbazole alkaloid;
organic heterooctacyclic compound		apoptosis inducer;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
geroprotector
ibandronic acid[no description available]medium20
trovafloxacin[no description available]medium60
ursolic acid[no description available]medium10hydroxy monocarboxylic acid;
pentacyclic triterpenoid		geroprotector;
plant metabolite
propamidine[no description available]medium10aromatic ether;
guanidines;
polyether		antimicrobial agent;
antiseptic drug
sinefungin[no description available]medium10adenosines;
non-proteinogenic alpha-amino acid		antifungal agent;
antimicrobial agent
droxicam[no description available]medium30organic heterotricyclic compound;
pyridines		cyclooxygenase 1 inhibitor;
hepatotoxic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
platelet aggregation inhibitor;
prodrug
etofibrate[no description available]medium10monocarboxylic acid
synthalin a[no description available]medium10guanidineshepatotoxic agent;
hypoglycemic agent;
nephrotoxin
zoledronic acid[no description available]medium401,1-bis(phosphonic acid);
imidazoles		bone density conservation agent
pirlindole[no description available]medium10carbazoles
artemether[no description available]medium20artemisinin derivative;
cyclic acetal;
organic peroxide;
semisynthetic derivative;
sesquiterpenoid		antimalarial
6-amino-1-hydroxyhexane-1,1-diphosphonate[no description available]medium101,1-bis(phosphonic acid)
rexigen[no description available]medium10
aceclofenac[no description available]medium40amino acid;
carboxylic ester;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
clociguanil[no description available]medium10
tebuquine[no description available]medium10
cryptolepine[no description available]medium10indole alkaloid;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound		anti-inflammatory agent;
antimalarial;
antineoplastic agent;
cysteine protease inhibitor;
plant metabolite
cinchonine[no description available]medium10(8xi)-cinchonan-9-ol;
cinchona alkaloid		metabolite
n-hexadecyl-n,n-dimethyl-3-ammonio-1-propanesulfonate[no description available]medium10
desethylchloroquine[no description available]medium10aminoquinoline
wr 159412[no description available]medium10
cinchonidine[no description available]medium10(8xi)-cinchonan-9-ol;
cinchona alkaloid		metabolite
benzyloxyamine[no description available]medium10
pyronaridine[no description available]medium10aminoquinoline
tafenoquine[no description available]medium10(trifluoromethyl)benzenes;
aminoquinoline;
aromatic ether;
primary amino compound;
secondary amino compound
desethylamodiaquine[no description available]medium10
n,n-dideethylchloroquine[no description available]medium10
3,6-diamino-9-(4-(methylsulfonyl)aminophenyl)aminoacridine[no description available]medium10
ne 58051[no description available]medium10
wr 242511[no description available]medium10
olpadronic acid[no description available]medium10
lupeol[no description available]medium10pentacyclic triterpenoid;
secondary alcohol		anti-inflammatory drug;
plant metabolite
neocryptolepine[no description available]medium10
1-hydroxypentane-1,1-bisphosphonate[no description available]medium10
cimadronate[no description available]medium10
1,1-hydroxyoctanodiphosphonate[no description available]medium10
canaline[no description available]medium10amino acid zwitterion;
non-proteinogenic L-alpha-amino acid		antimetabolite;
antineoplastic agent;
phytogenic insecticide;
plant metabolite
Tetrahydropiperine[no description available]medium10benzodioxoles
piperine[no description available]medium10benzodioxoles;
N-acylpiperidine;
piperidine alkaloid;
tertiary carboxamide		food component;
human blood serum metabolite;
NF-kappaB inhibitor;
plant metabolite
ilepcimide[no description available]medium10benzodioxoles
flunarizine[no description available]medium20diarylmethane
artemotil[no description available]medium10artemisinin derivative
alsterpaullone[no description available]medium10C-nitro compound;
caprolactams;
organic heterotetracyclic compound		anti-HIV-1 agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor
usambarensine[no description available]medium10harmala alkaloid
triprolidine[no description available]medium30N-alkylpyrrolidine;
olefinic compound;
pyridines		H1-receptor antagonist
licochalcone a[no description available]medium10chalcones
stilbamidine[no description available]medium10
piperic acid[no description available]medium10alpha,beta-unsaturated monocarboxylic acid;
benzodioxoles		plant metabolite
nifuroxime[no description available]medium10
chlorproguanil[no description available]medium10dichlorobenzene
n1-phenyl-3,5-dinitro-n4,n4-di-n-propylsulfanilamide[no description available]medium10
artenimol[no description available]medium10
4-phenoxyphenoxyethyl thiocyanate[no description available]medium10
deoxoartemisinin[no description available]medium10
butyrolactone i[no description available]medium10butenolide
3,4,5-trihydroxybenzamidoxime[no description available]medium10benzenetriol
ethylene dichloride[no description available]medium20chloroethaneshepatotoxic agent;
mutagen;
non-polar solvent
ethylene glycol[no description available]medium20ethanediol;
glycol		metabolite;
mouse metabolite;
solvent;
toxin
2,4-dinitrophenol[no description available]medium20dinitrophenolallergen;
antiseptic drug;
bacterial xenobiotic metabolite;
geroprotector;
oxidative phosphorylation inhibitor
3-methylcholanthrene[no description available]medium10ortho- and peri-fused polycyclic arenearyl hydrocarbon receptor agonist;
carcinogenic agent
bithionol[no description available]medium20aryl sulfide;
bridged diphenyl antifungal drug;
bridged diphenyl fungicide;
dichlorobenzene;
organochlorine pesticide;
polyphenol		antifungal agrochemical;
antiplatyhelmintic drug
candesartan[no description available]medium30benzimidazolecarboxylic acid;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
ciglitazone[no description available]medium30aromatic ether;
thiazolidinone		antineoplastic agent;
insulin-sensitizing drug
cromolyn[no description available]medium40chromones;
dicarboxylic acid		anti-asthmatic drug;
calcium channel blocker
donepezil[no description available]medium60aromatic ether;
indanones;
piperidines;
racemate		EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
nootropic agent
carbonyl cyanide p-trifluoromethoxyphenylhydrazone[no description available]medium20aromatic ether;
hydrazone;
nitrile;
organofluorine compound		ATP synthase inhibitor;
geroprotector;
ionophore
fipexide[no description available]medium40benzodioxoles
hycanthone[no description available]medium40thioxanthenesmutagen;
schistosomicide drug
isocarboxazid[no description available]medium40benzenes
memantine[no description available]medium40adamantanes;
primary aliphatic amine		antidepressant;
antiparkinson drug;
dopaminergic agent;
neuroprotective agent;
NMDA receptor antagonist
methapyrilene[no description available]medium30ethylenediamine derivativeanti-allergic agent;
carcinogenic agent;
H1-receptor antagonist;
sedative
oxibendazole[no description available]medium30benzimidazoles;
carbamate ester
pargyline[no description available]medium30aromatic amine
perhexiline[no description available]medium60piperidinescardiovascular drug
pioglitazone[no description available]medium80aromatic ether;
pyridines;
thiazolidinediones		antidepressant;
cardioprotective agent;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hypoglycemic agent;
insulin-sensitizing drug;
PPARgamma agonist;
xenobiotic
raloxifene[no description available]medium401-benzothiophenes;
aromatic ketone;
N-oxyethylpiperidine;
phenols		bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
sulfabenzamide[no description available]medium20benzenes;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
antimicrobial drug
tolmetin[no description available]medium30aromatic ketone;
monocarboxylic acid;
pyrroles		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
pirinixic acid[no description available]medium20aryl sulfide;
organochlorine compound;
pyrimidines
oxyphenonium[no description available]medium20acylcholine
2-acetylaminofluorene[no description available]medium102-acetamidofluorenesantimitotic;
carcinogenic agent;
epitope;
mutagen
isonicotinic acid[no description available]medium10pyridinemonocarboxylic acidalgal metabolite;
human metabolite
carbon tetrachloride[no description available]medium40chlorocarbon;
chloromethanes		hepatotoxic agent;
refrigerant
acetylcholine chloride[no description available]medium30quaternary ammonium salt
dimethylnitrosamine[no description available]medium20nitrosaminegeroprotector;
mutagen
primaquine phosphate[no description available]medium20
chloroform[no description available]medium20chloromethanes;
one-carbon compound		carcinogenic agent;
central nervous system drug;
inhalation anaesthetic;
non-polar solvent;
refrigerant
dimethylformamide[no description available]medium10formamides;
volatile organic compound		geroprotector;
hepatotoxic agent;
polar aprotic solvent
tromethamine[no description available]medium30primary amino compound;
triol		buffer
cyclizine[no description available]medium20N-alkylpiperazineantiemetic;
central nervous system depressant;
cholinergic antagonist;
H1-receptor antagonist;
local anaesthetic
hexachlorobutadiene[no description available]medium10organochlorine compound
phenothiazine[no description available]medium20phenothiazineferroptosis inhibitor;
plant metabolite;
radical scavenger
2-bromophenol[no description available]medium20bromophenolmarine metabolite
3-dinitrobenzene[no description available]medium10dinitrobenzeneneurotoxin
4,4'-diaminodiphenylmethane[no description available]medium20aromatic amineallergen;
carcinogenic agent
phenylisothiocyanate[no description available]medium20isothiocyanateallergen;
reagent
4-bromophenol[no description available]medium20bromophenolhuman urinary metabolite;
human xenobiotic metabolite;
marine metabolite;
mouse metabolite;
persistent organic pollutant;
rat metabolite
2-bromoethylamine[no description available]medium20
allyl alcohol[no description available]medium20primary allylic alcohol;
propenol		antibacterial agent;
fungicide;
herbicide;
insecticide;
plant metabolite
bromobenzene[no description available]medium20bromoarene;
bromobenzenes;
volatile organic compound		hepatotoxic agent;
mouse metabolite;
non-polar solvent
di-n-pentyl phthalate[no description available]medium20diester;
phthalate ester		plasticiser
phenazopyridine hydrochloride[no description available]medium20hydrochloridecarcinogenic agent;
local anaesthetic;
non-narcotic analgesic
tripelennamine hydrochloride[no description available]medium20
ethynodiol diacetate[no description available]medium30steroid ester;
terminal acetylenic compound		contraceptive drug;
estrogen receptor modulator;
synthetic oral contraceptive
hydrazine[no description available]medium70azane;
hydrazines		EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
monocrotaline[no description available]medium20pyrrolizidine alkaloid
pseudoephedrine hydrochloride[no description available]medium20hydrochlorideplant metabolite
procarbazine hydrochloride[no description available]medium30hydrochlorideantineoplastic agent
lithocholic acid[no description available]medium20bile acid;
C24-steroid;
monohydroxy-5beta-cholanic acid		geroprotector;
human metabolite;
mouse metabolite
1-naphthylisothiocyanate[no description available]medium30isothiocyanateinsecticide
isoxsuprine hydrochloride[no description available]medium20alkylbenzene
3-hydroxyacetanilide[no description available]medium20acetamides;
phenols		non-narcotic analgesic
methoxyacetic acid[no description available]medium20ether;
monocarboxylic acid		antineoplastic agent;
apoptosis inducer;
human xenobiotic metabolite;
mutagen
pregnenolone carbonitrile[no description available]medium20aliphatic nitrile
ibufenac[no description available]medium40monocarboxylic acidEC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
hepatotoxic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
2,3,7,8-tetrachlorodibenzodioxine[no description available]medium10polychlorinated dibenzodioxine
paraquat[no description available]medium20organic cationgeroprotector;
herbicide
ethylene dimethanesulfonate[no description available]medium20
beclomethasone dipropionate[no description available]medium2011beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
corticosteroid;
enone;
glucocorticoid;
propanoate ester;
steroid ester		anti-arrhythmia drug;
anti-asthmatic drug;
anti-inflammatory drug;
prodrug
carbendazim[no description available]medium20benzimidazole fungicide;
benzimidazoles;
benzimidazolylcarbamate fungicide;
carbamate ester		antifungal agrochemical;
antinematodal drug;
metabolite;
microtubule-destabilising agent
ethionine[no description available]medium20S-ethylhomocysteineantimetabolite;
carcinogenic agent
butylated hydroxytoluene[no description available]medium30phenolsantioxidant;
ferroptosis inhibitor;
food additive;
geroprotector
moricizine hydrochloride[no description available]medium20hydrochlorideanti-arrhythmia drug
serentil[no description available]medium20organosulfonate saltdopaminergic antagonist;
first generation antipsychotic
nonachlazine[no description available]medium10
indacrinone[no description available]medium20
butoconazole nitrate[no description available]medium20aryl sulfide;
conazole antifungal drug;
imidazole antifungal drug;
imidazoles;
organic nitrate salt
fialuridine[no description available]medium40
mitoxantrone hydrochloride[no description available]medium20hydrochlorideantineoplastic agent
alpidem[no description available]medium70imidazoles
temafloxacin[no description available]medium20amino acid;
monocarboxylic acid;
N-arylpiperazine;
organofluorine compound;
quinolone antibiotic;
quinolone;
secondary amino compound;
tertiary amino compound
clinafloxacin[no description available]medium20quinolines
tasosartan[no description available]medium40biphenyls
saquinavir monomethanesulfonate[no description available]medium20organic molecular entity
allyl formate[no description available]medium20
desferrioxamine b mesylate[no description available]medium20methanesulfonate saltantidote;
ferroptosis inhibitor;
iron chelator
ciprofloxacin hydrochloride anhydrous[no description available]medium20hydrochlorideantibacterial drug;
antiinfective agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
sulconazole, mononitrate, (+-)-isomer[no description available]medium20conazole antifungal drug;
imidazole antifungal drug;
organic nitrate salt
trimethobenzamide monohydrochloride[no description available]medium20
econazole nitrate[no description available]medium20
flunoxaprofen[no description available]medium201,3-benzoxazoles;
monocarboxylic acid;
organofluorine compound		antirheumatic drug;
hepatotoxic agent;
non-steroidal anti-inflammatory drug;
protein kinase C agonist
tianeptine[no description available]medium20dibenzothiazepine;
monocarboxylic acid;
organochlorine compound
grepafloxacin[no description available]medium20fluoroquinolone antibiotic;
quinolines;
quinolone antibiotic
2-naphthylisothiocyanate[no description available]medium20
orphenadrine citrate[no description available]medium20citrate saltH1-receptor antagonist;
muscarinic antagonist;
muscle relaxant;
NMDA receptor antagonist;
parasympatholytic
n-(3,5-dichlorophenyl)succinimide[no description available]medium20pyrrolidines
1-cyano-2-hydroxy-3-butene[no description available]medium10secondary alcohol
dilevalol[no description available]medium102-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide
aflatoxin b1[no description available]medium20aflatoxin;
aromatic ether;
aromatic ketone		carcinogenic agent;
human metabolite
fludrocortisone acetate[no description available]medium2011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
fluorinated steroid;
mineralocorticoid;
tertiary alpha-hydroxy ketone
acivicin[no description available]medium20isoxazoles;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		antileishmanial agent;
antimetabolite;
antimicrobial agent;
antineoplastic agent;
EC 2.3.2.2 (gamma-glutamyltransferase) inhibitor;
glutamine antagonist;
metabolite
puromycin[no description available]medium20puromycinsantiinfective agent;
antimicrobial agent;
antineoplastic agent;
EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor;
EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor;
nucleoside antibiotic;
protein synthesis inhibitor
(+)-limonene[no description available]medium20limoneneplant metabolite
moxalactam disodium[no description available]medium20
abacavir[no description available]medium402,6-diaminopurinesantiviral drug;
drug allergen;
HIV-1 reverse transcriptase inhibitor
mometasone furoate[no description available]medium2011beta-hydroxy steroid;
2-furoate ester;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
organochlorine compound;
steroid ester		anti-allergic agent;
anti-inflammatory drug
kanamycin sulfate[no description available]medium20aminoglycoside sulfate saltantibacterial drug;
geroprotector
chloramphenicol palmitate[no description available]medium20hexadecanoate ester
calcium pantothenate[no description available]medium20polymer
maleic acid[no description available]medium20butenedioic acidalgal metabolite;
mouse metabolite;
plant metabolite
cyanoginosin lr[no description available]medium20microcystinbacterial metabolite;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
environmental contaminant;
xenobiotic
arsenic trioxide[no description available]medium30arsenic oxideantineoplastic agent;
insecticide
idarubicin hydrochloride[no description available]medium20anthracycline
carbenoxolone sodium[no description available]medium20triterpenoid
thioacetamide[no description available]medium20thiocarboxamidehepatotoxic agent
retinol palmitate[no description available]medium20all-trans-retinyl ester;
retinyl palmitate		antioxidant;
Escherichia coli metabolite;
human xenobiotic metabolite
vitamin d 2[no description available]medium50hydroxy seco-steroid;
seco-ergostane;
vitamin D		bone density conservation agent;
nutraceutical;
plant metabolite;
rodenticide
eprosartan[no description available]medium40dicarboxylic acid;
imidazoles;
thiophenes		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
estradiol-17 beta-glucuronide[no description available]medium203-hydroxy steroid;
steroid glucosiduronic acid
octylmethoxycinnamate[no description available]medium20cinnamate ester
trientine hydrochloride[no description available]medium30
enclomiphene citrate[no description available]medium10
diphenoxylate hydrochloride[no description available]medium20hydrochlorideantidiarrhoeal drug
ergonovine maleate[no description available]medium20maleate saltdiagnostic agent;
oxytocic
ursodoxicoltaurine[no description available]medium10bile acid taurine conjugateanti-inflammatory agent;
apoptosis inhibitor;
bone density conservation agent;
cardioprotective agent;
human metabolite;
neuroprotective agent
molindone hydrochloride[no description available]medium20indoles
cytidine diphosphate choline[no description available]medium20nucleotide-(amino alcohol)s;
phosphocholines		human metabolite;
mouse metabolite;
neuroprotective agent;
psychotropic drug;
Saccharomyces cerevisiae metabolite
clindamycin hydrochloride[no description available]medium20S-glycosyl compound
cefotiam hydrochloride[no description available]medium20
potassium aminobenzoate[no description available]medium20
methicillin sodium[no description available]medium20organic sodium salt
nafcillin sodium[no description available]medium20organic sodium salt
penicillin g sodium[no description available]medium20organic sodium salt
cefamandole nafate[no description available]medium20organic sodium saltantibacterial drug
dicloxacillin sodium[no description available]medium20hydrate
azlocillin sodium[no description available]medium30organic sodium salt
isoxicam[no description available]medium30benzothiazine;
isoxazoles;
monocarboxylic acid amide		antirheumatic drug;
non-steroidal anti-inflammatory drug
chlortetracycline hydrochloride[no description available]medium20
methacycline monohydrochloride[no description available]medium20
citrovorum factor[no description available]medium40tetrahydrofolic acid
4-aminophenol[no description available]medium10aminophenolallergen;
metabolite
sulfobromophthalein[no description available]medium202-benzofurans;
organobromine compound;
organosulfonic acid;
phenols		dye
telenzepine[no description available]medium20benzodiazepine
diquat[no description available]medium10organic cationdefoliant;
herbicide
n-pentanoic acid[no description available]medium10short-chain fatty acid;
straight-chain saturated fatty acid		plant metabolite
tolrestat[no description available]medium40naphthalenesEC 1.1.1.21 (aldehyde reductase) inhibitor
cox 189[no description available]medium40amino acid;
monocarboxylic acid;
organochlorine compound;
organofluorine compound;
secondary amino compound		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
olmesartan[no description available]medium20biphenylyltetrazoleangiotensin receptor antagonist;
antihypertensive agent
lapatinib[no description available]medium50furans;
organochlorine compound;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor
taurolithocholic acid[no description available]medium10bile acid taurine conjugate;
monocarboxylic acid amide		human metabolite
indinavir sulfate[no description available]medium10azaheterocycle sulfate salt
ampicillin sodium[no description available]medium10organic sodium salt
sudoxicam[no description available]medium10
alminoprofen[no description available]medium10amino acid;
monocarboxylic acid;
secondary amino compound;
substituted aniline		antipyretic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 3.1.1.4 (phospholipase A2) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
amfenac[no description available]medium10amino acid;
benzophenones;
oxo monocarboxylic acid;
primary amino compound;
substituted aniline		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
nordazepam[no description available]medium101,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
GABA modulator;
human metabolite;
sedative
fenoprofen[no description available]medium30monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
pyranoprofen[no description available]medium20pyridochromene
propantheline[no description available]medium20xanthenes
cn 100[no description available]medium10organic molecular entity
taurocholic acid[no description available]medium30amino sulfonic acid;
bile acid taurine conjugate		human metabolite
tiotidine[no description available]medium10thiazoles
5-propynylarabinofuranosyluracil[no description available]medium10
tenidap[no description available]medium10
befloxatone[no description available]medium10
ziprasidone[no description available]medium201,2-benzisothiazole;
indolones;
organochlorine compound;
piperazines		antipsychotic agent;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
psychotropic drug;
serotonergic antagonist
ibuproxam[no description available]medium10hydroxamic acidiron chelator;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
fluparoxan[no description available]medium10
glycylsarcosine[no description available]medium10dipeptide zwitterion;
dipeptide
indobufen[no description available]medium10isoindoles
arginine vasopressin[no description available]medium30vasopressincardiovascular drug;
hematologic agent;
mitogen
raclopride[no description available]medium10salicylamides
acrivastine[no description available]medium10alpha,beta-unsaturated monocarboxylic acid;
N-alkylpyrrolidine;
olefinic compound;
pyridines		H1-receptor antagonist
cefatrizine[no description available]medium10amino acid amide;
carboxylic acid;
cephalosporin;
phenols;
semisynthetic derivative;
triazoles		antibacterial drug;
EC 2.7.11.20 (elongation factor 2 kinase) inhibitor
ethanolamine[no description available]medium10ethanolamines;
primary alcohol;
primary amine		Escherichia coli metabolite;
human metabolite;
mouse metabolite
alaproclate[no description available]medium20alpha-amino acid ester
bethanechol[no description available]medium30carbamate ester;
quaternary ammonium ion		muscarinic agonist
biperiden[no description available]medium20piperidines;
tertiary alcohol;
tertiary amino compound		antidote to sarin poisoning;
antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist;
parasympatholytic
carbinoxamine[no description available]medium30monochlorobenzenes;
pyridines;
tertiary amino compound		anti-allergic agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist
cyclofenil[no description available]medium20organic molecular entity
flavoxate[no description available]medium20carboxylic ester;
flavones;
piperidines;
tertiary amino compound		antispasmodic drug;
muscarinic antagonist;
parasympatholytic
metaproterenol[no description available]medium30aralkylamino compound;
phenylethanolamines;
resorcinols;
secondary alcohol;
secondary amino compound
oxybutynin[no description available]medium50acetylenic compound;
carboxylic ester;
racemate;
tertiary alcohol;
tertiary amino compound		antispasmodic drug;
calcium channel blocker;
local anaesthetic;
muscarinic antagonist;
muscle relaxant;
parasympatholytic
procyclidine[no description available]medium30pyrrolidines;
tertiary alcohol		antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist
succinylcholine[no description available]medium20quaternary ammonium ion;
succinate ester		drug allergen;
muscle relaxant;
neuromuscular agent
mepazine[no description available]medium20phenothiazines
mebanazine[no description available]medium20benzenes
benzonatate[no description available]medium30benzoate ester;
secondary amino compound;
substituted aniline		anaesthetic;
antitussive
edrophonium bromide[no description available]medium10
sulfanilylurea[no description available]medium20benzenes;
sulfonamide
isosorbide[no description available]medium10organic molecular entity
clomacran[no description available]medium20acridines
clemastine[no description available]medium30monochlorobenzenes;
N-alkylpyrrolidine		anti-allergic agent;
antipruritic drug;
H1-receptor antagonist;
muscarinic antagonist
cromolyn sodium[no description available]medium10organic sodium saltanti-asthmatic drug;
drug allergen
fenclozic acid[no description available]medium40
laxagetten 4,4'-diacetoxydiphenylpyridylemethane[no description available]medium20
alclofenac[no description available]medium20aromatic ether;
monocarboxylic acid;
monochlorobenzenes		drug allergen;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
clometacin[no description available]medium20N-acylindole
exifone[no description available]medium20benzophenones
oseltamivir[no description available]medium20acetamides;
amino acid ester;
cyclohexenecarboxylate ester;
primary amino compound		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
environmental contaminant;
prodrug;
xenobiotic
tilbroquinol[no description available]medium20organohalogen compound;
quinolines
ebrotidine[no description available]medium20sulfonamide
isaxonine[no description available]medium20aminopyrimidine
fenoxypropazine[no description available]medium20aromatic ether
nitrefazole[no description available]medium20imidazoles
tamsulosin[no description available]medium205-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamidealpha-adrenergic antagonist;
antineoplastic agent
pralnacasan[no description available]medium20
fiduxosin[no description available]medium20
aplaviroc[no description available]medium20
maraviroc[no description available]medium30tropane alkaloid
alatrofloxacin[no description available]medium10
benzphetamine[no description available]medium20amphetamines;
tertiary amine		adrenergic uptake inhibitor;
appetite depressant;
dopamine uptake inhibitor;
sympathomimetic agent
su 11248[no description available]medium40monocarboxylic acid amide;
pyrroles		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist
zimeldine[no description available]medium30styrenes
pafuramidine[no description available]medium20
bibx 1382bs[no description available]medium20substituted aniline
chlorhexidine[no description available]medium10biguanides;
monochlorobenzenes		antibacterial agent;
antiinfective agent
pazopanib[no description available]medium30aminopyrimidine;
indazoles;
sulfonamide		angiogenesis modulating agent;
antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist
tipranavir[no description available]medium20sulfonamideantiviral drug;
HIV protease inhibitor
amg531[no description available]medium60
amodiaquine[no description available]medium20aminoquinoline;
organochlorine compound;
phenols;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
drug allergen;
EC 2.1.1.8 (histamine N-methyltransferase) inhibitor;
non-steroidal anti-inflammatory drug;
prodrug
mefloquine[no description available]medium20[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanolantimalarial
ranolazine[no description available]medium20aromatic amide;
monocarboxylic acid amide;
monomethoxybenzene;
N-alkylpiperazine;
secondary alcohol
paroxetine hydrochloride[no description available]medium30hydrochlorideantidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor
quercetin[no description available]high407-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
guaifenesin[no description available]medium30methoxybenzenes
mecamylamine[no description available]medium20primary aliphatic amine
methocarbamol[no description available]medium30aromatic ether;
carbamate ester;
secondary alcohol
pyridostigmine[no description available]medium20pyridinium ion
pyrilamine[no description available]medium20aromatic ether;
ethylenediamine derivative		H1-receptor antagonist
metaraminol[no description available]medium20phenylethanolaminesalpha-adrenergic agonist;
sympathomimetic agent;
vasoconstrictor agent
leucine[no description available]medium30amino acid zwitterion;
L-alpha-amino acid;
leucine;
proteinogenic amino acid;
pyruvate family amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
phendimetrazine[no description available]medium10
remoxipride[no description available]medium30dimethoxybenzene
uk 68798[no description available]medium40aromatic ether;
sulfonamide;
tertiary amino compound		anti-arrhythmia drug;
potassium channel blocker
hyoscyamine[no description available]medium20tropane alkaloid
menthofuran[no description available]medium101-benzofurans;
monoterpenoid		nematicide;
plant metabolite
ipratropium[no description available]medium10
cyproterone[no description available]medium8017alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
chlorinated steroid;
tertiary alpha-hydroxy ketone		androgen antagonist
cyproterone[no description available]medium8117alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
chlorinated steroid;
tertiary alpha-hydroxy ketone		androgen antagonist
hydrocodone[no description available]medium10morphinane-like compound;
organic heteropentacyclic compound		antitussive;
mu-opioid receptor agonist;
opioid analgesic
nateglinide[no description available]medium30phenylalanine derivative
homatropine methylbromide[no description available]medium10
guaiacol[no description available]medium10guaiacolsdisinfectant;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
expectorant;
plant metabolite
histamine[no description available]medium20aralkylamino compound;
imidazoles		human metabolite;
mouse metabolite;
neurotransmitter
acetanilide[no description available]medium10acetamides;
anilide		analgesic
oxyquinoline[no description available]medium10monohydroxyquinolineantibacterial agent;
antifungal agrochemical;
antiseptic drug;
iron chelator
acetarsol[no description available]medium10acetamides;
anilide
ethacridine[no description available]medium10acridines
4-(acetylamino)benzeneacetic acid[no description available]medium10acetamides;
anilide
adiphenine[no description available]medium10diarylmethane
aklomide[no description available]medium10carbonyl compound;
organohalogen compound
p-aminohippuric acid[no description available]medium20N-acylglycineDaphnia magna metabolite
amprolium[no description available]medium10pyridinium ioncoccidiostat
antazoline[no description available]medium20aromatic amine;
imidazolines;
tertiary amino compound		cholinergic antagonist;
H1-receptor antagonist;
xenobiotic
6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol[no description available]medium10aporphine alkaloid
arecoline[no description available]medium10enoate ester;
methyl ester;
pyridine alkaloid;
tetrahydropyridine		metabolite;
muscarinic agonist
bendroflumethiazide[no description available]medium20benzothiadiazine;
sulfonamide		antihypertensive agent;
diuretic
benserazide[no description available]medium10carbohydrazide;
catechols;
primary alcohol;
primary amino compound		antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
benzocaine[no description available]medium20benzoate ester;
substituted aniline		allergen;
antipruritic drug;
sensitiser;
topical anaesthetic
benzothiazide[no description available]medium10benzothiadiazine;
sulfonamide		antihypertensive agent;
diuretic
bisacodyl[no description available]medium30diarylmethane
seratrodast[no description available]medium10organic molecular entity
butacaine[no description available]medium10benzoate ester
butamben[no description available]medium10amino acid ester;
benzoate ester;
primary amino compound;
substituted aniline		local anaesthetic
carbamylcholine[no description available]medium10
aricine[no description available]medium10cinchona alkaloid
cloxyquin[no description available]medium10organochlorine compound;
quinolines
dibenzothiophene[no description available]medium10dibenzothiophenes;
mancude organic heterotricyclic parent		keratolytic drug
dibucaine[no description available]medium10aromatic ether;
monocarboxylic acid amide;
tertiary amino compound		topical anaesthetic
dilacor xr[no description available]medium10acetate ester;
aromatic ether;
benzothiazepine;
lactam;
tertiary amino compound
dimethadione[no description available]medium10oxazolidinone
diphenylpyraline[no description available]medium10piperidines;
tertiary amine		cholinergic antagonist;
H1-receptor antagonist
doxylamine[no description available]medium20pyridines;
tertiary amine		anti-allergic agent;
antiemetic;
antitussive;
cholinergic antagonist;
H1-receptor antagonist;
histamine antagonist;
sedative
dyclonine[no description available]medium10aromatic ketone;
piperidines		topical anaesthetic
dyphylline[no description available]medium20oxopurine;
propane-1,2-diols		bronchodilator agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
muscle relaxant;
vasodilator agent
profenamine[no description available]medium10phenothiazines;
tertiary amino compound		adrenergic antagonist;
antidyskinesia agent;
antiparkinson drug;
histamine antagonist;
muscarinic antagonist
ethotoin[no description available]medium20imidazolidine-2,4-dioneanticonvulsant
fenoldopam[no description available]medium20benzazepinealpha-adrenergic agonist;
antihypertensive agent;
dopamine agonist;
dopaminergic antagonist;
vasodilator agent
hexoprenaline[no description available]medium10
hexamethylene bisacetamide[no description available]medium10acetamides
hydroflumethiazide[no description available]medium30benzothiadiazine;
thiazide		antihypertensive agent;
diuretic
iodoquinol[no description available]medium10monohydroxyquinoline;
organoiodine compound		antiamoebic agent;
antibacterial agent;
antiprotozoal drug;
antiseptic drug
isoetharine[no description available]medium10catecholamine
letrozole[no description available]medium30nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
ly 171883[no description available]medium10acetophenones;
aromatic ether;
phenols;
tetrazoles		anti-asthmatic drug;
leukotriene antagonist
mephenesin[no description available]medium10aromatic ether;
glycerol ether
benzoic acid [2-methyl-2-(propylamino)propyl] ester[no description available]medium10benzoate ester
acecainide[no description available]medium20acetamides;
benzamides		anti-arrhythmia drug
nadolol[no description available]medium30tetralins
nafronyl[no description available]medium10naphthalenes
naftopidil[no description available]medium10piperazines
naphazoline[no description available]medium10naphthalenes
neostigmine[no description available]medium20quaternary ammonium ionantidote to curare poisoning;
EC 3.1.1.7 (acetylcholinesterase) inhibitor
nilvadipine[no description available]medium10dihydropyridine;
isopropyl ester;
methyl ester;
nitrile
nitromide[no description available]medium10
6,7-dimethoxy-3-(4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3H-isobenzofuran-1-one[no description available]medium10isoquinolines
benoxinate[no description available]medium10amino acid ester;
benzoate ester;
substituted aniline;
tertiary amino compound		drug allergen;
local anaesthetic;
topical anaesthetic
1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl methylcarbamate[no description available]medium10pyrroloindole
piretanide[no description available]medium10aromatic ether
duodote[no description available]medium20pyridinium ionantidote to organophosphate poisoning;
antidote to sarin poisoning;
cholinergic drug;
cholinesterase reactivator
proadifen[no description available]medium10diarylmethane
protriptyline[no description available]medium20carbotricyclic compoundantidepressant
roxarsone[no description available]medium102-nitrophenols;
organoarsonic acid		agrochemical;
animal growth promotant;
antibacterial drug;
coccidiostat
salicylsalicylic acid[no description available]medium20benzoate ester;
benzoic acids;
phenols;
salicylates		antineoplastic agent;
antirheumatic drug;
EC 3.5.2.6 (beta-lactamase) inhibitor;
hypoglycemic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug
spiperone[no description available]medium10aromatic ketone;
azaspiro compound;
organofluorine compound;
piperidines;
tertiary amino compound		alpha-adrenergic antagonist;
antipsychotic agent;
dopaminergic antagonist;
psychotropic drug;
serotonergic antagonist
succinylsulfathiazole[no description available]medium101,3-thiazoles
tetrahydroxy-1,4-quinone[no description available]medium10hydroxybenzoquinonekeratolytic drug
2-thiosalicylic acid[no description available]medium10sulfanylbenzoic acidantipyretic;
non-narcotic analgesic
tolazoline[no description available]medium10imidazolesalpha-adrenergic antagonist;
antihypertensive agent;
vasodilator agent
tolnaftate[no description available]medium20monothiocarbamic esterantifungal drug
trapidil[no description available]medium10triazolopyrimidines
trifluperidol[no description available]medium10aromatic ketone
trimebutine[no description available]medium10trihydroxybenzoic acid
trimeprazine[no description available]medium10phenothiazines
trioxsalen[no description available]medium10psoralensdermatologic drug;
photosensitizing agent
tulobuterol[no description available]medium10organochlorine compound
urapidil[no description available]medium20piperazines
xylazine[no description available]medium101,3-thiazine;
methylbenzene;
secondary amino compound		alpha-adrenergic agonist;
analgesic;
emetic;
muscle relaxant;
sedative
xylometazoline[no description available]medium10alkylbenzene
ethopabate[no description available]medium10amidobenzoic acid
cysteamine[no description available]medium20amine;
thiol		geroprotector;
human metabolite;
mouse metabolite;
radiation protective agent
acepromazine[no description available]medium10aromatic ketone;
methyl ketone;
phenothiazines;
tertiary amino compound		phenothiazine antipsychotic drug
methoxamine[no description available]medium10amphetaminesalpha-adrenergic agonist;
antihypotensive agent
mepenzolate bromide[no description available]medium10diarylmethane
pantothenic acid[no description available]medium10pantothenic acid;
vitamin B5		antidote to curare poisoning;
geroprotector;
human blood serum metabolite
sulfachlorpyridazine[no description available]medium10organochlorine compound;
pyridazines;
sulfonamide		antibacterial drug;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor
phensuximide[no description available]medium10pyrrolidines
dimethisoquin[no description available]medium10isoquinolines
chloroprocaine[no description available]medium10benzoate ester;
monochlorobenzenes		central nervous system depressant;
local anaesthetic;
peripheral nervous system drug
ditiocarb[no description available]medium20dithiocarbamic acidschelator;
copper chelator
fluorometholone[no description available]medium1011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
tertiary alpha-hydroxy ketone		anti-inflammatory drug
dimenhydrinate[no description available]medium30diarylmethane
4-(benzoylamino)-2-hydroxybenzoic acid[no description available]medium10benzamides
trimetozine[no description available]medium10morpholines
docosanol[no description available]medium10docosanol;
long-chain primary fatty alcohol		antiviral drug;
plant metabolite
tetramethylpyrazine[no description available]medium10alkaloid;
pyrazines		antineoplastic agent;
apoptosis inhibitor;
bacterial metabolite;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent
flurandrenolone[no description available]medium1021-hydroxy steroid
flumethasone[no description available]medium1011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-inflammatory drug
(1S,2R)-tranylcypromine[no description available]medium102-phenylcyclopropan-1-amine
parbendazole[no description available]medium20benzimidazoles;
carbamate ester
capobenic acid[no description available]medium10benzamides
diftalone[no description available]medium10
indoramin[no description available]medium20tryptamines
carbidopa[no description available]medium30catechols;
hydrazines;
monocarboxylic acid		antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
indalpine[no description available]medium10indoles
lidamidine[no description available]medium10ureas
talniflumate[no description available]medium20benzofurans
dazoxiben[no description available]medium10
dopexamine[no description available]medium10catecholamine
lonapalene[no description available]medium10naphthalenes;
organochlorine compound
ipsapirone[no description available]medium10N-arylpiperazine
sematilide[no description available]medium10
remacemide[no description available]medium10stilbenoid
fenclofenac[no description available]medium20aromatic ether
proxicromil[no description available]medium10
torbafylline[no description available]medium10
enrofloxacin[no description available]medium10cyclopropanes;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone		antibacterial agent;
antimicrobial agent;
antineoplastic agent
mepindolol[no description available]medium10indoles
fpl 52791[no description available]medium10
epanolol[no description available]medium10acetamides
methotrimeprazine[no description available]medium10phenothiazines;
tertiary amine		anticoronaviral agent;
cholinergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
non-narcotic analgesic;
phenothiazine antipsychotic drug;
serotonergic antagonist
levcromakalim[no description available]medium101-benzopyran
hexylcaine hydrochloride[no description available]medium10
imipenem, anhydrous[no description available]medium10beta-lactam antibiotic allergen;
carbapenems;
zwitterion		antibacterial drug
fpl 55712[no description available]medium10aromatic ketone
sivelestat[no description available]medium10N-acylglycine;
pivalate ester
fpl-52694[no description available]medium10
ramatroban[no description available]medium10organic molecular entity
xaliproden[no description available]medium10(trifluoromethyl)benzenes;
naphthalenes;
tertiary amino compound;
tetrahydropyridine		serotonergic agonist
n-isobutyrylcysteine[no description available]medium10
dexpanthenol[no description available]medium20amino alcohol;
monocarboxylic acid amide		cholinergic drug;
provitamin
quilostigmine[no description available]medium10pyrroloindole
imiloxan[no description available]medium10benzodioxine
aspartame[no description available]medium10carboxylic acid;
dipeptide zwitterion;
dipeptide;
methyl ester		apoptosis inhibitor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
environmental contaminant;
micronutrient;
nutraceutical;
sweetening agent;
xenobiotic
tempol[no description available]medium10aminoxyls;
hydroxypiperidine		anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
catalyst;
hepatoprotective agent;
nephroprotective agent;
neuroprotective agent;
radical scavenger
vatalanib[no description available]medium10monochlorobenzenes;
phthalazines;
pyridines;
secondary amino compound		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist
clevidipine[no description available]medium20dihydropyridine
lactitol[no description available]medium10glycosyl alditolcathartic;
excipient;
laxative
fpl 52757[no description available]medium10
fpl 59257[no description available]medium10
zeneca zd 6169[no description available]medium10
sibenadet[no description available]medium10
latrepirdine[no description available]medium10methylpyridines;
pyridoindole		geroprotector
ramelteon[no description available]medium30indanes
sorafenib[no description available]medium30(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
salicin[no description available]medium10aromatic primary alcohol;
aryl beta-D-glucoside;
benzyl alcohols		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug
linezolid[no description available]medium30acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
(S)-bicalutamide[no description available]medium10N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide
halcinonide[no description available]medium10organic molecular entitySMO receptor agonist
chlorprothixene[no description available]medium10chlorprothixene
methylthiouracil[no description available]medium10pyrimidone
crotamiton[no description available]medium10
scopolamine[no description available]medium103-hydroxy carboxylic acid
ranitidine[no description available]medium30C-nitro compound;
furans;
organic sulfide;
tertiary amino compound		anti-ulcer drug;
drug allergen;
environmental contaminant;
H2-receptor antagonist;
xenobiotic
almokalant[no description available]medium10
vx-745[no description available]medium10aryl sulfide;
dichlorobenzene;
difluorobenzene;
pyrimidopyridazine		anti-inflammatory drug;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
deracoxib[no description available]medium10organofluorine compound;
pyrazoles;
sulfonamide		cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
2-aminohippuric acid[no description available]medium10N-acylglycine
rs-130830[no description available]medium10
sitagliptin[no description available]medium30triazolopyrazine;
trifluorobenzene		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
environmental contaminant;
hypoglycemic agent;
serine proteinase inhibitor;
xenobiotic
vitamin k semiquinone radical[no description available]medium20
homatropine[no description available]medium10tropane alkaloid
ar c67085mx[no description available]medium10
desoximetasone[no description available]medium1011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone		anti-inflammatory drug;
antipruritic drug
sb 223412[no description available]medium10
tiotropium[no description available]medium10
nw 1029[no description available]medium10
ici d1542[no description available]medium10
gavestinel[no description available]medium10
tipredane[no description available]medium103-hydroxy steroidandrogen
bentiromide[no description available]medium10dipeptidediagnostic agent;
indicator;
reagent
gemifloxacin[no description available]medium201,8-naphthyridine derivative;
fluoroquinolone antibiotic;
monocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antimicrobial agent;
topoisomerase IV inhibitor
utibapril[no description available]medium10
zd 9379[no description available]medium10
ly 450139[no description available]medium10peptide
cangrelor[no description available]medium10adenosine 5'-phosphate;
aryl sulfide;
nucleoside triphosphate analogue;
organochlorine compound;
organofluorine compound;
secondary amino compound		P2Y12 receptor antagonist;
platelet aggregation inhibitor
sch 527123[no description available]medium10
linaprazan[no description available]medium10
lecozotan[no description available]medium10
ar c155858[no description available]medium10
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one[no description available]medium10methoxybenzenes;
substituted aniline
azd 7545[no description available]medium10benzamides;
monochlorobenzenes;
organofluorine compound;
secondary carboxamide;
sulfone;
tertiary alcohol;
tertiary carboxamide		EC 2.7.11.2 - [pyruvate dehydrogenase (acetyl-transferring)] kinase inhibitor;
hypoglycemic agent
clavulanate potassium[no description available]medium20potassium saltantibacterial drug;
antimicrobial agent;
EC 3.5.2.6 (beta-lactamase) inhibitor
cytomel[no description available]medium10organic sodium salt
a 967079[no description available]medium10
carbadox[no description available]medium10quinoxaline derivative
fenobam[no description available]medium10ureas
1-(3-chlorophenyl)piperazine[no description available]medium10monochlorobenzenes;
N-arylpiperazine		drug metabolite;
environmental contaminant;
serotonergic agonist;
xenobiotic
diatrizoic acid[no description available]medium20acetamides;
benzoic acids;
organoiodine compound		environmental contaminant;
radioopaque medium;
xenobiotic
dan 2163[no description available]medium10aromatic amide;
aromatic amine;
benzamides;
pyrrolidines;
sulfone		environmental contaminant;
second generation antipsychotic;
xenobiotic
bromopride[no description available]medium10benzamides
bronopol[no description available]medium10nitro compound
cifenline[no description available]medium10diarylmethane
4-chloro-N-(2,6-dimethyl-1-piperidinyl)-3-sulfamoylbenzamide[no description available]medium10sulfonamide
ebastine[no description available]medium10organic molecular entity
4-biphenylylacetic acid[no description available]medium10biphenyls;
monocarboxylic acid		non-steroidal anti-inflammatory drug
fluorescite[no description available]medium20benzoic acids;
cyclic ketone;
hydroxy monocarboxylic acid;
organic heterotricyclic compound;
phenols;
xanthene dye		fluorescent dye;
radioopaque medium
nefopam[no description available]medium10benzoxazocine;
tertiary amino compound
piribedil[no description available]medium10N-arylpiperazine
ono 1078[no description available]medium20chromones
sulfanitran[no description available]medium10sulfonamide
tiapride[no description available]medium10benzamides
tilorone[no description available]medium10aromatic ether;
diether;
fluoren-9-ones;
tertiary amino compound		anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
interferon inducer;
nicotinic acetylcholine receptor agonist
tinidazole[no description available]medium20imidazolesantiamoebic agent;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug
nikethamide[no description available]medium10pyridinecarboxamide
thenoyltrifluoroacetone[no description available]medium10
undecylenic acid[no description available]medium10undecenoic acidantifungal drug;
plant metabolite
zaleplon[no description available]medium20nitrile;
pyrazolopyrimidine		anticonvulsant;
anxiolytic drug;
central nervous system depressant;
sedative
zonisamide[no description available]medium201,2-benzoxazoles;
sulfonamide		anticonvulsant;
antioxidant;
central nervous system drug;
protective agent;
T-type calcium channel blocker
tubocurarine[no description available]medium10bisbenzylisoquinoline alkaloiddrug allergen;
muscle relaxant;
nicotinic antagonist
triamcinolone diacetate[no description available]medium10corticosteroid hormone
galantamine[no description available]medium20benzazepine alkaloid fundamental parent;
benzazepine alkaloid;
organic heterotetracyclic compound;
tertiary amino compound		antidote to curare poisoning;
cholinergic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant metabolite
hydroxychloroquine sulfate[no description available]medium10
ethambutol hydrochloride[no description available]medium10hydrochlorideantitubercular agent
antimycin a[no description available]medium10benzamides;
formamides;
macrodiolide;
phenols		antifungal agent;
mitochondrial respiratory-chain inhibitor;
piscicide
metylperon[no description available]medium10aromatic ketone
metocurine[no description available]medium10isoquinolines
etidronate disodium[no description available]medium10organic sodium saltantineoplastic agent;
bone density conservation agent;
chelator
mafenide acetate[no description available]medium10carboxylic acid
diacerein[no description available]medium10anthraquinone
selegiline hydrochloride, (r)-isomer[no description available]medium10hydrochloride;
terminal acetylenic compound		antiparkinson drug;
dopaminergic agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor
ornidazole[no description available]medium10C-nitro compound;
imidazoles;
organochlorine compound;
secondary alcohol		antiamoebic agent;
antibacterial drug;
antiinfective agent;
antiprotozoal drug;
antitrichomonal drug;
epitope
feprazone[no description available]medium10organic molecular entity
nitazoxanide[no description available]medium20benzamides;
carboxylic ester
acarbose[no description available]medium20tetrasaccharide derivativeEC 3.2.1.1 (alpha-amylase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
geroprotector;
hypoglycemic agent
lorcainide[no description available]medium10acetamides
atracurium besylate[no description available]medium10organosulfonate salt;
quaternary ammonium salt		muscle relaxant;
nicotinic antagonist
fenoldopam mesylate[no description available]medium10benzazepine
pefloxacin[no description available]medium10fluoroquinolone antibiotic;
monocarboxylic acid;
N-alkylpiperazine;
N-arylpiperazine;
quinolone antibiotic;
quinolone		antibacterial drug;
antiinfective agent;
DNA synthesis inhibitor
flupirtine[no description available]medium10aminopyridine
stepronin[no description available]medium10N-acyl-amino acid
idazoxan[no description available]medium10benzodioxine;
imidazolines		alpha-adrenergic antagonist
imiquimod[no description available]medium10imidazoquinolineantineoplastic agent;
interferon inducer
sertindole[no description available]medium10heteroarylpiperidine;
imidazolidinone;
organochlorine compound;
organofluorine compound;
phenylindole		alpha-adrenergic antagonist;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic antagonist
aromasil[no description available]medium2017-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor;
environmental contaminant;
xenobiotic
gemcitabine hydrochloride[no description available]medium10hydrochloride;
organofluorine compound		anticoronaviral agent;
antimetabolite;
antineoplastic agent;
antiviral drug;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
immunosuppressive agent;
radiosensitizing agent
aripiprazole[no description available]medium20aromatic ether;
delta-lactam;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
quinolone		drug metabolite;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic agonist
atorvastatin calcium anhydrous[no description available]medium10organic calcium salt
duloxetine hydrochloride[no description available]medium10duloxetine hydrochlorideantidepressant
zolmitriptan[no description available]medium20oxazolidinone;
tryptamines		anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
emtricitabine[no description available]medium20monothioacetal;
nucleoside analogue;
organofluorine compound;
pyrimidone		antiviral drug;
HIV-1 reverse transcriptase inhibitor
bupivacaine hydrochloride[no description available]medium10hydrochloride;
racemate		adrenergic antagonist;
amphiphile;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor;
local anaesthetic
plerixafor[no description available]medium20azacycloalkane;
azamacrocycle;
benzenes;
crown amine;
secondary amino compound;
tertiary amino compound		anti-HIV agent;
antineoplastic agent;
C-X-C chemokine receptor type 4 antagonist;
immunological adjuvant
ticlopidine hydrochloride[no description available]medium10hydrochloride
epirubicin hydrochloride[no description available]medium10
pazufloxacin[no description available]medium10quinolines
repaglinide[no description available]medium20piperidines
miconazole nitrate[no description available]medium10
artemisinin[no description available]medium10organic peroxide;
sesquiterpene lactone		antimalarial;
plant metabolite
brinzolamide[no description available]medium10sulfonamide;
thienothiazine		antiglaucoma drug;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
drospirenone[no description available]medium103-oxo-Delta(4) steroid;
steroid lactone		aldosterone antagonist;
contraceptive drug;
progestin
hp 873[no description available]medium201,2-benzoxazoles;
aromatic ether;
aromatic ketone;
methyl ketone;
monoamine;
organofluorine compound;
piperidines;
tertiary amino compound		dopaminergic antagonist;
second generation antipsychotic;
serotonergic antagonist
betamipron[no description available]medium10organonitrogen compound;
organooxygen compound
uroxatral[no description available]medium10hydrochloride
thiocolchicoside[no description available]medium10glycoside
doripenem[no description available]medium20carbapenems
tamiflu[no description available]medium10phosphate salt
bexarotene[no description available]medium20benzoic acids;
naphthalenes;
retinoid		antineoplastic agent
s20098[no description available]medium10acetamides
gliquidone[no description available]medium10isoquinolines
moxifloxacin hydrochloride[no description available]medium10hydrochlorideantibacterial drug
fulvestrant[no description available]high3017beta-hydroxy steroid;
3-hydroxy steroid;
organofluorine compound;
sulfoxide		antineoplastic agent;
estrogen antagonist;
estrogen receptor antagonist
racecadotril[no description available]medium10N-acyl-amino acid
tadalafil[no description available]medium30benzodioxoles;
pyrazinopyridoindole		EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
plavix[no description available]medium10azaheterocycle sulfate salt;
organoammonium sulfate salt		anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
pramipexole[no description available]medium20benzothiazoles;
diamine		antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
radical scavenger
valdecoxib[no description available]medium20isoxazoles;
sulfonamide		antipyretic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
mk 0663[no description available]medium10bipyridines;
organochlorine compound;
sulfone		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
desloratadine[no description available]medium20benzocycloheptapyridineanti-allergic agent;
cholinergic antagonist;
drug metabolite;
H1-receptor antagonist
abiraterone[no description available]medium103beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
pyridines		antineoplastic agent;
EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor
febuxostat[no description available]medium201,3-thiazolemonocarboxylic acid;
aromatic ether;
nitrile		EC 1.17.3.2 (xanthine oxidase) inhibitor
lexapro[no description available]medium10
docetaxel anhydrous[no description available]medium20secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent
xamoterol[no description available]medium10morpholines
telbivudine[no description available]medium20pyrimidine 2'-deoxyribonucleosideantiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
bms204352[no description available]medium10
tolvaptan[no description available]medium20benzazepine;
benzenedicarboxamide		aquaretic;
vasopressin receptor antagonist
lenalidomide[no description available]medium40aromatic amine;
dicarboximide;
isoindoles;
piperidones		angiogenesis inhibitor;
antineoplastic agent;
immunomodulator
lenalidomide[no description available]medium41aromatic amine;
dicarboximide;
isoindoles;
piperidones		angiogenesis inhibitor;
antineoplastic agent;
immunomodulator
lacosamide[no description available]medium20N-acyl-amino acid
vincaleukoblastine[no description available]medium20acetate ester;
indole alkaloid fundamental parent;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid		antineoplastic agent;
immunosuppressive agent;
microtubule-destabilising agent;
plant metabolite
perindopril erbumine[no description available]medium10addition compoundantihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
miglitol[no description available]medium20piperidines
pemirolast potassium salt[no description available]medium10
eplerenone[no description available]medium203-oxo-Delta(4) steroid;
epoxy steroid;
gamma-lactone;
methyl ester;
organic heteropentacyclic compound;
oxaspiro compound;
steroid acid ester		aldosterone antagonist;
antihypertensive agent
loteprednol etabonate[no description available]medium1011beta-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
etabonate ester;
organochlorine compound;
steroid acid ester;
steroid ester		anti-inflammatory drug
fluticasone propionate[no description available]medium1011beta-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
corticosteroid;
fluorinated steroid;
propanoate ester;
steroid ester;
thioester		adrenergic agent;
anti-allergic agent;
anti-asthmatic drug;
anti-inflammatory drug;
bronchodilator agent;
dermatologic drug
valrubicin[no description available]medium10anthracycline;
trifluoroacetamide
posaconazole[no description available]medium20aromatic ether;
conazole antifungal drug;
N-arylpiperazine;
organofluorine compound;
oxolanes;
triazole antifungal drug;
triazoles		trypanocidal drug
trilostane[no description available]medium4017beta-hydroxy steroid;
3-hydroxy steroid;
androstanoid;
epoxy steroid;
nitrile		abortifacient;
antineoplastic agent;
EC 1.1.1.210 [3beta(or 20alpha)-hydroxysteroid dehydrogenase] inhibitor
trilostane[no description available]medium4117beta-hydroxy steroid;
3-hydroxy steroid;
androstanoid;
epoxy steroid;
nitrile		abortifacient;
antineoplastic agent;
EC 1.1.1.210 [3beta(or 20alpha)-hydroxysteroid dehydrogenase] inhibitor
leuprolide acetate[no description available]medium10acetate saltantineoplastic agent;
gonadotropin releasing hormone agonist
eszopiclone[no description available]medium20zopiclonecentral nervous system depressant;
sedative
epalrestat[no description available]medium10monocarboxylic acid;
thiazolidines		EC 1.1.1.21 (aldehyde reductase) inhibitor
drotaverin[no description available]medium10isoquinolines
valinomycin[no description available]medium10cyclodepsipeptide;
macrocycle		antimicrobial agent;
antiviral agent;
bacterial metabolite;
potassium ionophore
latoconazole[no description available]medium10conazole antifungal drug;
imidazole antifungal drug
toremifene citrate[no description available]medium10stilbenoidanticoronaviral agent
nelarabine[no description available]medium20beta-D-arabinoside;
monosaccharide derivative;
purine nucleoside		antineoplastic agent;
DNA synthesis inhibitor;
prodrug
azilect[no description available]medium10
dexchlorpheniramine maleate[no description available]medium10organic molecular entity
l 660,711[no description available]medium10quinolines
travoprost[no description available]medium10(trifluoromethyl)benzenes;
isopropyl ester;
prostaglandins Falpha		antiglaucoma drug;
antihypertensive agent;
ophthalmology drug;
prodrug;
prostaglandin receptor agonist
imipenem[no description available]medium10carbapenems
dinoprost tromethamine[no description available]medium10organic molecular entity
rosuvastatin calcium[no description available]medium10N-acyl-15-methylhexadecasphinganine-1-phosphoethanolamine;
organic calcium salt		anti-inflammatory agent;
cardioprotective agent;
CETP inhibitor
terbinafine hydrochloride[no description available]medium10allylamine antifungal drug;
hydrochloride		EC 1.14.13.132 (squalene monooxygenase) inhibitor;
P450 inhibitor
acipimox[no description available]medium10pyrazinecarboxylic acid
atosiban[no description available]medium10oligopeptide
bimatoprost[no description available]medium10monocarboxylic acid amideantiglaucoma drug;
antihypertensive agent
enalapril maleate[no description available]medium10maleate saltantihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
pregabalin[no description available]medium20gamma-amino acidanticonvulsant;
calcium channel blocker
alvimopan anhydrous[no description available]medium20peptide
tenofovir disoproxil fumarate[no description available]medium10fumarate saltantiviral drug;
HIV-1 reverse transcriptase inhibitor;
prodrug
dexbrompheniramine maleate[no description available]medium10brompheniramine maleateanti-allergic agent;
H1-receptor antagonist
rifaximin[no description available]medium20acetate ester;
cyclic ketal;
lactam;
macrocycle;
organic heterohexacyclic compound;
rifamycins;
semisynthetic derivative		antimicrobial agent;
gastrointestinal drug;
orphan drug
everolimus[no description available]medium20cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
primary alcohol;
secondary alcohol		anticoronaviral agent;
antineoplastic agent;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
fluphenazine[no description available]medium10
cefdinir[no description available]medium20cephalosporin;
ketoxime		antibacterial drug
etoposide phosphate[no description available]medium10furonaphthodioxole
ciclesonide[no description available]medium10organic molecular entity
temsirolimus[no description available]medium20macrolide lactam
dutasteride[no description available]medium20(trifluoromethyl)benzenes;
aza-steroid;
delta-lactam		antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
tekturna[no description available]medium10fumarate saltantihypertensive agent
vildagliptin[no description available]medium10amino acid amide
sgd 301-76[no description available]medium10conazole antifungal drug;
imidazole antifungal drug;
organic nitrate salt		antiinfective agent
dexlansoprazole[no description available]medium20benzimidazoles;
sulfoxide
gemifloxacin mesylate[no description available]medium10methanesulfonate saltantimicrobial agent;
topoisomerase IV inhibitor
rivaroxaban[no description available]medium20aromatic amide;
lactam;
monocarboxylic acid amide;
morpholines;
organochlorine compound;
oxazolidinone;
thiophenes		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor
hki 272[no description available]medium10nitrile;
quinolines		antineoplastic agent;
tyrosine kinase inhibitor
tofacitinib[no description available]medium10N-acylpiperidine;
nitrile;
pyrrolopyrimidine;
tertiary amino compound		antirheumatic drug;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
amg 009[no description available]medium10
losartan potassium[no description available]medium70
losartan potassium[no description available]medium71
dactolisib[no description available]medium10imidazoquinoline;
nitrile;
quinolines;
ring assembly;
ureas		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
rabeprazole sodium[no description available]medium10organic sodium salt
bivalirudin[no description available]medium20polypeptideanticoagulant;
EC 3.4.21.5 (thrombin) inhibitor
somatostatin[no description available]medium10heterodetic cyclic peptide;
peptide hormone
ly-146032[no description available]medium20heterodetic cyclic peptide;
lipopeptide antibiotic;
lipopeptide;
macrocycle;
macrolide		antibacterial drug;
bacterial metabolite;
calcium-dependent antibiotics
warfarin sodium[no description available]medium10
pravastatin sodium[no description available]medium10organic sodium salt;
statin (semi-synthetic)		anticholesteremic drug
alendronate sodium[no description available]medium10
sl 80.0750[no description available]medium10
piperacillin sodium[no description available]medium10organic sodium salt
roquinimex[no description available]medium10aromatic amide
tigecycline[no description available]medium20
valtrex[no description available]medium10organic molecular entity
rifapentine[no description available]medium20N-alkylpiperazine;
N-iminopiperazine;
rifamycins		antitubercular agent;
leprostatic drug
sildenafil citrate[no description available]medium10citrate saltEC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
aprepitant[no description available]medium30(trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
triazoles		antidepressant;
antiemetic;
neurokinin-1 receptor antagonist;
peripheral nervous system drug;
substance P receptor antagonist
tegaserod maleate[no description available]medium10maleate saltserotonergic agonist
brompheniramine[no description available]medium20organobromine compound;
pyridines		anti-allergic agent;
H1-receptor antagonist
cp 724714[no description available]medium102-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamideantineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
hepatotoxic agent
alisol b[no description available]medium10triterpenoid
alosetron[no description available]medium10imidazoles;
pyridoindole		antiemetic;
gastrointestinal drug;
serotonergic antagonist
ambenonium[no description available]medium10quaternary ammonium ionEC 3.1.1.8 (cholinesterase) inhibitor
secbutabarbital[no description available]medium10barbiturates
chlorcyclizine[no description available]medium10diarylmethane
clonazepam[no description available]medium101,4-benzodiazepinone;
monochlorobenzenes		anticonvulsant;
anxiolytic drug;
GABA modulator
doxapram[no description available]medium10morpholines;
pyrrolidin-2-ones		central nervous system stimulant
edrophonium[no description available]medium10phenols;
quaternary ammonium ion		antidote;
diagnostic agent;
EC 3.1.1.8 (cholinesterase) inhibitor
flurazepam[no description available]medium101,4-benzodiazepinone;
monofluorobenzenes;
organochlorine compound;
tertiary amino compound		anticonvulsant;
anxiolytic drug;
GABAA receptor agonist;
sedative
2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester[no description available]medium10benzenes
guanidine[no description available]medium10carboxamidine;
guanidines;
one-carbon compound
hydroxychloroquine[no description available]medium30aminoquinoline;
organochlorine compound;
primary alcohol;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
dermatologic drug
hydroxychloroquine[no description available]medium31aminoquinoline;
organochlorine compound;
primary alcohol;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
dermatologic drug
mepenzolate[no description available]medium10diarylmethane
mesoridazine[no description available]medium10phenothiazines;
sulfoxide;
tertiary amino compound		dopaminergic antagonist;
first generation antipsychotic
methazolamide[no description available]medium10sulfonamide;
thiadiazoles
naratriptan[no description available]medium20heteroarylpiperidine;
sulfonamide;
tryptamines		serotonergic agonist;
vasoconstrictor agent
4-phenylbutyric acid[no description available]medium10monocarboxylic acidantineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor;
prodrug
quetiapine[no description available]medium10dibenzothiazepine;
N-alkylpiperazine;
N-arylpiperazine		adrenergic antagonist;
dopaminergic antagonist;
histamine antagonist;
second generation antipsychotic;
serotonergic antagonist
rizatriptan[no description available]medium10tryptaminesanti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
ropinirole[no description available]medium10indolones;
tertiary amine		antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
dopamine agonist
secobarbital[no description available]medium10barbituratesanaesthesia adjuvant;
GABA modulator;
sedative
trihexyphenidyl[no description available]medium10amine
trimethobenzamide[no description available]medium10benzamides;
tertiary amino compound		antiemetic
tyramine[no description available]medium20monoamine molecular messenger;
primary amino compound;
tyramines		EC 3.1.1.8 (cholinesterase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter
delavirdine[no description available]medium10aminopyridine;
indolecarboxamide;
N-acylpiperazine;
sulfonamide		antiviral drug;
HIV-1 reverse transcriptase inhibitor
cysteine[no description available]medium10cysteine zwitterion;
cysteine;
L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid		EC 4.3.1.3 (histidine ammonia-lyase) inhibitor;
flour treatment agent;
human metabolite
edetic acid[no description available]medium10ethylenediamine derivative;
polyamino carboxylic acid;
tetracarboxylic acid		anticoagulant;
antidote;
chelator;
copper chelator;
geroprotector
calcium acetate[no description available]medium10calcium saltchelator
perflutren[no description available]medium10fluoroalkane;
fluorocarbon
fluoxymesterone[no description available]high6211beta-hydroxy steroid;
17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
anabolic androgenic steroid;
fluorinated steroid		anabolic agent;
antineoplastic agent
fluoxymesterone[no description available]high6011beta-hydroxy steroid;
17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
anabolic androgenic steroid;
fluorinated steroid		anabolic agent;
antineoplastic agent
methsuximide[no description available]medium10organic molecular entity
diethylpropion[no description available]medium10aromatic ketone;
tertiary amine		appetite depressant
methylergonovine[no description available]medium10ergoline alkaloid
4-hydroxybutyric acid[no description available]medium104-hydroxy monocarboxylic acid;
hydroxybutyric acid		general anaesthetic;
GHB receptor agonist;
neurotoxin;
sedative
pamabrom[no description available]medium10
diphenoxylate[no description available]medium10ethyl ester;
nitrile;
piperidinecarboxylate ester;
tertiary amine		antidiarrhoeal drug
metaxalone[no description available]medium10aromatic ether
spectinomycin[no description available]medium10cyclic acetal;
cyclic hemiketal;
cyclic ketone;
pyranobenzodioxin;
secondary alcohol;
secondary amino compound		antibacterial drug;
antimicrobial agent;
bacterial metabolite
dexbrompheniramine[no description available]medium10brompheniramineanti-allergic agent;
H1-receptor antagonist
megestrol[no description available]medium3017alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone		antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive
methenamine hippurate[no description available]medium10N-acylglycine
sodium thiosulfate[no description available]medium10inorganic sodium saltantidote to cyanide poisoning;
antifungal drug;
nephroprotective agent
fludrocortisone[no description available]medium1011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
fluorinated steroid;
mineralocorticoid		adrenergic agent;
anti-inflammatory drug
vecuronium[no description available]medium10acetate ester;
androstane;
quaternary ammonium ion		drug allergen;
muscle relaxant;
neuromuscular agent;
nicotinic antagonist
haloperidol decanoate[no description available]medium10organic molecular entity
balsalazide[no description available]medium10
adefovir[no description available]medium106-aminopurines;
ether;
phosphonic acids		antiviral drug;
DNA synthesis inhibitor;
drug metabolite;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent
tiagabine[no description available]medium10beta-amino acid;
piperidinemonocarboxylic acid;
tertiary amino compound;
thiophenes		anticonvulsant;
GABA reuptake inhibitor
tiludronic acid[no description available]medium10organochlorine compound
tirofiban[no description available]medium10L-tyrosine derivative;
piperidines;
sulfonamide		anticoagulant;
fibrin modulating drug;
platelet glycoprotein-IIb/IIIa receptor antagonist
fenofibric acid[no description available]medium10aromatic ketone;
chlorobenzophenone;
monocarboxylic acid		drug metabolite;
marine xenobiotic metabolite
histamine phosphate[no description available]medium10phosphate salthistamine agonist
acamprosate[no description available]medium10acetamides;
organosulfonic acid		environmental contaminant;
neurotransmitter agent;
xenobiotic
nebivolol[no description available]medium10chromanes;
diol;
organofluorine compound;
secondary alcohol;
secondary amino compound
rivastigmine[no description available]medium10carbamate ester;
tertiary amino compound		cholinergic drug;
EC 3.1.1.8 (cholinesterase) inhibitor;
neuroprotective agent
frovatriptan[no description available]medium10carbazoles
eletriptan[no description available]medium10indoles;
N-alkylpyrrolidine;
sulfone		non-steroidal anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
mci 9038[no description available]medium10peptide
paliperidone[no description available]medium101,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine;
secondary alcohol
almotriptan[no description available]medium10indoles;
sulfonamide;
tertiary amine		non-steroidal anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
desvenlafaxine[no description available]medium10cyclohexanols;
phenols;
tertiary amino compound		antidepressant;
drug metabolite;
marine xenobiotic metabolite
rufinamide[no description available]medium10aromatic amide;
heteroarene
fosamprenavir[no description available]medium10sulfonamideprodrug
escitalopram[no description available]medium101-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrileantidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
10-propargyl-10-deazaaminopterin[no description available]medium10N-acyl-L-glutamic acid;
pteridines;
terminal acetylenic compound		antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
ertapenem[no description available]medium10carbapenemcarboxylic acid;
pyrrolidinecarboxamide		antibacterial drug
conivaptan[no description available]medium10benzazepineaquaretic;
vasopressin receptor antagonist
solifenacin[no description available]medium10isoquinolines
dexmethylphenidate[no description available]medium10methyl phenyl(piperidin-2-yl)acetateadrenergic agent
cinacalcet[no description available]medium10(trifluoromethyl)benzenes;
naphthalenes;
secondary amino compound		calcimimetic;
P450 inhibitor
lubiprostone[no description available]medium10
anidulafungin[no description available]medium10antibiotic antifungal drug;
azamacrocycle;
echinocandin;
heterodetic cyclic peptide;
semisynthetic derivative
17 alpha-hydroxyprogesterone caproate[no description available]medium10corticosteroid hormone
varenicline[no description available]medium10
etravirine[no description available]medium20aminopyrimidine;
aromatic ether;
dinitrile;
organobromine compound		antiviral agent;
HIV-1 reverse transcriptase inhibitor
dronedarone[no description available]medium101-benzofurans;
aromatic ether;
aromatic ketone;
sulfonamide;
tertiary amino compound		anti-arrhythmia drug;
environmental contaminant;
xenobiotic
darunavir[no description available]medium10carbamate ester;
furofuran;
sulfonamide		antiviral drug;
HIV protease inhibitor
regadenoson[no description available]medium10purine nucleoside
pancuronium[no description available]medium10acetate ester;
steroid ester		cholinergic antagonist;
muscle relaxant;
nicotinic antagonist
clindamycin phosphate[no description available]medium10
darifenacin[no description available]medium101-benzofurans;
monocarboxylic acid amide;
pyrrolidines		antispasmodic drug;
muscarinic antagonist
octreotide[no description available]medium10
eptifibatide[no description available]medium10homodetic cyclic peptide;
macrocycle;
organic disulfide		anticoagulant;
platelet aggregation inhibitor
sr 90107[no description available]medium10
meglumine iodipamide[no description available]medium10organoammonium saltradioopaque medium
thyrotropin-releasing hormone[no description available]medium10peptide hormone;
tripeptide		human metabolite
s 1033[no description available]medium10(trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
pyrantel[no description available]medium101,4,5,6-tetrahydropyrimidines;
carboxamidine;
thiophenes		antinematodal drug
cancidas[no description available]medium10
dermatan sulfate[no description available]medium10amino disaccharide;
glycosylgalactose derivative;
iduronic acids;
oligosaccharide sulfate
dolasetron[no description available]medium10indolyl carboxylic acid
fospropofol[no description available]medium10alkylbenzene
rasagiline[no description available]medium10indanes;
secondary amine;
terminal acetylenic compound		EC 1.4.3.4 (monoamine oxidase) inhibitor;
neuroprotective agent
mivacurium[no description available]medium10isoquinolines
hemabate[no description available]medium10
paricalcitol[no description available]medium10hydroxy seco-steroid;
seco-cholestane		antiparathyroid drug
indocyanine green[no description available]medium101,1-diunsubstituted alkanesulfonate;
benzoindole;
cyanine dye
ethamolin[no description available]medium10long-chain fatty acid
estropipate[no description available]medium10piperazinium salt;
steroid sulfate
nabilone[no description available]medium10
oxycodone[no description available]medium10organic heteropentacyclic compound;
semisynthetic derivative		antitussive;
mu-opioid receptor agonist;
opioid analgesic
vitamin k 1[no description available]medium10phylloquinones;
vitamin K		cofactor;
human metabolite;
plant metabolite
trospium chloride[no description available]medium10
deamino arginine vasopressin[no description available]medium70heterodetic cyclic peptidediagnostic agent;
renal agent;
vasopressin receptor agonist
dexmedetomidine[no description available]medium10medetomidinealpha-adrenergic agonist;
analgesic;
non-narcotic analgesic;
sedative
goserelin[no description available]medium370organic molecular entity
goserelin[no description available]medium3712organic molecular entity
silodosin[no description available]medium10indolecarboxamide
levorphanol[no description available]medium10morphinane alkaloid
verteporfin[no description available]medium10
aliskiren[no description available]medium10monocarboxylic acid amide;
monomethoxybenzene		antihypertensive agent
palonosetron[no description available]medium10azabicycloalkane;
delta-lactam;
organic heterotricyclic compound		antiemetic;
serotonergic antagonist
fesoterodine[no description available]medium10diarylmethane
armodafinil[no description available]medium102-[(diphenylmethyl)sulfinyl]acetamidecentral nervous system stimulant;
eugeroic
sincalide[no description available]medium10oligopeptide
tapentadol[no description available]medium10alkylbenzene
cefditoren[no description available]medium10carboxylic acid;
cephalosporin		antibacterial drug
prasugrel hydrochloride[no description available]medium10
bms 477118[no description available]medium10adamantanes;
azabicycloalkane;
monocarboxylic acid amide;
nitrile;
tertiary alcohol		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent
milnacipran[no description available]medium10acetamides
enfuvirtide[no description available]medium10
ganirelix[no description available]medium10polypeptide
teriparatide[no description available]medium10polypeptide
salmon calcitonin[no description available]medium10heterodetic cyclic peptide;
peptide hormone;
polypeptide		bone density conservation agent;
metabolite
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ilys-prolyl-alaninamide[no description available]medium10polypeptide
exenatide[no description available]medium10
sodium lactate[no description available]medium10lactate salt;
organic sodium salt		food acidity regulator;
food preservative
sodium iothalamate[no description available]medium10
cetrorelix[no description available]medium20oligopeptideantineoplastic agent;
GnRH antagonist
raltegravir[no description available]medium101,2,4-oxadiazole;
dicarboxylic acid amide;
hydroxypyrimidine;
monofluorobenzenes;
pyrimidone;
secondary carboxamide		antiviral drug;
HIV-1 integrase inhibitor
fertinex[no description available]medium10
vardenafil[no description available]medium10imidazotriazine;
N-alkylpiperazine;
N-sulfonylpiperazine		EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
bl 4162a[no description available]medium10imidazoquinazolineanticoagulant;
antifibrinolytic drug;
cardiovascular drug;
platelet aggregation inhibitor
tegaserod[no description available]medium10carboxamidine;
guanidines;
hydrazines;
indoles		gastrointestinal drug;
serotonergic agonist
pemetrexed[no description available]medium10N-acyl-L-glutamic acid;
pyrrolopyrimidine		antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
EC 2.1.1.45 (thymidylate synthase) inhibitor;
EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
valganciclovir[no description available]medium10L-valyl ester;
purines		antiviral drug;
prodrug
fosaprepitant[no description available]medium10(trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
phosphoramide;
triazoles		antiemetic;
neurokinin-1 receptor antagonist;
prodrug
levomefolate calcium[no description available]medium10organic calcium saltantidepressant
incb-018424[no description available]medium42nitrile;
pyrazoles;
pyrrolopyrimidine		antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
putrescine[no description available]medium10alkane-alpha,omega-diamineantioxidant;
fundamental metabolite
n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide[no description available]medium33aminopyrimidine;
benzamides;
morpholines;
nitrile;
secondary amino compound;
tertiary amino compound		anti-anaemic agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
bradykinin[no description available]medium200oligopeptidehuman blood serum metabolite;
vasodilator agent
aminolevulinic acid[no description available]medium204-oxo monocarboxylic acid;
amino acid zwitterion;
delta-amino acid		antineoplastic agent;
dermatologic drug;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
orabase[no description available]medium10
cellulose[no description available]medium10glycoside
hydrogen[no description available]medium10elemental hydrogen;
elemental molecule;
gas molecular entity		antioxidant;
electron donor;
food packaging gas;
fuel;
human metabolite
docusate[no description available]medium10diester;
organosulfonic acid
phenanthrenes[no description available]medium40
betadex[no description available]medium60cyclodextrin
piperidines[no description available]medium40
heme[no description available]medium20
17-octadecynoic acid[no description available]medium10acetylenic fatty acid;
long-chain fatty acid;
monounsaturated fatty acid;
terminal acetylenic compound		EC 1.14.14.94 (leukotriene-B4 20-monooxygenase) inhibitor;
EC 1.14.15.3 (alkane 1-monooxygenase) inhibitor;
P450 inhibitor
n-methylsulfonyl-6-(2-propargyloxyphenyl)hexanamide[no description available]medium10
ulipristal[no description available]medium1020-oxo steroid
asoprisnil[no description available]medium20
sodium dodecyl sulfate[no description available]medium30organic sodium saltdetergent;
protein denaturant
ethylene oxide[no description available]medium10gas molecular entity;
oxacycle;
saturated organic heteromonocyclic parent		allergen;
mouse metabolite;
mutagen
cyclosporine[no description available]medium192
icatibant[no description available]medium90
sodium taurodeoxycholate[no description available]medium10bile acid taurine conjugatehuman metabolite
1-anilino-8-naphthalenesulfonate[no description available]medium40aminonaphthalene;
naphthalenesulfonic acid		fluorescent probe
andarine[no description available]medium10acetamides;
anilide
mk 2866[no description available]medium10
interleukin-8[no description available]medium10
mimosine[no description available]medium10alpha-amino acid
methenolone[no description available]medium413-hydroxy steroidandrogen
methenolone acetate[no description available]medium31steroid ester
pyrroles[no description available]medium10pyrrole;
secondary amine
triazoles[no description available]medium201,2,3-triazole
n-vinyl-2-pyrrolidinone[no description available]medium60pyrrolidin-2-ones
methylcellulose[no description available]medium30
hydroxypropylmethylcellulose acetate succinate[no description available]medium30
ecallantide[no description available]medium50
ulipristal acetate[no description available]medium1020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
steroid ester;
tertiary amino compound		contraceptive drug;
progesterone receptor modulator;
progestin
ergoline[no description available]medium10diamine;
ergoline alkaloid;
indole alkaloid fundamental parent;
indole alkaloid;
organic heterotetracyclic compound
dextrothyroxine[no description available]medium10
levocetirizine[no description available]medium10diarylmethane
fibrinogen[no description available]medium100iditolfungal metabolite
lynestrenol[no description available]medium114steroid
nafarelin[no description available]medium4619oligopeptideanti-estrogen;
gonadotropin releasing hormone agonist
8-bromo cyclic adenosine monophosphate[no description available]medium203',5'-cyclic purine nucleotide;
adenyl ribonucleotide;
organobromine compound		antidepressant;
protein kinase agonist
contraceptives, postcoital[no description available]medium183
fluorodeoxyglucose f18[no description available]medium102-deoxy-2-((18)F)fluoro-D-glucose;
2-deoxy-2-fluoro-aldehydo-D-glucose
thiazoles[no description available]medium201,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
buserelin[no description available]medium6517oligopeptide
sinomenine[no description available]medium10morphinane alkaloid
morphinans[no description available]medium10isoquinoline alkaloid fundamental parent;
morphinane alkaloid
loviride[no description available]medium10
iopanoic acid[no description available]medium10monocarboxylic acid
alizarin[no description available]medium10dihydroxyanthraquinonechromophore;
dye;
plant metabolite
cremophor el[no description available]medium20
itraconazole[no description available]medium20aromatic ether;
conazole antifungal drug;
cyclic ketal;
dichlorobenzene;
dioxolane;
N-arylpiperazine;
triazole antifungal drug;
triazoles		EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
Hedgehog signaling pathway inhibitor;
P450 inhibitor
barium sulfate[no description available]medium10barium salt;
inorganic barium salt;
metal sulfate		radioopaque medium
aluminum magnesium silicate[no description available]medium10
phosphatidylcholines[no description available]medium201,2-diacyl-sn-glycero-3-phosphocholine
gamma-linolenic acid[no description available]medium122linolenic acid;
omega-6 fatty acid		human metabolite;
mouse metabolite;
plant metabolite
trelstar[no description available]medium135
canrenone[no description available]medium10steroid lactone
carticaine[no description available]medium10thiophenecarboxylic acid
ethamsylate[no description available]medium10organosulfur compound;
sulfonic acid derivative
lhrh, ala(6)-gly(10)-ethylamide-[no description available]medium20
acetonitrile[no description available]medium20aliphatic nitrile;
volatile organic compound		EC 3.5.1.4 (amidase) inhibitor;
NMR chemical shift reference compound;
polar aprotic solvent
methylene chloride[no description available]medium10chloromethanes;
volatile organic compound		carcinogenic agent;
polar aprotic solvent;
refrigerant
epoetin alfa[no description available]medium10
transforming growth factor beta[no description available]medium10
20-alpha-dihydroprogesterone[no description available]medium1020-hydroxypregn-4-en-3-onehuman metabolite;
mouse metabolite
tert-butyl alcohol[no description available]medium10tertiary alcoholhuman xenobiotic metabolite
potassium chloride[no description available]medium30inorganic chloride;
inorganic potassium salt;
potassium salt		fertilizer
kiss1 protein, human[no description available]medium10
glycogen[no description available]medium10
acid phosphatase[no description available]medium20
promegestone[no description available]medium2020-oxo steroid;
3-oxo-Delta(4) steroid		antineoplastic agent;
progesterone receptor agonist;
progestin
ovalbumin[no description available]medium10
cosyntropin[no description available]medium10
17-ketosteroids[no description available]medium30
ay 25,205[no description available]medium20
elastin[no description available]medium10oligopeptide
menotropins[no description available]medium90
lutrelin acetate[no description available]medium10
norgestrel[no description available]medium122
n-acetylneuraminic acid[no description available]medium10N-acetylneuraminic acidsantioxidant;
bacterial metabolite;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
human metabolite;
mouse metabolite
glycerylphosphorylcholine[no description available]medium20glycerophosphocholine
D-fructopyranose[no description available]medium20cyclic hemiketal;
D-fructose;
fructopyranose		sweetening agent
quinbolone[no description available]medium103-hydroxy steroidandrogen
c-peptide[no description available]medium42
hydroxyproline[no description available]medium324-hydroxyproline;
L-alpha-amino acid zwitterion		human metabolite;
mouse metabolite;
plant metabolite
angiotensin i[no description available]medium10angiotensin;
peptide zwitterion		human metabolite;
neurotransmitter agent
methandrostenolone[no description available]medium60organic molecular entity
ici 164384[no description available]high1017beta-hydroxy steroid;
3-hydroxy steroid;
tertiary carboxamide		anti-estrogen;
antineoplastic agent;
estrogen receptor antagonist
tocopherols[no description available]medium10
tricalcium phosphate[no description available]medium20calcium phosphate
lysine[no description available]medium10aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid		algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
calcium phosphate, dibasic, anhydrous[no description available]medium20calcium phosphate
calcium phosphate, monobasic, anhydrous[no description available]medium20calcium phosphatefertilizer
calcium pyrophosphate[no description available]medium20
9,10-dimethyl-1,2-benzanthracene[no description available]medium40ortho-fused polycyclic arene;
tetraphenes		carcinogenic agent
potassium phosphate[no description available]medium11inorganic phosphate salt;
inorganic potassium salt
ethinyl estradiol-norgestrel combination[no description available]medium61
mibolerone[no description available]medium1017beta-hydroxy steroid;
3-oxo-Delta(4) steroid		anabolic agent;
androgen
16 alpha-ethyl-21-hydroxy-19-nor-4-pregnene-3,20-dione[no description available]medium10
thymidine[no description available]medium30pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
bromazepam[no description available]medium10organic molecular entity
picibanil[no description available]medium20penicillinate anion
s-adenosylmethionine[no description available]medium20organic cation;
sulfonium compound		coenzyme;
cofactor;
human metabolite;
micronutrient;
Mycoplasma genitalium metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
substance p[no description available]medium10peptideneurokinin-1 receptor agonist;
neurotransmitter;
vasodilator agent
procaterol[no description available]medium10quinolines
fk 888[no description available]medium10peptide
epidermal growth factor[no description available]medium20
caseins[no description available]medium10
transforming growth factor alpha[no description available]medium10
glucagon[no description available]medium52peptide hormone
epostane[no description available]medium10
bilirubin[no description available]medium20biladienes;
dicarboxylic acid		antioxidant;
human metabolite;
mouse metabolite
pregnanediol[no description available]medium22
eperisone[no description available]medium11aromatic ketone;
piperidines
fibrin[no description available]medium20peptide
tetrahydrocortisol[no description available]medium2011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3alpha-hydroxy steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone
nitrates[no description available]medium10monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species
nitroblue tetrazolium[no description available]medium10organic cation
pyrazolone[no description available]medium10
glycolipids[no description available]medium10
leptin[no description available]medium11
sepharose[no description available]medium10
methylnitrosourea[no description available]medium20N-nitrosoureasalkylating agent;
carcinogenic agent;
mutagen;
teratogenic agent
vitamin b 12[no description available]medium10
7-hydroxystaurosporine[no description available]medium10
staurosporine[no description available]medium10ammonium ion derivative
amoxicillin-potassium clavulanate combination[no description available]medium10
allotetrahydrocortisol[no description available]medium10corticosteroid hormone
tetrahydro-11-deoxycortisol[no description available]medium1021-hydroxy steroid
tetrahydrocortisone[no description available]medium2021-hydroxy steroid
6 beta-hydroxycortisol[no description available]medium1111beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
6beta-hydroxy steroid;
C21-steroid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		human metabolite;
mammalian metabolite;
probe
(9R)-9-chloro-11,17-dihydroxy-17-(2-hydroxy-1-oxoethyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one[no description available]medium1021-hydroxy steroid
lactulose[no description available]medium10
quinazolines[no description available]medium20azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
clidanac[no description available]medium10organic molecular entity
acronine[no description available]medium10acridone derivatives;
alkaloid		antineoplastic agent;
metabolite
porphobilinogen[no description available]medium10aralkylamino compound;
dicarboxylic acid;
pyrroles		Escherichia coli metabolite;
metabolite;
mouse metabolite
methallibure[no description available]medium10
acetylene[no description available]medium10alkyne;
gas molecular entity;
terminal acetylenic compound
alpha-chlorohydrin[no description available]medium10chloropropane-1,2-diol
sulprostone[no description available]medium10prostanoid
glycyrrhizic acid[no description available]medium10enone;
glucosiduronic acid;
pentacyclic triterpenoid;
tricarboxylic acid;
triterpenoid saponin		EC 3.4.21.5 (thrombin) inhibitor;
plant metabolite
mepitiostane[no description available]medium20organic molecular entity
13,14-dihydroprostaglandin f2alpha[no description available]medium10
norgestrienone[no description available]medium10steroidestrogen
boldenone[no description available]medium1017beta-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
anabolic androgenic steroid
histrelin[no description available]medium20oligopeptideantineoplastic agent;
gonadotropin releasing hormone agonist
gossypol acetic acid[no description available]medium10
aluminum[no description available]medium10boron group element atom;
elemental aluminium;
metal atom
bromochloroacetic acid[no description available]medium102-bromocarboxylic acid;
monocarboxylic acid;
organochlorine compound
inosine pranobex[no description available]medium10
testosterone undecanoate[no description available]medium10steroid ester
gamma-glutamylglutamine[no description available]medium10dipeptidehuman metabolite
lithium[no description available]medium10alkali metal atom
cyclopenthiazide[no description available]medium10benzothiadiazine
17-n,n-diethylcarbamoyl-4-methyl-4-azaandrostane-3-one[no description available]medium10
aclacinomycin[no description available]medium10aminoglycoside;
anthracycline;
deoxy hexoside;
methyl ester;
monosaccharide derivative;
phenols;
polyketide;
tertiary alcohol;
tetracenequinones;
zwitterion		antimicrobial agent;
antineoplastic agent;
metabolite
aclarubicin[no description available]medium10aminoglycoside;
anthracycline;
methyl ester;
phenols;
polyketide;
tetracenequinones;
trisaccharide derivative;
zwitterion		antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
nomegestrol[no description available]medium10corticosteroid hormone
carboplatin[no description available]medium10
isomethyleugenol[no description available]medium10isomethyleugenol
trolamine salicylate[no description available]medium30
cetylpyridinium chloride anhydrous[no description available]medium10chloride salt;
organic chloride salt		antiseptic drug;
surfactant
fomesafen[no description available]medium10aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-sulfonylcarboxamide;
organofluorine compound;
phenols		agrochemical;
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide
fusarium[no description available]medium20
sodium ethylxanthate[no description available]medium10
9,9-bis(4-hydroxyphenyl)fluorene[no description available]low00fluorenes;
polyphenol		anti-estrogen
monopentyl phthalate[no description available]low00phthalic acid monoesteranti-estrogen;
rat metabolite;
xenobiotic metabolite
tamoxifen n-oxide[no description available]low00aromatic ether;
tertiary amine oxide		anti-estrogen;
metabolite
ru 58668[no description available]medium0017beta-hydroxy steroid;
3-hydroxy steroid;
aromatic ether;
organofluorine compound;
sulfone		anti-estrogen;
antineoplastic agent;
estrogen receptor antagonist
gallic acid[no description available]low00trihydroxybenzoic acidantineoplastic agent;
antioxidant;
apoptosis inducer;
astringent;
cyclooxygenase 2 inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
geroprotector;
human xenobiotic metabolite;
plant metabolite
thioctic acid[no description available]low00dithiolanes;
heterocyclic fatty acid;
thia fatty acid		fundamental metabolite;
geroprotector
oxaloacetic acid[no description available]low00C4-dicarboxylic acid;
oxo dicarboxylic acid		geroprotector;
metabolite
spermidine[no description available]low00polyazaalkane;
triamine		autophagy inducer;
fundamental metabolite;
geroprotector
n-(3-(aminomethyl)benzyl)acetamidine[no description available]low00aralkylamine;
carboxamidine;
primary amino compound		angiogenesis inhibitor;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
geroprotector
mercaptoethanol[no description available]low00alkanethiol;
primary alcohol		geroprotector
ag 1295[no description available]low00quinoxaline derivativegeroprotector
berberine[no description available]low00alkaloid antibiotic;
berberine alkaloid;
botanical anti-fungal agent;
organic heteropentacyclic compound		antilipemic drug;
antineoplastic agent;
antioxidant;
EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor;
EC 1.21.3.3 (reticuline oxidase) inhibitor;
EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
EC 3.1.1.4 (phospholipase A2) inhibitor;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
hypoglycemic agent;
metabolite;
potassium channel blocker
buformin[no description available]low00biguanidesantineoplastic agent;
antiviral agent;
geroprotector;
hypoglycemic agent;
radiosensitizing agent
carbonyl cyanide m-chlorophenyl hydrazone[no description available]low00hydrazone;
monochlorobenzenes;
nitrile		antibacterial agent;
geroprotector;
ionophore
ethoxyquin[no description available]low00aromatic ether;
quinolines		antifungal agrochemical;
food antioxidant;
genotoxin;
geroprotector;
herbicide;
Hsp90 inhibitor;
neuroprotective agent;
UDP-glucuronosyltransferase activator
juglone[no description available]low00hydroxy-1,4-naphthoquinonegeroprotector;
herbicide;
reactive oxygen species generator
kinetin[no description available]low006-aminopurines;
furans		cytokinin;
geroprotector
ag 1879[no description available]low00aromatic amine;
monochlorobenzenes;
pyrazolopyrimidine		beta-adrenergic antagonist;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector
resveratrol[no description available]low00polyphenol;
resorcinols;
stilbenol		antioxidant;
geroprotector;
glioma-associated oncogene inhibitor;
phytoalexin
trehalose[no description available]low00trehaloseEscherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
naphthazarin[no description available]low00hydroxy-1,4-naphthoquinoneacaricide;
antibacterial agent;
antineoplastic agent;
apoptosis inducer;
geroprotector;
plant metabolite
4-hydroxyphenylethanol[no description available]low00phenolsanti-arrhythmia drug;
antioxidant;
cardiovascular drug;
fungal metabolite;
geroprotector;
plant metabolite;
protective agent
dibromoacetic acid[no description available]low002-bromocarboxylic acid;
monocarboxylic acid		apoptosis inducer;
geroprotector;
marine metabolite
2-(2'-hydroxyphenyl)benzoxazole[no description available]low001,3-benzoxazoles;
phenols		geroprotector
ethidium bromide[no description available]low00organic bromide saltgeroprotector;
intercalator;
trypanocidal drug
thioflavin t[no description available]low00organic chloride saltfluorochrome;
geroprotector;
histological dye
2-(2-hydroxyphenyl)benzothiazole[no description available]low00benzothiazoles;
phenols		geroprotector
epigallocatechin gallate[no description available]low00flavans;
gallate ester;
polyphenol		antineoplastic agent;
antioxidant;
apoptosis inducer;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent;
plant metabolite
1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose[no description available]low00gallate ester;
galloyl beta-D-glucose		anti-inflammatory agent;
antineoplastic agent;
geroprotector;
hepatoprotective agent;
plant metabolite;
radiation protective agent;
radical scavenger
pyrrolidine dithiocarbamate[no description available]low00dithiocarbamic acids;
pyrrolidines		anticonvulsant;
antineoplastic agent;
geroprotector;
neuroprotective agent;
NF-kappaB inhibitor;
radical scavenger
alfatradiol[no description available]low0017alpha-hydroxy steroid;
3-hydroxy steroid;
estradiol		estrogen;
geroprotector
amperozide[no description available]low00diarylmethane;
monofluorobenzenes;
N-alkylpiperazine;
secondary carboxamide;
ureas		anxiolytic drug;
dopamine uptake inhibitor;
geroprotector;
second generation antipsychotic;
serotonergic antagonist
2-(1H-benzimidazol-2-yl)aniline[no description available]low00benzimidazoles;
primary arylamine;
substituted aniline		geroprotector
thiazolidine-4-carboxylic acid, (r)-isomer[no description available]low00thiazolidinemonocarboxylic acid;
thioproline		geroprotector;
metabolite
paxilline[no description available]low00diterpene alkaloid;
enone;
organic heterohexacyclic compound;
terpenoid indole alkaloid;
tertiary alcohol		anticonvulsant;
Aspergillus metabolite;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor;
genotoxin;
geroprotector;
mycotoxin;
Penicillium metabolite;
potassium channel blocker
nitroflurbiprofen[no description available]low00biphenyls;
carboxylic ester;
nitrate ester;
organofluorine compound		cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
geroprotector;
non-steroidal anti-inflammatory drug;
vasodilator agent
fullerene c60[no description available]low00fullerenegeroprotector
oxoline[no description available]low00aromatic ketone;
tetralins		geroprotector
sb 203580[no description available]low00imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide		EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent
carnosine[no description available]low00amino acid zwitterion;
dipeptide		anticonvulsant;
antineoplastic agent;
antioxidant;
Daphnia magna metabolite;
geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent
theanine[no description available]low00amino acid zwitterion;
N(5)-alkyl-L-glutamine		geroprotector;
neuroprotective agent;
plant metabolite
nicotinamide-beta-riboside[no description available]low00N-glycosylnicotinamide;
pyridine nucleoside		geroprotector;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
glaucarubinone[no description available]low00carboxylic ester;
organic heteropentacyclic compound;
quassinoid;
secondary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone;
tetrol		antimalarial;
antineoplastic agent;
geroprotector;
plant metabolite
trichostatin a[no description available]low00antibiotic antifungal agent;
hydroxamic acid;
trichostatin		bacterial metabolite;
EC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector
fumaric acid[no description available]low00butenedioic acidfood acidity regulator;
fundamental metabolite;
geroprotector
curcumin[no description available]low00aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger
sodium butyrate[no description available]low00organic sodium saltEC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector
quercetin 3-o-glucopyranoside[no description available]low00beta-D-glucoside;
monosaccharide derivative;
quercetin O-glucoside;
tetrahydroxyflavone		antineoplastic agent;
antioxidant;
antipruritic drug;
bone density conservation agent;
geroprotector;
histamine antagonist;
osteogenesis regulator;
plant metabolite
kaempferol[no description available]low007-hydroxyflavonol;
flavonols;
tetrahydroxyflavone		antibacterial agent;
geroprotector;
human blood serum metabolite;
human urinary metabolite;
human xenobiotic metabolite;
plant metabolite
butein[no description available]low00chalcones;
polyphenol		antineoplastic agent;
antioxidant;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
geroprotector;
hypoglycemic agent;
plant metabolite;
radiosensitizing agent;
tyrosine kinase inhibitor
baicalein[no description available]low00trihydroxyflavoneangiogenesis inhibitor;
anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 4.1.1.17 (ornithine decarboxylase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hormone antagonist;
plant metabolite;
prostaglandin antagonist;
radical scavenger
fisetin[no description available]low003'-hydroxyflavonoid;
7-hydroxyflavonol;
tetrahydroxyflavone		anti-inflammatory agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
metabolite;
plant metabolite
polydatin[no description available]low00beta-D-glucoside;
monosaccharide derivative;
polyphenol;
stilbenoid		anti-arrhythmia drug;
antioxidant;
geroprotector;
hepatoprotective agent;
metabolite;
nephroprotective agent;
potassium channel modulator
chicoric acid[no description available]low00organooxygen compoundgeroprotector;
HIV-1 integrase inhibitor
rosmarinic acid[no description available]low00rosmarinic acidgeroprotector;
plant metabolite
ellagic acid[no description available]low00catechols;
cyclic ketone;
lactone;
organic heterotetracyclic compound;
polyphenol		antioxidant;
EC 1.14.18.1 (tyrosinase) inhibitor;
EC 2.3.1.5 (arylamine N-acetyltransferase) inhibitor;
EC 2.4.1.1 (glycogen phosphorylase) inhibitor;
EC 2.5.1.18 (glutathione transferase) inhibitor;
EC 2.7.1.127 (inositol-trisphosphate 3-kinase) inhibitor;
EC 2.7.1.151 (inositol-polyphosphate multikinase) inhibitor;
EC 2.7.4.6 (nucleoside-diphosphate kinase) inhibitor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
food additive;
fungal metabolite;
geroprotector;
plant metabolite;
skin lightening agent
kn 93[no description available]low00monochlorobenzenes;
monomethoxybenzene;
primary alcohol;
sulfonamide;
tertiary amino compound		EC 2.7.11.17 (Ca(2+)/calmodulin-dependent protein kinase) inhibitor;
geroprotector
10-hydroxy-2-decenoic acid[no description available]low00alpha,beta-unsaturated monocarboxylic acid;
hydroxy monounsaturated fatty acid;
omega-hydroxy-medium-chain fatty acid;
straight-chain fatty acid		animal metabolite;
geroprotector
methyl 2,5-dihydroxycinnamate[no description available]low00cinnamate ester;
hydroquinones;
methyl ester		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
geroprotector;
human urinary metabolite;
plant metabolite
3,8-dihydroxy-6h-dibenzo(b,d)pyran-6-one[no description available]low00coumarinsgeroprotector
l 744832[no description available]low00benzenes;
ether;
isopropyl ester;
secondary carboxamide;
sulfone;
thiol		antineoplastic agent;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor;
geroprotector
3,3-diethyl-2-pyrrolidinone[no description available]low00pyrrolidin-2-onesanticonvulsant;
geroprotector
n,n'-dibenzhydrylethane-1,2-diamine dihydrochloride[no description available]low00hydrochloridegeroprotector;
metabotropic glutamate receptor agonist;
neuroprotective agent
trametinib[no description available]low00acetamides;
aromatic amine;
cyclopropanes;
organofluorine compound;
organoiodine compound;
pyridopyrimidine;
ring assembly		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
4-(1-((5-((2,6-dimethylphenoxy)methyl)-3-isoxazolyl)carbonyl)-4-piperidinyl)pyridine[no description available]low00aromatic amide;
aromatic ether;
isoxazoles;
N-acylpiperidine;
pyridines		geroprotector;
P450 inhibitor
chromium tripicolinate[no description available]low00chromium coordination entityanti-obesity agent;
geroprotector;
hypoglycemic agent;
nutraceutical
ethylestrenol[no description available]low0017beta-hydroxy steroid;
tertiary alcohol		anabolic agent
ethynodiol[no description available]low0017beta-hydroxy steroid;
3beta-hydroxy steroid;
terminal acetylenic compound		progestin
6-dehydrotestosterone[no description available]low0017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
enone
estetrol[no description available]low0015alpha-hydroxy steroid;
16alpha-hydroxy steroid;
17beta-hydroxy steroid;
3-hydroxy steroid;
steroid hormone		estrogen receptor agonist;
estrogen;
human metabolite;
human xenobiotic metabolite;
oral contraceptive
estradiol-3-sulfate[no description available]low0017beta-hydroxy steroid;
steroid sulfate		mammalian metabolite
ethinylestradiol-3-sulfate[no description available]low0017beta-hydroxy steroid;
steroid sulfate		antineoplastic agent;
estrogen
4-methoxyestradiol[no description available]low0017beta-hydroxy steroid;
3-hydroxy steroid;
aromatic ether;
phenols		estrogen;
human metabolite;
rat metabolite
11-hydroxytestosterone[no description available]low0011beta-hydroxy steroid;
17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
androstanoid;
C19-steroid		bacterial xenobiotic metabolite;
human xenobiotic metabolite;
marine metabolite
estriol-16 alpha-glucuronide[no description available]low0017beta-hydroxy steroid;
3-hydroxy steroid;
beta-D-glucosiduronic acid;
phenols;
steroid glucosiduronic acid		human urinary metabolite
19-hydroxytestosterone[no description available]low0017beta-hydroxy steroid;
19-hydroxy steroid;
3-oxo-Delta(4) steroid		mouse metabolite
androstane-3,7,17-triol[no description available]low0017beta-hydroxy steroid;
3beta-sterol;
7alpha-hydroxy steroid;
triol		mammalian metabolite
androstane-3,6,17-triol[no description available]low0017beta-hydroxy steroid;
3beta-sterol;
6alpha-hydroxy steroid;
triol		mammalian metabolite
1-testosterone[no description available]low0017beta-hydroxy steroid;
3-oxo-Delta(1) steroid;
anabolic androgenic steroid		anabolic agent
5 alpha-androstane-3 beta,17 beta-diol[no description available]low0017beta-hydroxy steroid;
3beta-hydroxy steroid;
androstane-3,17-diol		Daphnia magna metabolite;
human metabolite
15-hydroxytestosterone[no description available]low0015alpha-hydroxy steroid;
17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
androstanoid		androgen;
Daphnia magna metabolite
2-hydroxyestradiol[no description available]low0017beta-hydroxy steroid;
2-hydroxy steroid		carcinogenic agent;
human metabolite;
metabolite;
mouse metabolite;
prodrug
metribolone[no description available]low0017beta-hydroxy steroid;
3-oxo steroid;
anabolic androgenic steroid		androgen
estradiol-3-glucuronide[no description available]low0017beta-hydroxy steroid;
beta-D-glucosiduronic acid;
steroid glucosiduronic acid		human metabolite;
mouse metabolite
estriol 3-glucuronide[no description available]low0016alpha-hydroxy steroid;
17beta-hydroxy steroid;
steroid glucosiduronic acid		epitope;
estrogen
tibolone[no description available]low0017beta-hydroxy steroid;
terminal acetylenic compound		bone density conservation agent;
hormone agonist
11-ketotestosterone[no description available]low0011-oxo steroid;
17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
androstanoid		androgen;
human metabolite;
marine xenobiotic metabolite
propargite[no description available]low00sulfite ester;
terminal acetylenic compound		sulfite ester acaricide
methylacetylene[no description available]low00alkyne;
gas molecular entity;
terminal acetylenic compound
propargyl alcohol[no description available]low00propynol;
terminal acetylenic compound;
volatile organic compound		antifungal agent;
Saccharomyces cerevisiae metabolite
propiolic acid[no description available]low00acetylenic fatty acid;
alpha,beta-unsaturated monocarboxylic acid;
monounsaturated fatty acid;
short-chain fatty acid;
terminal acetylenic compound		xenobiotic metabolite
ethyl propiolate[no description available]low00ethyl ester;
terminal acetylenic compound;
ynoate ester
propiolaldehyde[no description available]low00terminal acetylenic compound;
ynal		mouse metabolite
pronamide[no description available]low00benzamides;
dichlorobenzene;
terminal acetylenic compound		agrochemical;
herbicide
s 53482[no description available]low00benzoxazine;
dicarboximide;
organofluorine compound;
terminal acetylenic compound		agrochemical;
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide;
teratogenic agent
s 23121[no description available]low00aromatic ether;
dicarboximide;
monochlorobenzenes;
monofluorobenzenes;
pyrroline;
terminal acetylenic compound
erlotinib hydrochloride[no description available]low00hydrochloride;
terminal acetylenic compound		antineoplastic agent;
protein kinase inhibitor
zr 777[no description available]low00farnesane sesquiterpenoid;
terminal acetylenic compound		juvenile hormone mimic
norgestimate[no description available]low00ketoxime;
steroid ester;
terminal acetylenic compound		contraceptive drug;
progestin;
synthetic oral contraceptive
mandipropamid[no description available]low00aromatic ether;
monocarboxylic acid amide;
monochlorobenzenes;
terminal acetylenic compound
ConditionIndicatedRelationship StrengthStudiesTrials
2019 Novel Coronavirus Disease0medium31
2019 Novel Coronavirus Infection0medium31
2019-nCoV Disease0medium31
2019-nCoV Infection0medium31
47,XX,+210low10
47,XY,+210low10
Abdomen, Acute0low20
Abdominal Cramps0low30
Abdominal Migraine0medium51
Abdominal Neoplasms0low10
Abdominal Pain0medium131
Aberrant Tissue0low20
Abnormalities, Autosome0medium31
Abnormalities, Chromosomal0medium31
Abnormalities, Chromosome0medium31
Abnormalities, Drug-Induced0low40
Abnormalities, Sex Chromosome0low10
Abortion, Habitual0medium31
Abortion, Recurrent0medium31
Abortion, Spontaneous0low50
Abortion, Tubal0low50
Abscess0low30
Ache0medium6218
Acne0medium94
Acne Vulgaris0medium94
Acquired Autoimmune Hemolytic Anemia0medium252
Acquired Immune Deficiency Syndrome0medium81
Acquired Immuno-Deficiency Syndrome0medium81
Acquired Immunodeficiency Syndrome0medium81
Acromegaly0low20
Actinic Reticuloid Syndrome0low10
Acute Confusional Migraine0medium51
Acute Coronary Syndrome0low10
Acute Disease0medium172
Acute Edematous Pancreatitis0low40
Acute Hepatic Failure0low10
Acute Hypercapnic Respiratory Failure0low10
Acute Hypoxemic Respiratory Failure0low10
Acute Kidney Failure0low10
Acute Kidney Injury0low10
Acute Kidney Insufficiency0low10
Acute Liver Failure0low10
Acute Liver Injury, Drug-Induced0medium251
Acute Lymphoid Leukemia0low20
Acute Mesenteric Arterial Embolus0low10
Acute Mesenteric Arterial Thrombosis0low10
Acute Myelogenous Leukemia0medium163
Acute Myeloid Leukemia0medium163
Acute Myeloid Leukemia with Maturation0medium163
Acute Myeloid Leukemia without Maturation0medium163
Acute Necrotizing Pancreatitis0low10
Acute Pain0low10
Acute Pancreatitis0low40
Acute Post-operative Pain0low10
Acute Postoperative Pain0low10
Acute Promyelocytic Leukemia0low20
Acute Renal Failure0low10
Acute Renal Injury0low10
Acute Renal Insufficiency0low10
Acute Respiratory Distress Syndrome0low10
Adamantiades-Behcet Disease0low10
Adenocarcinoma0low110
Adenocarcinoma Of Kidney0low10
Adenocarcinoma, Basal Cell0low110
Adenocarcinoma, Endometrioid0low10
Adenocarcinoma, Granular Cell0low110
Adenocarcinoma, Oxyphilic0low110
Adenocarcinoma, Renal0low10
Adenocarcinoma, Renal Cell0low10
Adenocarcinoma, Tubular0low110
Adenofibroma0low20
Adenoma0low50
Adenoma, alpha-Cell0low10
Adenoma, Basal Cell0low50
Adenoma, Follicular0low50
Adenoma, Hepatocellular0low50
Adenoma, Liver Cell0low50
Adenoma, Malignant0low110
Adenoma, Microcystic0low50
Adenoma, Monomorphic0low50
Adenoma, Papillary0low50
Adenoma, Trabecular0low50
Adenomyoma0low10
Adenosis of Breast0medium5014
Adhesions, Tissue0medium134
Adnexal Diseases0low30
Adnexitis0low10
Adolescent Gynecomastia0medium152
Adrenal Gland Hypofunction0low10
Adrenal Hyperplasia, Congenital0low10
Adrenal Insufficiency0low10
Adult Periodontitis0low10
Adult Respiratory Distress Syndrome0low10
Adult Rickets0low10
Adverse Drug Event0low80
Adverse Drug Reaction0low80
Affective Disorders0low10
Affective Psychosis, Bipolar0low20
Afibrinogenemia0low20
Afibrinogenemia, Congenital0low20
Age-Related Osteoporosis0medium71
Aging0low40
Agnogenic Myeloid Metaplasia0medium2410
AIDS0medium81
AIDS Seroconversion0low10
AIDS Seropositivity0low10
AIDS-Related Complex0medium31
Airway Obstruction0low40
ALL, Childhood0low20
Allergic Reaction0low10
Allergy0low10
Allergy, Drug0low10
Alopecia0low20
Alopecia Cicatrisata0low20
Alopecia, Androgenetic0low20
Alopecia, Male Pattern0low20
alpha 1-Antitrypsin Deficiency0medium91
alpha-Cell Tumor0low10
Alveolar Bone Atrophy0low10
Alveolar Bone Loss0low10
Alveolar Process Atrophy0low10
Alveolar Resorption0low10
Alveolitis, Fibrosing0medium62
Ambiguous Genitalia0low70
Amenorrhea0medium216
American Trypanosomiasis0low20
AML M30low20
Amyotrophy, Thenar, Of Carpal Origin0low30
Anaphylactic Reaction0low10
Anaphylactoid Reaction0low10
Anaphylactoid Shock0low10
Anaphylaxis0low10
Anaplastic Astrocytoma0low10
Anasarca0low80
Androgen Insensitivity Syndrome0low40
Androgen Insensitivity, Partial0low40
Androgen Receptor Deficiency0low40
Androgen Resistance Syndrome0low40
Androgen-Insensitivity Syndrome0low40
Androgen-Insensitivity Syndrome, Complete0low40
Androgen-Insensitivity Syndrome, Partial0low40
Androgenetic Alopecia0low20
Androgenic Alopecia0low20
Androgenization0low60
Anemia0medium197
Anemia, Fanconi0low30
Anemia, Hemolytic0medium61
Anemia, Hemolytic, Acquired0medium61
Anemia, Hemolytic, Autoimmune0medium252
Anemia, Hemolytic, Cold Antibody0medium252
Anemia, Hemolytic, Idiopathic Acquired0medium252
Anemia, Hypochromic0low10
Anemia, Hypoplastic0medium282
Anemia, Iron-Deficiency0low10
Anemia, Megaloblastic0low10
Anemia, Microangiopathic0medium61
Anemia, Refractory0medium61
Anemia, Refractory, with Excess of Blasts0medium41
Anemia, Sickle Cell0low10
Anemia, Sideroblastic0medium31
Anemias, Iron-Deficiency0low10
Anesthesia0low20
Aneuploid0low10
Aneuploid Cell0low10
Aneuploidy0low10
Aneurysm, Aortic0low10
Angiitis0low50
Angiodysplasia0low20
Angioedema0medium1848
Angioedema, Hereditary0medium563
Angioedema, Hereditary, Type I0low120
Angioedema, Hereditary, Type II0low120
Angioedema, Hereditary, Type III0low20
Angioedema, Hereditary, Types I and II0low120
Angioedemas, Hereditary0medium563
Angiogenesis, Pathologic0low40
Angiogenesis, Pathological0low40
Angiohemophilia0low40
Angioimmunoblastic Lymphadenopathy0low10
Angioneurotic Edema0medium1848
Angioneurotic Edema, Hereditary0medium563
Angioneurotic Edema, Hereditary, with Normal C1 Inhibitor Concentration and Function0low20
Anhidrosis0low10
Ankylosing Spondylarthritis0low10
Ankylosing Spondylitis0low10
Ankylosing Spondyloarthritis0low10
ANLL0medium163
Anorectal Diseases0low50
Anorectal Disorders0low50
Anovulation0low30
Anti-HIV Positivity0low10
Anti-Phospholipid Antibody Syndrome0low50
Anti-Phospholipid Syndrome0low50
Antibody Deficiency Syndrome0low10
Antiphospholipid Antibody Syndrome0low50
Antiphospholipid Syndrome0low50
Antithrombin 3 Deficiency0low80
Antithrombin III Deficiency0low80
Anxiety0medium42
Aortic Aneurysm0low10
Aortic Dissection0low10
Aortic Incompetence0low10
Aortic Regurgitation0low10
Aortic Valve Incompetence0low10
Aortic Valve Insufficiency0low10
Aplasia Pure Red Cell0low40
Aplastic Anaemia0medium282
Aplastic Anemia0medium282
Appendiceal Cancer0low10
Appendiceal Neoplasms0low10
Appendicitis0low10
Appendix Cancer0low10
Appetite Disorders0medium11
AR Deficiency0low40
ARC0medium31
ARDS, Human0low10
Arterial Diseases, Carotid0medium11
Arterial Diseases, Common Carotid0medium11
Arterial Diseases, External Carotid0medium11
Arterial Diseases, Internal Carotid0medium11
Arteriosclerosis0medium21
Arteriovenous Malformations0low10
Arthritis0low20
Arthritis, Rheumatoid0medium61
Arthropathies0medium11
Ascites0low50
Aspergillosis0low10
Aspergillus Infection0low10
Asphyxia0low10
Asthma0low30
Asthma, Bronchial0low30
Astrocytoma0low10
Astrocytoma, Grade I0low10
Astrocytoma, Grade II0low10
Astrocytoma, Grade III0low10
Astrocytoma, Protoplasmic0low10
Astrocytoma, Subependymal Giant Cell0low10
Astroglioma0low10
Atherogenesis0medium21
Atherosclerosis0medium21
Atherosclerotic Disease, Carotid0medium11
Atrophy0low40
Atypical Endometrial Hyperplasia0medium193
Aura0low10
Autoimmune Demyelinating Disease, Peripheral0low10
Autoimmune Diabetes0low30
Autoimmune Disease0medium474
Autoimmune Diseases0medium474
Autoimmune Haemolytic Anaemia0medium252
Autoimmune Hemolytic Anemia0medium252
Autoimmune Lymphoproliferative Syndrome0low20
Autoimmune Lymphoproliferative Syndrome Type 1, Autosomal Dominant0low20
Autoimmune Lymphoproliferative Syndrome Type 2B0low20
Autoimmune Lymphoproliferative Syndrome Type 2B (ALPS2B)0low20
Autoimmune Lymphoproliferative Syndrome, Type I, Autosomal Dominant0low20
Autoimmune Lymphoproliferative Syndrome, Type IIb0low20
Autoimmune Thrombocytopenia0medium6310
Autoimmune Thrombocytopenic Purpura0medium6310
Autosomal Chromosome Disorders0low10
Autosomal Hemophilia A0medium184
Autosome Abnormalities0medium31
Awakening Epilepsy0low10
B-Cell Chronic Lymphocytic Leukemia0low40
B-Cell Leukemia, Chronic0low40
B-Cell Malignancy, Low-Grade0low40
B-Lymphocytic Leukemia, Chronic0low40
B16 Melanoma0low10
Back Ache0medium11
Back Pain0medium11
Back Pain with Radiation0medium11
Back Pain without Radiation0medium11
Backache0medium11
Baldness0low20
Baldness, Male Pattern0low20
Bechterew Disease0low10
Bechterew's Disease0low10
Behcet Disease0low10
Behcet Syndrome0low10
Behcet Triple Symptom Complex0low10
Behcet's Disease0low10
Behcet's Syndrome0low10
Behu00E7et Disease0low10
Benign Hypothalamic Neoplasms0low10
Benign Intracranial Hypertension0low70
Benign Neoplasms0low50
Benign Neoplasms, Brain0low10
Berger Disease0medium11
Berger's Disease0medium11
Bilateral Deafness0low10
Bilateral Headache0medium31
Bile Duct Obstruction0low40
Bile Duct Obstruction, Intrahepatic0low40
Biliary Stasis0low40
Biliary Stasis, Intrahepatic0low40
Bipolar Disorder0low20
Bipolar Mood Disorder0low20
Bladder Cancer0low70
Bladder Diseases0low20
Bladder Neoplasms0low70
Bladder Tumors0low70
Blast Crisis0medium31
Blast Phase0medium31
Bleb0low10
Bleeding0low80
Bleeding Between Periods0medium111
Blister0low10
Blood Clot0low100
Blood Coagulation Disorders0low20
Blood Coagulation Disorders, Inherited0low10
Blood Diseases0low50
Blood Loss, Surgical0medium42
Blood Platelet Disorders0low10
Blood Pressure, High0medium41
Blood Pressure, Low0low10
Blood Vessel Dissection0low10
Body Weight0medium287
Bone Cancer0low20
Bone Loss, Age-Related0medium71
Bone Loss, Alveolar0low10
Bone Loss, Osteoclastic0low20
Bone Loss, Perimenopausal0medium11
Bone Loss, Periodontal0low10
Bone Loss, Postmenopausal0medium11
Bone Marrow Diseases0medium71
Bone Marrow Failure0low20
Bone Marrow Failure Disorders0low20
Bone Marrow Failure Syndrome0low20
Bone Marrow Failure Syndromes0low20
Bone Marrow Fibrosis0medium2410
Bone Neoplasms0low20
Bone Resorption0low20
Bonnevie-Ullrich Syndrome0low10
Brain Cancer0low10
Brain Hemorrhage, Cerebral0low70
Brain Metastases0low10
Brain Neoplasm, Primary0low10
Brain Neoplasms0low10
Brain Neoplasms, Benign0low10
Brain Neoplasms, Malignant0low10
Brain Neoplasms, Malignant, Primary0low10
Brain Neoplasms, Primary Malignant0low10
Brain Tumor, Primary0low10
Brain Tumor, Recurrent0low10
Brain Tumors0low10
Brain Vascular Disorders0low10
Breakthrough Bleeding0medium111
Breast Cancer0medium5010
Breast Carcinoma0medium5010
Breast Diseases0medium6416
Breast Dysplasia0medium5014
Breast Neoplasms0medium5010
Breast Tumors0medium5010
Breathlessness0low10
Bright Disease0medium31
Bronchial Asthma0low30
Bronchial Diseases0low20
Bronchial Neoplasms0low20
Bronchitis0low10
Bulla0low10
Bullae0low10
Bullous Lesion0low10
C1 Esterase Inhibitor Deficiency0medium563
C1 Esterase Inhibitor, Deficiency Of0low120
C1 Inhibitor Deficiency0medium563
Canale Smith Syndrome0low20
Canale-Smith Syndrome0low20
Cancer0low50
Cancer of Appendix0low10
Cancer of Bladder0low70
Cancer of Bone0low20
Cancer of Brain0low10
Cancer of Breast0medium5010
Cancer of Cervix0low20
Cancer of Colon0low10
Cancer of Endometrium0medium142
Cancer of Gastrointestinal Tract0low10
Cancer of ILEUM0low10
Cancer of Intestines0low30
Cancer of Kidney0low20
Cancer of Liver0low210
Cancer of Lung0low140
Cancer of Ovary0medium353
Cancer of Pancreas0low20
Cancer of Pelvis0medium6313
Cancer of Pituitary0low10
Cancer of Prostate0low40
Cancer of Rectum0low60
Cancer of Sigmoid0low10
Cancer of Skin0low10
Cancer of Spleen0low10
Cancer of the Appendix0low10
Cancer of the Bladder0low70
Cancer of the Bone0low20
Cancer of the Brain0low10
Cancer of the Breast0medium5010
Cancer of the Cervix0low20
Cancer of the Colon0low10
Cancer of the Endometrium0medium142
Cancer of the Fallopian Tube0medium51
Cancer of the Gastrointestinal Tract0low10
Cancer of the ILEUM0low10
Cancer of the Intestines0low30
Cancer of the Kidney0low20
Cancer of the Liver0low210
Cancer of the Lung0low140
Cancer of the Ovary0medium353
Cancer of the Pancreas0low20
Cancer of the Pelvis0medium6313
Cancer of the Pituitary0low10
Cancer of the Prostate0low40
Cancer of the Rectum0low60
Cancer of the Sigmoid0low10
Cancer of the Skin0low10
Cancer of the Spleen0low10
Cancer of the Ureter0low80
Cancer of the Urinary Tract0low10
Cancer of the Uterine Cervix0low20
Cancer of the Uterus0medium9011
Cancer of the Vagina0low10
Cancer of Ureter0low80
Cancer of Urinary Tract0low10
Cancer of Uterus0medium9011
Cancer of Vagina0low10
Cancer, Appendiceal0low10
Cancer, Hepatocellular0low210
Cancer, Ileal0low10
Cancer, Second Primary0low20
Canine Diseases0low40
Capillary Leak Syndrome0low10
Carcinoma0medium21
Carcinoma of Endometrium0medium142
Carcinoma, Anaplastic0medium21
Carcinoma, Cribriform0low110
Carcinoma, Endometrioid0low10
Carcinoma, Granular Cell0low110
Carcinoma, Hepatocellular0low130
Carcinoma, Hypernephroid0low10
Carcinoma, Renal Cell0low10
Carcinoma, Spindle-Cell0medium21
Carcinoma, Tubular0low110
Carcinoma, Undifferentiated0medium21
Carcinomatosis0medium21
Cardiac Failure0low50
Cardiovascular Diseases0low10
Cardiovascular Pregnancy Complications0low80
Cardiovascular Stroke0medium31
Carotid Artery Diseases0medium11
Carotid Artery Disorders0medium11
Carotid Artery Thrombosis0low10
Carotid Atherosclerosis0medium11
Carotid Atherosclerotic Disease0medium11
Carotid Thrombosis0low10
Carpal Tunnel Syndrome0low30
Caspase 8 Deficiency0low20
Caspase-8 Deficiency0low20
Catastrophic Illness0low10
Catheter-Associated Infections0low10
Catheter-Related Infections0low10
Celiac Disease0low10
Celiac Sprue0low10
Cell Transformation, Neoplastic0low10
Central Hypothyroidism0medium41
Central Retinal Edema, Cystoid0low10
Centriacinar Emphysema0low50
Centrilobular Emphysema0low50
Cephalalgia0medium31
Cephalgia0medium31
Cephalodynia0medium31
Cerebral Astrocytoma0low10
Cerebral Hemorrhage0low70
Cerebral Parenchymal Hemorrhage0low70
Cerebrovascular Diseases0low10
Cerebrovascular Disorders0low10
Cerebrovascular Insufficiency0low10
Cerebrovascular Occlusion0low10
Cervical Cancer0low20
Cervical Migraine Syndrome0medium51
Cervical Neoplasms0low20
Cervix Cancer0low20
Cervix Neoplasms0low20
Chagas Disease0low20
Chagas' Disease0low20
Cheilitis Granulomatosa0low20
Cheilitis Granulomatosa, Facial Neuropathy, Orofacial Edema0low20
Cheilitis Granulomatosa, Orofacial Edema, Facial Neuropathy0low20
Chemical and Drug Induced Liver Injury0medium251
Chemically-Induced Liver Toxicity0medium251
Chest Pain0low20
Childhood Cerebral Astrocytoma0low10
Chlorosis0low10
Choked Disk0low20
Choking0low40
Cholangiitis, Sclerosing0low10
Cholangitis, Primary Sclerosing0low10
Cholangitis, Sclerosing0low10
Cholera Infantum0low20
Cholestasis0low40
Cholestasis, Intrahepatic0low40
Chondritis, Costal0medium11
Choristoma0low20
Christmas Disease0medium112
Chromophil Renal Cell Carcinoma0low10
Chromophobe Renal Cell Carcinoma0low10
Chromosomal Aberrations0medium31
Chromosomal Disorders0low10
Chromosomal Translocation0low10
Chromosome Aberrations0medium31
Chromosome Abnormalities0medium31
Chromosome Abnormalities, Sex0low10
Chromosome Abnormality Disorders0low10
Chromosome Disorders0low10
Chromosome Inversion0low10
Chronic Actinic Dermatitis0low10
Chronic Cystic Mastitis0medium5014
Chronic Disease0medium283
Chronic Hepatitis0low10
Chronic Hepatitis C0low20
Chronic Idiopathic Myelofibrosis0medium2410
Chronic Illness0medium283
Chronic Insomnia0low10
Chronic Kidney Failure0low30
Chronic Lymphocytic Leukemia0low40
Chronic Periodontitis0low10
Chronic Post-operative Pain0low10
Chronic Post-surgical Pain0low10
Chronic Postoperative Pain0low10
Chronic Postsurgical Pain0low10
Chronically Ill0medium283
Cicatrix0low30
Cicatrization0low30
Circulatory Collapse0low10
Circulatory Failure0low10
Cirrhosis0low10
Cirrhosis, Liver0medium31
Clarkson Disease0low10
Classic Hemophilia0medium184
Clear Cell Renal Carcinoma0low10
Clear Cell Renal Cell Carcinoma0low10
Clinical Capillary Leak Syndrome0low10
Clinically Isolated CNS Demyelinating Syndrome0low10
Clinically Isolated Syndrome, CNS Demyelinating0low10
Coagulation Disorders, Blood0low20
Coagulation Disorders, Inherited0low10
Coagulation, Disseminated Intravascular0low20
Cochlear Hearing Loss0low10
Cold Agglutinin Disease0medium252
Cold Antibody Disease0medium252
Cold Antibody Hemolytic Anemia0medium252
Colic0low30
Colicky Pain0medium131
Colitis0low10
Colitis Gravis0low10
Colitis, Ulcerative0low10
Collecting Duct Carcinoma0low10
Collecting Duct Carcinoma (Kidney)0low10
Collecting Duct Carcinoma of the Kidney0low10
Colon Cancer0low10
Colon Neoplasms0low10
Colonic Cancer0low10
Colonic Diseases0low20
Colonic Inertia0low10
Colonic Neoplasms0low10
Colonic Polyps0low10
Colorectal Cancer0low10
Colorectal Carcinoma0low10
Colorectal Neoplasms0low10
Colorectal Tumors0low10
Common Carotid Artery Diseases0medium11
Common Carotid Artery Thrombosis0low10
Common Variable Hypogammaglobulinemia0low10
Common Variable Immune Deficiency0low10
Common Variable Immunodeficiency0low10
Compensatory Hyperinsulinemia0low10
Complex Endometrial Hyperplasia0medium193
Complication, Intraoperative0low20
Complication, Peroperative0low20
Complication, Postoperative0medium181
Complications, Cardiovascular Pregnancy0low80
Complications, Hematologic Pregnancy0low90
Complications, Neoplastic Pregnancy0low40
Complications, Pregnancy0medium61
Compression Neuropathy, Carpal Tunnel0low30
Condition, Preneoplastic0low20
Conditions, Preneoplastic0low20
Congenital Adrenal Hyperplasia0low10
Congenital Afibrinogenaemia0low20
Congenital Afibrinogenemia0low20
Congenital Antithrombin III Deficiency0low80
Congenital Hypothyroidism0low10
Congenital Thrombotic Thrombocytopenic Purpura0low30
Congenital Zika Syndrome0low10
Congenital Zika Virus Infection0low10
Congestive Heart Failure0low50
Connective Tissue Diseases0low10
Constipation0low10
Constriction, Pathologic0low10
Constriction, Pathological0low10
Consumption Coagulopathy0low20
Coronary Disease0low20
Coronary Heart Disease0low20
Coronavirus Disease 20190medium31
Coronavirus Disease-190medium31
Corpus Luteum Cyst0medium51
Costal Chondritis0medium11
Cough0low30
COVID-190medium31
COVID-19 Pandemic0medium31
COVID-19 Pandemics0medium31
COVID-19 Virus Disease0medium31
COVID-19 Virus Infection0medium31
COVID190medium31
Cramp0low30
Cranial Nerve Diseases0low10
Cranial Nerve Disorders0low10
Cranial Nerve Palsies0low10
Cranial Neuropathies0low10
Cranial Neuropathies, Multiple0low10
Cranial Pain0medium31
Cranial Sinus Thrombosis0low10
Cretinism0low10
Cross Infection0low10
Cryptogenic Chronic Hepatitis0low10
Cyst0medium51
Cystadenocarcinoma, Serous0medium11
Cystic Breast Disease0medium5014
Cystic Disease of Breast0medium5014
Cystic Echinococcosis0low10
Cystitis0low20
Cystoid Macular Dystrophy0low10
Cystoid Macular Edema0low10
Cystoid Macular Edema, Postoperative0low10
Cystosarcoma Phyllodes0low10
Cystosarcoma Phylloides0low10
Cysts0medium51
Cysts, Hydatid0low10
Cytogenetic Aberrations0medium31
Cytogenetic Abnormalities0medium31
Deafness Bilateral0low10
Deafness Neurosensory0low10
Deafness, Transitory0low10
Decreased Intraocular Pressure-Associated Papilledema0low20
Decreased Muscle Tone0low10
Deep Vein Thrombosis0low30
Deep Venous Thrombosis0low30
Deep-Vein Thrombosis0low30
Deep-Venous Thrombosis0low30
Deficiency of C1 Esterase Inhibitor0low120
Deficiency Syndrome, Immunologic0low10
Deficiency Syndromes, Antibody0low10
Deficiency Syndromes, Immunologic0low10
Deficiency, Antithrombin III0low80
Deficiency, Factor 100low30
Deficiency, Factor II0low20
Deficiency, Factor IX0medium112
Deficiency, Factor Ten0low30
Deficiency, Factor VIII0medium184
Deficiency, Factor X0low30
Deficiency, Fibrinogen0low20
Deficiency, Protein0low10
Deficiency, Protein C0low30
Deficiency, Protein S0low20
Deficiency, Pyridoxine0low10
Deficiency, Stuart-Prower0low30
Deficiency, Stuart-Prower Factor0low30
Deficiency, Vitamin B 60low10
Deficiency, Vitamin B60low10
Delayed Puberty0low10
Demyelinating Autoimmune Disease, Peripheral0low10
Demyelinating Disease, Peripheral Autoimmune0low10
Demyelinating Diseases0low10
Demyelinating Disorders0low10
Demyelination0low10
Depression0medium21
Depression, Bipolar0low20
Depression, Endogenous0low20
Depression, Neurotic0low20
Depression, Unipolar0low20
Depressive Disorder0low20
Depressive Syndrome0low20
Dermatitis0low20
Dermatitis Medicamentosa0medium51
Dermatitis, Actinic0low10
Dermatitis, Adverse Drug Reaction0medium51
Dermatitis, Atopic0low10
Dermatomyositis0low10
Dermatomyositis, Adult Type0low10
Dermatomyositis, Childhood Type0low10
Dermatopolymyositis0low10
Dermatosclerosis0low20
Dermatoses0low40
Dermatosis0low40
DHTR Deficiency0low40
Diabetes Mellitus0low10
Diabetes Mellitus, Brittle0low30
Diabetes Mellitus, Insulin-Dependent0low30
Diabetes Mellitus, Insulin-Dependent, 10low30
Diabetes Mellitus, Juvenile-Onset0low30
Diabetes Mellitus, Ketosis-Prone0low30
Diabetes Mellitus, Sudden-Onset0low30
Diabetes Mellitus, Type 10low30
Diabetes Mellitus, Type I0low30
Diabetes, Autoimmune0low30
Diabetic Retinopathy0low10
Diarrhea0low10
Diathesis0low10
Diffuse Lymphocytic Lymphoma, Poorly-Differentiated0low10
Diffuse Mixed Small and Large Cell Lymphoma0low30
Diffuse Mixed-Cell Lymphoma0low30
Diffuse Parenchymal Lung Disease0low10
Diffuse Parenchymal Lung Diseases0low10
Diffuse Small Cleaved-Cell Lymphoma0low30
Diffuse Undifferentiated Lymphoma0low30
Diffuse Well-Differentiated Lymphocytic Lymphoma0low40
Dihydrotestosterone Receptor Deficiency0low40
Dilatation, Pathologic0low10
Dilatation, Pathological0low10
Dilatations, Pathologic0low10
Dilatations, Pathological0low10
DIMS (Disorders of Initiating and Maintaining Sleep)0low10
Disbacteriosis0low10
Disbiosis0low10
Disease Exacerbation0medium152
Disease Models, Animal0low190
Disease Progression0medium152
Disease Susceptibility0low10
Disease, Pulmonary0low50
Diseases in Twins0low10
Diseases of Endocrine System0low40
Diseases of Immune System0low10
Diseases, Pulmonary0low50
Disorders of Initiating and Maintaining Sleep0low10
Disorders of Sex Development0low70
Disorders of Sexual Development0low70
Disorders, Blood Coagulation0low20
Disrupted In B-Cell Malignancy0low40
Dissecting Aneurysm0low10
Dissection, Blood Vessel0low10
Disseminated Coagulation, Intravascular0low20
Disseminated Intravascular Coagulation0low20
Dog Diseases0low40
Down Syndrome0low10
Down Syndrome, Partial Trisomy 210low10
Down's Syndrome0low10
Dropsy0low80
Drug Allergy0low10
Drug Eruptions0medium51
Drug Hypersensitivity0low10
Drug Side Effects0low80
Drug Toxicity0low80
Drug Withdrawal Symptoms0low10
Drug-Induced Abnormalities0low40
Drug-Induced Acute Liver Injury0medium251
Drug-Induced Liver Disease0medium251
Drug-Induced Liver Injury0medium251
Drug-Induced Stevens Johnson Syndrome0low10
Drug-Induced Stevens-Johnson Syndrome0low10
Drug-Related Side Effects and Adverse Reactions0low80
Duncan Disease0low50
Duncan's Syndrome0low50
Dupre Syndrome0low10
Dupre's Syndrome0low10
Dwarfism, Growth Hormone Deficiency0low10
Dwarfism, Pituitary0low10
Dys-symbiosis0low10
Dysbacteriosis0low10
Dysbiosis0low10
Dyschezia0low10
Dysfunctional Uterine Bleeding0medium111
Dyskeratosis Congenita, X-Linked0low40
Dysmenorrhea0medium292
Dysmyelopoietic Syndromes0medium266
Dyspareunia0medium124
Dyspnea0low10
Early Awakening0low10
Early Pregnancy Loss0low50
Eating and Feeding Disorders0medium11
Eating Disorders0medium11
Echinococcosis0low10
Echinococcus Granulosus Infection0low10
Echinococcus Infection0low10
Ectasia0low10
Ectopic Pregnancy0low20
Ectopic Tissue0low20
Eczema, Atopic0low10
Eczema, Infantile0low10
Edema0low80
Edema of the Optic Disc0low20
Edema of the Optic Disk0low20
Edema-Proteinuria-Hypertension Gestosis0low10
Edema, Laryngeal0low80
Electrolytes0low10
Elevated Cholesterol0low10
Embolism, Pulmonary0low30
Embolisms, Pulmonary0low30
Embryopathies0low10
Emergencies0low60
Emesis0medium42
Emphysema, Pulmonary0low50
Emphysemas, Pulmonary0low50
Encephalitis, Polio0low10
End-Stage Kidney Disease0low30
End-Stage Renal Disease0low30
Endemic Cretinism0low10
Endocrine Breast Diseases0medium6416
Endocrine Diseases0low40
Endocrine System Diseases0low40
Endogenous Hyperinsulinism0low10
Endometrial Cancer0medium142
Endometrial Carcinoma0medium142
Endometrial Diseases0medium225
Endometrial Hyperplasia0medium193
Endometrioid Adenocarcinoma0low10
Endometrioma0medium709108
Endometritis0low10
Endometrium Cancer0medium142
Endomyometritis0low10
Enlarged Liver0low20
Enlarged Spleen0low40
Enteric Fever0low10
Entrapment Neuropathy, Carpal Tunnel0low30
EPH Complex0low10
EPH Gestosis0low10
EPH Toxemias0low10
Epidemic Acute Poliomyelitis0low10
Epidermal Necrolysis, Toxic0low10
Epilepsy0low10
Epilepsy, Cryptogenic0low10
Epistaxis0low30
Epithelial Neoplasms0medium11
Epithelial Neoplasms, Malignant0medium21
Epithelial Tumors, Malignant0medium21
Epithelioma0medium21
Epstein-Barr Virus Infection, Familial Fatal0low50
Epstein-Barr Virus-Induced Lymphoproliferative Disease In Males0low50
Erythema0low10
Erythema Multiforme0low20
Erythrocyte Aplasia0low40
Erythrocytosis0low30
Erythrophagocytic Lymphohistiocytosis, Familial0low10
Esophago-Pharyngeal Diverticula0low10
Esophago-Pharyngeal Diverticulum0low10
Esophagopharyngeal Diverticulum0low10
ESRD0low30
Estrogen-Related HAE0low20
Estrogen-Sensitive HAE0low20
Estrogen-Sensitive Hereditary Angioedema0low20
Exogenous Hyperinsulinism0low10
Experimental Lung Inflammation0low10
Experimental Mammary Neoplasms0medium51
Experimental Melanoma0low10
Experimental Melanomas0low10
Experimental Neoplasms0low20
Experimental Pneumococcal Meningitis0low10
External Carotid Artery Diseases0medium11
External Carotid Artery Thrombosis0low10
Extravascular Hemolysis0low10
F9 Deficiency0medium112
Facial Dermatoses0low20
Facial Dermatosis0low20
Facial Neoplasms0low10
Facial Neuropathy, Cheilitis Granulomatosa, Orofacial Edema0low20
Facial Neuropathy, Orofacial Edema, Cheilitis Granulomatosa0low20
Facial Palsy0low10
Facial Palsy, Lower Motor Neuron0low10
Facial Palsy, Upper Motor Neuron0low10
Facial Paralysis0low10
Facial Paralysis, Central0low10
Facial Paralysis, Peripheral0low10
Facial Paresis0low10
Factor 10 Deficiency0low30
Factor 8 Deficiency, Congenital0medium184
Factor II Deficiency0low20
Factor IX Deficiency0medium112
Factor Ten Deficiency0low30
Factor VIII Deficiency0medium184
Factor VIII Deficiency, Congenital0medium184
Factor X Deficiency0low30
Fallopian Tube Cancer0medium51
Fallopian Tube Diseases0low50
Fallopian Tube Neoplasms0medium51
Familial Afibrinogenemia0low20
Familial Erythrophagocytic Lymphohistiocytosis0low10
Familial Fatal Epstein-Barr Infection0low50
Familial Hemophagocytic Histiocytosis0low10
Familial Hemophagocytic Lymphocytosis0low10
Familial Hemophagocytic Lymphohistiocytosis0low10
Familial Hemophagocytic Reticulosis0low10
Familial Histiocytic Reticulosis0low10
Familial Precocious Puberty0low150
Familial Spastic Paraparesis, Htlv-1-Associated0medium41
Familial Thrombotic Thrombocytopenia Purpura0low30
Familial Thrombotic Thrombocytopenic Purpura0low30
Familial Waldenstrom's Macroglobulinaemia0low10
Fanconi Hypoplastic Anemia0low30
Fanconi Pancytopenia0low30
Fanconi Panmyelopathy0low30
Fanconi's Anemia0low30
Fasting Hypoglycemia0low10
Favre-Racouchot Syndrome0low20
Febrile Neutropenia0low10
Feeding and Eating Disorders0medium11
Feeding Disorders0medium11
Female Genital Diseases0low50
Female Genital Neoplasms0medium374
Female Pattern Baldness0low20
Fetal Death0low10
Fetal Demise0low10
Fetal Diseases0low10
Fetal Growth Restriction0low10
Fetal Growth Retardation0low10
Fetal Iodine Deficiency Disorder0low10
Fetal Mummification0low10
Fever0medium11
Fever, Zika0low10
Fibrillary Astrocytoma0low10
Fibrinogen Deficiency0low20
Fibroadenoma0low20
Fibroadenosis0low20
Fibrocystic Changes of Breast0medium5014
Fibrocystic Disease of Breast0medium5014
Fibrocystic Mastopathy0medium5014
Fibroid0medium323
Fibroid Tumor0medium323
Fibroid Uterus0medium323
Fibroids, Uterine0medium323
Fibroma, Uterine0medium323
Fibromyoma0medium323
Fibroses, Pulmonary0medium62
Fibrosis0low10
Fibrosis, Bone Marrow0medium2410
Fibrosis, Liver0medium31
Fibrosis, Pulmonary0medium62
Flaccid Muscle Tone0low10
Floppy Muscles0low10
Flushing0low10
FMR1-Related Primary Ovarian Insufficiency0medium21
Focal Emphysema0low50
Focal Infection0low10
Focal Nodular Hyperplasia0low10
Fragile X Premature Ovarian Failure0medium21
Fragile X-Associated Primary Ovarian Insufficiency0medium21
Frontal Linear Scleroderma en Coup de Sabre0low20
Fulminant Hepatic Failure0low10
Fulminating Hepatic Failure0low10
Fulminating Liver Failure0low10
Functional Gastrointestinal Disorders0low20
Furcation Defects0low10
Galactorrhea0low10
Gammapathy, Monoclonal0low20
Gammopathy, Monoclonal0low20
Gasser Syndrome0low10
Gasser's Syndrome0low10
Gastric Diseases0low10
Gastrointestinal Cancer0low10
Gastrointestinal Diseases0low20
Gastrointestinal Disorders0low20
Gastrointestinal Disorders, Functional0low20
Gastrointestinal Hemorrhage0low50
Gastrointestinal Neoplasms0low10
Gemistocytic Astrocytoma0low10
Generalized Headache0medium31
Genetic Diseases0low70
Genetic Diseases, Inborn0low70
Genetic Disorders0low70
Genetic Predisposition0low20
Genetic Predisposition to Disease0low20
Genetic Susceptibility0low20
Genital Ambiguity0low70
Genital Diseases, Female0low50
Genital Neoplasms, Female0medium374
Germinoblastoma0low10
Gestosis, EPH0low10
Gigantism0low10
Gingival Hemorrhage0low30
Glandular and Epithelial Neoplasms0medium11
Glandular Neoplasms0medium11
Glioma, Astrocytic0low10
Glomerulonephritis0medium31
Glomerulonephritis, IGA0medium11
Glucagonoma0low10
Glucagonoma Syndrome0low10
Gluten Enteropathy0low10
Gluten-Sensitive Enteropathy0low10
Gonadal Agenesis0low10
Gonadal Dysgenesis0low10
Gonadal Dysgenesis, 45,X0low10
Gonadal Dysgenesis, XO0low10
Gonadotropin-Resistant Ovary Syndrome0medium21
Graft vs Host Disease0low10
Graft-Versus-Host Disease0low10
Graft-vs-Host Disease0low10
Granulocytic Leukemia0medium32
Granulomatous Cheilitis0low20
Grawitz Tumor0low10
Growth Disorders0low10
Growth Hormone Deficiency Dwarfism0low10
Growth Retardation, Intrauterine0low10
Gynecologic Diseases0low50
Gynecologic Neoplasms0medium374
Gynecomastia0medium152
HAE with Normal C1 Inhibitor Concentration and Function0low20
Haemolysis0low10
Haemolytic Anaemia0medium61
Haemophilia0medium184
Haemophilia B0medium112
Hair Loss0low20
Hamartoma0low10
Harding Passey Melanoma0low10
HbS Disease0low10
Head Pain0medium31
Headache0medium31
Headache, Migraine0medium51
Health Care Associated Infection0low10
Health Care Associated Infections0low10
Healthcare Associated Infections0low10
Hearing Impairment0low10
Hearing Loss0low10
Hearing Loss, Bilateral0low10
Hearing Loss, Cochlear0low10
Hearing Loss, Sensorineural0low10
Hearing Loss, Transitory0low10
Heart Attack0medium31
Heart Decompensation0low50
Heart Failure0low50
Heart Failure, Congestive0low50
Heart Failure, Left-Sided0low50
Heart Failure, Right-Sided0low50
Heart Septal Defects, Ventricular0low10
Heart Valve Diseases0low10
Heart Valvular Disease0low10
Heavy Menstrual Bleeding0medium8618
Heavy Periods0medium8618
Helicobacter Infections0medium31
HELLP Syndrome0low10
Hemarthrosis0low10
Hematemesis0low10
Hematochezia0low50
Hematologic Diseases0low50
Hematologic Malignancies0low10
Hematologic Malignancy0low10
Hematologic Neoplasms0low10
Hematologic Pregnancy Complications0low90
Hematological Diseases0low50
Hematological Malignancies0low10
Hematological Neoplasms0low10
Hematoma0low10
Hematoma, Subdural0low10
Hematopoetic Myelodysplasia0medium266
Hematopoietic Malignancies0low10
Hematopoietic Neoplasms0low10
Hematuria0medium41
Hemicrania0medium31
Hemicrania Migraine0medium51
Hemifacial Paralysis0low10
Hemoglobin S Disease0low10
Hemoglobinuria, Paroxysmal0medium121
Hemolysis0low10
Hemolysis, Elevated Liver Enzymes, Lowered Platelets0low10
Hemolytic Anemia0medium61
Hemolytic Anemia, Acquired0medium61
Hemolytic Anemia, Autoimmune0medium252
Hemolytic-Uremic Syndrome0low10
Hemoperitoneum0low10
Hemophagocytic Lymphohistiocytosis Familial -10low10
Hemophagocytic Lymphohistiocytosis, Familial0low10
Hemophagocytic Lymphohistiocytosis, Familial, 10low10
Hemophagocytic Reticulosis, Familial0low10
Hemophagocytic Syndrome0low10
Hemophagocytic Syndrome, Infection-Associated0low10
Hemophagocytic Syndrome, Reactive0low10
Hemophagocytic Syndromes0low10
Hemophilia0medium184
Hemophilia A0medium184
Hemophilia A, Congenital0medium184
Hemophilia B0medium112
Hemophilia B Leyden0medium112
Hemophilia B(M)0medium112
Hemophilia, Classic0medium184
Hemophilia, Vascular0low40
Hemopneumothorax0low10
Hemoptysis0low150
Hemorrhage0low80
Hemorrhage, Cerebral0low70
Hemorrhage, Cerebrum0low70
Hemorrhage, Gastrointestinal0low50
Hemorrhage, Gingival0low30
Hemorrhage, Subarachnoid0low10
Hemorrhage, Subdural0low10
Hemorrhage, Surgical0medium42
Hemorrhage, Uterine0medium289
Hemorrhagic Diathesis0low10
Hemorrhagic Disorders0low10
Hemorrhagic Necrotic Pancreatitis0low10
Hemothorax0low20
Hepatic Cancer0low210
Hepatic Cirrhosis0medium31
Hepatic Failure0low10
Hepatic Failure, Acute0low10
Hepatic Failure, Fulminant0low10
Hepatic Neoplasms0low210
Hepatic Veno Occlusive Disease0low10
Hepatic Veno-Occlusive Disease0low10
Hepatitis B0low10
Hepatitis B Virus Infection0low10
Hepatitis C0low20
Hepatitis C, Chronic0low20
Hepatitis, Chronic0low10
Hepatitis, Chronic Active0low10
Hepatitis, Chronic Persistent0low10
Hepatitis, Chronic, Cryptogenic0low10
Hepatitis, Drug-Induced0medium251
Hepatitis, Toxic0medium251
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted0low20
Hepatoblastoma0low10
Hepatocellular Cancer0low210
Hepatocellular Carcinoma0low130
Hepatoma0low130
Hepatoma, Benign0low50
Hepatomegaly0low20
Hereditary Angioedema0medium563
Hereditary Angioedema Type 10low120
Hereditary Angioedema Type I0low120
Hereditary Angioedema Type II0low120
Hereditary Angioedema Type III0low20
Hereditary Angioedema Types I and II0low120
Hereditary Angioedema with Normal C1 Inhibitor Activity0low20
Hereditary Angioedemas0medium563
Hereditary Angioneurotic Edema0medium563
Hereditary Antithrombin Deficiency0low80
Hereditary Blood Coagulation Disorders0low10
Hereditary Coagulation Disorders0low10
Hereditary Disease0low70
Hereditary Diseases0low70
Hereditary Hemorrhagic Telangiectasia0low10
Hereditary Thrombophilia Due To Protein C Deficiency0low30
Hereditary Thrombophilia Due To Protein S Deficiency0low20
Hermaphroditism0low70
Heterotopic Tissue0low20
High Cholesterol Levels0low10
Hirsutism0medium62
Histiocytosis, Non-Langerhans-Cell0low10
HIV Antibody Positivity0low10
HIV Coinfection0low10
HIV Infections0low10
HIV Seroconversion0low10
HIV Seropositivity0low10
Hives0medium111
Homologous Wasting Disease0low10
Hormone-Dependent Neoplasms0medium61
Hospital Infections0low10
Hospital-Acquired Condition0low10
HTLV I Associated Myelopathies0medium41
HTLV-I-Associated Myelopathy0medium41
HTLV-I-Associated Myelopathy-Tropical Spastic Paraparesis0medium41
HTLV-III Infections0low10
HTLV-III Seroconversion0low10
HTLV-III Seropositivity0low10
HTLV-III-LAV Infections0low10
Hughes Syndrome0low50
Human Mammary Carcinoma0medium5010
Human T-Lymphotropic Virus Type 1 Associated Myelopathy0medium41
Hydatid Cyst0low10
Hydatid Disease0low10
Hydatidosis0low10
Hydronephrosis0low20
Hydrops0low80
Hyperandrogenism0medium21
Hypercalcemia0low20
Hypercapnic Acute Respiratory Failure0low10
Hypercapnic Respiratory Failure0low10
Hypercholesteremia0low10
Hypercholesterolemia0low10
Hypercoagulability0low10
Hypergonadotropic Hypogonadism0low10
Hypergonadotropic Ovarian Failure, X-Linked0medium21
Hyperinsulinemia0low10
Hyperinsulinism0low10
Hyperlipoproteinemia0low10
Hyperlipoproteinemias0low10
Hypermelanosis0low10
Hypermenorrhea0medium8618
Hypernephroma0low10
Hyperparathyroidism0low10
Hyperpigmentation0low10
Hyperplasia0low50
Hyperplasia, Congenital Adrenal0low10
Hyperplasia, Focal Nodular0low10
Hyperprolactinaemia0low10
Hyperprolactinemia0low10
Hypersensitivity0low10
Hypersensitivity, Drug0low10
Hypersensitivity, Type III0low10
Hypertension0medium41
Hypertension-Edema-Proteinuria Gestosis0low10
Hypertension, Pulmonary0low30
Hyperthyroid0low50
Hyperthyroidism0low50
Hyperthyroxinemia0low10
Hypertrophy0low20
Hypoacusis0low10
Hypoadrenalism0low10
Hypofibrinogenemia, Congenital0low20
Hypogalactia0low10
Hypogammaglobulinemia, Acquired0low10
Hypoglycemia0low10
Hypogonadism0low10
Hypogonadism, Isolated Hypogonadotropic0low10
Hypogonadotropic Hypogonadism0low10
Hypohidrosis0low10
Hypolipoproteinemia0low10
Hypolipoproteinemias0low10
Hypomenorrhea0medium183
Hypomyotonia0low10
Hypoparathyroidism0low30
Hypophysial Dwarf0low10
Hypoprebetalipoproteinemia0low10
Hypoprothrombinemia0low20
Hypoprothrombinemias0low20
Hyposomatotrophic Dwarfism0low10
Hypospermatogenesis0low20
Hypotension0low10
Hypotension, Vascular0low10
Hypothalamic Cancer0low10
Hypothalamic Neoplasms0low10
Hypothalamic Neoplasms, Benign0low10
Hypothalamic Neoplasms, Malignant0low10
Hypothalamic Teratomas0low10
Hypothalamic Tumors0low10
Hypothalamic-Chiasmatic Neoplasms0low10
Hypothalamic-Pituitary Neoplasms0low10
Hypothalamo-Neurohypophysial Region Neoplasms0low10
Hypothalamus Neoplasms0low10
Hypothyroidism0medium41
Hypotonia0low10
Hypotony, Muscle0low10
Hypovolemic Shock0low10
Hypoxemic Acute Respiratory Failure0low10
Hypoxemic Respiratory Failure0low10
Iatrogenic Disease0low10
Icterus0low20
IDDM0low30
Idiopathic Autoimmune Hemolytic Anemia0medium252
Idiopathic Diffuse Interstitial Pulmonary Fibrosis0medium62
Idiopathic Hypoparathyroidism0low30
Idiopathic Intracranial Hypertension0low70
Idiopathic Myelofibrosis0medium2410
Idiopathic Parkinson Disease0low20
Idiopathic Parkinson's Disease0low20
Idiopathic Proctocolitis0low10
Idiopathic Sexual Precocity0low150
Idiopathic Thrombocytopenic Purpura0medium6310
IGA Glomerulonephritis0medium11
IGA Nephropathy0medium11
Iga Nephropathy 10medium11
IgA Vasculitis0low10
Ileal Cancer0low10
Ileal Neoplasms0low10
Immune Complex Diseases0low10
Immune Diseases0low10
Immune Disorders0low10
Immune System Diseases0low10
Immune System Disorders0low10
Immune Thrombocytopenia0medium6310
Immune Thrombocytopenic Purpura0medium6310
Immunoblastic Lymphadenopathy0low10
Immunodeficiency 50low50
Immunodeficiency Syndrome, Acquired0medium81
Immunodeficiency, Common Variable0low10
Immunodeficiency, X-Linked Progressive Combined Variable0low50
Immunoglobulin A Nephropathy0medium11
Immunoglobulin Deficiency, Late-Onset0low10
Immunologic Deficiency Syndrome0low10
Immunologic Deficiency Syndrome, Acquired0medium81
Immunologic Deficiency Syndromes0low10
Immunologic Diseases0low10
Immunological Deficiency Syndromes0low10
Immunological Diseases0low10
Inappropriate GH Secretion Syndrome (Acromegaly)0low20
Inappropriate Growth Hormone Secretion Syndrome (Acromegaly)0low20
Inappropriate Prolactin Secretion0low10
Inappropriate Prolactin Secretion Syndrome0low10
Inborn Errors of Metabolism0low10
Inborn Genetic Diseases0low70
Increased Intracranial Pressure-Associated Papilledema0low20
Infant Gynecomastia0medium152
Infant, Premature, Diseases0low10
Infantile Colic0low30
Infantile Paralysis0low10
Infarct of the Spleen0low10
Infection0low10
Infection and Infestation0low10
Infection, Cross0low10
Infections0low10
Infections and Infestations0low10
Infections, Helicobacter0medium31
Infections, Hospital0low10
Infections, Nosocomial0low10
Infertility, Female0medium13922
Infertility, Male0low30
Inflammation0low50
Inflammatory Bowel Disease, Ulcerative Colitis Type0low10
Inflammatory Disease, Pelvic0low10
Inflammatory Pelvic Disease0low10
Inherited Blood Coagulation Disorders0low10
Inherited Coagulation Disorders0low10
Injuries, Surgical0low20
Injuries, Teeth0low10
Injuries, Tooth0low10
Innate Inflammatory Response0low50
Insomnia0low10
Insomnia Disorder0low10
Insulin Resistance0medium31
Insulin Sensitivity0medium31
Insulin-Dependent Diabetes Mellitus 10low30
Intermenstrual Bleeding0medium111
Internal Carotid Artery Diseases0medium11
Internal Carotid Artery Thrombosis0low10
Intersex Conditions0low70
Intersexuality0low70
Interstitial Lung Disease0low10
Interstitial Lung Diseases0low10
Intestinal Cancer0low30
Intestinal Diseases0low20
Intestinal Neoplasms0low30
Intestinal Obstruction0low10
Intestines Cancer0low30
Intestines Neoplasms0low30
Intracerebral Hemorrhage0low70
Intracranial Astrocytoma0low10
Intracranial Hypertension, Benign0low70
Intracranial Hypertension, Idiopathic0low70
Intracranial Neoplasms0low10
Intracranial Sinus Thrombophlebitis0low10
Intracranial Vascular Disorders0low10
Intrahepatic Cholestasis0low40
Intraoperative Complications0low20
Intrauterine Growth Restriction0low10
Intrauterine Growth Retardation0low10
Intravascular Coagulation, Disseminated0low20
Intravascular Disseminated Coagulation0low20
Intravascular Hemolysis0low10
Intraventricular Septal Defects0low10
Invasiveness, Neoplasm0medium31
Inversion, Chromosomal0low10
Inversion, Chromosome0low10
Iron Overload0low10
Iron-Deficiency Anemia0low10
Iron-Deficiency Anemias0low10
Irregular Menses0medium183
Irregular Menstruation0medium183
Irvine-Gass Syndrome0low10
Ischemia0low10
Isolated GH Deficiency0low10
Isolated Growth Hormone Deficiency0low10
Isolated HGH Deficiency0low10
Isolated Human Growth Hormone Deficiency0low10
Isolated Somatotropin Deficiency0low10
Isolated Somatotropin Deficiency Disorder0low10
Itching0medium31
Jaundice0low20
Jaundice, Hemolytic0low20
Joint Diseases0medium11
Juvenile Dermatomyositis0low10
Juvenile Myositis0low10
Juvenile Pilocytic Astrocytoma0low10
Juvenile-Onset Diabetes0low30
Kahler Disease0low10
Kidney Cancer0low20
Kidney Diseases0low10
Kidney Failure, Acute0low10
Kidney Failure, Chronic0low30
Kidney Insufficiency, Acute0low10
Kidney Neoplasms0low20
Kidney Scarring0medium31
Lactation Disorders0low10
Laryngeal Edema0low80
Laryngitis0low10
Left-Sided Heart Failure0low50
Leg Dermatoses0low20
Leg Dermatosis0low20
Leiomyoblastoma0low10
Leiomyoma0medium323
Leiomyoma, Epithelioid0low10
Leiomyoma, Uterine0medium323
Leiomyosarcoma0medium11
Leiomyosarcoma, Epithelioid0medium11
Leiomyosarcoma, Myxoid0medium11
Leucocythaemia0low20
Leucocythemia0low20
Leukemia0low20
Leukemia, Acute Lymphoblastic0low20
Leukemia, Acute Monocytic0low10
Leukemia, Acute Myelogenous0medium163
Leukemia, Acute Myeloid0medium163
Leukemia, Acute Promyelocytic0low20
Leukemia, B Cell, Chronic0low40
Leukemia, B-Cell, Chronic0low40
Leukemia, Chronic Lymphatic0low40
Leukemia, Chronic Lymphocytic0low40
Leukemia, Chronic Lymphocytic, B-Cell0low40
Leukemia, Granulocytic0medium32
Leukemia, Lymphoblastic0low20
Leukemia, Lymphoblastic, Acute0low20
Leukemia, Lymphoblastic, Acute, L10low20
Leukemia, Lymphoblastic, Acute, L20low20
Leukemia, Lymphoblastic, Acute, Philadelphia-Positive0low20
Leukemia, Lymphoblastic, Chronic0low40
Leukemia, Lymphocytic, Acute0low20
Leukemia, Lymphocytic, Acute, L10low20
Leukemia, Lymphocytic, Acute, L20low20
Leukemia, Lymphocytic, Chronic0low40
Leukemia, Lymphocytic, Chronic, B Cell0low40
Leukemia, Lymphocytic, Chronic, B-Cell0low40
Leukemia, Lymphoid, Acute0low20
Leukemia, Monoblastic, Acute0low10
Leukemia, Monocytic, Acute0low10
Leukemia, Monocytic, Chronic0medium32
Leukemia, Myeloblastic, Acute0medium163
Leukemia, Myelocytic0medium32
Leukemia, Myelocytic, Acute0medium163
Leukemia, Myelogenous0medium32
Leukemia, Myelogenous, Acute0medium163
Leukemia, Myeloid0medium32
Leukemia, Myeloid, Acute0medium163
Leukemia, Myeloid, Acute, M10medium163
Leukemia, Myeloid, Acute, M20medium163
Leukemia, Myeloid, Acute, M30low20
Leukemia, Myeloid, Acute, M40low10
Leukemia, Myeloid, Acute, M50low10
Leukemia, Myeloid, Naegeli-Type0low10
Leukemia, Myeloid, Schilling Type0low10
Leukemia, Myeloid, Schilling-Type0low10
Leukemia, Myelomonocytic, Acute0low10
Leukemia, Myelomonocytic, Chronic0medium21
Leukemia, Nonlymphoblastic, Acute0medium163
Leukemia, Nonlymphocytic, Acute0medium163
Leukemia, Plasma Cell0low10
Leukemia, Plasmacytic0low10
Leukemia, Progranulocytic0low20
Leukemia, Promyelocytic, Acute0low20
Leukemia, Smoldering0medium41
Leukemia, Smouldering0medium41
Leukocytopenia0low10
Leukopenia0low10
Lewy Body Parkinson Disease0low20
Lewy Body Parkinson's Disease0low20
Libman-Sacks Disease0medium403
Limb Cramp0low30
Linear Scleroderma0low20
Liver Cancer0low210
Liver Cancer, Adult0low130
Liver Cell Carcinoma0low130
Liver Cell Carcinoma, Adult0low130
Liver Cirrhosis0medium31
Liver Diseases0low40
Liver Dysfunction0low40
Liver Failure0low10
Liver Failure, Acute0low10
Liver Failure, Fulminant0low10
Liver Fibrosis0medium31
Liver Injury, Drug-Induced0medium251
Liver Injury, Drug-Induced, Acute0medium251
Liver Neoplasms0low210
Lobar Pneumonia0low10
Local Neoplasm Recurrence0medium51
Local Neoplasm Recurrences0medium51
Locoregional Neoplasm Recurrence0medium51
Long Sleeper Syndrome0low10
Low Blood Pressure0low10
Low Sperm Count0low20
Lower Motor Neuron Facial Palsy0low10
Lung Cancer0low140
Lung Diseases0low50
Lung Diseases, Interstitial0low10
Lung Inflammation0low10
Lung Neoplasms0low140
Lupus Erythematosus Disseminatus0medium403
Lupus Erythematosus, Chronic Cutaneous0low40
Lupus Erythematosus, Cutaneous, Chronic0low40
Lupus Erythematosus, Discoid0low40
Lupus Erythematosus, Systemic0medium403
Lupus Vulgaris0low10
Lyell's Syndrome0low10
Lymphadenopathy Syndrome0medium31
Lymphadenopathy, Immunoblastic0low10
Lymphangioleiomyoma0low10
Lymphangioleiomyomatosis0low10
Lymphangiomyoma0low10
Lymphangiomyomatosis0low10
Lymphatic Diseases0low20
Lymphatic Sarcoma0low30
Lymphatism0low20
Lymphoblastic Leukemia0low20
Lymphoblastic Leukemia, Acute0low20
Lymphoblastic Leukemia, Acute, Adult0low20
Lymphoblastic Leukemia, Acute, Childhood0low20
Lymphoblastic Leukemia, Acute, L10low20
Lymphoblastic Leukemia, Acute, L20low20
Lymphoblastic Leukemia, Chronic0low40
Lymphoblastic Lymphoma0low20
Lymphocytic Leukemia, Acute0low20
Lymphocytic Leukemia, Chronic0low40
Lymphocytic Leukemia, Chronic, B Cell0low40
Lymphocytic Leukemia, Chronic, B-Cell0low40
Lymphocytic Leukemia, L10low20
Lymphocytic Leukemia, L20low20
Lymphocytic Lymphoma0low40
Lymphocytic Lymphoma, Diffuse, Poorly Differentiated0low10
Lymphocytic Lymphoma, Diffuse, Poorly-Differentiated0low10
Lymphocytic Lymphoma, Diffuse, Well Differentiated0low40
Lymphocytic Lymphoma, Diffuse, Well-Differentiated0low40
Lymphocytic Lymphoma, Well Differentiated0low40
Lymphocytic Lymphoma, Well-Differentiated0low40
Lymphocytosis0low10
Lymphohistiocytosis, Hemophagocytic0low10
Lymphoma0low10
Lymphoma of Mucosa-Associated Lymphoid Tissue0low20
Lymphoma, Atypical Diffuse Small Lymphoid0low30
Lymphoma, B-Cell, Marginal Zone0low20
Lymphoma, Centrocytic Small-Cell0low10
Lymphoma, Diffuse0low30
Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic0low30
Lymphoma, High-Grade0low30
Lymphoma, Intermediate-Grade0low30
Lymphoma, Low-Grade0low30
Lymphoma, Lymphoblastic0low20
Lymphoma, Lymphocytic0low40
Lymphoma, Lymphocytic, Diffuse, Intermediate Differentiated0low10
Lymphoma, Lymphocytic, Diffuse, Poorly-Differentiated0low10
Lymphoma, Lymphocytic, Diffuse, Well Differentiated0low40
Lymphoma, Lymphocytic, Diffuse, Well-Differentiated0low40
Lymphoma, Lymphocytic, Intermediate0low10
Lymphoma, Lymphocytic, Plasmacytoid0low10
Lymphoma, Lymphocytic, Well Differentiated0low40
Lymphoma, Lymphocytic, Well-Differentiated0low40
Lymphoma, Lymphoplasmacytoid0low10
Lymphoma, Lymphoplasmacytoid, CLL0low40
Lymphoma, Malignant0low10
Lymphoma, Mantle-Cell0low10
Lymphoma, Mixed0low30
Lymphoma, Mixed Cell, Diffuse0low30
Lymphoma, Mixed Lymphocytic-Histiocytic0low30
Lymphoma, Mixed Small and Large Cell, Diffuse0low30
Lymphoma, Mixed-Cell0low30
Lymphoma, Mixed-Cell, Diffuse0low30
Lymphoma, Mucosa-Associated Lymphoid Tissue0low20
Lymphoma, Non-Hodgkin0low30
Lymphoma, Non-Hodgkin, Familial0low30
Lymphoma, Non-Hodgkin's0low30
Lymphoma, Non-Hodgkins0low30
Lymphoma, Nonhodgkin's0low30
Lymphoma, Nonhodgkins0low30
Lymphoma, Pleomorphic0low30
Lymphoma, Small and Large Cleaved-Cell, Diffuse0low30
Lymphoma, Small Cleaved Cell, Diffuse0low30
Lymphoma, Small Cleaved-Cell, Diffuse0low30
Lymphoma, Small Lymphocytic0low40
Lymphoma, Small Lymphocytic, Plasmacytoid0low40
Lymphoma, Small Non-Cleaved-Cell0low30
Lymphoma, Small Noncleaved-Cell0low30
Lymphoma, Small-Cell0low40
Lymphoma, Small-Cell, Centrocytic0low10
Lymphoma, Undifferentiated0low30
Lymphoma, Undifferentiated, Diffuse0low30
Lymphoplasmacytoid Lymphoma, CLL0low40
Lymphoproliferative Disease, X-Linked0low50
Lymphoproliferative Disorders0low50
Lymphoproliferative Syndrome, X-Linked, 10low50
Lymphosarcoma0low30
M3 ANLL0low20
Macrocheilia, Facial Palsy, Edema0low20
Macroglobulinemia0low10
Macular Dystrophy, Dominant Cystoid0low10
Macular Edema0low10
Macular Edema, Cystoid0low10
Maculopapular Drug Eruption0medium51
Maculopapular Exanthem0medium51
Male Breast Enlargement0medium152
Male Pattern Baldness0low20
Male Pseudohermaphroditism Due to Androgen Insensitivity0low40
Malignancies, Hematologic0low10
Malignancy0low50
Malignancy, Hematologic0low10
Malignant Cystosarcoma Phyllodes0low10
Malignant Epithelial Neoplasms0medium21
Malignant Hypothalamic Neoplasms0low10
Malignant Melanoma0low10
Malignant Neoplasm of Breast0medium5010
Malignant Neoplasms0low50
Malignant Neoplasms, Brain0low10
Malignant Primary Brain Neoplasms0low10
Malignant Primary Brain Tumors0low10
Malignant Tumor of Breast0medium5010
Malignant Tumor of Urinary Bladder0low70
MALT Lymphoma0low20
Mammary Cancer0medium5010
Mammary Carcinoma, Human0medium5010
Mammary Dysplasia0medium5014
Mammary Neoplasm, Human0medium5010
Mammary Neoplasms, Experimental0medium51
Mammary Neoplasms, Human0medium5010
Manic Depression0low20
Manic Disorder0low20
Manic-Depressive Psychosis0low20
Mantle-Cell Lymphoma0low10
Mantle-Zone Lymphoma0low10
Marchiafava-Micheli Syndrome0medium121
Marginal Zone B-Cell Lymphoma0low20
Marie-Struempell Disease0low10
Mastitis0low30
Median Neuropathy, Carpal Tunnel0low30
Melancholia0low20
Melanoma0low10
Melanoma, B160low10
Melanoma, Cloudman S910low10
Melanoma, Experimental0low10
Melanoma, Harding-Passey0low10
Melanomas, Experimental0low10
Melkerson-Rosenthal Syndrome0low20
Melkersson Syndrome0low20
Melkersson-Rosenthal Syndrome0low20
Melkersson-Rosenthal-Miescher Syndrome0low20
Meningism0low10
Meningismus0low10
Meningitis-Like Reaction0low10
Meningitis, Pneumococcal0low10
Meningitis, Pneumococcal, Experimental0low10
Meningitis, Pneumococcal, Penicillin-Resistant0low10
Meningitis, Pneumococcal, Recurrent0low10
Meningitis, Streptococcus pneumoniae0low10
Menopause0medium349
Menopause, Premature0low10
Menorrhagia0medium8618
Menstrual Irregularities0medium183
Menstrual Irregularity0medium183
Menstruation Disorders0medium183
Menstruation Disturbances0medium183
Menstruation, Painful0medium292
Menstruation, Retrograde0medium183
Mesenteric Ischemia0low10
Mesenteric Vascular Insufficiency0low10
Mesenteric Venous Thrombosis0low10
Metabolism Errors, Inborn0low10
Metabolism, Inborn Errors0low10
Metachronous Neoplasms0low20
Metachronous Second Primary Neoplasms0low20
Metastase0medium72
Metastases, Neoplasm0medium72
Metastasis0medium72
Metastasis, Neoplasm0medium72
Methemoglobinemia0medium11
Metrorrhagia0medium111
Microangiopathic Hemolytic Anemia0medium61
Microangiopathic Hemolytic Anemia, Congenital0low30
Microglandular Adenosis0medium5014
Miescher-Melkersson-Rosenthal Granulomatous Cheilitis0low20
Migraine0medium51
Migraine Disorders0medium51
Migraine Headache0medium51
Migraine Variant0medium51
Milk-Alkali Syndrome0low20
Miscarriage0low50
Miscarriage, Recurrent0medium31
Mitral Incompetence0low10
Mitral Insufficiency0low10
Mitral Regurgitation0low10
Mitral Stenosis0low10
Mitral Valve Incompetence0low10
Mitral Valve Insufficiency0low10
Mitral Valve Regurgitation0low10
Mitral Valve Stenosis0low10
Mixed Small and Large Cell Lymphoma, Diffuse0low30
Mixed-Cell Lymphoma0low30
Mixed-Cell Lymphoma, Diffuse0low30
Mongolism0low10
Monoblastic Leukemia, Acute0low10
Monoclonal Gammapathies0low20
Monoclonal Gammopathies0low20
Monoclonal Gammopathy0low20
Monocytic Leukemia, Acute0low10
Monocytic Leukemia, Chronic0medium32
Mononeuritis0low10
Mononeuritis Multiplex0low10
Mononeuropathies0low10
Mononeuropathy Multiplex0low10
Mononeuropathy Multiplex Syndrome0low10
Monosomy0low10
Monosomy X0low10
Mood Disorders0low10
Morbilliform Drug Reaction0medium51
Morbilliform Exanthem0medium51
Morphea0low20
Moschcowitz Disease0low30
Moschkowitz Disease0low30
Mouth Diseases0low20
MS (Multiple Sclerosis)0low10
Mucosa-Associated Lymphoid Tissue Lymphoma0low20
Multiple Myeloma0low10
Multiple Primary Neoplasms0low30
Multiple Primary Neoplasms, Synchronous0low30
Multiple Sclerosis0low10
Multiple Sclerosis, Acute Fulminating0low10
Muscle Cramp0low30
Muscle Disorders0low20
Muscle Flaccidity0low10
Muscle Hypotonia0low10
Muscle Spasm0low10
Muscle Tone Atonic0low10
Muscle Tone Poor0low10
Muscular Cramp0low30
Muscular Diseases0low20
Muscular Flaccidity0low10
Muscular Hypotonia0low10
Muscular Spasm0low10
Mycoplasma-Induced Stevens Johnson Syndrome0low10
Mycoplasma-Induced Stevens-Johnson Syndrome0low10
Myeloblastic Leukemia, Acute0medium163
Myelocytic Leukemia0medium32
Myelocytic Leukemia, Acute0medium163
Myelofibrosis0medium2410
Myelofibrosis With Myeloid Metaplasia0medium2410
Myelogenous Leukemia0medium32
Myelogenous Leukemia, Acute0medium163
Myeloid Leukemia0medium32
Myeloid Leukemia, Acute0medium163
Myeloid Leukemia, Acute, M10medium163
Myeloid Leukemia, Acute, M20medium163
Myeloid Leukemia, Acute, M30low20
Myeloid Leukemia, Acute, M40low10
Myeloid Leukemia, Acute, M50low10
Myeloid Leukemia, Naegeli-Type0low10
Myeloid Leukemia, Schilling-Type0low10
Myeloid Metaplasia0medium2410
Myeloma-Multiple0low10
Myeloma, Multiple0low10
Myeloma, Plasma-Cell0low10
Myelomatosis0low10
Myelomonocytic Leukemia, Acute0low10
Myelomonocytic Leukemia, Chronic0medium21
Myelopathies, HTLV I Associated0medium41
Myelopathy, Htlv-1-Associated0medium41
Myelopathy, Human T-Lymphotropic Virus Type 1 Associated0medium41
Myeloproliferative Disorders0medium51
Myelosclerosis0medium2410
Myelosis, Nonleukemic0medium2410
Myocardial Failure0low50
Myocardial Infarct0medium31
Myocardial Infarction0medium31
Myoma0low10
Myopathic Conditions0low20
Myopathies0low20
Myxedema, Congenital0low10
Nanism, Pituitary0low10
Nasal Bleeding0low30
Nausea0medium52
Necrolytic Migratory Erythema0low10
Necrotizing Pancreatitis, Acute0low10
Neonatal Hypotonia0low10
Neoplasia0low50
Neoplasm0low50
Neoplasm Invasion0medium31
Neoplasm Invasiveness0medium31
Neoplasm Metastases0medium72
Neoplasm Metastasis0medium72
Neoplasm Recurrence, Local0medium51
Neoplasm Recurrence, Locoregional0medium51
Neoplasm Recurrences, Local0medium51
Neoplasm Regression, Spontaneous0low10
Neoplasm Remission, Spontaneous0low10
Neoplasm Seeding0low10
Neoplasms0low50
Neoplasms of Pelvis0medium6313
Neoplasms of Ureter0low80
Neoplasms, Appendiceal0low10
Neoplasms, Benign0low50
Neoplasms, Bladder0low70
Neoplasms, Bone0low20
Neoplasms, Brain0low10
Neoplasms, Brain, Benign0low10
Neoplasms, Brain, Malignant0low10
Neoplasms, Brain, Primary0low10
Neoplasms, Breast0medium5010
Neoplasms, Bronchial0low20
Neoplasms, Cervical0low20
Neoplasms, Cervix0low20
Neoplasms, Colonic0low10
Neoplasms, Colorectal0low10
Neoplasms, Endometrial0medium142
Neoplasms, Epithelial0medium11
Neoplasms, Experimental0low20
Neoplasms, Experimental Mammary0medium51
Neoplasms, Female Genital0medium374
Neoplasms, Gastrointestinal0low10
Neoplasms, Glandular0medium11
Neoplasms, Glandular and Epithelial0medium11
Neoplasms, Glandular Epithelial0medium11
Neoplasms, Gynecologic0medium374
Neoplasms, Hematologic0low10
Neoplasms, Hematopoietic0low10
Neoplasms, Hepatic0low210
Neoplasms, Hormone-Dependent0medium61
Neoplasms, Hypothalamic0low10
Neoplasms, Hypothalamic-Chiasmatic0low10
Neoplasms, Hypothalamic-Pituitary0low10
Neoplasms, Hypothalamic, Benign0low10
Neoplasms, Hypothalamic, Malignant0low10
Neoplasms, Hypothalamo-Neurohypophysial Region0low10
Neoplasms, Hypothalamus0low10
Neoplasms, Intestinal0low30
Neoplasms, Intracranial0low10
Neoplasms, Kidney0low20
Neoplasms, Liver0low210
Neoplasms, Lung0low140
Neoplasms, Malignant Epithelial0medium21
Neoplasms, Metachronous0low20
Neoplasms, Metachronous Second Primary0low20
Neoplasms, Multiple Primary0low30
Neoplasms, Ovarian0medium353
Neoplasms, Pancreatic0low20
Neoplasms, Pleural0low10
Neoplasms, Prostate0low40
Neoplasms, Prostatic0low40
Neoplasms, Pulmonary0low140
Neoplasms, Rectal0low60
Neoplasms, Second Primary0low20
Neoplasms, Sigmoid0low10
Neoplasms, Skin0low10
Neoplasms, Splenic0low10
Neoplasms, Synchronous0low30
Neoplasms, Synchronous Multiple Primary0low30
Neoplasms, Therapy-Associated0low20
Neoplasms, Therapy-Related0low20
Neoplasms, Treatment-Associated0low20
Neoplasms, Treatment-Related0low20
Neoplasms, Ureteral0low80
Neoplasms, Urologic0low10
Neoplasms, Uterine0medium9011
Neoplasms, Uterus0medium9011
Neoplasms, Vaginal0low10
Neoplastic Cell Transformation0low10
Neoplastic Pregnancy Complications0low40
Neoplastic Transformation, Cell0low10
Neovascularization, Pathologic0low40
Neovascularization, Pathological0low40
Nephritis0low10
Nephritis, IGA Type0medium11
Nephroid Carcinoma0low10
Nephropathy, IGA0medium11
Nervus Cranialis Disorders0low10
Neurodermatitis, Atopic0low10
Neurodermatitis, Disseminated0low10
Neurologic Voice Disorder0low40
Neuropathies, Cranial0low10
Neurosis, Depressive0low20
Neutropenia0medium41
Newborn Gynecomastia0medium152
Nodular Elastoidosis0low20
Nodular Elastosis0low20
Non-Hodgkin Lymphoma0low30
Non-Hodgkin's Lymphoma0low30
Nonlymphoblastic Leukemia, Acute0medium163
Nonlymphocytic Leukemia, Acute0medium163
Nonocclusive Mesenteric Ischemia0low10
Nonorganic Insomnia0low10
Nonstaphylococcal Scalded Skin Syndrome0low10
Nose Bleed0low30
Nosebleed0low30
Nosebleeds0low30
Nosocomial Infections0low10
Obesity0medium32
Occlusive Mesenteric Arterial Ischemia0low10
Ocular Headache0medium31
Old Silk Route Disease0low10
Oligoasthenoteratozoospermia0low20
Oligoastrocytoma, Mixed0low10
Oligomenorrhea0low10
Oligospermia0low20
Oligozoospermia0low20
Opportunistic Infections0low10
Optic Disc Edema0low20
Optic Disk Edema0low20
Optic Nerve Papillitis0low20
Optic Papilla Edema0low20
Orofacial Edema, Cheilitis Granulomatosa, Facial Neuropathy0low20
Orofacial Edema, Facial Neuropathy, Cheilitis Granulomatosa0low20
Orphan Diseases0low30
Orthostatic Headache0medium31
Osler-Rendu Disease0low10
Osler-Rendu-Weber Disease0low10
Osler-Weber-Rendu Syndrome0low10
Osler's Disease0low10
Osteoclastic Bone Loss0low20
Osteolysis0low10
Osteomalacia0low10
Osteoporosis0medium71
Osteoporosis, Age-Related0medium71
Osteoporosis, Involutional0medium71
Osteoporosis, Post-Menopausal0medium11
Osteoporosis, Post-Traumatic0medium71
Osteoporosis, Postmenopausal0medium11
Osteoporosis, Senile0medium71
Ovarian Cancer0medium353
Ovarian Cysts0medium51
Ovarian Diseases0low120
Ovarian Failure, Premature0medium21
Ovarian Hyperstimulation Syndrome0low10
Ovarian Hyperstimulation Syndrome, Familial Gestational Spontaneous0low10
Ovarian Neoplasms0medium353
Ovary Cancer0medium353
Ovary Neoplasms0medium353
Pain0medium6218
Pain, Burning0medium6218
Pain, Crushing0medium6218
Pain, Menstrual0medium292
Pain, Migratory0medium6218
Pain, Post-operative0low10
Pain, Postoperative0low10
Pain, Radiating0medium6218
Pain, Splitting0medium6218
Panacinar Emphysema0low50
Pancreas Cancer0low20
Pancreas Neoplasms0low20
Pancreatic Cancer0low20
Pancreatic Necrosis0low10
Pancreatic Neoplasms0low20
Pancreatic Parenchyma with Edema0low40
Pancreatic Parenchymal Edema0low40
Pancreatitis0low40
Pancreatitis Necrotising0low10
Pancreatitis Necrotizing0low10
Pancreatitis, Acute0low40
Pancreatitis, Acute Edematous0low40
Pancreatitis, Acute Necrotizing0low10
Pancytopenia0low10
Panlobular Emphysema0low50
Papillary Renal Cell Carcinoma0low10
Papilledema0low20
Papilledema Associated with Decreased Intraocular Pressure0low20
Papilledema Associated with Increased Intracranial Pressure0low20
Papillitis0low20
Papillitis, Optic0low20
Papilloma0low10
Papilloma, Squamous Cell0low10
Papillomatosis0low10
Paraimmunoglobulinemias0low20
Paralysis Agitans0low20
Paraneoplastic Syndromes0low10
Paraparesis, Tropical Spastic0medium41
Paraplegia, Tropical Spastic0medium41
Paraproteinemias0low20
Parasite Infections0low10
Parasitic Diseases0low10
Parasitic Infections0low10
Parenterally-Transmitted Non-A, Non-B Hepatitis0low20
Parkinson Disease0low20
Parkinson Disease, Idiopathic0low20
Parkinson's Disease0low20
Parkinson's Disease, Idiopathic0low20
Parkinson's Disease, Lewy Body0low20
Paroxysmal Cold Hemoglobinuria0medium121
Paroxysmal Hemoglobinuria0medium121
Paroxysmal Hemoglobinuria, Cold0medium121
Paroxysmal Hemoglobinuria, Nocturnal0medium121
Paroxysmal Nocturnal Hemoglobinuria0medium121
Partial Trisomy 21 Down Syndrome0low10
Pathologic Angiogenesis0low40
Pathologic Constriction0low10
Pathologic Dilatation0low10
Pathologic Dilatations0low10
Pathologic Neovascularization0low40
Pattern Baldness0low20
Pediatric Respiratory Distress Syndrome0low10
Peliosis Hepatis0low60
Pelvic Cancer0medium6313
Pelvic Disease, Inflammatory0low10
Pelvic Inflammatory Disease0low10
Pelvic Neoplasms0medium6313
Pelvic Pain0medium435
Pelvis Cancer0medium6313
Pelvis Neoplasms0medium6313
Perforated Appendicitis0low10
Perimenopausal Bone Loss0medium11
Perinatal Subarachnoid Hemorrhage0low10
Periodontal Bone Loss0low10
Periodontal Resorption0low10
Periodontitis, Adult0low10
Periodontitis, Chronic0low10
Periorbital Headache0medium31
Peripancreatic Fat Necrosis0low40
Peripheral Autoimmune Demyelinating Disease0low10
Peripheral Nerve Neoplasms0low10
Peripheral Nerve Neoplasms, Benign0low10
Peripheral Nerve Neoplasms, Malignant0low10
Peripheral Nerve Neoplastic Infiltration0low10
Peripheral Nerve Tumors0low10
Peripheral Nervous System Benign Neoplasms0low10
Peripheral Nervous System Malignant Neoplasms0low10
Peripheral Nervous System Neoplasms0low10
Periphlebitis0low10
Peritoneal Carcinomatosis0low40
Peritoneal Diseases0low40
Peritoneal Neoplasms0low40
Peritoneal Surface Malignancy0low40
Peritonitis0low10
Peroperative Complications0low20
Persistent Postsurgical Pain0low10
Petechiae0low30
Petrous Sinus Thrombophlebitis0low10
Petrous Sinus Thrombosis0low10
Pharyngeal Diverticula0low10
Pharyngeal Diverticulum0low10
Pharyngo-Esophageal Diverticula0low10
Pharyngo-Esophageal Diverticulum0low10
Pharyngoesophageal Diverticula0low10
Pharyngoesophageal Diverticulum0low10
Pharyngoesophageal Pulsion Diverticula0low10
Pharyngoesophageal Pulsion Diverticulum0low10
Phlebitis0low10
Phlebothrombosis0low30
Phlegmasia Alba Dolens0low50
Photodermatitis0low10
Photosensitivity Disorders0low10
Photosensitization0low10
Phyllodes Tumor0low10
Pilocytic Astrocytoma0low10
Pituitary Adenoma0low10
Pituitary Cancer0low10
Pituitary Carcinoma0low10
Pituitary Dwarf0low10
Pituitary Gigantism0low10
Pituitary Neoplasms0low10
Pituitary Tumors0low10
Pityriasis Rubra Pilaris0low10
Plasma Cell Dyscrasias0low20
Plasma Cell Leukemia0low10
Plasma Cell Myeloma0low10
Plasma Cell Tumor0low10
Plasma Thromboplastin Component Deficiency0medium112
Plasmacytic Leukemia0low10
Plasmacytoma0low10
Plasmocytoma0low10
Pleural Diseases0low10
Pleural Effusion0low10
Pleural Neoplasms0low10
Plica Syndrome0low10
Pneumonia0low10
Pneumonia, Interstitial0low10
Pneumonia, Lobar0low10
Pneumonitis0low10
Pneumonitis, Interstitial0low10
Pneumoperitoneum0low10
Pneumothorax0low140
Pneumothorax, Primary Spontaneous0low140
Poisoning0low10
Polio0low10
Polio Encephalitis0low10
Poliomyelitis0low10
Poliomyelitis Infection0low10
Poliomyelitis, Acute0low10
Poliomyelitis, Nonpoliovirus0low10
Poliomyelitis, Preparalytic0low10
Polyarthritis0low20
Polycystic Ovarian Syndrome0medium51
Polycystic Ovary Syndrome0medium51
Polycystic Ovary Syndrome 10medium51
Polycythemia0low30
Polymenorrhea0medium183
Polymyositis-Dermatomyositis0low10
Polyps0medium31
Polyradiculoneuritis0low10
Polyradiculoneuropathy0low10
Porphyria0low10
Porphyrias0low10
Porphyrin Disorder0low10
Post-operative Pain0low10
Post-operative Pain, Acute0low10
Post-operative Pain, Chronic0low10
Post-surgical Pain0low10
Postabsorptive Hypoglycemia0low10
Postmenopausal Bone Loss0medium11
Postmenopausal Osteoporosis0medium11
Postoperative Complications0medium181
Postoperative Pain0low10
Postoperative Pain, Acute0low10
Postoperative Pain, Chronic0low10
Postpartum Amenorrhea0medium216
Postprandial Hypoglycemia0low10
Postsurgical Pain0low10
Pre-Eclampsia0low10
Precancerous Conditions0low20
Precocious Puberty0low150
Precocious Puberty, Central0low150
Precocious Puberty, Male Limited0low150
Precocious Puberty, Male-Limited0low150
Precordial Catch0low20
Precordial Catch Syndrome0low20
Precursor Cell Lymphoblastic Leukemia-Lymphoma0low20
Predisposition, Genetic0low20
Preeclampsia0low10
Preeclampsia Eclampsia 10low10
Pregnancy0medium19631
Pregnancy Complications0medium61
Pregnancy Complications, Cardiovascular0low80
Pregnancy Complications, Hematologic0low90
Pregnancy Complications, Hematological0low90
Pregnancy Complications, Neoplastic0low40
Pregnancy Toxemias0low10
Pregnancy, Cardiovascular Complications0low80
Pregnancy, Ectopic0low20
Pregnancy, Extrauterine0low20
Pregnancy, Hematologic Complications0low90
Pregnancy, Neoplastic Complications0low40
Pregnancy, Tubal0low30
Preleukemia0low20
Premature Ovarian Failure0medium21
Premature Ovarian Failure 10medium21
Premature Ovarian Failure, X-Linked0medium21
Premenstrual Syndrome0medium3610
Premenstrual Tension0medium3610
Preneoplastic Condition0low20
Preneoplastic Conditions0low20
Pressure Pneumothorax0low140
Priapism0low10
Primary Brain Neoplasms0low10
Primary Hemophagocytic Hymphohistiocytosis0low10
Primary Hemophagocytic Lymphohistiocytosis0low10
Primary Hyperthyroidism0low50
Primary Hypothyroidism0medium41
Primary Insomnia0low10
Primary Macroglobulinemia0low10
Primary Malignant Brain Neoplasms0low10
Primary Malignant Brain Tumors0low10
Primary Myelofibrosis0medium2410
Primary Ovarian Insufficiency0medium21
Primary Ovarian Insufficiency, Fragile X-Associated0medium21
Primary Parkinsonism0low20
Primary Peritonitis0low10
Primary Sclerosing Cholangitis0low10
Primary Spontaneous Pneumothorax0low140
Progranulocytic Leukemia0low20
Prolactin Hypersecretion Syndrome0low10
Prolactin, Inappropriate Secretion0low10
Promyelocytic Leukemia, Acute0low20
Prostate Cancer0low40
Prostate Neoplasms0low40
Prostatic Cancer0low40
Prostatic Neoplasms0low40
Protein C Deficiency0low30
Protein Deficiency0low10
Protein S Deficiency0low20
Proteinuria0medium52
Proteinuria-Edema-Hypertension Gestosis0low10
Prothrombin Deficiency0low20
Pruritis0medium31
Pruritus0medium31
Pseudoglucagonoma Syndrome0low10
Pseudohermaphroditism0low70
Pseudomeningitis0low10
Pseudopelade0low20
Pseudotumor Cerebri0low70
Psychophysiologic Disorders0medium11
Psychophysiological Disorders0medium11
Psychophysiological Insomnia0low10
Psychoses0low10
Psychoses, Manic-Depressive0low20
Psychosis0low10
Psychosis, Brief Reactive0low10
Psychosis, Manic-Depressive0low20
Psychosomatic Disorders0medium11
Psychotic Disorders0low10
PT-NANBH0low20
Pubertas Praecox0low150
Puberty, Delayed0low10
Puberty, Precocious0low150
Puerperal Disorders0low10
Pulmonary Cancer0low140
Pulmonary Disease0low50
Pulmonary Diseases0low50
Pulmonary Embolism0low30
Pulmonary Embolisms0low30
Pulmonary Emphysema0low50
Pulmonary Emphysemas0low50
Pulmonary Fibroses0medium62
Pulmonary Fibrosis0medium62
Pulmonary Hypertension0low30
Pulmonary Inflammation0low10
Pulmonary Neoplasms0low140
Pulmonary Thromboembolism0low30
Pulmonary Thromboembolisms0low30
Pure Red-Cell Aplasia0low40
Purpura0low30
Purpura, Thrombocytopenic0medium531
Purpura, Thrombocytopenic, Autoimmune0medium6310
Purpura, Thrombopenic0medium531
Purpura, Thrombotic Thrombopenic0low30
Purtilo Syndrome0low50
Pyrexia0medium11
Pyridoxine Deficiency0low10
Quincke's Edema0medium1848
Rachitis0low10
RAEB0medium41
RAEM0medium41
Rare Diseases0low30
Reactive Hemophagocytic Syndrome0low10
Reactive Hypoglycemia0low10
Rebound Insomnia0low10
Recrudescence0medium8415
Rectal Cancer0low60
Rectal Diseases0low50
Rectal Disorders0low50
Rectal Neoplasms0low60
Rectal Tumors0low60
Rectum Cancer0low60
Rectum Neoplasms0low60
Recurrence0medium8415
Recurrence, Local Neoplasm0medium51
Recurrence, Locoregional Neoplasm0medium51
Recurrences, Local Neoplasm0medium51
Recurrent Early Pregnancy Loss0medium31
Red-Cell Aplasia, Pure0low40
Refractory Anemia0medium61
Refractory Anemia with Excess of Blasts0medium41
Regression, Spontaneous Neoplasm0low10
Regurgitation, Aortic Valve0low10
Reifenstein Syndrome0low40
Reifenstein's Syndrome0low40
Relapse0medium8415
Remission, Spontaneous0low30
Remission, Spontaneous Neoplasm0low10
Renal Cancer0low20
Renal Carcinoma0low10
Renal Cell Cancer0low10
Renal Cell Carcinoma0low10
Renal Cell Carcinoma, Papillary0low10
Renal Collecting Duct Carcinoma0low10
Renal Disease, End-Stage0low30
Renal Failure, Acute0low10
Renal Failure, Chronic0low30
Renal Failure, End-Stage0low30
Renal Insufficiency, Acute0low10
Renal Neoplasms0low20
Rendu-Osler-Weber Disease0low10
Reproductive Sterility0medium111
Resistant Ovary Syndrome0medium21
Respiratory Depression0low10
Respiratory Distress Syndrome0low10
Respiratory Distress Syndrome, Acute0low10
Respiratory Distress Syndrome, Adult0low10
Respiratory Distress Syndrome, Pediatric0low10
Respiratory Failure0low10
Respiratory Insufficiency0low10
Reticulohistiocytoma0low10
Reticulolymphosarcoma0low10
Reticulosarcoma0low30
Reticulosis, Familial Histiocytic0low10
Reticulum Cell Sarcoma0low30
Reticulum-Cell Sarcoma0low30
Retinal Edema0low20
Retro-Ocular Headache0medium31
Retroperitoneal Neoplasms0low10
Rhabdomyolysis0low60
Rheumatic Diseases0medium11
Rheumatism0medium11
Rheumatoid Arthritis0medium61
Rheumatoid Spondylitis0low10
Rickets0low10
Right-Sided Heart Failure0low50
Rosenthal-Melkerson Syndrome0low20
Rosenthal-Melkersson Syndrome0low20
Runt Disease0low10
Rupture, Spontaneous0low10
Ruptured Appendicitis0low10
SAH (Subarachnoid Hemorrhage)0low10
Salmonella typhi Infection0low10
Salpingitis0low10
Sarcoma, Germinoblastic0low10
Sarcoma, Lymphatic0low30
Sarcoma, Reticulum-Cell0low30
Sarcomatoid Renal Cell Carcinoma0low10
SARS Coronavirus 2 Infection0medium31
SARS-CoV-2 Infection0medium31
Scalded Skin Syndrome, Nonstaphylococcal0low10
Scalp Dermatoses0low10
Scalp Dermatosis0low10
Scar0low30
Scarring0low30
Scars0low30
Schizoaffective Disorder0low10
Schizophreniform Disorders0low10
Schulman-Upshaw Syndrome0low30
Sclerocystic Ovarian Degeneration0medium51
Sclerocystic Ovaries0medium51
Sclerocystic Ovary Syndrome0medium51
Scleroderma, Circumscribed0low20
Scleroderma, Linear0low20
Scleroderma, Localized0low20
Scleroderma, Systemic0low20
Sclerosing Cholangitis0low10
Sclerosis, Disseminated0low10
Sclerosis, Systemic0low20
Second Cancer0low20
Second Malignancy0low20
Second Neoplasm0low20
Second Primary Neoplasms0low20
Second Primary Neoplasms, Metachronous0low20
Secondary Hypothyroidism0medium41
Secondary Insomnia0low10
Secondary Peritonitis0low10
Seeding, Neoplasm0low10
Seizure Disorder0low10
Senile Osteoporosis0medium71
Sensitivity and Specificity0medium71
Sensorineural Hearing Loss0low10
Sex Chromosome Aberrations0low10
Sex Chromosome Abnormalities0low10
Sex Development Disorders0low70
Sex Differentiation Disorders0low70
Sexual Development Disorders0low70
Sexual Differentiation Disorders0low70
Sexual Precocity0low150
Sharp Headache0medium31
Shock0low10
Shock Lung0low10
Shock, Anaphylactic0low10
Short Sleep Phenotype0low10
Short Sleeper Syndrome0low10
Shortness of Breath0low10
Sicca Syndrome0low10
Sick Headache0medium51
Sickle Cell Anemia0low10
Sickle Cell Disease0low10
Sickle Cell Disorders0low10
Sickling Disorder Due to Hemoglobin S0low10
Side Effects of Drugs0low80
Sigmoid Cancer0low10
Sigmoid Colon Cancer0low10
Sigmoid Colon Neoplasms0low10
Sigmoid Neoplasms0low10
Sigmoidal Cancer0low10
Simple Endometrial Hyperplasia0medium193
Single-Gene Defects0low70
Sinus Thrombosis0low10
Sinus Thrombosis, Intracranial0low10
Sinusoidal Obstruction Syndrome0low10
Sjogren Syndrome0low10
Sjogren's Syndrome0low10
Skin and Subcutaneous Tissue Disorders0low40
Skin Cancer0low10
Skin Diseases0low40
Skin Diseases, Vascular0low40
Skin Neoplasms0low10
Skin Ulcer0low10
Sleep Disorders0low10
Sleep Initiation and Maintenance Disorders0low10
Sleep Initiation Dysfunction0low10
Sleep Wake Disorders0low10
Sleep-Related Neurogenic Tachypnea0low10
Sleeplessness0low10
Small Cleaved-Cell Lymphoma, Diffuse0low30
Small Non-Cleaved-Cell Lymphoma0low30
Small Noncleaved-Cell Lymphoma0low30
Small-Cell Lymphoma0low40
Somatotropin Hypersecretion Syndrome (Acromegaly)0low20
Spasm0low10
Spasm, Ciliary Body0low10
Spasm, Generalized0low10
Spider Veins0low10
Spinal Neoplasms0low10
Spleen Cancer0low10
Spleen Neoplasms0low10
Splenic Cancer0low10
Splenic Diseases0low40
Splenic Infarct0low10
Splenic Infarction0low10
Splenic Infarcts0low10
Splenic Neoplasms0low10
Splenic Rupture0low20
Splenomegaly0low40
Spondylarthritis Ankylopoietica0low10
Spondylitis Ankylopoietica0low10
Spondylitis, Ankylosing0low10
Spondyloarthritis Ankylopoietica0low10
Spontaneous Abortion0low50
Spontaneous Neoplasm Regression0low10
Spontaneous Neoplasm Remission0low10
Spontaneous Pneumothorax0low140
Spotting0medium111
Sprue0low10
Sprue, Celiac0low10
Sprue, Nontropical0low10
Status Bonnevie-Ullrich0low10
Status Lymphaticus0low20
Status Migrainosus0medium51
Stein-Leventhal Syndrome0medium51
Stenosis0low10
Sterility0medium111
Sterility, Female0medium13922
Sterility, Male0low30
Sterility, Postpartum0medium13922
Sterility, Reproductive0medium111
Stevens Johnson Syndrome Toxic Epidermal Necrolysis0low10
Stevens Johnson Syndrome Toxic Epidermal Necrolysis Spectrum0low10
Stevens-Johnson Syndrome0low10
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis0low10
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum0low10
Stomach Diseases0low10
Stricture0low10
Stuart-Prower Deficiency0low30
Stuart-Prower Factor Deficiency0low30
Stunted Growth0low10
Stunting0low10
Sub-Fertility0medium111
Sub-Fertility, Female0medium13922
Sub-Fertility, Male0low30
Subarachnoid Hemorrhage0low10
Subarachnoid Hemorrhage, Aneurysmal0low10
Subarachnoid Hemorrhage, Intracranial0low10
Subarachnoid Hemorrhage, Spontaneous0low10
Subdural Hematoma0low10
Subdural Hematoma, Traumatic0low10
Subependymal Giant Cell Astrocytoma0low10
Subfertility0medium111
Subfertility, Female0medium13922
Subfertility, Male0low30
Substance Withdrawal Syndrome0low10
Subwakefullness Syndrome0low10
Suffering, Physical0medium6218
Suffocation0low10
Surgery-Induced Tissue Adhesions0medium134
Surgical Adhesions0medium134
Surgical Blood Loss0medium42
Surgical Hemorrhage0medium42
Surgical Injuries0low20
Susceptibility, Disease0low10
Susceptibility, Genetic0low20
Symptom Cluster0medium131
Synchronous Multiple Primary Neoplasms0low30
Synchronous Neoplasms0low30
Syndrome0medium131
Syndrome, Melkerson Rosenthal0low20
Synovial Hypertrophy0low10
Synovial Plica Syndrome0low10
Synovial Thickening0low10
Synovitis0low10
Systemic Capillary Leak Syndrome0low10
Systemic Lupus Erythematosus0medium403
Systemic Scleroderma0low20
Systemic Sclerosis0low20
T-Lymphotropic Virus Type III Infections, Human0low10
Teeth Injuries0low10
Telangiectasia0low10
Telangiectasia, Hereditary Hemorrhagic0low10
Telangiectasia, Hereditary Hemorrhagic, of Rendu, Osler, and Weber0low10
Telangiectasia, Hereditary Hemorrhagic, Type 10low10
Telangiectasis0low10
Tension Pneumothorax0low140
Testicular Feminization0low40
Testicular Feminization Syndrome0low40
Testotoxicosis0low150
Texidor's Twinge0low20
Therapy-Associated Cancer0low20
Therapy-Associated Neoplasms0low20
Therapy-Related Cancer0low20
Therapy-Related Neoplasms0low20
Thoracic Diseases0low20
Thoracic Neoplasms0low10
Throbbing Headache0medium31
Thrombocythemia0low20
Thrombocytopathy0low10
Thrombocytopenia0medium585
Thrombocytopenic Purpura, Autoimmune0medium6310
Thrombocytosis0low20
Thromboembolism0low60
Thromboembolism, Pulmonary0low30
Thromboembolisms, Pulmonary0low30
Thrombopenia0medium585
Thrombophilia0low10
Thrombophlebitis0low50
Thrombosis0low100
Thrombosis, Carotid0low10
Thrombosis, Carotid Artery0low10
Thrombosis, Common Carotid Artery0low10
Thrombosis, Deep Vein0low30
Thrombosis, External Carotid Artery0low10
Thrombosis, Internal Carotid Artery0low10
Thrombosis, Venous0low30
Thrombotic Microangiopathy, Familial0low30
Thrombotic Thrombocytopenic Purpura0low30
Thrombotic Thrombocytopenic Purpura, Congenital0low30
Thrombotic Thrombocytopenic Purpura, Familial0low30
Thrombus0low100
Thyroid-Stimulating Hormone Deficiency0medium41
Tietze's Syndrome0medium11
Tissue Adhesions0medium134
Tonsillitis0low10
Tooth Injuries0low10
Tooth Mobility0low10
Toxemia Of Pregnancy0low10
Toxemias, Pregnancy0low10
Toxic Epidermal Necrolysis0low10
Toxic Epidermal Necrolysis Stevens Johnson Syndrome0low10
Toxic Epidermal Necrolysis Stevens Johnson Syndrome Spectrum0low10
Toxic Epidermal Necrolysis Stevens-Johnson Syndrome0low10
Toxic Epidermal Necrolysis Stevens-Johnson Syndrome Spectrum0low10
Toxic Hepatitis0medium251
Toxicity, Drug0low80
Transformation, Neoplastic Cell0low10
Transient Insomnia0low10
Transitory Hearing Loss0low10
Translocation, Chromosomal0low10
Translocation, Genetic0low10
Treatment-Associated Cancer0low20
Treatment-Associated Neoplasms0low20
Treatment-Related Cancer0low20
Treatment-Related Neoplasms0low20
Triple Symptom Complex0low10
Triple-Symptom Complex0low10
Trisomy 210low10
Trisomy 21, Meiotic Nondisjunction0low10
Trisomy 21, Mitotic Nondisjunction0low10
Trisomy G0low10
Tropical Spastic Paraparesis0medium41
Trypanosoma cruzi Infection0low20
Trypanosomiasis, South American0low20
TSH Deficiency0medium41
Tubal Obstruction0low50
Tubal Pregnancy0low30
Tumorigenic Transformation0low10
Tumors0low50
Tumors, Breast0medium5010
Tumors, Hypothalamus0low10
Turner Syndrome0low10
Turner's Syndrome0low10
Type 1 Diabetes0low30
Type 1 Diabetes Mellitus0low30
Type III Hypersensitivity0low10
Typhoid0low10
Typhoid Fever0low10
Typhus, Abdominal0low10
Ulcerative Colitis0low10
Ullrich-Turner Syndrome0low10
Undifferentiated Lymphoma0low30
Unilateral Headache0medium31
Unilateral Hypotonia0low10
Unipolar Depression0low20
Upper Motor Neuron Facial Palsy0low10
Upshaw Factor, Deficiency of0low30
Upshaw-Schulman Syndrome0low30
Ureter Cancer0low80
Ureter Neoplasms0low80
Ureter, Cancer Of0low80
Ureteral Cancer0low80
Ureteral Diseases0low20
Ureteral Neoplasms0low80
Ureteral Obstruction0low80
Urinary Bladder Cancer0low70
Urinary Bladder Diseases0low20
Urinary Bladder Neoplasms0low70
Urinary Incontinence0low10
Urinary Tract Cancer0low10
Urinary Tract Diseases0low10
Urinary Tract Infections0low20
Urinary Tract Neoplasms0low10
Urologic Cancer0low10
Urologic Diseases0low10
Urologic Neoplasms0low10
Urological Cancer0low10
Urological Diseases0low10
Urological Neoplasms0low10
Urticaria0medium111
Urticaria, Giant0medium1848
Uterine Bleeding0medium289
Uterine Cancer0medium9011
Uterine Cervical Cancer0low20
Uterine Cervical Neoplasms0low20
Uterine Diseases0medium225
Uterine Hemorrhage0medium289
Uterine Neoplasms0medium9011
Uterus Cancer0medium9011
Uterus Neoplasms0medium9011
Uveitis, Anterior0low10
Vagina Cancer0low10
Vagina Neoplasms0low10
Vaginal Bleeding0medium289
Vaginal Cancer0low10
Vaginal Diseases0low60
Vaginal Neoplasms0low10
Valvular Heart Diseases0low10
Varices0low20
Varicose Veins0low20
Varix0low20
Vascular Diseases, Intracranial0low10
Vascular Hypotension0low10
Vascular Pseudohemophilia0low40
Vascular Skin Diseases0low40
Vasculitis0low50
Veno-Occlusive Disease, Hepatic0low10
Venous Sinus Thrombosis, Cranial0low10
Venous Thrombosis0low30
Ventilatory Depression0low10
Ventricular Septal Defect0low10
Ventricular Septal Defects0low10
Vertebrogenic Pain Syndrome0medium11
Vertex Headache0medium31
Vesication0low10
Vesico-Vaginal Fistula0low10
Vesico-Vaginal Fistulae0low10
Vesicovaginal Fistula0low10
Vesicovaginal Fistulae0low10
Virilism0low60
Virilization0low60
Vitamin B 6 Deficiency0low10
Vitamin B6 Deficiency0low10
Vitamin Deficiency, B60low10
Voice Disorder, Neurologic0low40
Voice Disorders0low40
Voice Disturbance0low40
Voice Fatigue0low40
Vomiting0medium42
von Willebrand Disease0low40
von Willebrand Disease, Recessive Form0low40
von Willebrand Diseases0low40
Von Willebrand Disorder0low40
von Willebrand's Disease0low40
von Willebrand's Diseases0low40
Von Willebrand's Factor Deficiency0low40
Vulvar Diseases0low10
Waldenstrom Macroglobulinemia0low10
Waldenstrom's Macroglobulinaemia0low10
Waldenstrom's Macroglobulinemia0low10
Weber-Osler Disease0low10
Weber-Osler Syndrome0low10
Weight Gain0medium73
Weight Loss0medium11
Weight Reduction0medium11
Werlhof Disease0medium6310
Werlhof's Disease0medium6310
Withdrawal Symptoms0low10
X-Linked Hypergonadotropic Ovarian Failure0medium21
X-Linked Lymphoproliferative Disease0low50
X-Linked Lymphoproliferative Disorder0low50
X-Linked Lymphoproliferative Syndrome0low50
Xanthoma Disseminatum0low10
Zenker Diverticulum0low10
Zenker's Diverticula0low10
Zenker's Diverticulum0low10
Zika Fever0low10
Zika Virus Disease0low10
Zika Virus Infection0low10
ZikV Infection0low10
Zinsser-Cole-Engman Syndrome0low40

Research Highlights

Safety/Toxicity (21)

ArticleYear
Efficacy and safety of different subsequent therapies after fertility preserving surgery for endometriosis: A systematic review and network meta-analysis.
Medicine, Aug-04, Volume: 102, Issue: 31		2023
Evaluation of safety and effectiveness of gestrinone in the treatment of endometriosis: a systematic review and meta-analysis.
Archives of gynecology and obstetrics, Volume: 307, Issue: 1		2023
Danazol induces apoptosis and cytotoxicity of leukemic cells alone and in combination with purine nucleoside analogs in chronic lymphocytic leukemia.
Annals of hematology, Volume: 95, Issue: 3		2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Chemical research in toxicology, Oct-15, Volume: 25, Issue: 10		2012
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
PLoS computational biology, Volume: 7, Issue: 12		2011
Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, Jul-19, Volume: 23, Issue: 7		2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Current drug discovery technologies, Volume: 1, Issue: 4		2004
A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan.
Journal of the Chinese Medical Association : JCMA, Volume: 68, Issue: 7		2005
Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema.
The Journal of allergy and clinical immunology, Volume: 115, Issue: 4		2005
Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group.
American journal of obstetrics and gynecology, Volume: 169, Issue: 1		1993
Immunosuppressive effect of danazol on lymphocyte-mediated cytotoxicity toward human endometrial stromal cells.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, Volume: 8, Issue: 1		1994
Side effects of danazol compared with an ethinyloestradiol/norgestrel combination when used for postcoital contraception.
Contraception, Volume: 27, Issue: 1		1983
The long-term safety of danazol in women with hereditary angioedema.
Fertility and sterility, Volume: 54, Issue: 1		1990
Efficacy and safety of nafarelin in the treatment of endometriosis.
American journal of obstetrics and gynecology, Volume: 162, Issue: 2		1990
Efficacy and safety of intranasal buserelin acetate in the treatment of endometriosis: a review of six clinical trials and comparison with danazol.
Progress in clinical and biological research, Volume: 323		1990
The development of cytotoxicity in peritoneal macrophages from women with endometriosis.
Fertility and sterility, Volume: 57, Issue: 6		1992
Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up. The Nafarelin European Endometriosis Trial Group (NEET).
Fertility and sterility, Volume: 57, Issue: 3		1992
Comparison of cytokine levels and embryo toxicity in peritoneal fluid in infertile women with untreated or treated endometriosis.
American journal of obstetrics and gynecology, Volume: 167, Issue: 1		1992
Danazol suppresses both spontaneous and activated human lymphocyte-mediated cytotoxicity.
American journal of reproductive immunology (New York, N.Y. : 1989), Volume: 28, Issue: 1		1992
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Long-term Use (18)

ArticleYear
Danazol-induced peliosis hepatis accompanied by disseminated intravascular coagulation in a patient with myelodysplastic syndrome transformed from aplastic anemia.
[Rinsho ketsueki] The Japanese journal of clinical hematology, Volume: 57, Issue: 8		2016
Development of hepatocellular carcinoma after long-term immunosuppressive therapy including danazol in a dog.
The Journal of veterinary medical science, Nov-01, Volume: 78, Issue: 10		2016
[Maintenance therapy for endometriosis].
Nihon rinsho. Japanese journal of clinical medicine, Volume: 68, Issue: 1		2010
Long-term danazol prophylaxis does not lead to increased carotid intima-media thickness in hereditary angioedema patients.
Atherosclerosis, Volume: 198, Issue: 1		2008
Maintenance therapy involving a tapering dose of danazol or mid/low doses of oral contraceptive after gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain.
Fertility and sterility, Volume: 89, Issue: 6		2008
Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema.
The Journal of allergy and clinical immunology, Volume: 115, Issue: 4		2005
Abnormal uterine bleeding: medical treatment with vaginal danazol and five-year follow-up.
The Journal of the American Association of Gynecologic Laparoscopists, Volume: 11, Issue: 3		2004
Hepatocellular adenoma and focal nodular hyperplasia after long-term use of danazol for endometriosis: a case report.
Archives of gynecology and obstetrics, Volume: 269, Issue: 4		2004
Emerging drugs for endometriosis.
Expert opinion on emerging drugs, Volume: 9, Issue: 1		2004
Benefits and risks of pharmacological agents used for the treatment of menorrhagia.
Drug safety, Volume: 27, Issue: 2		2004
Therapies for the treatment of abnormal uterine bleeding.
Current women's health reports, Volume: 1, Issue: 3		2001
Endometriosis: medical therapy.
Bailliere's clinical obstetrics and gynaecology, Volume: 7, Issue: 4		1993
Assessment of medical treatments for menorrhagia.
British journal of obstetrics and gynaecology, Volume: 101 Suppl 11		1994
Very low dose danazol for relief of endometriosis-associated pelvic pain: a pilot study.
Fertility and sterility, Volume: 62, Issue: 6		1994
Male contraception properties of a new synthetic steroid derivative (danazol) in Rattus rattus rufescens.
Endokrinologie, Volume: 77, Issue: 1		1981
Danazol for the treatment of idiopathic thrombocytopenic purpura.
Acta haematologica, Volume: 74, Issue: 2		1985
Phyllodes tumor in a patient with a preexistent fibrocystic disease.
Gynecologic and obstetric investigation, Volume: 34, Issue: 1		1992
Chemical sterilization: effects of danazol administration on the testes and epididymides of male rabbit.
Acta biologica et medica Germanica, Volume: 36, Issue: 1		1977
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pharmacokinetics (7)

ArticleYear
Danazol oral absorption modelling in the fasted dog: An example of mechanistic understanding of formulation effects on drug pharmacokinetics.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Volume: 141		2019
Optimization of PEGylated nanoemulsions for improved pharmacokinetics of BCS class II compounds.
Drug delivery, Volume: 22, Issue: 4		2015
A report on alterations to the speaking and singing voices of four women following hormonal therapy with virilizing agents.
Journal of voice : official journal of the Voice Foundation, Volume: 13, Issue: 4		1999
Absorption of danazol after administration to different sites of the gastrointestinal tract and the relationship to single- and double-peak phenomena in the plasma profiles.
Journal of clinical pharmacology, Volume: 33, Issue: 12		1993
Effect of estradiol and steroid analogues on the clearance of immunoglobulin G-coated erythrocytes.
The Journal of clinical investigation, Volume: 75, Issue: 1		1985
Peritoneal fluid volume and sex steroids in the pre-ovulatory period in mild endometriosis.
British journal of obstetrics and gynaecology, Volume: 98, Issue: 2		1991
Single oral dose pharmacokinetics and comparative bioavailability of danazol in humans.
Biopharmaceutics & drug disposition, Volume: 12, Issue: 8		1991
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (41)

ArticleYear
Danazol.
Profiles of drug substances, excipients, and related methodology, Volume: 47		2022
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, Volume: 96, Issue: 5		2019
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
The Journal of biological chemistry, 11-15, Volume: 294, Issue: 46		2019
Danazol oral absorption modelling in the fasted dog: An example of mechanistic understanding of formulation effects on drug pharmacokinetics.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Volume: 141		2019
Solution or suspension - Does it matter for lipid based systems? In vivo studies of chase dosing lipid vehicles with aqueous suspensions of a poorly soluble drug.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Volume: 117		2017
Computational Models of the Gastrointestinal Environment. 2. Phase Behavior and Drug Solubilization Capacity of a Type I Lipid-Based Drug Formulation after Digestion.
Molecular pharmaceutics, 03-06, Volume: 14, Issue: 3		2017
Prediction of positive food effect: Bioavailability enhancement of BCS class II drugs.
International journal of pharmaceutics, Jun-15, Volume: 506, Issue: 1-2		2016
Effect of cyclodextrin concentration on the oral bioavailability of danazol and cinnarizine in rats.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Volume: 101		2016
High-Throughput Raman Spectroscopy Screening of Excipients for the Stabilization of Amorphous Drugs.
Applied spectroscopy, Volume: 69, Issue: 11		2015
Dissolution of Danazol Amorphous Solid Dispersions: Supersaturation and Phase Behavior as a Function of Drug Loading and Polymer Type.
Molecular pharmaceutics, Jan-04, Volume: 13, Issue: 1		2016
Formulation and performance of danazol nano-crystalline suspensions and spray dried powders.
Pharmaceutical research, Volume: 32, Issue: 5		2015
Toward the establishment of standardized in vitro tests for lipid-based formulations, part 6: effects of varying pancreatin and calcium levels.
The AAPS journal, Volume: 16, Issue: 6		2014
An in vitro digestion test that reflects rat intestinal conditions to probe the importance of formulation digestion vs first pass metabolism in Danazol bioavailability from lipid based formulations.
Molecular pharmaceutics, Nov-03, Volume: 11, Issue: 11		2014
'Stealth' lipid-based formulations: poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug.
Journal of controlled release : official journal of the Controlled Release Society, Oct-28, Volume: 192		2014
Endometriosis: translation of molecular insights to management.
Minerva endocrinologica, Volume: 39, Issue: 3		2014
Non-linear increases in danazol exposure with dose in older vs. younger beagle dogs: the potential role of differences in bile salt concentration, thermodynamic activity, and formulation digestion.
Pharmaceutical research, Volume: 31, Issue: 6		2014
Evaluation of a nanoemulsion formulation strategy for oral bioavailability enhancement of danazol in rats and dogs.
Journal of pharmaceutical sciences, Volume: 102, Issue: 10		2013
Formulation of a danazol cocrystal with controlled supersaturation plays an essential role in improving bioavailability.
Molecular pharmaceutics, Aug-05, Volume: 10, Issue: 8		2013
Incomplete desorption of liquid excipients reduces the in vitro and in vivo performance of self-emulsifying drug delivery systems solidified by adsorption onto an inorganic mesoporous carrier.
Molecular pharmaceutics, Sep-04, Volume: 9, Issue: 9		2012
Soluplus® as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Feb-14, Volume: 45, Issue: 3		2012
Solubility advantage of amorphous pharmaceuticals, part 3: Is maximum solubility advantage experimentally attainable and sustainable?
Journal of pharmaceutical sciences, Volume: 100, Issue: 10		2011
Early development drug formulation on a chip: fabrication of nanoparticles using a microfluidic spray dryer.
Lab on a chip, Jul-21, Volume: 11, Issue: 14		2011
Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: A mechanistic basis for utility.
Journal of drug targeting, Volume: 18, Issue: 10		2010
Nanoparticulation of poorly water soluble drugs using a wet-mill process and physicochemical properties of the nanopowders.
Chemical & pharmaceutical bulletin, Volume: 57, Issue: 10		2009
Lipid-based formulations for danazol containing a digestible surfactant, Labrafil M2125CS: in vivo bioavailability and dynamic in vitro lipolysis.
Pharmaceutical research, Volume: 25, Issue: 12		2008
Improved understanding of the effect of food on drug absorption and bioavailability for lipophilic compounds using an intestinal pig perfusion model.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, May-10, Volume: 34, Issue: 1		2008
Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs.
Journal of pharmaceutical sciences, Volume: 97, Issue: 2		2008
Increasing the proportional content of surfactant (Cremophor EL) relative to lipid in self-emulsifying lipid-based formulations of danazol reduces oral bioavailability in beagle dogs.
Pharmaceutical research, Volume: 24, Issue: 4		2007
Novel ultra-rapid freezing particle engineering process for enhancement of dissolution rates of poorly water-soluble drugs.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Volume: 65, Issue: 1		2007
Supersaturation produces high bioavailability of amorphous danazol particles formed by evaporative precipitation into aqueous solution and spray freezing into liquid technologies.
Drug development and industrial pharmacy, Volume: 32, Issue: 5		2006
In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Volume: 24, Issue: 4		2005
Effect of liquid volume and food intake on the absolute bioavailability of danazol, a poorly soluble drug.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Volume: 24, Issue: 4		2005
Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation.
Pharmaceutical research, Volume: 21, Issue: 8		2004
Potential drug interaction between simvastatin and danazol causing rhabdomyolysis.
The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique,Winter, Volume: 10, Issue: 4		2003
Development and in vivo evaluation of buccal tablets prepared using danazol-sulfobutylether 7 beta-cyclodextrin (SBE 7) complexes.
Journal of pharmaceutical sciences, Volume: 91, Issue: 7		2002
[Relationship between osteoporosis and metabolism of calcium and bone].
Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University, Volume: 23, Issue: 3		1998
Relative bioavailability of danazol in dogs from liquid-filled hard gelatin capsules.
International journal of pharmaceutics, Mar-01, Volume: 179, Issue: 1		1999
Use of truncated areas to measure extent of drug absorption in bioequivalence studies: effects of drug absorption rate and elimination rate variability on this metric.
Pharmaceutical research, Volume: 16, Issue: 1		1999
Effect of food and a monoglyceride emulsion formulation on danazol bioavailability.
Journal of clinical pharmacology, Volume: 33, Issue: 4		1993
Single oral dose pharmacokinetics and comparative bioavailability of danazol in humans.
Biopharmaceutics & drug disposition, Volume: 12, Issue: 8		1991
The absorption, distribution and metabolic fate of danazol in rats, monkeys and human volunteers.
Archives internationales de pharmacodynamie et de therapie, Volume: 221, Issue: 2		1976
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (92)

ArticleYear
Role of wetting agents and disintegrants in development of danazol nanocrystalline tablets.
International journal of pharmaceutics, Mar-15, Volume: 577		2020
Progesterone receptor modulators for endometriosis.
The Cochrane database of systematic reviews, Jul-25, Volume: 7		2017
"Per vaginam" topical use of hormonal drugs in women with symptomatic deep endometriosis: a narrative literature review.
Archives of gynecology and obstetrics, Volume: 296, Issue: 3		2017
Solution or suspension - Does it matter for lipid based systems? In vivo studies of chase dosing lipid vehicles with aqueous suspensions of a poorly soluble drug.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Volume: 117		2017
In Vivo Precipitation of Poorly Soluble Drugs from Lipid-Based Drug Delivery Systems.
Molecular pharmaceutics, 10-03, Volume: 13, Issue: 10		2016
A heuristic model to quantify the impact of excess cyclodextrin on oral drug absorption from aqueous solution.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Volume: 102		2016
The effect of long-term danazol treatment on haematological parameters in hereditary angioedema.
Orphanet journal of rare diseases, Feb-25, Volume: 11		2016
Effect of cyclodextrin concentration on the oral bioavailability of danazol and cinnarizine in rats.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Volume: 101		2016
The Effect of Danazol in Primary Immune Thrombocytopenia: An Analysis of a Large Cohort From a Single Center in China.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, Volume: 22, Issue: 8		2016
'Stealth' lipid-based formulations: poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug.
Journal of controlled release : official journal of the Controlled Release Society, Oct-28, Volume: 192		2014
Formulation of a danazol cocrystal with controlled supersaturation plays an essential role in improving bioavailability.
Molecular pharmaceutics, Aug-05, Volume: 10, Issue: 8		2013
Luminal lipid phases after administration of a triglyceride solution of danazol in the fed state and their contribution to the flux of danazol across Caco-2 cell monolayers.
Molecular pharmaceutics, May-07, Volume: 9, Issue: 5		2012
Successful management of hereditary angioedema during tonsillectomy: a case report.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, Volume: 23, Issue: 2		2012
Application of dissolution/permeation system for evaluation of formulation effect on oral absorption of poorly water-soluble drugs in drug development.
Pharmaceutical research, Volume: 29, Issue: 6		2012
A comparative evaluation of mono-, di- and triglyceride of medium chain fatty acids by lipid/surfactant/water phase diagram, solubility determination and dispersion testing for application in pharmaceutical dosage form development.
Pharmaceutical research, Volume: 29, Issue: 1		2012
FDA-approved drug labeling for the study of drug-induced liver injury.
Drug discovery today, Volume: 16, Issue: 15-16		2011
Danazol therapy combined with intermittent application of chemotherapy induces lasting remission in myeloproliferative disorder (MPD): an alternative for the elderly with advanced MPD.
Hematology (Amsterdam, Netherlands), Volume: 16, Issue: 2		2011
Gonadotrophin-releasing hormone analogues for pain associated with endometriosis.
The Cochrane database of systematic reviews, 12-08, Issue: 12		2010
Intravaginal oestrogen and progestin administration: advantages and disadvantages.
Best practice & research. Clinical obstetrics & gynaecology, Volume: 22, Issue: 2		2008
Danazol for heavy menstrual bleeding.
The Cochrane database of systematic reviews, Jul-18, Issue: 3		2007
Supersaturation produces high bioavailability of amorphous danazol particles formed by evaporative precipitation into aqueous solution and spray freezing into liquid technologies.
Drug development and industrial pharmacy, Volume: 32, Issue: 5		2006
Approaches toward reversal of increased vascular permeability in C1 inhibitor deficient mice.
Immunology letters, Oct-31, Volume: 89, Issue: 2-3		2003
Hormonal interventions for menstrual migraines.
Pharmacotherapy, Volume: 22, Issue: 11		2002
Danazol for heavy menstrual bleeding.
The Cochrane database of systematic reviews, Issue: 2		2002
Management of breast pain.
International journal of clinical practice, Volume: 54, Issue: 4		2000
Danazol treatment of idiopathic myelofibrosis with severe anemia.
Haematologica, Volume: 85, Issue: 6		2000
[Methimazole-induced aplastic anemia].
Recenti progressi in medicina, Volume: 90, Issue: 9		1999
[Adjuvant therapy in uterine myoma].
Vestnik Rossiiskoi akademii meditsinskikh nauk, Issue: 2		1997
Successful therapy with danazol in refractory autoimmune thrombocytopenia associated with rheumatic diseases.
British journal of rheumatology, Volume: 36, Issue: 10		1997
The efficacy of drugs in the management of endometriosis.
The Journal of the American Association of Gynecologic Laparoscopists, Volume: 3, Issue: 4		1996
A comparison of goserelin and danazol as endometrial thinning agents prior to endometrial laser ablation.
British journal of obstetrics and gynaecology, Volume: 103, Issue: 4		1996
Danazol relieves refractory pruritus associated with myeloproliferative disorders and other diseases.
American journal of hematology, Volume: 51, Issue: 2		1996
Angiotensin-converting enzyme inhibitor and danazol increase sensitivity of cough reflex in female guinea pigs.
American journal of respiratory and critical care medicine, Volume: 153, Issue: 2		1996
[Treatment of elderly patients with chronic idiopathic thrombocytopenic purpura].
[Rinsho ketsueki] The Japanese journal of clinical hematology, Volume: 34, Issue: 4		1993
[SHBG serum level in women with endometriosis before, during and after long-term danazol therapy].
Geburtshilfe und Frauenheilkunde, Volume: 53, Issue: 2		1993
Absorption of danazol after administration to different sites of the gastrointestinal tract and the relationship to single- and double-peak phenomena in the plasma profiles.
Journal of clinical pharmacology, Volume: 33, Issue: 12		1993
Considerations in selecting appropriate medical therapy for endometriosis.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, Volume: 40 Suppl		1993
The effect of sustained delivery of danazol and antioxidants on lipoprotein profiles of adult female mice.
Biomedical sciences instrumentation, Volume: 31		1995
[Danazol for treatment of fibrocystic mastopathy].
Zentralblatt fur Gynakologie, Volume: 117, Issue: 9		1995
Long-term therapy of hereditary angioedema with danazol.
Annals of internal medicine, Volume: 93, Issue: 6		1980
The effectivenss of danazol on subsequent fertility in minimal endometriosis.
Fertility and sterility, Volume: 38, Issue: 5		1982
Treatment of endometriosis with reduced dosage schedules of danazol.
Scottish medical journal, Volume: 27, Issue: 2		1982
Danazol in the treatment of mammary dysplasia.
Drugs, Volume: 19, Issue: 5		1980
Short-term effects of danazol on endometrial histology.
Acta obstetricia et gynecologica Scandinavica. Supplement, Volume: 123		1984
Danazol treatment of severely symptomatic fibrocystic breast disease and long-term follow-up--the Hjørring project.
Acta obstetricia et gynecologica Scandinavica. Supplement, Volume: 123		1984
[Lipoprotein changes during hormonal treatment of endometriosis with lynestrenol and danazol].
Geburtshilfe und Frauenheilkunde, Volume: 44, Issue: 3		1984
Dosage aspects of danazol therapy in endometriosis: short-term and long-term effectiveness.
American journal of obstetrics and gynecology, Mar-15, Volume: 139, Issue: 6		1981
Effect of danazol on thyroid function in postmenopausal women.
Acta obstetricia et gynecologica Scandinavica. Supplement, Volume: 123		1984
A French double-blind crossover study (danazol versus placebo) in the treatment of severe fibrocystic breast disease.
European journal of gynaecological oncology, Volume: 5, Issue: 2		1984
A comparative study of various dosages of danazol in the treatment of endometriosis.
British journal of obstetrics and gynaecology, Volume: 91, Issue: 2		1984
Danazol: endocrine and endometrial effects.
International journal of fertility, Volume: 25, Issue: 1		1980
Treatment of familial antithrombin-III deficiency with danazol.
Haemostasis, Volume: 15, Issue: 2		1985
Treatment of endometriosis with danazol: report of a 6-year prospective study.
Fertility and sterility, Volume: 43, Issue: 3		1985
Treatment of dysfunctional uterine bleeding with danazol.
The Australian & New Zealand journal of obstetrics & gynaecology, Volume: 25, Issue: 3		1985
Therapeutic effect of danazol on metrorrhagia in patients with idiopathic thrombocytopenic purpura (ITP).
Nouvelle revue francaise d'hematologie, Volume: 28, Issue: 5		1986
[Mechanisms of the antitumor action of gestagens on endometrial cancer].
Nihon Sanka Fujinka Gakkai zasshi, Volume: 38, Issue: 12		1986
Preliminary report on postmenopausal endometrial hyperplasia treatment with Danazol: histological and endocrinological aspects.
Cancer detection and prevention, Volume: 9, Issue: 3-4		1986
Effects of danazol on mineral homeostasis in normal postmenopausal women: preliminary communication.
Journal of the Royal Society of Medicine, Volume: 80, Issue: 11		1987
Low-dose danazol therapy in idiopathic thrombocytopenic purpura.
Annals of internal medicine, Volume: 107, Issue: 2		1987
Bronchopulmonary endometriosis: a rare cause of hemoptysis.
Southern medical journal, Volume: 81, Issue: 9		1988
Dosage-related effects of danazol on sex hormone binding globulin and free and total androgen levels.
Clinical endocrinology, Volume: 25, Issue: 5		1986
Danazol therapy in refractory chronic immune thrombocytopenic purpura.
Acta haematologica, Volume: 77, Issue: 1		1987
[Prolonged preventive treatment of hereditary angioneurotic edema with anabolic androgenic steroids].
Presse medicale (Paris, France : 1983), Feb-01, Volume: 15, Issue: 4		1986
Use of danazol for treatment of corticosteroid-resistant immune-mediated thrombocytopenia in a dog.
Journal of the American Veterinary Medical Association, Jan-01, Volume: 194, Issue: 1		1989
Long-term danazol therapy in autoimmune thrombocytopenia: unmaintained remission and age-dependent response in women.
Annals of internal medicine, Nov-01, Volume: 111, Issue: 9		1989
Very low dose danazol in idiopathic thrombocytopenic purpura and its role as an immune modulator.
The American journal of the medical sciences, Volume: 298, Issue: 4		1989
Maintenance therapy of cyclical mastalgia using low-dose danazol.
Journal of the Royal College of Surgeons of Edinburgh, Volume: 34, Issue: 2		1989
[Use of low-dose danazol in adenosis of the breast].
Minerva ginecologica, Volume: 41, Issue: 9		1989
Low-dose danazol for mastalgia.
British journal of clinical practice. Supplement, Volume: 68		1989
Hormonal management of fibrocystic disease of the breast.
The Journal of reproductive medicine, Volume: 35, Issue: 1 Suppl		1990
[Idiopathic autoimmune hemolytic anemia successfully treated with danazol].
[Rinsho ketsueki] The Japanese journal of clinical hematology, Volume: 31, Issue: 2		1990
[Low-dose danazol therapy in idiopathic thrombocytopenic purpura].
[Rinsho ketsueki] The Japanese journal of clinical hematology, Volume: 31, Issue: 10		1990
[Hereditary angioedema type II with predominantly abdominal symptoms].
Deutsche medizinische Wochenschrift (1946), Jun-21, Volume: 116, Issue: 25		1991
Pharmacologic management of endometriosis.
Clinical pharmacy, Volume: 10, Issue: 7		1991
[Danazol in treatment of cystic mastopathy].
Wiener klinische Wochenschrift, Volume: 103, Issue: 23		1991
The effects of fetal exposure to danazol.
British journal of obstetrics and gynaecology, Volume: 99, Issue: 3		1992
Danazol in the treatment of menorrhagia: the effect of a 1 month induction dose (200 mg) and 2 month's maintenance therapy (200 mg, 100 mg, 50 mg or placebo).
The Australian & New Zealand journal of obstetrics & gynaecology, Volume: 32, Issue: 4		1992
Danazol: an antigonadotropic agent in the treatment of pelvic endometriosis.
American journal of obstetrics and gynecology, Dec-01, Volume: 123, Issue: 7		1975
Danazol treatment and follow-up of patients with endometriosis.
The Journal of international medical research, Volume: 5 Suppl 3		1977
The absorption, distribution and metabolic fate of danazol in rats, monkeys and human volunteers.
Archives internationales de pharmacodynamie et de therapie, Volume: 221, Issue: 2		1976
Metabolic activation of acetylenic substituents to derivatives in the rat causing the loss of hepatic cytochrome P-450 and haem.
The Biochemical journal, Sep-15, Volume: 174, Issue: 3		1978
A radioimmunoassay for danazol (17alpha-pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol).
Steroids, Volume: 31, Issue: 2		1978
Danazol therapy in gynaecomastia; recent experience and indications for therapy.
Postgraduate medical journal, Volume: 55 Suppl 5		1979
Follow-up of patients with endometriosis treated with danazol.
Postgraduate medical journal, Volume: 55 Suppl 5		1979
Danazol administration to females with menses-associated exacerbations of acute intermittent porphyria.
The Journal of clinical endocrinology and metabolism, Volume: 48, Issue: 1		1979
Dosage aspects of danazol therapy in the treatment of endometriosis.
Postgraduate medical journal, Volume: 55 Suppl 5		1979
Danazol treatment of chronic cystic mastopathy: a clinical and hormonal evaluation.
Postgraduate medical journal, Volume: 55 Suppl 5		1979
Danazol treatment of benign breast disease: a survey of U.S.A. multi-centre studies.
Postgraduate medical journal, Volume: 55 Suppl 5		1979
Endogenous antispermatogenic agents: prospects for male contraception.
Annual review of pharmacology and toxicology, Volume: 18		1978
[A new antigonadotropin in the treatment of precocious puberty and pubertal gynaecomastia (author's transl)].
Padiatrie und Padologie. Supplementum, Issue: 5		1977
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Interactions (7)

ArticleYear
Effect of laparoscopy combined with mifepristone in the treatment of endometriosis and drug reaction analysis.
Pakistan journal of pharmaceutical sciences, Volume: 31, Issue: 3(Special)		2018
Danazol induces apoptosis and cytotoxicity of leukemic cells alone and in combination with purine nucleoside analogs in chronic lymphocytic leukemia.
Annals of hematology, Volume: 95, Issue: 3		2016
[Comparison of low-dose thalidomide and prednisone combined with or without danazol for the treatment of primary myelofibrosis-associated anemia].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, Volume: 35, Issue: 8		2014
Potential drug interaction between simvastatin and danazol causing rhabdomyolysis.
The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique,Winter, Volume: 10, Issue: 4		2003
Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis.
American journal of obstetrics and gynecology, Volume: 175, Issue: 2		1996
Carbamazepine-danazol drug interaction: its mechanism examined by a stable isotope technique.
Therapeutic drug monitoring, Volume: 8, Issue: 4		1986
[Studies on antifertility effect of testosterone undecanoate in combination with danazol in male rats].
Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, Volume: 11, Issue: 3		1989
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]